{"PMC7428695": [["She receives funding for research into FASD from the NHMRC, Australian Government Department of Health, and philanthropic organisations and has no conflicts of interest to declare.", [["FASD", "DISEASE", 39, 43]]]], "41199e837e1c706b7a8a1a8a0970856974235566": [["Background Acute respiratory distress syndrome (ARDS), also known as acute lung injury (ALI), is one of the most challenging clinical conditions in critical care medicine.", [["respiratory", "ANATOMY", 17, 28], ["lung", "ANATOMY", 75, 79], ["Acute respiratory distress syndrome", "DISEASE", 11, 46], ["ARDS", "DISEASE", 48, 52], ["acute lung injury", "DISEASE", 69, 86], ["ALI", "DISEASE", 88, 91], ["lung", "ORGAN", 75, 79], ["Background Acute respiratory distress syndrome", "PROBLEM", 0, 46], ["ARDS", "PROBLEM", 48, 52], ["acute lung injury", "PROBLEM", 69, 86], ["Acute", "OBSERVATION_MODIFIER", 11, 16], ["respiratory distress syndrome", "OBSERVATION", 17, 46], ["ARDS", "OBSERVATION", 48, 52], ["acute", "OBSERVATION_MODIFIER", 69, 74], ["lung", "ANATOMY", 75, 79], ["injury", "OBSERVATION", 80, 86], ["ALI", "OBSERVATION", 88, 91]]], ["It is a severe, life-threatening medical condition characterized by acute and widespread inflammation in the lungs [1] , which leads to protein-rich nonhydrostatic pulmonary edema and refractory hypoxemia [2] .", [["lungs", "ANATOMY", 109, 114], ["pulmonary", "ANATOMY", 164, 173], ["inflammation", "DISEASE", 89, 101], ["pulmonary edema", "DISEASE", 164, 179], ["hypoxemia", "DISEASE", 195, 204], ["lungs", "ORGAN", 109, 114], ["pulmonary", "ORGAN", 164, 173], ["a severe, life-threatening medical condition", "PROBLEM", 6, 50], ["acute and widespread inflammation in the lungs", "PROBLEM", 68, 114], ["protein", "TEST", 136, 143], ["nonhydrostatic pulmonary edema", "PROBLEM", 149, 179], ["refractory hypoxemia", "PROBLEM", 184, 204], ["severe", "OBSERVATION_MODIFIER", 8, 14], ["acute", "OBSERVATION_MODIFIER", 68, 73], ["widespread", "OBSERVATION_MODIFIER", 78, 88], ["inflammation", "OBSERVATION", 89, 101], ["lungs", "ANATOMY", 109, 114], ["rich", "OBSERVATION_MODIFIER", 144, 148], ["nonhydrostatic", "OBSERVATION_MODIFIER", 149, 163], ["pulmonary", "ANATOMY", 164, 173], ["edema", "OBSERVATION", 174, 179], ["refractory", "OBSERVATION_MODIFIER", 184, 194], ["hypoxemia", "OBSERVATION", 195, 204]]], ["It increases lung \"stiffness\" and impairs the ability of the lung to remove carbon dioxide [3] .", [["lung", "ANATOMY", 13, 17], ["lung", "ANATOMY", 61, 65], ["carbon dioxide", "CHEMICAL", 76, 90], ["carbon dioxide", "CHEMICAL", 76, 90], ["lung", "ORGAN", 13, 17], ["lung", "ORGAN", 61, 65], ["carbon dioxide", "SIMPLE_CHEMICAL", 76, 90], ["lung \"stiffness\"", "PROBLEM", 13, 29], ["carbon dioxide", "TREATMENT", 76, 90], ["lung", "ANATOMY", 13, 17], ["\"stiffness", "OBSERVATION", 18, 28], ["lung", "ANATOMY", 61, 65]]], ["Many pathogenic conditions can trigger ARDS, such as sepsis and pneumonia [4] .", [["ARDS", "DISEASE", 39, 43], ["sepsis", "DISEASE", 53, 59], ["pneumonia", "DISEASE", 64, 73], ["Many pathogenic conditions", "PROBLEM", 0, 26], ["ARDS", "PROBLEM", 39, 43], ["sepsis", "PROBLEM", 53, 59], ["pneumonia", "PROBLEM", 64, 73], ["ARDS", "OBSERVATION", 39, 43], ["sepsis", "OBSERVATION", 53, 59], ["pneumonia", "OBSERVATION", 64, 73]]], ["Although the outcome of ARDS has improved with advances in ventilator strategies, mortality is still high.", [["ARDS", "DISEASE", 24, 28], ["ARDS", "PROBLEM", 24, 28], ["ventilator strategies", "TREATMENT", 59, 80], ["ARDS", "OBSERVATION", 24, 28], ["improved", "OBSERVATION_MODIFIER", 33, 41]]], ["The LUNG SAFE study reports a 40% hospital mortality rate, with a significant increase across the ARDS severity categories, in line with the Berlin definition (34.9% in mild ARDS, 40.3% in moderate ARDS, and 46.1% in severe ARDS) [5] .", [["ARDS", "DISEASE", 98, 102], ["ARDS", "DISEASE", 174, 178], ["ARDS", "DISEASE", 198, 202], ["ARDS", "DISEASE", 224, 228], ["The LUNG SAFE study", "TEST", 0, 19], ["a significant increase across the ARDS severity categories", "PROBLEM", 64, 122], ["the Berlin definition", "TEST", 137, 158], ["mild ARDS", "PROBLEM", 169, 178], ["moderate ARDS", "PROBLEM", 189, 202], ["severe ARDS)", "PROBLEM", 217, 229], ["LUNG", "ANATOMY", 4, 8], ["significant", "OBSERVATION_MODIFIER", 66, 77], ["increase", "OBSERVATION_MODIFIER", 78, 86], ["ARDS", "OBSERVATION", 98, 102], ["mild", "OBSERVATION_MODIFIER", 169, 173], ["ARDS", "OBSERVATION", 174, 178], ["moderate", "OBSERVATION_MODIFIER", 189, 197], ["ARDS", "OBSERVATION", 198, 202], ["severe", "OBSERVATION_MODIFIER", 217, 223], ["ARDS", "OBSERVATION", 224, 228]]], ["No specific and effective pharmacological intervention for ARDS is currently available [3] ; therefore, it is critical to develop new clinical drugs for the treatment of ARDS.", [["ARDS", "DISEASE", 59, 63], ["ARDS", "DISEASE", 170, 174], ["effective pharmacological intervention", "TREATMENT", 16, 54], ["ARDS", "PROBLEM", 59, 63], ["new clinical drugs", "TREATMENT", 130, 148], ["ARDS", "PROBLEM", 170, 174], ["effective", "OBSERVATION_MODIFIER", 16, 25], ["ARDS", "OBSERVATION", 170, 174]]]], "472421f02b0ea341ff006713b1970f090a05dadb": [["En el caso que nos ocupa este sentido se centra en: 1. la fragilidad humana (el virus puede matar a cualquier ser humano); 2. impotencia humana (nuestra situaci\u00f3n es esencialmente id\u00e9ntica a la de las antiguas epidemias: nuestra defensa se reduce al aislamiento); 3. eficiencia limitada de la tecnociencia (a\u00fan no se ha encontrado la terapia decisiva para esta enfermedad, a pesar de los esfuerzos de cientos de laboratorios y empresas farmac\u00e9uticas); 4. redescubrimiento del bien com\u00fan y la solidaridad humana (la protecci\u00f3n de los individuos es necesaria para la protecci\u00f3n de la sociedad y viceversa); 5.La presencia predominante de la muerte (en cuya luz se puede remodelar la jerarqu\u00eda de valores que orientan la existencia humana).", [["virus puede", "SPECIES", 80, 91], ["la fragilidad humana (el virus", "TREATMENT", 55, 85], ["a cualquier ser humano)", "TREATMENT", 98, 121], ["impotencia humana (nuestra situaci\u00f3n es", "TREATMENT", 126, 165], ["a la de las antiguas epidemias", "TREATMENT", 189, 219], ["nuestra defensa", "TREATMENT", 221, 236], ["y la solidaridad humana (la protecci\u00f3n de los individuos es necesaria para la protecci\u00f3n", "TREATMENT", 487, 575], ["La presencia", "TEST", 607, 619]]], ["Los resultados de estas reflexiones pueden evidenciar responsabilidades del poder pol\u00edtico y producir hostilidad contra los fil\u00f3sofos y el esfuerzo de silenciar su voz, record\u00e1ndonos entre otros el ejemplo de S\u00f3crates \u00a9 2020 Centros Culturales de M\u00e9xico, A.C. Publicado por Masson Doyma M\u00e9xico S.A. Todos los derechos reservados.An analogyThinking about the pandemic?", [["derechos reservados", "TREATMENT", 309, 328]]], ["Although, it must be said, we do not all suffer the pandemic in the same way Is it possible to find an analogy between the spread of the virus and the spread of philosophical ideas?", [["the virus", "PROBLEM", 133, 142]]], ["It is certainly possible: philosophy, for example, is similar to the virus in that it pushes us to set priorities and make us aware of our finiteness, but also in that it forces us to pose new problems.", [["the virus", "PROBLEM", 65, 74], ["new problems", "PROBLEM", 189, 201], ["certainly possible", "UNCERTAINTY", 6, 24], ["philosophy", "OBSERVATION", 26, 36], ["virus", "OBSERVATION", 69, 74]]], ["In fact, even a simple virus can mobilize more ideas than a philosophy treatise (Benarde, 1973) .An analogyThere are deeper reasons for this analogy and the first is that both are invisible and are transmitted from one person to another.", [["person", "SPECIES", 219, 225], ["a simple virus", "PROBLEM", 14, 28]]], ["Philosophy is transmitted through ideas most of the time in an oral form, and also viruses, such as covid-19, are transmitted through very small drops of saliva that come out of the mouth, while their diffusion is so rapid that even in the case of ideas it is used say that they have becomeviral.", [["oral", "ANATOMY", 63, 67], ["mouth", "ANATOMY", 182, 187], ["oral", "ORGANISM_SUBDIVISION", 63, 67], ["saliva", "ORGANISM_SUBSTANCE", 154, 160], ["mouth", "ORGANISM_SUBDIVISION", 182, 187], ["covid", "TEST", 100, 105], ["very small drops of saliva", "PROBLEM", 134, 160], ["viruses", "OBSERVATION", 83, 90], ["small", "OBSERVATION_MODIFIER", 139, 144], ["drops", "OBSERVATION", 145, 150], ["mouth", "ANATOMY", 182, 187]]], ["The virus, entering the body, acts as a dangerous agent that puts our health at risk.", [["body", "ANATOMY", 24, 28], ["body", "ORGANISM_SUBDIVISION", 24, 28], ["The virus", "PROBLEM", 0, 9], ["a dangerous agent", "TREATMENT", 38, 55], ["virus", "OBSERVATION", 4, 9], ["body", "ANATOMY", 24, 28]]], ["Philosophy does not enter the body but into the mind, yet certain philosophical ideas can also be considered a threat to man, as happened during some historical occasions: Socrates was put to death, because his ideas were considered as a threat to the power structures of the time (Platon, 2003) .", [["body", "ANATOMY", 30, 34], ["death", "DISEASE", 192, 197], ["body", "ORGANISM_SUBDIVISION", 30, 34], ["man", "ORGANISM", 121, 124], ["man", "SPECIES", 121, 124]]], ["Jean Paul Sartre's philosophy was also considered a danger, so much so that in Great Britain his play The closed door was prohibited, as well as in the Soviet Union his play The dirty hands, while Pope Pius XII put all his works in the Index of prohibited books (Waterfield, 2002) ; Gabriel Marcel said that Sartre's thought corrupted the young people (Aloi, 2014) , repeating the accusation formulated against Socrates at his time.", [["people", "ORGANISM", 345, 351], ["Pope Pius XII", "PROTEIN", 197, 210], ["people", "SPECIES", 345, 351], ["closed", "OBSERVATION", 106, 112], ["dirty", "OBSERVATION", 178, 183]]], ["These three examples alone are enough to mention philosophers whose thinking represented a public threat to many, just like viruses.", [["viruses", "OBSERVATION", 124, 131]]], ["In this way the philosopher appears (as well as the virus) an\u00ebpidemos\u00efn the true Greek sense of the word, that is, someone who is in thedemos, who circulates among people of a certain community and endangers their lives.", [["people", "ORGANISM", 164, 170], ["people", "SPECIES", 164, 170]]], ["This is why philosophy and viruses, if taken in isolation, when they spread in societies can provoke and determine profound changes in mentality, when they recall previously neglected needs and awareness and in this way they can profoundly influence the course of history, for better or for worse.", [["viruses", "PROBLEM", 27, 34], ["profound changes in mentality", "PROBLEM", 115, 144], ["viruses", "OBSERVATION", 27, 34]]], ["G. Lourdes Vel\u00e1zquez / BIOETHICS UPdate xxx (2020) xxx-xxxWhat is philosophy for?Let us leave the analogy aside and ask ourselves what philosophers are doing during the current pandemic.", [["G. Lourdes Vel\u00e1zquez / BIOETHICS UPdate xxx", "SPECIES", 0, 43]]], ["There are spontaneous questions that arise in the face of the current situation and which seem reducible to a single fundamental one: What is philosophy for?", [["spontaneous", "OBSERVATION_MODIFIER", 10, 21], ["philosophy", "OBSERVATION", 142, 152]]], ["Or:\u1e84hat have philosophers written in the past in the face of thousands of deaths caused by the event of an epidemic?Some ask themselves more concretely in what philosophers can contribute, what effective contribution they have made or can give to the solution of the problems that are oppressing us, as if they were a caste of specialists.", [["deaths", "DISEASE", 74, 80]]], ["This perspective, rather than magnifying the figure of philosophers, diminishes them.What is philosophy for?Perhaps the pandemic will serve to remind us that philosophy cannot be reduced to any professional category.", [["philosophy", "OBSERVATION", 93, 103]]], ["In fact, no philosopher before has written directly on epidemics or pandemics (perhaps with the sole exception of Camus who wrote The plague (Camus, 1947) , although some such as Fichte, Hegel, William of Ockham, the Mexican Sor Juana In\u00e9s de la Cruz and very likely St. Augustine as well died during one of them.What is philosophy for?But let's go back to the more direct and crucial question:\u1e84hat is philosophy for?", [["pandemics", "PROBLEM", 68, 77], ["no", "UNCERTAINTY", 9, 11], ["plague", "OBSERVATION_MODIFIER", 134, 140], ["philosophy", "OBSERVATION", 321, 331], ["philosophy", "OBSERVATION", 402, 412]]], ["Many people reply thatPhilosophy is the thing with which or without which everything remains as it is.", [["people", "ORGANISM", 5, 11], ["people", "SPECIES", 5, 11]]], ["However, it expresses something true: philosophy does not have the task of providing tools or instruments to be used in concrete life.", [["instruments", "TREATMENT", 94, 105]]], ["We will therefore try to identify which are, in the current situation, some themes on which philosophical reflection is focused.Some important topicsA first point concerns the fragility of man.", [["man", "ORGANISM", 189, 192], ["man", "SPECIES", 189, 192]]], ["The pandemic does not look at anyone and has shown that fragilty is a typical condition of the human being as such.", [["human", "ORGANISM", 95, 100], ["human", "SPECIES", 95, 100], ["human", "SPECIES", 95, 100]]], ["This is important because, as modern man grew, he lost the sense of his fragility: he had the impression of gradually becoming the master of the world, of history and also, of life, through the progress of medicine, technology and ways in which he could organize his existence.", [["fragility", "DISEASE", 72, 81], ["man", "ORGANISM", 37, 40], ["man", "SPECIES", 37, 40]]], ["On the other hand, we realize, and the pandemic has been very clear from this point of view, that this underlying fragility is not completely eliminated.Some important topicsAt this first point another one is connected: that of vulnerability.", [["this underlying fragility", "PROBLEM", 98, 123], ["fragility", "OBSERVATION", 114, 123], ["not completely", "UNCERTAINTY", 127, 141]]], ["Vulnerability is partly synonymous with fragility, but with an extra accent, since who is vulnerable is the one who can be injured and this is important because it indicates that the human condition is also exposed, apart from its initial fragility, to be further affected.", [["human", "ORGANISM", 183, 188], ["human", "SPECIES", 183, 188], ["human", "SPECIES", 183, 188], ["fragility", "PROBLEM", 40, 49], ["the human condition", "PROBLEM", 179, 198], ["synonymous", "OBSERVATION", 24, 34], ["fragility", "OBSERVATION", 40, 49], ["injured", "OBSERVATION", 123, 130]]], ["This is what is happening today: we are affected in our everyday way of living, we can no longer do what we used to do and this regardless of whether we have to go to hospital and maybe even lose our lives.Some important topicsA third point is that of the impotence of the human being, which is different from what we have previously considered.", [["impotence", "DISEASE", 256, 265], ["human", "ORGANISM", 273, 278], ["human", "SPECIES", 273, 278], ["human", "SPECIES", 273, 278], ["impotence", "OBSERVATION", 256, 265]]], ["Impotence means being in the condition of not being able to do anything substantial.", [["Impotence means", "PROBLEM", 0, 15]]], ["Let's try to consider how we are behaving towards this pandemic and how people were behaving 200,300, 1000 years ago.", [["people", "ORGANISM", 72, 78], ["people", "SPECIES", 72, 78]]], ["Practically in the same way: the only defence that we are able to offer is isolation because, despite all our progress, this sudden appearance of a new, unknown virus is such that even the most advanced technologies we have available cold not help us.", [["a new, unknown virus", "PROBLEM", 146, 166], ["new", "OBSERVATION_MODIFIER", 148, 151], ["virus", "OBSERVATION", 161, 166]]], ["After all, when they tell us to go out with masks, respecting the safety distances and avoiding the contagions corresponds to what people did at the time of the Manzonian plague, of the plague mentioned by Boccaccio (Asor Rosa, 1992) , of that narrated by Thucydides (1996) and so on . . .", [["people", "ORGANISM", 131, 137], ["people", "SPECIES", 131, 137], ["masks", "TREATMENT", 44, 49]]], ["This fact is very significant because the man was gradually taking the attitude of the one who, giving time to time, could do everything.", [["man", "ORGANISM", 42, 45], ["man", "SPECIES", 42, 45], ["very", "OBSERVATION_MODIFIER", 13, 17], ["significant", "OBSERVATION_MODIFIER", 18, 29]]], ["There was no longer a sense of intrinsic limits.", [["no longer", "UNCERTAINTY", 10, 19], ["intrinsic limits", "OBSERVATION", 31, 47]]], ["Instead, this experience is showing us that in the most fundamental situations, such as that of surviving a particularly violent disease, we are unable to react much more effectively than by hiding, or isolating or protecting ourselves as our ancient ancestors did.Some important topicsAll this leads us to reflect on the reasons that gave man the impression of being omnipotent.", [["man", "SPECIES", 340, 343], ["a particularly violent disease", "PROBLEM", 106, 136]]], ["We do not want to underestimate the progress of science or technology: there is no doubt that today we know much more and much better than our grandparents, great grandparents and ancestors; not only that, but that we can do many things that our grandparents did not even imagine.", [["no doubt", "UNCERTAINTY", 80, 88]]], ["No, man is not the builder of his own existence, man is still a creature, that is, a being, privileged from many points of view, but who is always part of creation, even if he has qualities that allow him to progress in a certain sense indefinitely.", [["man", "ORGANISM", 4, 7], ["man", "ORGANISM", 49, 52], ["man", "SPECIES", 4, 7], ["man", "SPECIES", 49, 52]]], ["This must be especially emphasized today, when there are ideologies that even imagine proposing a future created by man himself through technology.", [["man", "ORGANISM", 116, 119], ["man", "SPECIES", 116, 119]]], ["I speak of transhumanism and posthumanism which even come to speculate that man can go beyond himself, thanks to technologies that he somehow incorporates.", [["man", "ORGANISM", 76, 79], ["man", "SPECIES", 76, 79], ["transhumanism", "PROBLEM", 11, 24]]], ["He incorporates them into his body and in this way he thinks of changing his ontological constitution, as is said in philosophy, that is, his true human substance.Some important topicsIs all this possible?", [["body", "ANATOMY", 30, 34], ["body", "ORGANISM_SUBDIVISION", 30, 34], ["human", "ORGANISM", 147, 152], ["human", "SPECIES", 147, 152], ["human", "SPECIES", 147, 152]]], ["What we are experiencing now is showing us that, despite the great progress that exists, today we are not yet in possession of a precise and specific drug and not even a vaccine against coronavirus, despite the fact that there are hundreds of laboratories in the world working in those research, behind which are very powerful pharmaceutical industries that pay for these research with the prospect of obtaining large profits.", [["coronavirus", "DISEASE", 186, 197], ["coronavirus", "ORGANISM", 186, 197], ["a vaccine", "TREATMENT", 168, 177], ["coronavirus", "PROBLEM", 186, 197]]], ["Man cannot predict with certainty, for example, that within two years we will have the expected drug, rather than within four months.", [["Man", "SPECIES", 0, 3]]], ["We will therefore say that the volume of our knowledge certainly increases, however, as it happens when we increase the volume of a sphere by inflating it, the surfaces, that is the border with the infinite space of the unknown, also increases, both from the point of view of knowledge and from the point of view of being able to do.Some important topicsWe do not enter into complicated discussions concerning the consequences of technological development, that is, the unpredictable consequences of many things that we are doing today.", [["volume", "OBSERVATION_MODIFIER", 120, 126], ["surfaces", "OBSERVATION_MODIFIER", 160, 168], ["increases", "OBSERVATION_MODIFIER", 234, 243]]], ["The most common masks are not those that protect the wearer from contagion, but those that prevent one from bringing any pathogens to the outside.", [["most common", "OBSERVATION_MODIFIER", 4, 15]]], ["It may seem that the individual accepts the discomfort of the mask for the sake of society, but in reality it is clear that if everyone used the masks, he too would be protected from contagion.", [["the discomfort", "PROBLEM", 40, 54], ["the mask", "TREATMENT", 58, 66], ["the masks", "TREATMENT", 141, 150]]], ["It is a very basic example that makes us understand how this coronavirus experience has made us discover a very important dimension and an essential value of our current life.Some important topicsThe last aspect of this pandemic that forced us to reflect was the presence of death always looming.", [["coronavirus", "DISEASE", 61, 72], ["death", "DISEASE", 275, 280], ["coronavirus", "ORGANISM", 61, 72]]], ["Contemporary society has tried to marginalize death.", [["death", "DISEASE", 46, 51], ["death", "PROBLEM", 46, 51]]], ["Conversely, in these months death has been brought under our gaze continuously and this has also led us to recover the most precise sense of medicine.", [["death", "DISEASE", 28, 33]]], ["The aim of medicine was traditionally considered to cure and recover health, since it was obvious that death was an inevitable natural fact.", [["death", "DISEASE", 103, 108], ["death", "PROBLEM", 103, 108]]], ["Today, on the other hand, it seems that the main purpose of medicine is to defeat immediate death, to save the patient's life even at the cost of condemning the residual part to an extremely painful state from many points of view.", [["death", "DISEASE", 92, 97], ["patient", "ORGANISM", 111, 118], ["patient", "SPECIES", 111, 118]]], ["The fact that in recent months we were put in the presence of so many deaths prompted us to reflect on the event of death itself, that is, to think that, once we arrive at that moment, we could ask ourselves what sense our life had, what are the things for which it was worth living and what instead those who have left no trace of themselves in our existence.", [["deaths", "DISEASE", 70, 76], ["death", "DISEASE", 116, 121]]], ["This too is an aspect on which philosophy has long reflected, proposing hierarchies of values of different type.", [["different type", "OBSERVATION_MODIFIER", 97, 111]]], ["This is certainly a noble tradition of philosophy ranging from Plato, Cicero, Seneca, to Montaigne and Schopenhauer and beyond; however, it is based on the idea that in a difficult moment, as we have already pointed out, philosophy cannot do much because its task is not to find solutions to problems but simply to teach us how to accept them.\u1e84hoever taught men to die would teach them to live,Montaigne observed (Montaigne De, 2012) .Some important topicsThe topics mentioned so far are not part of the usual university teaching programs.", [["men", "ORGANISM", 358, 361], ["men", "SPECIES", 358, 361], ["noble", "OBSERVATION_MODIFIER", 20, 25]]], ["What is at stake is our way of life, the society we would like to have, the way we have to educate ourselves and others, and it does not seem that the faculty programs, with their evaluation methods, their indexed journals, their conferences and accreditation committees are very open to these problemsWhat help can we expect from philosophy?Let's now return to our second initial question: what contribution can philosophers offer in the Covid-19 emergency?", [["their evaluation", "TEST", 174, 190], ["these problems", "PROBLEM", 288, 302]]], ["Let's start by simply acknowledging that there are no experts on Covid-19 at the moment: everything is being learned in the field.", [["Covid", "TEST", 65, 70]]], ["And very often the urgency puts doctors in front of difficult choices which they should not be obliged to make directly but relying on protocols established by a body of bioethics experts who should prepare new guidelines to make ethically responsible decisions and to know how to better spend limited available resources in order to improve the health of the population and rationalize the funds for medical care.What help can we expect from philosophy?A final observation that I would like to underline (and with this I conclude) is that philosophy and the pandemic teach us that we are all passing through in this life, but also that the crisis (another Greek concept introduced in medicine by Hippocrates) leads to two possible outcomes: relapse or recovery.", [["medical care", "TREATMENT", 401, 413], ["the crisis", "PROBLEM", 637, 647]]], ["The feeling of frustration and discouragement towards philosophy shouldn't win.", [["frustration", "PROBLEM", 15, 26]]]], "PMC7266127": [["BackgroundNeurogenic pulmonary edema (NPE) is characterized by the development of pulmonary edema within minutes to hours of a significant central nervous system (CNS) insult, often resolving spontaneously within 24\u201348 h [1\u20133].", [["Neurogenic pulmonary edema", "ANATOMY", 10, 36], ["NPE", "ANATOMY", 38, 41], ["pulmonary", "ANATOMY", 82, 91], ["central nervous system", "ANATOMY", 139, 161], ["CNS", "ANATOMY", 163, 166], ["Neurogenic pulmonary edema", "DISEASE", 10, 36], ["NPE", "DISEASE", 38, 41], ["pulmonary edema", "DISEASE", 82, 97], ["central nervous system (CNS) insult", "DISEASE", 139, 174], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 21, 36], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 82, 97], ["central nervous system", "ANATOMICAL_SYSTEM", 139, 161], ["CNS", "ANATOMICAL_SYSTEM", 163, 166], ["BackgroundNeurogenic pulmonary edema", "PROBLEM", 0, 36], ["pulmonary edema", "PROBLEM", 82, 97], ["a significant central nervous system (CNS) insult", "PROBLEM", 125, 174], ["Neurogenic", "OBSERVATION_MODIFIER", 10, 20], ["pulmonary", "ANATOMY", 21, 30], ["edema", "OBSERVATION", 31, 36], ["pulmonary", "ANATOMY", 82, 91], ["edema", "OBSERVATION", 92, 97], ["significant", "OBSERVATION_MODIFIER", 127, 138], ["central", "ANATOMY_MODIFIER", 139, 146], ["nervous system", "ANATOMY", 147, 161], ["CNS", "ANATOMY", 163, 166]]], ["Febrile seizures (FS) is the most common convulsive event, affecting 2\u20135% of children younger than 60 months [4\u20137].", [["Febrile seizures", "DISEASE", 0, 16], ["FS", "DISEASE", 18, 20], ["convulsive", "DISEASE", 41, 51], ["children", "ORGANISM", 77, 85], ["children", "SPECIES", 77, 85], ["Febrile seizures", "PROBLEM", 0, 16]]], ["The majority of FS cases follow a benign clinical course; however, approximately 5\u20138% of FS cases develop status epilepticus (SE) [8, 9].", [["status epilepticus", "DISEASE", 106, 124], ["SE", "DISEASE", 126, 128], ["FS cases", "TEST", 16, 24], ["FS cases", "TEST", 89, 97], ["status epilepticus", "PROBLEM", 106, 124]]], ["NPE following febrile SE in children is a rare complication, although its incidence rate might be underestimated [10\u201313].BackgroundMolecular biological diagnostic methods such as multiplex PCR and next generation sequencing (NGS) can detect pathogens from clinical specimens with high sensitivity; this also leads to co-detection of multiple pathogens from the same clinical specimen.", [["specimens", "ANATOMY", 265, 274], ["specimen", "ANATOMY", 375, 383], ["NPE", "CHEMICAL", 0, 3], ["febrile SE", "DISEASE", 14, 24], ["children", "ORGANISM", 28, 36], ["children", "SPECIES", 28, 36], ["NPE", "PROBLEM", 0, 3], ["febrile", "PROBLEM", 14, 21], ["a rare complication", "PROBLEM", 40, 59], ["multiplex PCR", "TEST", 179, 192], ["next generation sequencing", "TREATMENT", 197, 223], ["pathogens", "PROBLEM", 241, 250], ["clinical specimens", "TEST", 256, 274], ["high sensitivity", "PROBLEM", 280, 296], ["multiple pathogens", "PROBLEM", 333, 351], ["multiple", "OBSERVATION_MODIFIER", 333, 341], ["pathogens", "OBSERVATION", 342, 351]]], ["With the increased application of multiplex PCR in clinical settings, there have been reports of multiple pathogen co-detection rates from 10 to 50% of human respiratory specimens [14\u201317].", [["respiratory specimens", "ANATOMY", 158, 179], ["human", "ORGANISM", 152, 157], ["human", "SPECIES", 152, 157], ["human", "SPECIES", 152, 157], ["multiplex PCR", "TEST", 34, 47], ["multiple pathogen co-detection rates", "PROBLEM", 97, 133], ["human respiratory specimens", "TEST", 152, 179], ["increased", "OBSERVATION_MODIFIER", 9, 18], ["multiple", "OBSERVATION_MODIFIER", 97, 105], ["pathogen", "OBSERVATION", 106, 114]]], ["It has also been revealed that multiple pathogens, both viral and bacterial, are prevalent even in respiratory specimens from healthy, asymptomatic children [14, 18].", [["respiratory specimens", "ANATOMY", 99, 120], ["children", "ORGANISM", 148, 156], ["children", "SPECIES", 148, 156], ["multiple pathogens", "PROBLEM", 31, 49], ["both viral and bacterial", "PROBLEM", 51, 75], ["multiple", "OBSERVATION_MODIFIER", 31, 39], ["pathogens", "OBSERVATION", 40, 49], ["viral", "OBSERVATION_MODIFIER", 56, 61], ["bacterial", "OBSERVATION_MODIFIER", 66, 75]]], ["The interaction among co-detected multiple pathogens and their association with clinical symptoms remain controversial [17, 20\u201323].BackgroundWe report the case of a 22-month-old girl with febrile SE who developed acute respiratory failure due to NPE.", [["respiratory", "ANATOMY", 219, 230], ["febrile SE", "DISEASE", 188, 198], ["acute respiratory failure", "DISEASE", 213, 238], ["NPE", "CHEMICAL", 246, 249], ["girl", "ORGANISM", 178, 182], ["girl", "SPECIES", 178, 182], ["multiple pathogens", "PROBLEM", 34, 52], ["clinical symptoms", "PROBLEM", 80, 97], ["febrile SE", "PROBLEM", 188, 198], ["acute respiratory failure", "PROBLEM", 213, 238], ["NPE", "PROBLEM", 246, 249], ["multiple", "OBSERVATION_MODIFIER", 34, 42], ["pathogens", "OBSERVATION", 43, 52], ["acute", "OBSERVATION_MODIFIER", 213, 218], ["respiratory failure", "OBSERVATION", 219, 238], ["NPE", "OBSERVATION", 246, 249]]], ["We also describe the co-detection of three respiratory viruses from the patient\u2019s nasopharyngeal specimens using molecular biological diagnostic methods.BackgroundThe Institutional Medical Ethics Committee of the National Institute of Infectious Diseases and the Ethics Committee of Showa General Hospital approved this study (Approval Nos. 553 and 677, and REC-094, respectively).", [["nasopharyngeal specimens", "ANATOMY", 82, 106], ["Infectious Diseases", "DISEASE", 235, 254], ["patient", "ORGANISM", 72, 79], ["nasopharyngeal specimens", "CANCER", 82, 106], ["patient", "SPECIES", 72, 79], ["three respiratory viruses", "PROBLEM", 37, 62], ["nasopharyngeal specimens", "TEST", 82, 106], ["this study", "TEST", 315, 325], ["respiratory viruses", "OBSERVATION", 43, 62], ["nasopharyngeal", "ANATOMY", 82, 96], ["Infectious", "OBSERVATION", 235, 245]]], ["The patient\u2019s parents provided written informed consent for analysis of the patient\u2019s clinical specimens and publication of this case report.Case presentationThe patient is a previously healthy 22-month-old girl without perinatal abnormalities or personal or family history of seizure.", [["seizure", "DISEASE", 277, 284], ["patient", "ORGANISM", 4, 11], ["patient", "ORGANISM", 76, 83], ["patient", "ORGANISM", 162, 169], ["girl", "ORGANISM", 207, 211], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 76, 83], ["patient", "SPECIES", 162, 169], ["girl", "SPECIES", 207, 211], ["perinatal abnormalities", "PROBLEM", 220, 243], ["seizure", "PROBLEM", 277, 284]]], ["The patient had not been to any nursery school prior to the event.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["She had two siblings, 11 and 5 years old, who had no respiratory symptoms.", [["respiratory", "ANATOMY", 53, 64], ["respiratory symptoms", "DISEASE", 53, 73], ["respiratory symptoms", "PROBLEM", 53, 73], ["no", "UNCERTAINTY", 50, 52], ["respiratory", "ANATOMY", 53, 64], ["symptoms", "OBSERVATION", 65, 73]]], ["Clonic seizure of the patient\u2019s right side commenced 12 h after fever development, followed by generalized tonic and tonic-clonic seizures without self-resolution.", [["seizure", "DISEASE", 7, 14], ["fever", "DISEASE", 64, 69], ["seizures", "DISEASE", 130, 138], ["patient", "ORGANISM", 22, 29], ["patient", "SPECIES", 22, 29], ["Clonic seizure", "PROBLEM", 0, 14], ["fever development", "PROBLEM", 64, 81], ["generalized tonic and tonic-clonic seizures", "PROBLEM", 95, 138], ["self-resolution", "PROBLEM", 147, 162], ["right", "ANATOMY_MODIFIER", 32, 37]]], ["The seizure activity had persisted for 40 min when the patient arrived at our emergency room (ER) by ambulance.", [["seizure", "DISEASE", 4, 11], ["patient", "ORGANISM", 55, 62], ["patient", "SPECIES", 55, 62], ["The seizure activity", "PROBLEM", 0, 20]]], ["Spontaneous breathing was absent with SpO2 of 50% upon ER arrival.", [["ER", "GENE_OR_GENE_PRODUCT", 55, 57], ["ER", "PROTEIN", 55, 57], ["SpO2", "TEST", 38, 42]]], ["Bag valve mask (BVM) ventilation supplied with 100% oxygen was commenced immediately, and SpO2 increased to 92%.", [["Bag valve", "ANATOMY", 0, 9], ["BVM", "ANATOMY", 16, 19], ["oxygen", "CHEMICAL", 52, 58], ["oxygen", "CHEMICAL", 52, 58], ["oxygen", "SIMPLE_CHEMICAL", 52, 58], ["Bag valve mask", "TREATMENT", 0, 14], ["BVM) ventilation", "TREATMENT", 16, 32], ["100% oxygen", "TREATMENT", 47, 58], ["SpO2", "TEST", 90, 94], ["valve mask", "OBSERVATION", 4, 14]]], ["The seizure activity was terminated by intravenous administration of 0.2 mg/kg of midazolam and 2 \u03bcg/kg of fentanyl.", [["intravenous", "ANATOMY", 39, 50], ["seizure", "DISEASE", 4, 11], ["midazolam", "CHEMICAL", 82, 91], ["fentanyl", "CHEMICAL", 107, 115], ["midazolam", "CHEMICAL", 82, 91], ["fentanyl", "CHEMICAL", 107, 115], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 39, 50], ["midazolam", "SIMPLE_CHEMICAL", 82, 91], ["fentanyl", "SIMPLE_CHEMICAL", 107, 115], ["The seizure activity", "PROBLEM", 0, 20], ["midazolam", "TREATMENT", 82, 91], ["fentanyl", "TREATMENT", 107, 115]]], ["Her vital signs upon seizure termination were as follows: Glasgow Coma Scale (GCS) of 3 (eyes 1, verbal 1, motor 1), pupils 3 mm in diameter and reactive to light stimuli bilaterally, body temperature 38.2 \u00b0C, heart rate 185 beats per minute (bpm), systolic blood pressure 107 mmHg, diastolic blood pressure 60 mmHg, and SpO2 99% under BVM ventilation with 100% oxygen supplementation.", [["eyes", "ANATOMY", 89, 93], ["body", "ANATOMY", 184, 188], ["heart", "ANATOMY", 210, 215], ["blood", "ANATOMY", 258, 263], ["blood", "ANATOMY", 293, 298], ["seizure", "DISEASE", 21, 28], ["Coma", "DISEASE", 66, 70], ["oxygen", "CHEMICAL", 362, 368], ["oxygen", "CHEMICAL", 362, 368], ["body", "ORGANISM_SUBDIVISION", 184, 188], ["heart", "ORGAN", 210, 215], ["blood", "ORGANISM_SUBSTANCE", 258, 263], ["blood", "ORGANISM_SUBSTANCE", 293, 298], ["oxygen", "SIMPLE_CHEMICAL", 362, 368], ["Her vital signs", "TEST", 0, 15], ["seizure termination", "TEST", 21, 40], ["Glasgow Coma Scale", "TEST", 58, 76], ["GCS", "TEST", 78, 81], ["light stimuli", "TEST", 157, 170], ["body temperature", "TEST", 184, 200], ["\u00b0C", "TEST", 206, 208], ["heart rate", "TEST", 210, 220], ["bpm", "TEST", 243, 246], ["systolic blood pressure", "TEST", 249, 272], ["diastolic blood pressure", "TEST", 283, 307], ["SpO2", "TEST", 321, 325], ["BVM ventilation", "TREATMENT", 336, 351], ["100% oxygen supplementation", "TREATMENT", 357, 384], ["reactive", "OBSERVATION_MODIFIER", 145, 153], ["bilaterally", "ANATOMY_MODIFIER", 171, 182]]], ["The patient remained apneic, and SpO2 quickly dropped to 50% when BVM ventilation was temporally interrupted.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["apneic", "PROBLEM", 21, 27], ["SpO2", "TEST", 33, 37], ["BVM ventilation", "TREATMENT", 66, 81], ["apneic", "OBSERVATION", 21, 27]]], ["Venous blood gas analysis revealed respiratory and metabolic acidosis.", [["Venous blood", "ANATOMY", 0, 12], ["respiratory", "ANATOMY", 35, 46], ["respiratory and metabolic acidosis", "DISEASE", 35, 69], ["Venous", "ORGANISM_SUBSTANCE", 0, 6], ["blood", "ORGANISM_SUBSTANCE", 7, 12], ["Venous blood gas analysis", "TEST", 0, 25], ["respiratory and metabolic acidosis", "PROBLEM", 35, 69], ["respiratory", "ANATOMY", 35, 46], ["metabolic acidosis", "OBSERVATION", 51, 69]]], ["An endotracheal tube of 4 mm in diameter was inserted for airway protection.", [["endotracheal tube", "ANATOMY", 3, 20], ["airway", "ANATOMY", 58, 64], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 3, 20], ["airway", "MULTI-TISSUE_STRUCTURE", 58, 64], ["An endotracheal tube", "TREATMENT", 0, 20], ["airway protection", "TREATMENT", 58, 75], ["endotracheal tube", "OBSERVATION", 3, 20], ["4 mm", "OBSERVATION_MODIFIER", 24, 28], ["airway protection", "OBSERVATION", 58, 75]]], ["Copious pink frothy airway secretions were identified upon intubation, and the discharge continued until the application of mechanical ventilation with positive end-expiratory pressure (PEEP) of 6 cmH2O.", [["airway", "ANATOMY", 20, 26], ["Copious pink frothy airway secretions", "PROBLEM", 0, 37], ["intubation", "TREATMENT", 59, 69], ["mechanical ventilation", "TREATMENT", 124, 146], ["positive end-expiratory pressure", "TREATMENT", 152, 184], ["PEEP", "TREATMENT", 186, 190], ["pink", "OBSERVATION_MODIFIER", 8, 12], ["frothy airway secretions", "OBSERVATION", 13, 37]]], ["SpO2 was maintained above 95% after introduction of mechanical ventilation.", [["SpO2", "TEST", 0, 4], ["mechanical ventilation", "TREATMENT", 52, 74], ["mechanical ventilation", "OBSERVATION", 52, 74]]], ["There were no apparent injuries or hemorrhage in the oral and nasopharyngeal cavities, nor was there laryngeal edema or airway obstruction.Case presentationChest auscultation revealed bilateral coarse crackles, but no heart murmur was detected.", [["oral", "ANATOMY", 53, 57], ["nasopharyngeal cavities", "ANATOMY", 62, 85], ["laryngeal edema", "ANATOMY", 101, 116], ["airway", "ANATOMY", 120, 126], ["heart", "ANATOMY", 218, 223], ["injuries", "DISEASE", 23, 31], ["hemorrhage", "DISEASE", 35, 45], ["edema", "DISEASE", 111, 116], ["airway obstruction", "DISEASE", 120, 138], ["heart murmur", "DISEASE", 218, 230], ["oral", "ORGANISM_SUBDIVISION", 53, 57], ["nasopharyngeal cavities", "MULTI-TISSUE_STRUCTURE", 62, 85], ["laryngeal edema", "PATHOLOGICAL_FORMATION", 101, 116], ["airway obstruction", "PATHOLOGICAL_FORMATION", 120, 138], ["heart", "ORGAN", 218, 223], ["apparent injuries", "PROBLEM", 14, 31], ["hemorrhage in the oral and nasopharyngeal cavities", "PROBLEM", 35, 85], ["laryngeal edema", "PROBLEM", 101, 116], ["airway obstruction", "PROBLEM", 120, 138], ["Chest auscultation", "TEST", 156, 174], ["bilateral coarse crackles", "PROBLEM", 184, 209], ["heart murmur", "PROBLEM", 218, 230], ["no apparent", "UNCERTAINTY", 11, 22], ["injuries", "OBSERVATION", 23, 31], ["hemorrhage", "OBSERVATION", 35, 45], ["oral", "ANATOMY", 53, 57], ["nasopharyngeal cavities", "ANATOMY", 62, 85], ["laryngeal", "ANATOMY", 101, 110], ["edema", "OBSERVATION", 111, 116], ["airway", "ANATOMY", 120, 126], ["obstruction", "OBSERVATION", 127, 138], ["bilateral", "ANATOMY_MODIFIER", 184, 193], ["coarse", "OBSERVATION_MODIFIER", 194, 200], ["crackles", "OBSERVATION", 201, 209], ["no", "UNCERTAINTY", 215, 217], ["heart", "ANATOMY", 218, 223], ["murmur", "OBSERVATION", 224, 230]]], ["An abdominal examination revealed no hepatomegaly or splenomegaly.", [["abdominal", "ANATOMY", 3, 12], ["hepatomegaly", "DISEASE", 37, 49], ["splenomegaly", "DISEASE", 53, 65], ["abdominal", "ORGAN", 3, 12], ["splenomegaly", "PATHOLOGICAL_FORMATION", 53, 65], ["An abdominal examination", "TEST", 0, 24], ["hepatomegaly", "PROBLEM", 37, 49], ["splenomegaly", "PROBLEM", 53, 65], ["abdominal", "ANATOMY", 3, 12], ["no", "UNCERTAINTY", 34, 36], ["hepatomegaly", "OBSERVATION", 37, 49], ["splenomegaly", "OBSERVATION", 53, 65]]], ["Chest radiography showed bilateral, centrally distributed opacities without cardiac dilation (Fig. 1a).", [["opacities", "ANATOMY", 58, 67], ["cardiac", "ANATOMY", 76, 83], ["opacities", "DISEASE", 58, 67], ["cardiac dilation", "DISEASE", 76, 92], ["cardiac", "ORGAN", 76, 83], ["Chest radiography", "TEST", 0, 17], ["bilateral, centrally distributed opacities", "PROBLEM", 25, 67], ["cardiac dilation", "PROBLEM", 76, 92], ["bilateral", "ANATOMY_MODIFIER", 25, 34], ["centrally", "OBSERVATION_MODIFIER", 36, 45], ["distributed", "OBSERVATION_MODIFIER", 46, 57], ["opacities", "OBSERVATION", 58, 67], ["without", "UNCERTAINTY", 68, 75], ["cardiac", "ANATOMY", 76, 83], ["dilation", "OBSERVATION", 84, 92]]], ["Echocardiography demonstrated normal cardiac wall motion with ejection fraction of 69% and non-pathological trivial tricuspid regurgitation.", [["cardiac wall", "ANATOMY", 37, 49], ["tricuspid", "ANATOMY", 116, 125], ["tricuspid regurgitation", "DISEASE", 116, 139], ["cardiac wall", "TISSUE", 37, 49], ["tricuspid", "PATHOLOGICAL_FORMATION", 116, 125], ["Echocardiography", "TEST", 0, 16], ["ejection fraction", "TEST", 62, 79], ["non-pathological trivial tricuspid regurgitation", "PROBLEM", 91, 139], ["normal", "OBSERVATION", 30, 36], ["cardiac", "ANATOMY", 37, 44], ["wall", "ANATOMY_MODIFIER", 45, 49], ["motion", "OBSERVATION", 50, 56], ["ejection fraction", "OBSERVATION", 62, 79], ["trivial tricuspid regurgitation", "OBSERVATION", 108, 139]]], ["An electrocardiogram revealed sinus tachycardia of 151 bpm without significant ST-T changes, atrial overload, or ventricular hypertrophy.", [["sinus", "ANATOMY", 30, 35], ["atrial", "ANATOMY", 93, 99], ["ventricular", "ANATOMY", 113, 124], ["sinus tachycardia", "DISEASE", 30, 47], ["atrial overload", "DISEASE", 93, 108], ["ventricular hypertrophy", "DISEASE", 113, 136], ["atrial", "MULTI-TISSUE_STRUCTURE", 93, 99], ["ventricular", "MULTI-TISSUE_STRUCTURE", 113, 124], ["An electrocardiogram", "TEST", 0, 20], ["sinus tachycardia", "PROBLEM", 30, 47], ["significant ST-T changes", "PROBLEM", 67, 91], ["atrial overload", "PROBLEM", 93, 108], ["ventricular hypertrophy", "PROBLEM", 113, 136], ["sinus", "ANATOMY", 30, 35], ["tachycardia", "OBSERVATION", 36, 47], ["atrial", "ANATOMY", 93, 99], ["overload", "OBSERVATION", 100, 108], ["ventricular", "ANATOMY", 113, 124], ["hypertrophy", "OBSERVATION", 125, 136]]], ["Laboratory examinations revealed a mildly elevated white blood cell count, hyperglycemia, hyperammonemia, acidemia, hypercapnia, and lactic acidosis (Table 1).", [["white blood cell", "ANATOMY", 51, 67], ["elevated white blood cell count", "DISEASE", 42, 73], ["hyperglycemia", "DISEASE", 75, 88], ["hyperammonemia", "DISEASE", 90, 104], ["acidemia", "DISEASE", 106, 114], ["hypercapnia", "DISEASE", 116, 127], ["lactic acidosis", "DISEASE", 133, 148], ["blood cell", "CELL", 57, 67], ["Laboratory examinations", "TEST", 0, 23], ["a mildly elevated white blood cell count", "PROBLEM", 33, 73], ["hyperglycemia", "PROBLEM", 75, 88], ["hyperammonemia", "PROBLEM", 90, 104], ["acidemia", "PROBLEM", 106, 114], ["hypercapnia", "PROBLEM", 116, 127], ["lactic acidosis", "PROBLEM", 133, 148], ["mildly", "OBSERVATION_MODIFIER", 35, 41], ["elevated", "OBSERVATION_MODIFIER", 42, 50], ["hyperglycemia", "OBSERVATION_MODIFIER", 75, 88], ["hyperammonemia", "OBSERVATION", 90, 104], ["acidemia", "OBSERVATION", 106, 114], ["hypercapnia", "OBSERVATION_MODIFIER", 116, 127], ["lactic acidosis", "OBSERVATION", 133, 148]]], ["Creatine kinase (CK), platelet count and coagulation times were within normal limits.", [["platelet", "ANATOMY", 22, 30], ["Creatine", "CHEMICAL", 0, 8], ["Creatine", "CHEMICAL", 0, 8], ["Creatine kinase", "GENE_OR_GENE_PRODUCT", 0, 15], ["CK", "GENE_OR_GENE_PRODUCT", 17, 19], ["platelet", "CELL", 22, 30], ["Creatine kinase", "PROTEIN", 0, 15], ["CK", "PROTEIN", 17, 19], ["Creatine kinase", "TEST", 0, 15], ["CK", "TEST", 17, 19], ["platelet count", "TEST", 22, 36], ["coagulation times", "TEST", 41, 58], ["normal limits", "OBSERVATION", 71, 84]]], ["Computed tomography (CT) of the head revealed no abnormal findings, and continuous electroencephalography (EEG) findings did not suggest encephalopathy.", [["head", "ANATOMY", 32, 36], ["encephalopathy", "DISEASE", 137, 151], ["head", "ORGAN", 32, 36], ["Computed tomography (CT) of the head", "TEST", 0, 36], ["abnormal findings", "PROBLEM", 49, 66], ["continuous electroencephalography", "TEST", 72, 105], ["EEG", "TEST", 107, 110], ["encephalopathy", "PROBLEM", 137, 151], ["head", "ANATOMY", 32, 36], ["no", "UNCERTAINTY", 46, 48], ["abnormal", "OBSERVATION_MODIFIER", 49, 57], ["encephalopathy", "OBSERVATION", 137, 151]]], ["A cerebrospinal fluid examination revealed no elevation in cell counts.", [["cerebrospinal fluid", "ANATOMY", 2, 21], ["cell", "ANATOMY", 59, 63], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 2, 21], ["cell", "CELL", 59, 63], ["A cerebrospinal fluid examination", "TEST", 0, 33], ["elevation in cell counts", "PROBLEM", 46, 70], ["cerebrospinal", "ANATOMY", 2, 15], ["fluid", "OBSERVATION", 16, 21], ["no", "UNCERTAINTY", 43, 45], ["elevation", "OBSERVATION_MODIFIER", 46, 55], ["cell counts", "OBSERVATION", 59, 70]]], ["Rapid immunochromatographic tests of nasopharyngeal specimen for influenza A and B viruses were negative.", [["nasopharyngeal specimen", "ANATOMY", 37, 60], ["nasopharyngeal specimen", "CANCER", 37, 60], ["influenza A", "ORGANISM", 65, 76], ["B viruses", "ORGANISM", 81, 90], ["influenza A", "SPECIES", 65, 76], ["B viruses", "SPECIES", 81, 90], ["Rapid immunochromatographic tests", "TEST", 0, 33], ["nasopharyngeal specimen", "TEST", 37, 60], ["influenza", "PROBLEM", 65, 74], ["B viruses", "PROBLEM", 81, 90], ["nasopharyngeal", "ANATOMY", 37, 51]]]], "PMC7102028": [["BegriffsbestimmungenDa es viele verschiedene Begriffe rund um das Thema tempor\u00e4re Lungen- und Herz-Kreislauf-Ersatzverfahren gibt und diese h\u00e4ufig irref\u00fchrend sowie uneinheitlich sind, hat die Deutsche Interdisziplin\u00e4re Vereinigung f\u00fcr Intensivmedizin (DIVI) sich auf die im Folgenden ausgef\u00fchrten Empfehlungen geeinigt ([1]; Abb.", [["BegriffsbestimmungenDa es viele verschiedene Begriffe rund um das Thema tempor\u00e4re Lungen- und Herz-Kreislauf-Ersatzverfahren gibt und diese h\u00e4ufig irref\u00fchrend sowie uneinheitlich sind, hat die Deutsche Interdisziplin\u00e4re Vereinigung f\u00fcr Intensivmedizin (DIVI) sich auf die im Folgenden ausgef\u00fchrten Empfehlungen geeinigt", "SPECIES", 0, 319], ["BegriffsbestimmungenDa", "TEST", 0, 22], ["Lungen", "TEST", 82, 88], ["Herz-Kreislauf", "TEST", 94, 108], ["Intensivmedizin (DIVI) sich auf die", "TREATMENT", 236, 271]]], ["1):BegriffsbestimmungenAls \u201eextracorporeal membrane oxygenation\u201c (ECMO) wird die venoven\u00f6s angeschlossene, pumpenbetriebene Lungenunterst\u00fctzungstherapie mit Oxygenator bezeichnet.", [["membrane", "ANATOMY", 43, 51], ["BegriffsbestimmungenAls \u201eextracorporeal membrane oxygenation", "TREATMENT", 3, 63], ["ECMO)", "TREATMENT", 66, 71], ["mit Oxygenator bezeichnet", "TREATMENT", 153, 178], ["membrane oxygenation", "OBSERVATION", 43, 63]]], ["Sie zeichnet sich durch Oxygenierung sowie Decarboxylierung aus dem ven\u00f6sen Blut aus und wird zur Therapie von konservativ nichtbeherrschbarem, hpyox\u00e4mischem Lungenversagen eingesetzt.", [["Sie zeichnet sich durch Oxygenierung sowie Decarboxylierung aus dem ven\u00f6sen Blut aus und wird zur Therapie von konservativ nichtbeherrschbarem, hpyox\u00e4mischem Lungenversagen eingesetzt", "SPECIES", 0, 183], ["Sie zeichnet sich durch", "TREATMENT", 0, 23]]], ["Eine Herz-Kreislauf-Unterst\u00fctzung ist mit diesem Verfahren aufgrund der Kan\u00fclierung nicht m\u00f6glich.BegriffsbestimmungenAbzugrenzen davon ist die \u201epumpless extracorporeal lung assist\u201c (pECLA), ein arterioven\u00f6s angeschlossenes, nichtpumpenbetriebenes Lungenunterst\u00fctzungsystem mit einem \u201eLow-resistance\u201c-Oxygenator, das aufgrund der arterioven\u00f6sen Blutdruckdifferenz und damit abh\u00e4ngig vom Herzzeitvolumen (HZV) des Patienten eine suffiziente Decarboxylierung, jedoch keine ausreichende Oxygenierung gew\u00e4hrleistet.", [["lung", "ANATOMY", 169, 173], ["lung", "ORGAN", 169, 173], ["Eine Herz-Kreislauf-Unterst\u00fctzung ist mit diesem Verfahren aufgrund der Kan\u00fclierung nicht m\u00f6glich", "SPECIES", 0, 97], ["BegriffsbestimmungenAbzugrenzen davon ist die \u201epumpless extracorporeal lung assist\u201c (pECLA), ein arterioven\u00f6s angeschlossenes, nichtpumpenbetriebenes Lungenunterst\u00fctzungsystem mit einem \u201eLow-resistance\u201c-Oxygenator, das aufgrund der arterioven\u00f6sen Blutdruckdifferenz und damit abh\u00e4ngig vom Herzzeitvolumen (HZV) des Patienten eine suffiziente Decarboxylierung, jedoch keine ausreichende Oxygenierung gew\u00e4hrleistet", "SPECIES", 98, 510], ["BegriffsbestimmungenAbzugrenzen davon", "TREATMENT", 98, 135], ["extracorporeal lung assist", "TREATMENT", 154, 180], ["ein arterioven\u00f6s angeschlossenes", "TREATMENT", 191, 223], ["nichtpumpenbetriebenes", "TREATMENT", 225, 247], ["Oxygenator", "TREATMENT", 301, 311], ["das aufgrund der arterioven\u00f6sen Blutdruckdifferenz", "TREATMENT", 313, 363], ["Herzzeitvolumen (HZV)", "TREATMENT", 387, 408], ["des Patienten eine suffiziente Decarboxylierung", "TREATMENT", 409, 456], ["lung", "ANATOMY", 169, 173]]], ["Somit wird dieses System nahezu ausschlie\u00dflich beim prim\u00e4r hyperkapnischen Lungenversagen eingesetzt.BegriffsbestimmungenAls \u201eextracorporeal life support\u201c (ECLS) \u2013 fr\u00fcher u. a. als venoarterielle ECMO bezeichnet \u2013 wird ein venoarteriell angeschlossenes pumpenbetriebenes Herz-Kreislauf-Unterst\u00fctzungsystem bezeichnet, das nicht nur den Gasaustausch gew\u00e4hrleistet, sondern nahezu das gesamte HZV des Patienten \u00fcbernehmen kann.Aufbau ::: \u201eExtracorporeal membrane oxygenation\u201cPrinzipiell besteht ein ECMO-System aus folgenden Komponenten (Abb.", [["Extracorporeal membrane", "ANATOMY", 437, 460], ["a. als venoarterielle ECMO bezeichnet \u2013 wird ein venoarteriell angeschlossenes pumpenbetriebenes Herz-Kreislauf-Unterst\u00fctzungsystem bezeichnet, das nicht nur den Gasaustausch gew\u00e4hrleistet, sondern nahezu das gesamte HZV des Patienten \u00fcbernehmen kann", "SPECIES", 174, 424], ["ECMO", "TEST", 196, 200], ["bezeichnet", "TEST", 201, 211], ["Extracorporeal membrane oxygenation", "TREATMENT", 437, 472], ["Prinzipiell besteht ein ECMO", "TREATMENT", 473, 501], ["Extracorporeal", "ANATOMY_MODIFIER", 437, 451], ["membrane oxygenation", "OBSERVATION", 452, 472]]], ["2):extrakorporaler Blutkreislauf mit Entnahme- und R\u00fcckgabekan\u00fclen und einem in der Regel heparinbeschichteten Schlauchsystem,Pumpe (in der Regel Zentrifugalpumpe) mit Steuereinheit sowieOxygenator mit W\u00e4rmetauscher.", [["extrakorporaler Blutkreislauf mit Entnahme", "TREATMENT", 3, 45]]]], "PMC3355321": [["Chemicals. ::: ::: ::: MATERIALS AND METHODSDON, anisomycin, PKR inhibitor C-16, and Hck inhibitor PP1 were purchased from Sigma-Aldrich (St Louis, MO).", [["anisomycin", "CHEMICAL", 49, 59], ["C-16", "CHEMICAL", 75, 79], ["anisomycin", "CHEMICAL", 49, 59], ["C-16", "CHEMICAL", 75, 79], ["PP1", "CHEMICAL", 99, 102], ["anisomycin", "SIMPLE_CHEMICAL", 49, 59], ["PKR", "GENE_OR_GENE_PRODUCT", 61, 64], ["C-16", "SIMPLE_CHEMICAL", 75, 79], ["Hck", "GENE_OR_GENE_PRODUCT", 85, 88], ["PP1", "GENE_OR_GENE_PRODUCT", 99, 102], ["Sigma-Aldrich", "ORGANISM", 123, 136], ["St Louis, MO", "ORGANISM", 138, 150], ["PKR", "PROTEIN", 61, 64], ["Hck", "PROTEIN", 85, 88], ["PP1", "PROTEIN", 99, 102], ["METHODSDON", "TREATMENT", 37, 47], ["anisomycin", "TREATMENT", 49, 59], ["PKR inhibitor C", "TEST", 61, 76], ["Hck inhibitor PP1", "TREATMENT", 85, 102]]], ["Ricin was obtained from Vector Labs Inc. (Burlingame, CA).", [["Ricin", "CHEMICAL", 0, 5], ["Ricin", "CHEMICAL", 0, 5], ["Ricin", "SIMPLE_CHEMICAL", 0, 5], ["Burlingame", "GENE_OR_GENE_PRODUCT", 42, 52], ["CA", "GENE_OR_GENE_PRODUCT", 54, 56]]], ["The p38 inhibitor SB 203580, JNK inhibitor SP600125, ERK inhibitor PD 98059, RNase L Activator, p53 inhibitor pifithrin-\u03b1, and pifithrin-\u03bc were purchased from EMD Chemicals Inc. (Gibbstown, NJ).", [["SB 203580", "CHEMICAL", 18, 27], ["SP600125", "CHEMICAL", 43, 51], ["PD 98059", "CHEMICAL", 67, 75], ["pifithrin-\u03b1", "CHEMICAL", 110, 121], ["pifithrin-\u03bc", "CHEMICAL", 127, 138], ["SB 203580", "CHEMICAL", 18, 27], ["SP600125", "CHEMICAL", 43, 51], ["PD 98059", "CHEMICAL", 67, 75], ["pifithrin-\u03b1", "CHEMICAL", 110, 121], ["pifithrin-\u03bc", "CHEMICAL", 127, 138], ["p38", "GENE_OR_GENE_PRODUCT", 4, 7], ["SB 203580", "SIMPLE_CHEMICAL", 18, 27], ["JNK", "GENE_OR_GENE_PRODUCT", 29, 32], ["SP600125", "SIMPLE_CHEMICAL", 43, 51], ["ERK", "GENE_OR_GENE_PRODUCT", 53, 56], ["PD 98059", "SIMPLE_CHEMICAL", 67, 75], ["RNase L Activator", "GENE_OR_GENE_PRODUCT", 77, 94], ["p53", "GENE_OR_GENE_PRODUCT", 96, 99], ["pifithrin-\u03b1", "SIMPLE_CHEMICAL", 110, 121], ["pifithrin-\u03bc", "SIMPLE_CHEMICAL", 127, 138], ["JNK", "PROTEIN", 29, 32], ["RNase L Activator", "PROTEIN", 77, 94], ["p53", "PROTEIN", 96, 99], ["The p38 inhibitor SB", "TEST", 0, 20], ["JNK inhibitor SP600125", "TEST", 29, 51], ["ERK inhibitor PD", "TREATMENT", 53, 69], ["RNase L Activator", "TREATMENT", 77, 94], ["p53 inhibitor pifithrin", "TREATMENT", 96, 119], ["pifithrin", "TREATMENT", 127, 136]]], ["Pan caspase inhibitor Z-VAD-FMK was supplied by BD Biosciences (San Diego, CA). [\u03b3-32P]ATP was purchased from PerkinElmer.", [["Z-VAD-FMK", "CHEMICAL", 22, 31], ["[\u03b3-32P", "CHEMICAL", 80, 86], ["ATP", "CHEMICAL", 87, 90], ["Z-VAD-FMK", "CHEMICAL", 22, 31], ["[\u03b3-32P]ATP", "CHEMICAL", 80, 90], ["caspase", "GENE_OR_GENE_PRODUCT", 4, 11], ["Z-VAD-FMK", "SIMPLE_CHEMICAL", 22, 31], ["[\u03b3-32P]ATP", "SIMPLE_CHEMICAL", 80, 90], ["Pan caspase inhibitor Z", "TREATMENT", 0, 23], ["VAD", "TREATMENT", 24, 27], ["FMK", "TREATMENT", 28, 31], ["ATP", "TREATMENT", 87, 90]]], ["All other chemicals and media components were obtained from Sigma-Aldrich, except where noted.Cell culture. ::: ::: ::: MATERIALS AND METHODSRAW 264.7 cells (ATCC, Rockville, MD) were cultured in Dulbecco\u2019s modified Eagle\u2019s medium supplemented with 10% (vol/vol) heat-inactivated fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA), streptomycin (100 \u03bcg/ml), and penicillin (100 U/ml) at 37\u00b0C in a humidified incubator with 5% CO2.", [["Cell", "ANATOMY", 94, 98], ["264.7 cells", "ANATOMY", 145, 156], ["ATCC", "ANATOMY", 158, 162], ["serum", "ANATOMY", 293, 298], ["streptomycin", "CHEMICAL", 341, 353], ["penicillin", "CHEMICAL", 371, 381], ["CO2", "CHEMICAL", 435, 438], ["streptomycin", "CHEMICAL", 341, 353], ["penicillin", "CHEMICAL", 371, 381], ["CO2", "CHEMICAL", 435, 438], ["Sigma-Aldrich", "ORGANISM", 60, 73], ["Cell", "CELL", 94, 98], ["METHODSRAW 264.7 cells", "CELL", 134, 156], ["ATCC", "CELL", 158, 162], ["bovine", "ORGANISM", 286, 292], ["serum", "ORGANISM_SUBSTANCE", 293, 298], ["Lawrenceville", "SIMPLE_CHEMICAL", 321, 334], ["GA", "SIMPLE_CHEMICAL", 336, 338], ["streptomycin", "SIMPLE_CHEMICAL", 341, 353], ["penicillin", "SIMPLE_CHEMICAL", 371, 381], ["C", "SIMPLE_CHEMICAL", 399, 400], ["CO2", "SIMPLE_CHEMICAL", 435, 438], ["METHODSRAW 264.7 cells", "CELL_LINE", 134, 156], ["bovine", "SPECIES", 286, 292], ["bovine", "SPECIES", 286, 292], ["Cell culture", "TEST", 94, 106], ["heat", "TEST", 263, 267], ["fetal bovine serum (Atlanta Biologicals", "TREATMENT", 280, 319], ["Lawrenceville, GA", "TREATMENT", 321, 338], ["streptomycin", "TREATMENT", 341, 353], ["penicillin", "TREATMENT", 371, 381], ["a humidified incubator", "TREATMENT", 404, 426], ["5% CO2", "TREATMENT", 432, 438]]], ["Cell number and viability were assessed by trypan blue dye exclusion using a hematocytometer.", [["Cell", "ANATOMY", 0, 4], ["trypan blue", "CHEMICAL", 43, 54], ["trypan blue", "CHEMICAL", 43, 54], ["Cell", "CELL", 0, 4], ["trypan blue dye", "SIMPLE_CHEMICAL", 43, 58], ["a hematocytometer", "TREATMENT", 75, 92]]], ["Prior to exposure of toxins (DON, SG, anisomycin, and ricin) or inhibitors, cells (2.5 \u00d7 106) were seeded and cultured in 100-mm tissue culture plates for 24 h to achieve approximately 80% confluency.RNA purification and fragmentation analysis. ::: ::: ::: MATERIALS AND METHODSRNAs were extracted by TRIZOL (Invitrogen, Carlsbad, CA) following the manufacturer\u2019s protocol and their concentrations were measured using a NanoDrop reader (ThermoFisher, Wilmington, DE).", [["cells", "ANATOMY", 76, 81], ["DON", "CHEMICAL", 29, 32], ["SG", "CHEMICAL", 34, 36], ["anisomycin", "CHEMICAL", 38, 48], ["ricin", "CHEMICAL", 54, 59], ["DON", "CHEMICAL", 29, 32], ["anisomycin", "CHEMICAL", 38, 48], ["ricin", "CHEMICAL", 54, 59], ["DON", "SIMPLE_CHEMICAL", 29, 32], ["SG", "SIMPLE_CHEMICAL", 34, 36], ["anisomycin", "SIMPLE_CHEMICAL", 38, 48], ["ricin", "SIMPLE_CHEMICAL", 54, 59], ["cells", "CELL", 76, 81], ["toxins", "TREATMENT", 21, 27], ["DON", "TREATMENT", 29, 32], ["SG", "TREATMENT", 34, 36], ["anisomycin", "TREATMENT", 38, 48], ["ricin", "TREATMENT", 54, 59], ["inhibitors", "TREATMENT", 64, 74], ["cells", "TEST", 76, 81], ["tissue culture plates", "TEST", 129, 150], ["RNA purification", "TEST", 200, 216], ["fragmentation analysis", "TEST", 221, 243], ["TRIZOL", "TREATMENT", 301, 307], ["Invitrogen", "TREATMENT", 309, 319], ["the manufacturer\u2019s protocol", "TREATMENT", 345, 372], ["a NanoDrop reader", "TREATMENT", 418, 435], ["fragmentation", "OBSERVATION_MODIFIER", 221, 234]]], ["Fragmentation of RNA was assessed by denaturing agarose gel electrophoresis (Li and Pestka, 2008) or capillary electrophoresis using an Agilent 2100 Bioanalyzer with a NanoChip (Agilent, Santa Clara, CA) according to manufacturer\u2019s instructions.Northern blot analysis. ::: ::: ::: MATERIALS AND METHODSNorthern blot analysis was performed by a modification of a previously described procedure (Li and Pestka, 2008).", [["Li", "CHEMICAL", 77, 79], ["agarose", "SIMPLE_CHEMICAL", 48, 55], ["capillary", "TISSUE", 101, 110], ["Fragmentation of RNA", "PROBLEM", 0, 20], ["denaturing agarose gel electrophoresis", "TEST", 37, 75], ["Pestka", "TEST", 84, 90], ["capillary electrophoresis", "TEST", 101, 126], ["an Agilent 2100 Bioanalyzer", "TREATMENT", 133, 160], ["a NanoChip (Agilent, Santa Clara, CA)", "TREATMENT", 166, 203], ["Northern blot analysis", "TEST", 245, 267], ["METHODSNorthern blot analysis", "TEST", 295, 324], ["a previously described procedure", "TREATMENT", 360, 392], ["RNA", "ANATOMY", 17, 20]]], ["Briefly, probes (Table 1) were labeled with \u03b3-32P by DNA 5\u2032 end-labeling system (Promega, Madison, WI) and purified by Micro-Bio-Spin6 chromatography column (Bio-Rad, Hercules, CA).", [["\u03b3-32P", "CHEMICAL", 44, 49], ["\u03b3-32P", "SIMPLE_CHEMICAL", 44, 49], ["DNA", "CELLULAR_COMPONENT", 53, 56], ["Bio-Spin6 chromatography column", "TEST", 125, 156], ["Bio", "TEST", 158, 161]]], ["Label incorporation was measured using a TopCount NXT (PerkinElmer, Shelton, CT).", [["a TopCount NXT", "TREATMENT", 39, 53], ["CT", "TEST", 77, 79]]], ["Total RNA (10 \u03bcg per lane) was separated on a 1.2% (wt/vol) formaldehyde denaturing agarose gel and transferred to a Biodyne membrane (Pall Gelman Laboratory, Ann Arbor, MI).", [["Biodyne membrane", "ANATOMY", 117, 133], ["formaldehyde", "CHEMICAL", 60, 72], ["formaldehyde", "SIMPLE_CHEMICAL", 60, 72], ["agarose", "SIMPLE_CHEMICAL", 84, 91], ["Total RNA", "TEST", 0, 9], ["a 1.2% (wt/vol) formaldehyde denaturing agarose gel", "TREATMENT", 44, 95]]], ["After ultraviolet (UV) crosslinking (Stratagene, Cedar Creek, TX), membranes containing immobilized RNA were prehybridized for 1 h at 68\u00b0C and then incubated with [\u03b3-32P]-labeled probes (1 \u00d7 106 cpm/ml) in Quickhyb solution (Stratagene) containing 200 \u03bcg/ml of herring sperm DNA at 68\u00b0C for 2 h.", [["membranes", "ANATOMY", 67, 76], ["sperm", "ANATOMY", 269, 274], ["ultraviolet (UV", "CHEMICAL", 6, 21], ["[\u03b3-32P", "CHEMICAL", 163, 169], ["[\u03b3-32P", "CHEMICAL", 163, 169], ["membranes", "CELLULAR_COMPONENT", 67, 76], ["C", "SIMPLE_CHEMICAL", 137, 138], ["[\u03b3-32P", "SIMPLE_CHEMICAL", 163, 169], ["Quickhyb", "SIMPLE_CHEMICAL", 206, 214], ["immobilized RNA", "RNA", 88, 103], ["herring sperm", "CELL_TYPE", 261, 274], ["herring", "SPECIES", 261, 268], ["ultraviolet (UV) crosslinking (Stratagene, Cedar Creek", "TREATMENT", 6, 60], ["TX)", "TREATMENT", 62, 65], ["membranes containing immobilized RNA", "TREATMENT", 67, 103], ["32P]-labeled probes", "TREATMENT", 166, 185], ["Quickhyb solution (Stratagene)", "TREATMENT", 206, 236]]], ["Blots were washed twice with 2\u00d7 Side Scatter (SSC) containing 0.1% (wt/vol) SDS at room temperature and once for 15 min with 0.1\u00d7 SSC containing 0.1% (wt/vol) SDS at 50\u00b0C. The membranes were assembled with the Hyblot autoradiography film (Denville, Metuchen, NJ) into an X-ray exposure cassette and the film was developed after 24 h.Immunoblotting. ::: ::: ::: MATERIALS AND METHODSWestern blot analyses were conducted using primary antibodies specific for murine forms of total/cleaved caspase 9, cleaved caspase 3 (Asp 175), total caspase 8, and cleaved caspase 8 (Asp387) (Cell Signaling, Beverly, MA).", [["membranes", "ANATOMY", 176, 185], ["Cell", "ANATOMY", 576, 580], ["SDS", "CHEMICAL", 159, 162], ["Asp", "CHEMICAL", 517, 520], ["Asp", "CHEMICAL", 567, 570], ["membranes", "CELLULAR_COMPONENT", 176, 185], ["murine", "ORGANISM", 457, 463], ["caspase 9", "GENE_OR_GENE_PRODUCT", 487, 496], ["caspase 3", "GENE_OR_GENE_PRODUCT", 506, 515], ["Asp 175", "GENE_OR_GENE_PRODUCT", 517, 524], ["caspase 8", "GENE_OR_GENE_PRODUCT", 533, 542], ["caspase 8", "GENE_OR_GENE_PRODUCT", 556, 565], ["Asp387", "AMINO_ACID", 567, 573], ["Cell", "CELL", 576, 580], ["X-ray exposure cassette", "DNA", 271, 294], ["primary antibodies", "PROTEIN", 425, 443], ["cleaved caspase 9", "PROTEIN", 479, 496], ["cleaved caspase 3", "PROTEIN", 498, 515], ["Asp 175", "PROTEIN", 517, 524], ["caspase 8", "PROTEIN", 533, 542], ["cleaved caspase 8", "PROTEIN", 548, 565], ["Asp387", "PROTEIN", 567, 573], ["murine", "SPECIES", 457, 463], ["Side Scatter (SSC)", "TREATMENT", 32, 50], ["SSC containing", "TREATMENT", 130, 144], ["the Hyblot autoradiography film", "TEST", 206, 237], ["an X-ray exposure cassette", "TREATMENT", 268, 294], ["the film", "TEST", 299, 307], ["METHODSWestern blot analyses", "TEST", 375, 403], ["primary antibodies", "TEST", 425, 443], ["total/cleaved caspase", "TREATMENT", 473, 494], ["cleaved caspase", "TEST", 498, 513], ["Asp", "TEST", 517, 520], ["total caspase", "TEST", 527, 540], ["cleaved caspase", "TEST", 548, 563], ["Asp", "TEST", 567, 570]]], ["Mouse \u03b2-actin antibody (Sigma) was also used to verify equal loading.", [["Mouse", "ORGANISM", 0, 5], ["\u03b2-actin antibody", "GENE_OR_GENE_PRODUCT", 6, 22], ["Mouse \u03b2-actin antibody", "PROTEIN", 0, 22], ["Sigma", "PROTEIN", 24, 29], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5]]], ["Cells were washed twice with ice-cold phosphate-buffered saline (PBS), lysed in boiling lysis buffer (1% [wt/vol] SDS, 1 mM sodium ortho-vanadate, and 10 mM Tris, pH 7.4), boiled for 5 min, and sonicated briefly, the resultant lysate centrifuged at 12,000 \u00d7 g for 10 min at 4\u00b0C and protein concentration measured with a BCA Protein Assay Kit (ThermoFisher, Pittsburgh, PA).", [["Cells", "ANATOMY", 0, 5], ["lysate", "ANATOMY", 227, 233], ["phosphate", "CHEMICAL", 38, 47], ["sodium ortho-vanadate", "CHEMICAL", 124, 145], ["phosphate", "CHEMICAL", 38, 47], ["sodium ortho-vanadate", "CHEMICAL", 124, 145], ["Tris", "CHEMICAL", 157, 161], ["Cells", "CELL", 0, 5], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 38, 63], ["sodium ortho-vanadate", "SIMPLE_CHEMICAL", 124, 145], ["C", "GENE_OR_GENE_PRODUCT", 276, 277], ["Cells", "TEST", 0, 5], ["ice-cold phosphate", "TREATMENT", 29, 47], ["buffered saline (PBS", "TREATMENT", 48, 68], ["boiling lysis buffer", "TREATMENT", 80, 100], ["SDS", "TEST", 114, 117], ["sodium", "TEST", 124, 130], ["vanadate", "TREATMENT", 137, 145], ["pH", "TEST", 163, 165], ["protein concentration", "TEST", 282, 303], ["a BCA Protein", "TEST", 318, 331]]], ["Total cellular proteins (40 \u03bcg) were separated on Bio-Rad precast 4\u201320% polyacrylamide gels (Bio-Rad) and transferred to a polyvinylidene difluoride membrane (Amersham, Arlington Heights, IL).", [["cellular", "ANATOMY", 6, 14], ["polyacrylamide", "CHEMICAL", 72, 86], ["polyvinylidene", "CHEMICAL", 123, 137], ["difluoride", "CHEMICAL", 138, 148], ["cellular", "CELL", 6, 14], ["polyacrylamide gels", "SIMPLE_CHEMICAL", 72, 91], ["membrane", "CELLULAR_COMPONENT", 149, 157], ["cellular proteins", "PROTEIN", 6, 23], ["Total cellular proteins", "TEST", 0, 23], ["Bio-Rad precast", "TREATMENT", 50, 65], ["polyacrylamide gels", "TREATMENT", 72, 91], ["a polyvinylidene difluoride membrane", "TREATMENT", 121, 157], ["Arlington Heights, IL)", "TREATMENT", 169, 191]]], ["After incubating with blocking buffer (Li-Cor, Lincoln, NE) for 1 h at 25\u00b0C, membranes were incubated with murine and/or rabbit primary antibodies (1:1000 dilution in Li-Cor blocking buffer) to immobilized proteins of interest overnight at 4\u00b0C. Blots were washed three times of 10 min with Tris-buffered saline and Tween 20 (50 mM Tris-HCl, 150 mM NaCl, and 0.1% Tween 20, pH 7.5) and then incubated with secondary IRDye 680 goat anti-rabbit and/or IRDye 800CW goat anti-mouse IgG antibodies (Li-Cor) (1:2000 dilution in Li-Cor blocking buffer) for 1 h at 25\u00b0C. After washing three times, infrared fluorescence from these two antibody conjugates were simultaneously measured using a Li-Cor Odyssey Infrared Imaging System.Apoptosis measurement by acridine orange/ethidium bromide staining. ::: ::: ::: MATERIALS AND METHODSAcridine orange/ethidium bromide (AO/EB) staining was carried out using an adaptation of a previously described procedure (Muppidi et al., 2004).", [["membranes", "ANATOMY", 77, 86], ["NE", "CHEMICAL", 56, 58], ["Tween 20", "CHEMICAL", 315, 323], ["Tris-HCl", "CHEMICAL", 331, 339], ["NaCl", "CHEMICAL", 348, 352], ["acridine orange", "CHEMICAL", 747, 762], ["ethidium bromide", "CHEMICAL", 763, 779], ["METHODSAcridine orange/", "CHEMICAL", 816, 839], ["ethidium bromide", "CHEMICAL", 839, 855], ["AO/EB", "CHEMICAL", 857, 862], ["Tris", "CHEMICAL", 290, 294], ["Tween 20", "CHEMICAL", 315, 323], ["Tris-HCl", "CHEMICAL", 331, 339], ["NaCl", "CHEMICAL", 348, 352], ["Tween 20", "CHEMICAL", 363, 371], ["acridine orange", "CHEMICAL", 747, 762], ["ethidium bromide", "CHEMICAL", 763, 779], ["METHODSAcridine orange", "CHEMICAL", 816, 838], ["ethidium bromide", "CHEMICAL", 839, 855], ["Li-Cor", "SIMPLE_CHEMICAL", 39, 45], ["Lincoln", "SIMPLE_CHEMICAL", 47, 54], ["NE", "SIMPLE_CHEMICAL", 56, 58], ["membranes", "CELLULAR_COMPONENT", 77, 86], ["murine", "ORGANISM", 107, 113], ["rabbit", "ORGANISM", 121, 127], ["Tris-buffered saline", "SIMPLE_CHEMICAL", 290, 310], ["Tween 20", "SIMPLE_CHEMICAL", 315, 323], ["Tris-HCl", "SIMPLE_CHEMICAL", 331, 339], ["IRDye", "SIMPLE_CHEMICAL", 415, 420], ["IRDye", "GENE_OR_GENE_PRODUCT", 449, 454], ["Li-Cor", "SIMPLE_CHEMICAL", 493, 499], ["acridine orange", "SIMPLE_CHEMICAL", 747, 762], ["ethidium bromide", "SIMPLE_CHEMICAL", 763, 779], ["METHODSAcridine orange", "SIMPLE_CHEMICAL", 816, 838], ["ethidium bromide", "SIMPLE_CHEMICAL", 839, 855], ["AO", "SIMPLE_CHEMICAL", 857, 859], ["EB", "SIMPLE_CHEMICAL", 860, 862], ["rabbit primary antibodies", "PROTEIN", 121, 146], ["immobilized proteins", "PROTEIN", 194, 214], ["IRDye 680 goat anti-rabbit", "PROTEIN", 415, 441], ["IRDye 800CW goat anti-mouse IgG antibodies", "PROTEIN", 449, 491], ["Li-Cor", "PROTEIN", 493, 499], ["murine", "SPECIES", 107, 113], ["rabbit", "SPECIES", 121, 127], ["goat", "SPECIES", 425, 429], ["anti-rabbit", "SPECIES", 430, 441], ["goat", "SPECIES", 461, 465], ["anti-mouse", "SPECIES", 466, 476], ["rabbit", "SPECIES", 121, 127], ["goat", "SPECIES", 425, 429], ["goat", "SPECIES", 461, 465], ["blocking buffer", "TREATMENT", 22, 37], ["rabbit primary antibodies", "TREATMENT", 121, 146], ["Li-Cor blocking buffer", "TREATMENT", 167, 189], ["Blots", "TEST", 245, 250], ["Tris-buffered saline", "TREATMENT", 290, 310], ["NaCl", "TEST", 348, 352], ["pH", "TEST", 373, 375], ["secondary IRDye 680 goat anti-rabbit", "TREATMENT", 405, 441], ["IRDye", "TREATMENT", 449, 454], ["goat anti-mouse IgG antibodies", "TREATMENT", 461, 491], ["Li-Cor blocking buffer", "TREATMENT", 521, 543], ["infrared fluorescence", "TEST", 589, 610], ["these two antibody conjugates", "TEST", 616, 645], ["Apoptosis measurement", "TEST", 722, 743], ["acridine orange", "TEST", 747, 762], ["ethidium bromide staining", "TEST", 763, 788], ["METHODSAcridine orange/ethidium bromide", "TREATMENT", 816, 855], ["a previously described procedure", "TREATMENT", 912, 944]]], ["Briefly, slides were cleaned and sterilized by UV light, placed into 100-mm tissue culture plates, and cultured with RAW 264.7 cells (2.5 \u00d7 106) for 24 h to achieve approximately 80% confluency.", [["tissue", "ANATOMY", 76, 82], ["RAW 264.7 cells", "ANATOMY", 117, 132], ["RAW 264.7 cells", "CELL", 117, 132], ["RAW 264.7 cells", "CELL_LINE", 117, 132], ["mm tissue culture plates", "TEST", 73, 97], ["cells", "TEST", 127, 132]]], ["DON-exposed RAW 264.7 cells were stained for 2 min with 100 \u03bcg/ml AO and 100 \u03bcg/ml EB in PBS.", [["RAW 264.7 cells", "ANATOMY", 12, 27], ["DON", "CHEMICAL", 0, 3], ["EB", "CHEMICAL", 83, 85], ["DON", "CHEMICAL", 0, 3], ["DON", "SIMPLE_CHEMICAL", 0, 3], ["RAW 264.7 cells", "CELL", 12, 27], ["AO", "SIMPLE_CHEMICAL", 66, 68], ["EB", "SIMPLE_CHEMICAL", 83, 85], ["RAW 264.7 cells", "CELL_LINE", 12, 27], ["264.7 cells", "OBSERVATION", 16, 27]]], ["The slides were washed twice with cold PBS and then covered with coverslip and examined at \u00d7400 under Nikon fluorescence microscope equipped with a wide-band fluorescein isothiocyanate filter.", [["fluorescein isothiocyanate", "CHEMICAL", 158, 184], ["fluorescein isothiocyanate", "CHEMICAL", 158, 184], ["fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 158, 184], ["cold PBS", "TREATMENT", 34, 42], ["a wide-band fluorescein isothiocyanate filter", "TREATMENT", 146, 191], ["isothiocyanate filter", "OBSERVATION", 170, 191]]], ["Cells (\u2265 200) were classified based on their nuclear morphology (bright chromatin, highly condensed, or fragmented nuclei) in to four categories: viable normal (VN), viable apoptotic (VA), nonviable apoptotic (NVA), and nonviable necrotic (NVN).", [["Cells", "ANATOMY", 0, 5], ["nuclear", "ANATOMY", 45, 52], ["chromatin", "ANATOMY", 72, 81], ["nuclei", "ANATOMY", 115, 121], ["NVN", "ANATOMY", 240, 243], ["necrotic", "DISEASE", 230, 238], ["Cells", "CELL", 0, 5], ["nuclear", "CELLULAR_COMPONENT", 45, 52], ["chromatin", "CELLULAR_COMPONENT", 72, 81], ["nuclei", "CELLULAR_COMPONENT", 115, 121], ["nonviable necrotic (NVN", "CANCER", 220, 243], ["Cells", "TEST", 0, 5], ["nonviable necrotic (NVN)", "PROBLEM", 220, 244], ["normal", "OBSERVATION", 153, 159], ["apoptotic", "OBSERVATION_MODIFIER", 173, 182], ["apoptotic", "OBSERVATION_MODIFIER", 199, 208], ["necrotic", "OBSERVATION_MODIFIER", 230, 238]]], ["The apoptotic index was calculated as follows: (VA + NVA)/(VN + VA + NVN + NVA) \u00d7 100.Apoptosis measurement by flow cytometry. ::: ::: ::: MATERIALS AND METHODSRAW 264.7 cells were treated with vehicle PBS or DON (1000 ng/ml) for 6 h.", [["264.7 cells", "ANATOMY", 164, 175], ["DON", "CHEMICAL", 209, 212], ["DON", "CHEMICAL", 209, 212], ["METHODSRAW 264.7 cells", "CELL", 153, 175], ["DON", "SIMPLE_CHEMICAL", 209, 212], ["METHODSRAW 264.7 cells", "CELL_LINE", 153, 175], ["The apoptotic index", "TEST", 0, 19], ["NVA", "TEST", 53, 56], ["VN", "TEST", 59, 61], ["VA", "TEST", 64, 66], ["NVN", "TEST", 69, 72], ["Apoptosis measurement", "TEST", 86, 107], ["flow cytometry", "TEST", 111, 125], ["vehicle PBS", "TREATMENT", 194, 205], ["flow cytometry", "OBSERVATION", 111, 125]]], ["Total DON-treated cells and adherent DON-treated cells were collected separately.", [["cells", "ANATOMY", 18, 23], ["cells", "ANATOMY", 49, 54], ["DON", "CHEMICAL", 6, 9], ["DON", "CHEMICAL", 37, 40], ["DON", "CHEMICAL", 6, 9], ["DON", "CHEMICAL", 37, 40], ["DON", "SIMPLE_CHEMICAL", 6, 9], ["cells", "CELL", 18, 23], ["DON", "SIMPLE_CHEMICAL", 37, 40], ["cells", "CELL", 49, 54], ["DON-treated cells", "CELL_LINE", 6, 23], ["adherent DON-treated cells", "CELL_LINE", 28, 54], ["Total DON-treated cells", "TREATMENT", 0, 23], ["adherent DON-treated cells", "TREATMENT", 28, 54]]], ["After washing twice with cold PBS, annexin staining was performed according to the manufacturer\u2019s protocol (BD Biosciences).", [["annexin", "GENE_OR_GENE_PRODUCT", 35, 42], ["cold PBS", "TREATMENT", 25, 33], ["annexin staining", "TEST", 35, 51]]], ["Briefly, cells were resuspended to 1\u00d7 binding buffer at a concentration of 2.5 \u00d7 106 cells/ml, and 100 \u03bcl of the cell suspension was transferred to fluorescence activated cell sorter tubes.", [["cells", "ANATOMY", 9, 14], ["cells", "ANATOMY", 85, 90], ["cell", "ANATOMY", 113, 117], ["cell", "ANATOMY", 171, 175], ["cells", "CELL", 9, 14], ["cells", "CELL", 85, 90], ["cell", "CELL", 113, 117], ["cell", "CELL", 171, 175], ["the cell suspension", "TREATMENT", 109, 128], ["fluorescence activated cell sorter tubes", "TREATMENT", 148, 188], ["cell sorter tubes", "OBSERVATION", 171, 188]]], ["Cells were incubated with 5 \u03bcl of annexin V and propidium iodide (PI) for 15 min at room temperature in dark.", [["Cells", "ANATOMY", 0, 5], ["annexin V", "CHEMICAL", 34, 43], ["propidium iodide", "CHEMICAL", 48, 64], ["PI", "CHEMICAL", 66, 68], ["propidium iodide", "CHEMICAL", 48, 64], ["Cells", "CELL", 0, 5], ["annexin V", "GENE_OR_GENE_PRODUCT", 34, 43], ["propidium iodide", "SIMPLE_CHEMICAL", 48, 64], ["PI", "SIMPLE_CHEMICAL", 66, 68], ["annexin V", "TREATMENT", 34, 43], ["propidium iodide", "TREATMENT", 48, 64]]], ["Finally, samples were resuspended to 400 \u03bcl volume with binding buffer, acquired on the Accuri C6 Flow Cytometer (Ann Arbor, MI), and analyzed using FlowJo software (Tree Star, Ashland, OR).", [["samples", "ANATOMY", 9, 16], ["samples", "TEST", 9, 16], ["binding buffer", "TREATMENT", 56, 70]]], ["Live Raw 264.7 cells were gated using Forward Scatter versus SSC.Statistics. ::: ::: ::: MATERIALS AND METHODSData were analyzed by Student\u2019s t-test using Sigma Stat 3.11 (Jandel Scientific, San Rafael, CA).", [["Raw 264.7 cells", "ANATOMY", 5, 20], ["Raw 264.7 cells", "CELL", 5, 20], ["Raw 264.7 cells", "CELL_LINE", 5, 20], ["Sigma Stat", "TEST", 155, 165]]], ["Data sets were considered significantly different when p < 0.05.DON Induces rRNA Cleavage ::: ::: RESULTSThe capacity of DON to induce rRNA cleavage in RAW 264.7 macrophages was assessed by denaturing gel electrophoresis (Fig. 1A) and capillary electrophoresis (Figs.", [["RAW 264.7 macrophages", "ANATOMY", 152, 173], ["DON", "CHEMICAL", 64, 67], ["DON", "CHEMICAL", 121, 124], ["DON", "CHEMICAL", 64, 67], ["DON", "CHEMICAL", 121, 124], ["DON", "SIMPLE_CHEMICAL", 64, 67], ["DON", "SIMPLE_CHEMICAL", 121, 124], ["RAW 264.7 macrophages", "CELL", 152, 173], ["capillary", "TISSUE", 235, 244], ["RAW 264.7 macrophages", "CELL_LINE", 152, 173], ["Data sets", "TEST", 0, 9], ["rRNA cleavage", "PROBLEM", 135, 148], ["denaturing gel electrophoresis", "TEST", 190, 220], ["capillary electrophoresis", "TEST", 235, 260], ["rRNA Cleavage", "OBSERVATION", 76, 89]]], ["Distinct 18S and 28S rRNA bands were evident in both control and DON-treated RAW 264.7 cells, whereas over five additional rRNA fragment bands were detected in DON-treated cells.", [["RAW 264.7 cells", "ANATOMY", 77, 92], ["cells", "ANATOMY", 172, 177], ["DON", "CHEMICAL", 65, 68], ["DON", "CHEMICAL", 160, 163], ["DON", "CHEMICAL", 65, 68], ["DON", "CHEMICAL", 160, 163], ["18S", "GENE_OR_GENE_PRODUCT", 9, 12], ["28S", "CELLULAR_COMPONENT", 17, 20], ["rRNA", "CELLULAR_COMPONENT", 21, 25], ["DON", "SIMPLE_CHEMICAL", 65, 68], ["RAW 264.7 cells", "CELL", 77, 92], ["DON", "SIMPLE_CHEMICAL", 160, 163], ["cells", "CELL", 172, 177], ["RAW 264.7 cells", "CELL_LINE", 77, 92], ["DON-treated cells", "CELL_LINE", 160, 177], ["Distinct 18S", "TEST", 0, 12], ["28S rRNA bands", "TEST", 17, 31], ["five additional rRNA fragment bands", "PROBLEM", 107, 142]]], ["Based on its high resolution and reproducibility as compared with conventional electrophoresis, capillary electrophoresis was employed to monitor cleavage in subsequent experiments.", [["capillary", "TISSUE", 96, 105], ["conventional electrophoresis", "TEST", 66, 94], ["capillary electrophoresis", "TEST", 96, 121], ["high", "OBSERVATION_MODIFIER", 13, 17], ["resolution", "OBSERVATION_MODIFIER", 18, 28]]], ["When the kinetics of the response were measured, DON at 1000 ng/ml was found to cause rRNA cleavage as early as 2 h that was very robust by 6 h (Figure 2A).", [["DON", "CHEMICAL", 49, 52], ["DON", "CHEMICAL", 49, 52], ["DON", "SIMPLE_CHEMICAL", 49, 52], ["DON", "TREATMENT", 49, 52], ["rRNA cleavage", "PROBLEM", 86, 99], ["rRNA cleavage", "OBSERVATION", 86, 99]]], ["Cleavage at 6 h was concentration dependent with 200 ng/ml of DON evoking modest rRNA cleavage as compared with more marked rRNA cleavage induced by 1000 ng/ml (Figure 2B).", [["DON", "CHEMICAL", 62, 65], ["DON", "CHEMICAL", 62, 65], ["DON", "SIMPLE_CHEMICAL", 62, 65], ["rRNA", "CELLULAR_COMPONENT", 124, 128], ["concentration dependent", "PROBLEM", 20, 43], ["DON", "TREATMENT", 62, 65], ["modest rRNA cleavage", "PROBLEM", 74, 94], ["more marked rRNA cleavage", "PROBLEM", 112, 137]]], ["Based on these findings, incubation with DON at 1000 ng/ml for 6 h was uniformly employed for subsequent mechanistic studies.DON Induces Cleavage of Both 28S and 18S rRNA ::: ::: RESULTSNorthern blot analyses using32P-labeled oligonucleotide probes (Table 1) for 18S and 28S rRNAs were performed to identify and map sites of rRNA cleavage.", [["DON", "CHEMICAL", 41, 44], ["DON", "CHEMICAL", 125, 128], ["DON", "CHEMICAL", 41, 44], ["DON", "CHEMICAL", 125, 128], ["DON", "SIMPLE_CHEMICAL", 41, 44], ["DON", "SIMPLE_CHEMICAL", 125, 128], ["28S", "CELLULAR_COMPONENT", 154, 157], ["32P", "SIMPLE_CHEMICAL", 214, 217], ["rRNA", "CELLULAR_COMPONENT", 325, 329], ["28S", "DNA", 154, 157], ["18S and 28S rRNAs", "RNA", 263, 280], ["DON", "TREATMENT", 41, 44], ["subsequent mechanistic studies", "TEST", 94, 124], ["blot analyses", "TEST", 195, 208], ["32P-labeled oligonucleotide probes", "TREATMENT", 214, 248], ["18S and 28S rRNAs", "PROBLEM", 263, 280], ["rRNA cleavage", "PROBLEM", 325, 338], ["rRNA cleavage", "OBSERVATION", 325, 338]]], ["Incubation with five probes complementary to 28S rRNA revealed six fragments (a\u2013f) with sizes approximating 4000, 3200, 2800, 1500, 1000, and 500 nts (Fig. 3A).", [["28S rRNA", "DNA", 45, 53], ["Incubation", "TREATMENT", 0, 10], ["28S rRNA", "TEST", 45, 53], ["six fragments", "PROBLEM", 63, 76], ["six", "OBSERVATION_MODIFIER", 63, 66], ["fragments", "OBSERVATION_MODIFIER", 67, 76], ["sizes", "OBSERVATION_MODIFIER", 88, 93]]], ["Based on rRNA fragment sizes, probe position and Northern blotting, putative cleavage sites of 28S rRNA were deduced (Figure 3B).", [["28S", "GENE_OR_GENE_PRODUCT", 95, 98], ["rRNA", "CELLULAR_COMPONENT", 99, 103], ["putative cleavage sites", "DNA", 68, 91], ["28S rRNA", "DNA", 95, 103], ["rRNA fragment sizes", "TREATMENT", 9, 28], ["probe position", "TREATMENT", 30, 44], ["Northern blotting", "TREATMENT", 49, 66], ["putative cleavage sites", "PROBLEM", 68, 91], ["28S rRNA", "TEST", 95, 103], ["rRNA", "OBSERVATION", 9, 13], ["fragment", "OBSERVATION_MODIFIER", 14, 22], ["sizes", "OBSERVATION_MODIFIER", 23, 28], ["position", "OBSERVATION_MODIFIER", 36, 44], ["Northern", "OBSERVATION_MODIFIER", 49, 57], ["blotting", "OBSERVATION_MODIFIER", 58, 66], ["28S rRNA", "OBSERVATION", 95, 103]]], ["DON appeared to cleave 28S rRNA into one of two pairs of fragments: a + e (approximately 5000 nts) and b + d (approximately 4700 nts).", [["fragments", "ANATOMY", 57, 66], ["DON", "CHEMICAL", 0, 3], ["DON", "CHEMICAL", 0, 3], ["DON", "SIMPLE_CHEMICAL", 0, 3], ["28S", "CELLULAR_COMPONENT", 23, 26], ["rRNA", "CELLULAR_COMPONENT", 27, 31], ["28S rRNA", "RNA", 23, 31], ["28S rRNA", "OBSERVATION", 23, 31], ["fragments", "OBSERVATION", 57, 66]]], ["Because no complementary fragment (approximately 2000 nts) to fragment c was detected, it was likely to be a product of the subsequent degradation of a or b.DON Induces Cleavage of Both 28S and 18S rRNA ::: ::: RESULTSAutoradiography following hybridization with three probes complementary to 18S rRNA indicated the presence of five fragments (A-E) with approximate sizes of 1000, 800, 600, 500, and 300 nts (Fig. 4 A).", [["fragments", "ANATOMY", 333, 342], ["fragment", "CELLULAR_COMPONENT", 25, 33], ["fragment c", "GENE_OR_GENE_PRODUCT", 62, 72], ["28S", "CELLULAR_COMPONENT", 186, 189], ["18S", "GENE_OR_GENE_PRODUCT", 293, 296], ["rRNA", "CELLULAR_COMPONENT", 297, 301], ["complementary fragment", "DNA", 11, 33], ["fragment c", "DNA", 62, 72], ["b.DON", "PROTEIN", 155, 160], ["28S", "DNA", 186, 189], ["18S rRNA", "DNA", 293, 301], ["complementary fragment", "PROBLEM", 11, 33], ["fragment c", "PROBLEM", 62, 72], ["hybridization", "TEST", 244, 257], ["18S rRNA", "TEST", 293, 301], ["five fragments", "PROBLEM", 328, 342], ["no", "UNCERTAINTY", 8, 10], ["complementary", "OBSERVATION_MODIFIER", 11, 24], ["fragment", "OBSERVATION", 25, 33], ["five", "OBSERVATION_MODIFIER", 328, 332], ["fragments", "OBSERVATION", 333, 342], ["sizes", "OBSERVATION_MODIFIER", 366, 371]]], ["The putative 18S rRNA cleavage pattern suggested that fragments A (approximately 1000 nts) and B (approximately 800 nts) are derived from intact 18S rRNA, whereas the remaining fragments (C, D, and E, approximately 600, 500, and 300 nts, respectively) resulted from further secondary cleavage of the two primary fragments (C and E from A and D from B) (Fig. 4B).DON-induced rRNA Cleavage Is Concurrent With Apoptosis ::: ::: RESULTSAO/EB staining of adherent RAW 264.7 cells revealed that DON exposure (1000 ng/ml, 6 h) induced significant apoptosis concurrent with rRNA degradation (Fig. 5A).", [["fragments", "ANATOMY", 177, 186], ["fragments", "ANATOMY", 312, 321], ["RAW 264.7 cells", "ANATOMY", 459, 474], ["DON", "CHEMICAL", 362, 365], ["DON", "CHEMICAL", 489, 492], ["DON", "CHEMICAL", 362, 365], ["DON", "CHEMICAL", 489, 492], ["18S", "GENE_OR_GENE_PRODUCT", 13, 16], ["18S", "GENE_OR_GENE_PRODUCT", 145, 148], ["rRNA", "CELLULAR_COMPONENT", 149, 153], ["DON", "SIMPLE_CHEMICAL", 362, 365], ["RAW 264.7 cells", "CELL", 459, 474], ["DON", "SIMPLE_CHEMICAL", 489, 492], ["18S rRNA", "DNA", 145, 153], ["primary fragments", "DNA", 304, 321], ["adherent RAW 264.7 cells", "CELL_LINE", 450, 474], ["The putative 18S rRNA cleavage pattern", "PROBLEM", 0, 38], ["fragments A", "PROBLEM", 54, 65], ["further secondary cleavage", "PROBLEM", 266, 292], ["the two primary fragments", "PROBLEM", 296, 321], ["RESULTSAO/EB staining", "TEST", 425, 446], ["DON exposure", "PROBLEM", 489, 501], ["significant apoptosis", "PROBLEM", 528, 549], ["rRNA degradation", "PROBLEM", 566, 582], ["18S rRNA cleavage", "OBSERVATION", 13, 30], ["fragments", "OBSERVATION_MODIFIER", 54, 63], ["18S rRNA", "OBSERVATION", 145, 153], ["remaining", "OBSERVATION_MODIFIER", 167, 176], ["fragments", "OBSERVATION_MODIFIER", 177, 186], ["secondary cleavage", "OBSERVATION", 274, 292], ["two", "OBSERVATION_MODIFIER", 300, 303], ["primary fragments", "OBSERVATION", 304, 321], ["rRNA Cleavage", "OBSERVATION", 374, 387], ["significant", "OBSERVATION_MODIFIER", 528, 539], ["apoptosis", "OBSERVATION", 540, 549], ["rRNA degradation", "OBSERVATION", 566, 582]]], ["Because RAW 264.7 cells attach to the bottom of the cell culture plate under normal physiological conditions but detach during apoptosis, flow cytometry was additionally employed to measure apoptosis in adherent and suspended cells following DON treatment (Fig. 5B).", [["RAW 264.7 cells", "ANATOMY", 8, 23], ["cell", "ANATOMY", 52, 56], ["cells", "ANATOMY", 226, 231], ["RAW", "CHEMICAL", 8, 11], ["DON", "CHEMICAL", 242, 245], ["DON", "CHEMICAL", 242, 245], ["RAW 264.7 cells", "CELL", 8, 23], ["cell", "CELL", 52, 56], ["cells", "CELL", 226, 231], ["DON", "SIMPLE_CHEMICAL", 242, 245], ["RAW 264.7 cells", "CELL_LINE", 8, 23], ["adherent and suspended cells", "CELL_TYPE", 203, 231], ["the cell culture plate", "TEST", 48, 70], ["flow cytometry", "TEST", 138, 152], ["apoptosis", "PROBLEM", 190, 199], ["DON treatment", "TREATMENT", 242, 255], ["264.7 cells", "OBSERVATION", 12, 23], ["normal physiological conditions", "OBSERVATION", 77, 108], ["adherent", "OBSERVATION_MODIFIER", 203, 211]]], ["Both adherent and total populations contained markedly higher annexin V-positive cells (early apoptotic) (60 and 78%, respectively) than the control total cells (31%).", [["cells", "ANATOMY", 81, 86], ["cells", "ANATOMY", 155, 160], ["annexin V", "GENE_OR_GENE_PRODUCT", 62, 71], ["cells", "CELL", 155, 160], ["annexin V-positive cells", "CELL_TYPE", 62, 86], ["total populations", "TEST", 18, 35], ["markedly higher annexin V", "PROBLEM", 46, 71], ["positive cells", "PROBLEM", 72, 86], ["the control total cells", "TEST", 137, 160], ["adherent", "OBSERVATION_MODIFIER", 5, 13], ["total", "OBSERVATION_MODIFIER", 18, 23], ["populations", "OBSERVATION_MODIFIER", 24, 35], ["markedly", "OBSERVATION_MODIFIER", 46, 54], ["higher", "OBSERVATION_MODIFIER", 55, 61], ["annexin V", "OBSERVATION", 62, 71], ["positive cells", "OBSERVATION", 72, 86]]], ["Similarly, the percentage of annexin V/PI-double positive cells (late apoptotic) were much higher in adherent (4.8%) and total (10.8%) populations than that of the control (1.2%).DON-Induced rRNA Cleavage Requires PKR, Hck, p38, p53, and Caspase Activation ::: ::: RESULTSBecause DON-induced apoptosis involves activation of PKR, Hck, and MAPKs (Zhou et al., 2003b; Zhou et al., 2005b), the role of these kinases in rRNA cleavage was determined using selective inhibitors.", [["cells", "ANATOMY", 58, 63], ["DON", "CHEMICAL", 179, 182], ["DON", "CHEMICAL", 280, 283], ["DON", "CHEMICAL", 179, 182], ["DON", "CHEMICAL", 280, 283], ["annexin V", "GENE_OR_GENE_PRODUCT", 29, 38], ["PI", "GENE_OR_GENE_PRODUCT", 39, 41], ["DON", "SIMPLE_CHEMICAL", 179, 182], ["PKR", "GENE_OR_GENE_PRODUCT", 214, 217], ["Hck", "GENE_OR_GENE_PRODUCT", 219, 222], ["p38", "GENE_OR_GENE_PRODUCT", 224, 227], ["p53", "GENE_OR_GENE_PRODUCT", 229, 232], ["Caspase", "GENE_OR_GENE_PRODUCT", 238, 245], ["DON", "SIMPLE_CHEMICAL", 280, 283], ["PKR", "GENE_OR_GENE_PRODUCT", 325, 328], ["Hck", "GENE_OR_GENE_PRODUCT", 330, 333], ["MAPKs", "GENE_OR_GENE_PRODUCT", 339, 344], ["rRNA", "CELLULAR_COMPONENT", 416, 420], ["annexin V/PI-double positive cells", "CELL_LINE", 29, 63], ["PKR", "PROTEIN", 214, 217], ["Hck", "PROTEIN", 219, 222], ["p38", "PROTEIN", 224, 227], ["p53", "PROTEIN", 229, 232], ["Caspase", "PROTEIN", 238, 245], ["PKR", "PROTEIN", 325, 328], ["Hck", "PROTEIN", 330, 333], ["MAPKs", "PROTEIN", 339, 344], ["kinases", "PROTEIN", 405, 412], ["annexin V/PI", "TEST", 29, 41], ["double positive cells", "PROBLEM", 42, 63], ["PKR", "TEST", 214, 217], ["Hck", "TEST", 219, 222], ["p38", "TEST", 224, 227], ["p53", "TEST", 229, 232], ["apoptosis", "PROBLEM", 292, 301], ["PKR", "TEST", 325, 328], ["Hck", "TEST", 330, 333], ["these kinases", "TREATMENT", 399, 412], ["rRNA cleavage", "TREATMENT", 416, 429], ["selective inhibitors", "TREATMENT", 451, 471], ["percentage", "OBSERVATION_MODIFIER", 15, 25], ["annexin V", "OBSERVATION", 29, 38], ["positive cells", "OBSERVATION", 49, 63], ["higher", "OBSERVATION_MODIFIER", 91, 97]]], ["Both the PKR inhibitor C-16 (0.1 and 0.3 \u03bcM) (Fig. 6A) and the Hck inhibitor PP1 (5 and 25 \u03bcM) (Fig. 6B) were found to concentration dependently suppress DON-induced rRNA cleavage.", [["C-16", "CHEMICAL", 23, 27], ["DON", "CHEMICAL", 154, 157], ["C-16", "CHEMICAL", 23, 27], ["PP1", "CHEMICAL", 77, 80], ["DON", "CHEMICAL", 154, 157], ["PKR", "GENE_OR_GENE_PRODUCT", 9, 12], ["C-16", "SIMPLE_CHEMICAL", 23, 27], ["Hck", "GENE_OR_GENE_PRODUCT", 63, 66], ["PP1", "GENE_OR_GENE_PRODUCT", 77, 80], ["DON", "SIMPLE_CHEMICAL", 154, 157], ["rRNA", "CELLULAR_COMPONENT", 166, 170], ["PKR", "PROTEIN", 9, 12], ["Hck", "PROTEIN", 63, 66], ["PP1", "PROTEIN", 77, 80], ["the PKR inhibitor C", "TEST", 5, 24], ["the Hck inhibitor PP1", "TEST", 59, 80], ["induced rRNA cleavage", "PROBLEM", 158, 179]]], ["Although the p38 inhibitor (SB 203580; 1 and 5 \u03bcM) also inhibited DON-induced rRNA cleavage concentration dependently (Fig. 6C), inhibitors of JNK (SP600125; 0.2, 1, and 5 \u03bcM) and ERK (PO 98059; 20 and 100 \u03bcM) did not (data not shown) have suppressive effects.", [["SB 203580", "CHEMICAL", 28, 37], ["DON", "CHEMICAL", 66, 69], ["SP600125", "CHEMICAL", 148, 156], ["PO 98059", "CHEMICAL", 185, 193], ["SB 203580", "CHEMICAL", 28, 37], ["DON", "CHEMICAL", 66, 69], ["SP600125", "CHEMICAL", 148, 156], ["PO 98059", "CHEMICAL", 185, 193], ["p38", "GENE_OR_GENE_PRODUCT", 13, 16], ["DON", "SIMPLE_CHEMICAL", 66, 69], ["JNK", "GENE_OR_GENE_PRODUCT", 143, 146], ["SP600125", "SIMPLE_CHEMICAL", 148, 156], ["ERK", "GENE_OR_GENE_PRODUCT", 180, 183], ["JNK", "PROTEIN", 143, 146], ["ERK", "PROTEIN", 180, 183], ["the p38 inhibitor", "TEST", 9, 26], ["SB", "TEST", 28, 30], ["DON", "TREATMENT", 66, 69], ["rRNA cleavage concentration dependently", "PROBLEM", 78, 117], ["JNK", "TEST", 143, 146], ["SP600125", "TEST", 148, 156], ["ERK", "TEST", 180, 183]]], ["Thus, as has been observed for DON-induced apoptosis, PKR, Hck, and p38 appeared to be key upstream elements for DON-induced rRNA cleavage.DON-Induced rRNA Cleavage Requires PKR, Hck, p38, p53, and Caspase Activation ::: ::: RESULTSIt was previously shown that p38 mediates the sequential activation of p53 and caspase 3 to induce apoptosis in RAW 264.7 cells (Zhou et al., 2005a).", [["RAW 264.7 cells", "ANATOMY", 344, 359], ["DON", "CHEMICAL", 31, 34], ["DON", "CHEMICAL", 113, 116], ["DON", "CHEMICAL", 139, 142], ["DON", "CHEMICAL", 31, 34], ["DON", "CHEMICAL", 113, 116], ["DON", "CHEMICAL", 139, 142], ["DON", "SIMPLE_CHEMICAL", 31, 34], ["PKR", "GENE_OR_GENE_PRODUCT", 54, 57], ["Hck", "GENE_OR_GENE_PRODUCT", 59, 62], ["p38", "GENE_OR_GENE_PRODUCT", 68, 71], ["DON", "SIMPLE_CHEMICAL", 113, 116], ["rRNA", "CELLULAR_COMPONENT", 125, 129], ["DON", "SIMPLE_CHEMICAL", 139, 142], ["PKR", "GENE_OR_GENE_PRODUCT", 174, 177], ["Hck", "GENE_OR_GENE_PRODUCT", 179, 182], ["p38", "GENE_OR_GENE_PRODUCT", 184, 187], ["p53", "GENE_OR_GENE_PRODUCT", 189, 192], ["Caspase", "GENE_OR_GENE_PRODUCT", 198, 205], ["p38", "GENE_OR_GENE_PRODUCT", 261, 264], ["p53", "GENE_OR_GENE_PRODUCT", 303, 306], ["caspase 3", "GENE_OR_GENE_PRODUCT", 311, 320], ["RAW 264.7 cells", "CELL", 344, 359], ["PKR", "PROTEIN", 54, 57], ["Hck", "PROTEIN", 59, 62], ["p38", "PROTEIN", 68, 71], ["upstream elements", "DNA", 91, 108], ["PKR", "PROTEIN", 174, 177], ["Hck", "PROTEIN", 179, 182], ["p38", "PROTEIN", 184, 187], ["p53", "PROTEIN", 189, 192], ["Caspase", "PROTEIN", 198, 205], ["p38", "PROTEIN", 261, 264], ["p53", "PROTEIN", 303, 306], ["caspase 3", "PROTEIN", 311, 320], ["RAW 264.7 cells", "CELL_LINE", 344, 359], ["DON", "PROBLEM", 31, 34], ["apoptosis", "PROBLEM", 43, 52], ["PKR", "TEST", 54, 57], ["Hck", "TEST", 59, 62], ["p38", "TEST", 68, 71], ["DON", "PROBLEM", 113, 116], ["induced rRNA cleavage", "PROBLEM", 117, 138], ["PKR", "TEST", 174, 177], ["Hck", "TEST", 179, 182], ["p38", "TEST", 184, 187], ["p53", "TEST", 189, 192], ["the sequential activation of p53", "TREATMENT", 274, 306], ["caspase", "TREATMENT", 311, 318], ["apoptosis", "PROBLEM", 331, 340]]], ["Suppression of DON-induced rRNA cleavage was observed here both for pifithrin-\u03b1 (80 and 100 \u03bcM) (Fig. 6D), which can reversibly inhibit p53-dependent transactivation of p53-responsive genes and apoptosis and for pifithrin-\u03bc (10 and 25 \u03bcM) (Fig. 6E), which blocks p53 interaction with Bcl-2 family proteins and selectively inhibits p53 translocation to mitochondria.", [["mitochondria", "ANATOMY", 352, 364], ["DON", "CHEMICAL", 15, 18], ["pifithrin-\u03b1", "CHEMICAL", 68, 79], ["pifithrin-\u03bc", "CHEMICAL", 212, 223], ["DON", "CHEMICAL", 15, 18], ["pifithrin-\u03b1", "CHEMICAL", 68, 79], ["pifithrin-\u03bc", "CHEMICAL", 212, 223], ["DON", "SIMPLE_CHEMICAL", 15, 18], ["rRNA", "CELLULAR_COMPONENT", 27, 31], ["pifithrin-\u03b1", "SIMPLE_CHEMICAL", 68, 79], ["p53", "GENE_OR_GENE_PRODUCT", 136, 139], ["p53", "GENE_OR_GENE_PRODUCT", 169, 172], ["pifithrin-\u03bc", "SIMPLE_CHEMICAL", 212, 223], ["p53", "GENE_OR_GENE_PRODUCT", 263, 266], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 284, 289], ["p53", "GENE_OR_GENE_PRODUCT", 331, 334], ["mitochondria", "CELLULAR_COMPONENT", 352, 364], ["p53", "PROTEIN", 136, 139], ["p53", "PROTEIN", 169, 172], ["responsive genes", "DNA", 173, 189], ["p53", "PROTEIN", 263, 266], ["Bcl-2 family proteins", "PROTEIN", 284, 305], ["p53", "PROTEIN", 331, 334], ["DON", "PROBLEM", 15, 18], ["induced rRNA cleavage", "PROBLEM", 19, 40], ["pifithrin", "TEST", 68, 77], ["p53", "TEST", 136, 139], ["p53-responsive genes", "PROBLEM", 169, 189], ["apoptosis", "PROBLEM", 194, 203], ["pifithrin", "TEST", 212, 221], ["p53 translocation to mitochondria", "PROBLEM", 331, 364], ["responsive genes", "OBSERVATION", 173, 189]]], ["The caspase inhibitor Z-VAD-FMK also caused concentration-dependent inhibition of DON-induced rRNA cleavage (Fig. 6F).", [["Z-VAD-FMK", "CHEMICAL", 22, 31], ["DON", "CHEMICAL", 82, 85], ["Z-VAD-FMK", "CHEMICAL", 22, 31], ["DON", "CHEMICAL", 82, 85], ["caspase", "GENE_OR_GENE_PRODUCT", 4, 11], ["Z-VAD-FMK", "SIMPLE_CHEMICAL", 22, 31], ["DON", "SIMPLE_CHEMICAL", 82, 85], ["The caspase inhibitor Z", "TREATMENT", 0, 23], ["VAD-FMK", "TREATMENT", 24, 31], ["DON", "TREATMENT", 82, 85], ["induced rRNA cleavage", "PROBLEM", 86, 107]]], ["Accordingly, both p53 and caspase activation are additional upstream elements in the signaling pathway leading to DON-induced rRNA cleavage.DON-Induced rRNA Cleavage Requires PKR, Hck, p38, p53, and Caspase Activation ::: ::: RESULTSExtrinsic and intrinsic apoptotic pathways activate caspase 3 through caspases 8 and 9, respectively.", [["DON", "CHEMICAL", 114, 117], ["DON", "CHEMICAL", 140, 143], ["DON", "CHEMICAL", 114, 117], ["DON", "CHEMICAL", 140, 143], ["p53", "GENE_OR_GENE_PRODUCT", 18, 21], ["caspase", "GENE_OR_GENE_PRODUCT", 26, 33], ["DON", "SIMPLE_CHEMICAL", 114, 117], ["rRNA", "CELLULAR_COMPONENT", 126, 130], ["DON", "SIMPLE_CHEMICAL", 140, 143], ["PKR", "GENE_OR_GENE_PRODUCT", 175, 178], ["Hck", "GENE_OR_GENE_PRODUCT", 180, 183], ["p38", "GENE_OR_GENE_PRODUCT", 185, 188], ["p53", "GENE_OR_GENE_PRODUCT", 190, 193], ["Caspase", "GENE_OR_GENE_PRODUCT", 199, 206], ["caspase 3", "GENE_OR_GENE_PRODUCT", 285, 294], ["caspases 8", "GENE_OR_GENE_PRODUCT", 303, 313], ["p53", "PROTEIN", 18, 21], ["caspase", "PROTEIN", 26, 33], ["upstream elements", "DNA", 60, 77], ["PKR", "PROTEIN", 175, 178], ["Hck", "PROTEIN", 180, 183], ["p38", "PROTEIN", 185, 188], ["p53", "PROTEIN", 190, 193], ["Caspase", "PROTEIN", 199, 206], ["caspase 3", "PROTEIN", 285, 294], ["caspases 8 and 9", "PROTEIN", 303, 319], ["both p53", "TREATMENT", 13, 21], ["caspase activation", "TREATMENT", 26, 44], ["additional upstream elements", "PROBLEM", 49, 77], ["DON", "PROBLEM", 114, 117], ["induced rRNA cleavage", "PROBLEM", 118, 139], ["PKR", "TEST", 175, 178], ["Hck", "TEST", 180, 183], ["p38", "TEST", 185, 188], ["p53", "TEST", 190, 193], ["RESULTSExtrinsic", "TREATMENT", 226, 242], ["intrinsic apoptotic pathways", "TREATMENT", 247, 275], ["caspase", "TEST", 285, 292], ["caspases", "TEST", 303, 311]]], ["To discern possible contributions of these two pathways, RAW 264.7 cells were treated with DON for 3 and 6 h and the presence of cleaved caspases 8, 9, and 3 was determined by Western blot analysis.", [["RAW 264.7 cells", "ANATOMY", 57, 72], ["DON", "CHEMICAL", 91, 94], ["DON", "CHEMICAL", 91, 94], ["RAW 264.7 cells", "CELL", 57, 72], ["DON", "SIMPLE_CHEMICAL", 91, 94], ["caspases 8", "GENE_OR_GENE_PRODUCT", 137, 147], ["9", "GENE_OR_GENE_PRODUCT", 149, 150], ["3", "GENE_OR_GENE_PRODUCT", 156, 157], ["RAW 264.7 cells", "CELL_LINE", 57, 72], ["cleaved caspases 8, 9, and 3", "PROTEIN", 129, 157], ["DON", "TREATMENT", 91, 94], ["cleaved caspases", "PROBLEM", 129, 145], ["blot analysis", "TEST", 184, 197]]], ["Cleavage of caspases 3, 8, and 9 was observed (Figs.", [["caspases 3", "GENE_OR_GENE_PRODUCT", 12, 22], ["8", "GENE_OR_GENE_PRODUCT", 24, 25], ["9", "GENE_OR_GENE_PRODUCT", 31, 32], ["caspases 3, 8, and 9", "PROTEIN", 12, 32], ["Cleavage of caspases", "TREATMENT", 0, 20]]], ["7A and 7B), suggesting that extrinsic and intrinsic pathways could potentially be involved in DON-induced rRNA fragmentation (Fig. 8).SG, Anisomycin, and Ricin but Not Lipopolysaccharide Evoke rRNA Cleavages ::: ::: RESULTSLipopolysaccharide, a major component of the outer membrane of Gram-negative bacteria that can activate macrophages via the Toll-like receptor 4 receptor, did not affect rRNA integrity indicating that the macrophage activation per se was insufficient to induce RNA cleavage.", [["outer membrane", "ANATOMY", 268, 282], ["macrophages", "ANATOMY", 327, 338], ["macrophage", "ANATOMY", 428, 438], ["DON", "CHEMICAL", 94, 97], ["SG", "CHEMICAL", 134, 136], ["Anisomycin", "CHEMICAL", 138, 148], ["Ricin", "CHEMICAL", 154, 159], ["Lipopolysaccharide", "CHEMICAL", 168, 186], ["RESULTSLipopolysaccharide", "CHEMICAL", 216, 241], ["DON", "CHEMICAL", 94, 97], ["Anisomycin", "CHEMICAL", 138, 148], ["Ricin", "CHEMICAL", 154, 159], ["DON", "SIMPLE_CHEMICAL", 94, 97], ["rRNA", "CELLULAR_COMPONENT", 106, 110], ["SG", "SIMPLE_CHEMICAL", 134, 136], ["Anisomycin", "SIMPLE_CHEMICAL", 138, 148], ["Ricin", "SIMPLE_CHEMICAL", 154, 159], ["RESULTSLipopolysaccharide", "SIMPLE_CHEMICAL", 216, 241], ["outer membrane", "CELLULAR_COMPONENT", 268, 282], ["Gram", "GENE_OR_GENE_PRODUCT", 286, 290], ["macrophages", "CELL", 327, 338], ["Toll-like receptor 4 receptor", "GENE_OR_GENE_PRODUCT", 347, 376], ["rRNA", "CELLULAR_COMPONENT", 393, 397], ["macrophage", "CELL", 428, 438], ["macrophages", "CELL_TYPE", 327, 338], ["Toll-like receptor 4 receptor", "PROTEIN", 347, 376], ["extrinsic and intrinsic pathways", "PROBLEM", 28, 60], ["induced rRNA fragmentation", "PROBLEM", 98, 124], ["SG", "TREATMENT", 134, 136], ["Anisomycin", "TREATMENT", 138, 148], ["Ricin", "TREATMENT", 154, 159], ["RESULTSLipopolysaccharide", "TREATMENT", 216, 241], ["Gram-negative bacteria", "PROBLEM", 286, 308], ["the Toll-like receptor 4 receptor", "TREATMENT", 343, 376], ["rRNA integrity", "PROBLEM", 393, 407], ["the macrophage activation", "PROBLEM", 424, 449], ["RNA cleavage", "PROBLEM", 484, 496], ["rRNA fragmentation", "OBSERVATION", 106, 124], ["major", "OBSERVATION_MODIFIER", 245, 250], ["component", "OBSERVATION_MODIFIER", 251, 260], ["outer membrane", "ANATOMY", 268, 282], ["negative bacteria", "OBSERVATION", 291, 308]]], ["Because DON is a translational inhibitor and causes rRNA cleavage indirectly, we questioned whether this might be a common effect for other ribotoxins.", [["DON", "CHEMICAL", 8, 11], ["DON", "CHEMICAL", 8, 11], ["DON", "SIMPLE_CHEMICAL", 8, 11], ["ribotoxins", "SIMPLE_CHEMICAL", 140, 150], ["a translational inhibitor", "TREATMENT", 15, 40], ["rRNA cleavage", "PROBLEM", 52, 65], ["other ribotoxins", "TREATMENT", 134, 150]]], ["Cells were incubated with SG and anisomycin, which can freely diffuse through cell membrane and ricin, a RIP, which can enter the cells by endocytosis and retrograde translocation to ER and cytosol.", [["Cells", "ANATOMY", 0, 5], ["cell membrane", "ANATOMY", 78, 91], ["cells", "ANATOMY", 130, 135], ["ER", "ANATOMY", 183, 185], ["cytosol", "ANATOMY", 190, 197], ["SG", "CHEMICAL", 26, 28], ["anisomycin", "CHEMICAL", 33, 43], ["anisomycin", "CHEMICAL", 33, 43], ["Cells", "CELL", 0, 5], ["SG", "SIMPLE_CHEMICAL", 26, 28], ["anisomycin", "SIMPLE_CHEMICAL", 33, 43], ["cell membrane", "CELLULAR_COMPONENT", 78, 91], ["ricin", "GENE_OR_GENE_PRODUCT", 96, 101], ["RIP", "GENE_OR_GENE_PRODUCT", 105, 108], ["cells", "CELL", 130, 135], ["ER", "GENE_OR_GENE_PRODUCT", 183, 185], ["cytosol", "CELLULAR_COMPONENT", 190, 197], ["RIP", "PROTEIN", 105, 108], ["ER", "PROTEIN", 183, 185], ["SG", "TREATMENT", 26, 28], ["anisomycin", "TREATMENT", 33, 43], ["a RIP", "TREATMENT", 103, 108], ["cell membrane", "OBSERVATION", 78, 91]]], ["Unlike SG and anisomycin that directly bind to ribosome to inhibit translation, ricin possesses inherent RNA N-glycosidase activity to depurinate RNA.", [["SG", "CHEMICAL", 7, 9], ["anisomycin", "CHEMICAL", 14, 24], ["anisomycin", "CHEMICAL", 14, 24], ["SG", "SIMPLE_CHEMICAL", 7, 9], ["anisomycin", "SIMPLE_CHEMICAL", 14, 24], ["ribosome", "CELLULAR_COMPONENT", 47, 55], ["ricin", "GENE_OR_GENE_PRODUCT", 80, 85], ["N-glycosidase", "GENE_OR_GENE_PRODUCT", 109, 122], ["glycosidase", "PROTEIN", 111, 122], ["depurinate RNA", "RNA", 135, 149], ["anisomycin", "TREATMENT", 14, 24], ["glycosidase activity to depurinate RNA", "PROBLEM", 111, 149]]], ["Although these toxins have apparently different mechanisms for inhibiting translation, SG, anisomycin, and ricin induced a similar apoptosis-mediated cleavage profile to that of DON (Fig. 8), suggesting that ribotoxins might share conserved pathway for mediating rRNA cleavage.DISCUSSIONUnderstanding how DON induces rRNA degradation will provide insight into the mechanisms by which trichothecenes and other ribotoxins incapacitate or kill immunocompetent cells.", [["cells", "ANATOMY", 457, 462], ["SG", "CHEMICAL", 87, 89], ["anisomycin", "CHEMICAL", 91, 101], ["ricin", "CHEMICAL", 107, 112], ["DON", "CHEMICAL", 178, 181], ["ribotoxins", "CHEMICAL", 208, 218], ["DON", "CHEMICAL", 305, 308], ["trichothecenes", "CHEMICAL", 384, 398], ["anisomycin", "CHEMICAL", 91, 101], ["DON", "CHEMICAL", 178, 181], ["DON", "CHEMICAL", 305, 308], ["trichothecenes", "CHEMICAL", 384, 398], ["SG", "SIMPLE_CHEMICAL", 87, 89], ["anisomycin", "SIMPLE_CHEMICAL", 91, 101], ["ricin", "SIMPLE_CHEMICAL", 107, 112], ["DON", "SIMPLE_CHEMICAL", 178, 181], ["ribotoxins", "GENE_OR_GENE_PRODUCT", 208, 218], ["rRNA", "CELLULAR_COMPONENT", 263, 267], ["DON", "SIMPLE_CHEMICAL", 305, 308], ["rRNA", "CELLULAR_COMPONENT", 317, 321], ["trichothecenes", "SIMPLE_CHEMICAL", 384, 398], ["ribotoxins", "GENE_OR_GENE_PRODUCT", 409, 419], ["cells", "CELL", 457, 462], ["ribotoxins", "PROTEIN", 208, 218], ["immunocompetent cells", "CELL_TYPE", 441, 462], ["SG", "TREATMENT", 87, 89], ["anisomycin", "TREATMENT", 91, 101], ["ricin", "TREATMENT", 107, 112], ["a similar apoptosis", "PROBLEM", 121, 140], ["mediating rRNA cleavage", "PROBLEM", 253, 276], ["rRNA degradation", "PROBLEM", 317, 333], ["other ribotoxins incapacitate", "TREATMENT", 403, 432], ["kill immunocompetent cells", "PROBLEM", 436, 462]]], ["The results presented here establish for the first time that (1) DON-induced cleavage at a limited number of sites in both 18S rRNA and 28S rRNA, (2) these cleavages result from PKR-driven p38 activation, (3) these events closely parallel induction of apoptosis by this mycotoxin, and (4) DON\u2019s effects are shared with other ribotoxic agents.DISCUSSIONIn higher eukaryotes, 28S rRNA contains 12 conserved but variable divergent domains (D1\u2013D12), originating from evolutionary large-scale length and diversity expansions (Michot et al., 1984).", [["DON", "CHEMICAL", 65, 68], ["DON", "CHEMICAL", 289, 292], ["DON", "CHEMICAL", 65, 68], ["DON", "CHEMICAL", 289, 292], ["DON", "SIMPLE_CHEMICAL", 65, 68], ["18S", "GENE_OR_GENE_PRODUCT", 123, 126], ["rRNA", "CELLULAR_COMPONENT", 127, 131], ["28S", "CELLULAR_COMPONENT", 136, 139], ["rRNA", "CELLULAR_COMPONENT", 140, 144], ["PKR", "GENE_OR_GENE_PRODUCT", 178, 181], ["p38", "GENE_OR_GENE_PRODUCT", 189, 192], ["DON", "SIMPLE_CHEMICAL", 289, 292], ["28S", "CELLULAR_COMPONENT", 374, 377], ["rRNA", "CELLULAR_COMPONENT", 378, 382], ["D1\u2013D12", "GENE_OR_GENE_PRODUCT", 437, 443], ["18S rRNA", "RNA", 123, 131], ["28S rRNA", "RNA", 136, 144], ["PKR", "PROTEIN", 178, 181], ["p38", "PROTEIN", 189, 192], ["28S rRNA", "DNA", 374, 382], ["divergent domains", "DNA", 418, 435], ["D1", "PROTEIN", 437, 439], ["induced cleavage", "PROBLEM", 69, 85], ["28S rRNA", "TEST", 136, 144], ["these cleavages", "TEST", 150, 165], ["PKR", "TEST", 178, 181], ["apoptosis", "PROBLEM", 252, 261], ["this mycotoxin", "TREATMENT", 265, 279], ["other ribotoxic agents", "TREATMENT", 319, 341], ["28S rRNA", "TEST", 374, 382], ["diversity expansions", "PROBLEM", 499, 519], ["large", "OBSERVATION_MODIFIER", 476, 481], ["scale length", "OBSERVATION_MODIFIER", 482, 494], ["diversity", "OBSERVATION_MODIFIER", 499, 508], ["expansions", "OBSERVATION_MODIFIER", 509, 519]]], ["Although the functions of D domains are not clearly understood, D2 and D8 have higher divergency rates than other domains (Houge et al., 1995).", [["D", "GENE_OR_GENE_PRODUCT", 26, 27], ["D domains", "PROTEIN", 26, 35], ["D2", "PROTEIN", 64, 66], ["D8", "PROTEIN", 71, 73], ["higher divergency rates", "PROBLEM", 79, 102]]], ["Mouse 28S rRNA cleavage sites have been mapped to be within D2 (approximately 400\u20131140 nts) and/or D8 domains (approximately 2700\u20133280 nts) (Houge et al., 1993; Houge et al., 1995; Houge and Doskeland, 1996; Naito et al., 2009).", [["Mouse", "ORGANISM", 0, 5], ["28S", "GENE_OR_GENE_PRODUCT", 6, 9], ["D2", "DNA", 60, 62], ["D8 domains", "DNA", 99, 109], ["Mouse", "SPECIES", 0, 5], ["Mouse 28S rRNA cleavage sites", "PROBLEM", 0, 29]]], ["Apoptosis-associated cleavage pathways were previously reported to target D2 and D8 followed by secondary cleavage in other domains.", [["D2", "PROTEIN", 74, 76], ["D8", "PROTEIN", 81, 83], ["Apoptosis", "TEST", 0, 9], ["cleavage pathways", "PROBLEM", 21, 38], ["secondary cleavage in other domains", "PROBLEM", 96, 131]]], ["As demonstrated here, DON-induced rRNA cleavage fragments (b\u2013f) were from the D8 region, whereas two other cleavage sites (a and e) were within D10 (approximately 3785\u20133822 nts) (Michot et al., 1984) rather than canonical D2.", [["DON", "CHEMICAL", 22, 25], ["DON", "CHEMICAL", 22, 25], ["DON", "SIMPLE_CHEMICAL", 22, 25], ["D8 region", "DNA", 78, 87], ["cleavage sites", "DNA", 107, 121], ["D10", "DNA", 144, 147], ["D2", "DNA", 222, 224], ["DON-induced rRNA cleavage fragments", "PROBLEM", 22, 57], ["rRNA cleavage", "OBSERVATION", 34, 47], ["fragments", "OBSERVATION_MODIFIER", 48, 57]]], ["It might be speculated that DON treatment rendered D8 and D10 accessible to constitutive and/or inducible RNases, whereas D2 did not.DISCUSSIONWe have previously reported that upregulated expression of several RNases in DON-treated RAW 264.7 cells occurs prior to or simultaneously with rRNA degradation (Li and Pestka, 2008).", [["RAW 264.7 cells", "ANATOMY", 232, 247], ["DON", "CHEMICAL", 28, 31], ["DON", "CHEMICAL", 220, 223], ["RAW", "CHEMICAL", 232, 235], ["DON", "CHEMICAL", 28, 31], ["DON", "CHEMICAL", 220, 223], ["DON", "SIMPLE_CHEMICAL", 28, 31], ["DON", "SIMPLE_CHEMICAL", 220, 223], ["RAW 264.7 cells", "CELL", 232, 247], ["RNases", "PROTEIN", 106, 112], ["D2", "PROTEIN", 122, 124], ["RNases", "PROTEIN", 210, 216], ["DON-treated RAW 264.7 cells", "CELL_LINE", 220, 247], ["DON treatment", "TREATMENT", 28, 41], ["D8", "TREATMENT", 51, 53], ["D10", "TREATMENT", 58, 61], ["constitutive and/or inducible RNases", "PROBLEM", 76, 112], ["several RNases in DON", "PROBLEM", 202, 223], ["rRNA degradation", "PROBLEM", 287, 303]]], ["Particularly notable was RNase L, an enzyme that can mediate inhibition of protein synthesis, apoptosis induction, and antiviral activity (Stark et al., 1998).", [["RNase L", "GENE_OR_GENE_PRODUCT", 25, 32], ["RNase L", "PROTEIN", 25, 32], ["an enzyme", "TEST", 34, 43], ["protein synthesis", "PROBLEM", 75, 92], ["apoptosis induction", "TREATMENT", 94, 113], ["protein synthesis", "OBSERVATION", 75, 92]]], ["Although RNase L is activated by a number of stressors, its only known endogenous direct activator is 2-5A, a product of oligoadenylate synthetase (Pandey et al., 2004; Liang et al., 2006).", [["oligoadenylate", "CHEMICAL", 121, 135], ["RNase L", "GENE_OR_GENE_PRODUCT", 9, 16], ["2-5A", "GENE_OR_GENE_PRODUCT", 102, 106], ["oligoadenylate synthetase", "GENE_OR_GENE_PRODUCT", 121, 146], ["RNase L", "PROTEIN", 9, 16], ["oligoadenylate synthetase", "PROTEIN", 121, 146], ["oligoadenylate synthetase", "TREATMENT", 121, 146], ["oligoadenylate synthetase", "OBSERVATION", 121, 146]]], ["Upon binding to 2\u20135A, RNase L is activated by dimerization and possibly inhibits protein synthesis via the degradation of both messenger RNA and 28S rRNA (Clemens and Vaquero, 1978; Wreschner et al., 1981).", [["2\u20135A", "GENE_OR_GENE_PRODUCT", 16, 20], ["RNase L", "GENE_OR_GENE_PRODUCT", 22, 29], ["28S rRNA", "GENE_OR_GENE_PRODUCT", 145, 153], ["2\u20135A", "PROTEIN", 16, 20], ["RNase L", "PROTEIN", 22, 29], ["messenger RNA", "RNA", 127, 140], ["28S rRNA", "DNA", 145, 153], ["protein synthesis", "PROBLEM", 81, 98], ["messenger RNA", "OBSERVATION", 127, 140]]], ["We found that under cell-free conditions in the presence of 2-5A, RNase L readily cleaved both FRET probe and purified rRNA; however, it did not degrade rRNA in purified whole ribosomes (see supplementary fig. 1).", [["cell", "ANATOMY", 20, 24], ["ribosomes", "ANATOMY", 176, 185], ["cell", "CELL", 20, 24], ["2-5A", "SIMPLE_CHEMICAL", 60, 64], ["RNase L", "GENE_OR_GENE_PRODUCT", 66, 73], ["rRNA", "CELLULAR_COMPONENT", 119, 123], ["rRNA", "CELLULAR_COMPONENT", 153, 157], ["ribosomes", "CELLULAR_COMPONENT", 176, 185], ["RNase L", "PROTEIN", 66, 73], ["FRET probe", "DNA", 95, 105], ["rRNA", "RNA", 153, 157]]], ["Furthermore, transfection of 2-5A and RNase L activator (RLA) into RAW 264.7 cells did not induce rRNA cleavage.", [["RAW 264.7 cells", "ANATOMY", 67, 82], ["2-5A", "GENE_OR_GENE_PRODUCT", 29, 33], ["RNase L activator", "GENE_OR_GENE_PRODUCT", 38, 55], ["RLA", "GENE_OR_GENE_PRODUCT", 57, 60], ["RAW 264.7 cells", "CELL", 67, 82], ["RNase L activator", "PROTEIN", 38, 55], ["RLA", "PROTEIN", 57, 60], ["RAW 264.7 cells", "CELL_LINE", 67, 82], ["transfection", "TEST", 13, 25], ["RNase L activator (RLA)", "TREATMENT", 38, 61], ["rRNA cleavage", "PROBLEM", 98, 111]]], ["Thus, increased RNase L activity alone might likely be insufficient for inducing rRNA cleavage in RAW 264.7.DISCUSSIONThe observation that p38 but not JNK mediated DON-induced rRNA cleavage is consistent with previous observations that p38 is a central regulator of cell fate in DON-exposed macrophages (Zhou et al., 2005a).", [["RAW 264.7", "ANATOMY", 98, 107], ["cell", "ANATOMY", 266, 270], ["macrophages", "ANATOMY", 291, 302], ["RAW", "CHEMICAL", 98, 101], ["DON", "CHEMICAL", 164, 167], ["DON", "CHEMICAL", 279, 282], ["DON", "CHEMICAL", 164, 167], ["DON", "CHEMICAL", 279, 282], ["RNase L", "GENE_OR_GENE_PRODUCT", 16, 23], ["rRNA", "CELLULAR_COMPONENT", 81, 85], ["RAW 264.7", "CELL", 98, 107], ["p38", "GENE_OR_GENE_PRODUCT", 139, 142], ["JNK", "GENE_OR_GENE_PRODUCT", 151, 154], ["DON", "SIMPLE_CHEMICAL", 164, 167], ["rRNA", "CELLULAR_COMPONENT", 176, 180], ["p38", "GENE_OR_GENE_PRODUCT", 236, 239], ["cell", "CELL", 266, 270], ["DON", "SIMPLE_CHEMICAL", 279, 282], ["macrophages", "CELL", 291, 302], ["RNase L", "PROTEIN", 16, 23], ["RAW 264.7", "CELL_LINE", 98, 107], ["p38", "PROTEIN", 139, 142], ["JNK", "PROTEIN", 151, 154], ["p38", "PROTEIN", 236, 239], ["DON-exposed macrophages", "CELL_LINE", 279, 302], ["increased RNase L activity", "TREATMENT", 6, 32], ["inducing rRNA cleavage", "PROBLEM", 72, 94], ["p38", "TEST", 139, 142], ["JNK mediated DON", "PROBLEM", 151, 167], ["rRNA cleavage", "PROBLEM", 176, 189], ["increased", "OBSERVATION_MODIFIER", 6, 15], ["RNase L activity", "OBSERVATION_MODIFIER", 16, 32], ["consistent with", "UNCERTAINTY", 193, 208], ["macrophages", "ANATOMY", 291, 302]]], ["Our findings further demonstrate that PKR and Hck also mediate DON-induced rRNA cleavage.", [["DON", "CHEMICAL", 63, 66], ["DON", "CHEMICAL", 63, 66], ["PKR", "GENE_OR_GENE_PRODUCT", 38, 41], ["Hck", "GENE_OR_GENE_PRODUCT", 46, 49], ["DON", "SIMPLE_CHEMICAL", 63, 66], ["rRNA", "CELLULAR_COMPONENT", 75, 79], ["PKR", "PROTEIN", 38, 41], ["Hck", "PROTEIN", 46, 49], ["PKR", "TEST", 38, 41], ["Hck", "TEST", 46, 49], ["induced rRNA cleavage", "PROBLEM", 67, 88]]], ["Although crosstalk between PKR and Hck is still not completely understood, these kinases are well-established upstream mediators of DON-induced p38 activation (Zhou et al., 2003b, 2005b).", [["DON", "CHEMICAL", 132, 135], ["DON", "CHEMICAL", 132, 135], ["PKR", "GENE_OR_GENE_PRODUCT", 27, 30], ["Hck", "GENE_OR_GENE_PRODUCT", 35, 38], ["DON", "SIMPLE_CHEMICAL", 132, 135], ["p38", "GENE_OR_GENE_PRODUCT", 144, 147], ["PKR", "PROTEIN", 27, 30], ["Hck", "PROTEIN", 35, 38], ["kinases", "PROTEIN", 81, 88], ["p38", "PROTEIN", 144, 147], ["PKR", "TEST", 27, 30]]], ["These data are consistent with our previous observations that 40S ribosome subunit-associated PKR, Hck, and p38 are activated upon DON exposure (Bae et al., 2010).DISCUSSIONWe have previously hypothesized that rRNA cleavage might yield a double-stranded (ds) hairpin fragments capable of activating ribosome-associated PKR through its dsRNA-binding sites (Li and Pestka, 2008).", [["fragments", "ANATOMY", 267, 276], ["ribosome", "ANATOMY", 299, 307], ["DON", "CHEMICAL", 131, 134], ["DON", "CHEMICAL", 131, 134], ["40S ribosome subunit", "GENE_OR_GENE_PRODUCT", 62, 82], ["PKR", "GENE_OR_GENE_PRODUCT", 94, 97], ["Hck", "GENE_OR_GENE_PRODUCT", 99, 102], ["p38", "GENE_OR_GENE_PRODUCT", 108, 111], ["DON", "SIMPLE_CHEMICAL", 131, 134], ["rRNA", "CELLULAR_COMPONENT", 210, 214], ["ribosome", "CELLULAR_COMPONENT", 299, 307], ["PKR", "GENE_OR_GENE_PRODUCT", 319, 322], ["40S ribosome subunit", "PROTEIN", 62, 82], ["PKR", "PROTEIN", 94, 97], ["Hck", "PROTEIN", 99, 102], ["p38", "PROTEIN", 108, 111], ["double-stranded (ds) hairpin fragments", "DNA", 238, 276], ["PKR", "PROTEIN", 319, 322], ["dsRNA-binding sites", "DNA", 335, 354], ["PKR", "TEST", 94, 97], ["Hck", "TEST", 99, 102], ["rRNA cleavage", "PROBLEM", 210, 223], ["a double-stranded (ds) hairpin fragments", "TREATMENT", 236, 276], ["activating ribosome", "PROBLEM", 288, 307], ["consistent with", "UNCERTAINTY", 15, 30]]], ["The data presented here do not support this hypothesis.", [["this hypothesis", "PROBLEM", 39, 54]]], ["First, PKR and Hck are activated by DON within minutes (Zhou et al., 2003b, 2005b), whereas DON-induced rRNA cleavage was detectable only after 2 h and required relatively higher DON concentrations.", [["DON", "CHEMICAL", 36, 39], ["DON", "CHEMICAL", 92, 95], ["DON", "CHEMICAL", 179, 182], ["DON", "CHEMICAL", 36, 39], ["DON", "CHEMICAL", 92, 95], ["DON", "CHEMICAL", 179, 182], ["PKR", "GENE_OR_GENE_PRODUCT", 7, 10], ["Hck", "GENE_OR_GENE_PRODUCT", 15, 18], ["DON", "SIMPLE_CHEMICAL", 36, 39], ["DON", "SIMPLE_CHEMICAL", 92, 95], ["rRNA", "CELLULAR_COMPONENT", 104, 108], ["DON", "SIMPLE_CHEMICAL", 179, 182], ["PKR", "PROTEIN", 7, 10], ["Hck", "PROTEIN", 15, 18], ["PKR", "TEST", 7, 10], ["rRNA cleavage", "PROBLEM", 104, 117], ["relatively higher DON concentrations", "TREATMENT", 161, 197]]], ["Second, suppression of DON-induced rRNA cleavage by PKR, Hck, and p38 inhibitors suggests that their activation is an upstream rather than downstream event.", [["DON", "CHEMICAL", 23, 26], ["DON", "CHEMICAL", 23, 26], ["DON", "SIMPLE_CHEMICAL", 23, 26], ["rRNA", "CELLULAR_COMPONENT", 35, 39], ["PKR", "GENE_OR_GENE_PRODUCT", 52, 55], ["Hck", "GENE_OR_GENE_PRODUCT", 57, 60], ["p38", "GENE_OR_GENE_PRODUCT", 66, 69], ["PKR", "PROTEIN", 52, 55], ["Hck", "PROTEIN", 57, 60], ["DON", "PROBLEM", 23, 26], ["induced rRNA cleavage", "PROBLEM", 27, 48], ["PKR", "TEST", 52, 55], ["Hck", "TEST", 57, 60], ["p38 inhibitors", "TREATMENT", 66, 80]]], ["We therefore propose an alternative hypothesis in which entry of DON into the cell rapidly disrupts the conformation of rRNA yielding accessible intact hairpin loops at the surface of ribosome that would be capable of activating PKR or other double-stranded RNA\u2013binding proteins.", [["cell", "ANATOMY", 78, 82], ["surface", "ANATOMY", 173, 180], ["ribosome", "ANATOMY", 184, 192], ["DON", "CHEMICAL", 65, 68], ["DON", "CHEMICAL", 65, 68], ["DON", "SIMPLE_CHEMICAL", 65, 68], ["cell", "CELL", 78, 82], ["rRNA", "CELLULAR_COMPONENT", 120, 124], ["surface", "CELLULAR_COMPONENT", 173, 180], ["ribosome", "CELLULAR_COMPONENT", 184, 192], ["PKR", "GENE_OR_GENE_PRODUCT", 229, 232], ["PKR", "PROTEIN", 229, 232], ["double-stranded RNA\u2013binding proteins", "PROTEIN", 242, 278], ["an alternative hypothesis", "PROBLEM", 21, 46], ["rRNA", "PROBLEM", 120, 124], ["accessible intact hairpin loops", "PROBLEM", 134, 165], ["activating PKR", "PROBLEM", 218, 232], ["other double-stranded RNA\u2013binding proteins", "PROBLEM", 236, 278], ["intact", "OBSERVATION", 145, 151], ["hairpin loops", "OBSERVATION", 152, 165]]], ["These events would initiate a stress response that would, especially at high toxin concentrations, ultimately drive rRNA cleavage in concert with apoptosis.", [["rRNA", "CELLULAR_COMPONENT", 116, 120], ["a stress response", "PROBLEM", 28, 45], ["high toxin concentrations", "PROBLEM", 72, 97], ["rRNA cleavage", "PROBLEM", 116, 129], ["apoptosis", "PROBLEM", 146, 155]]], ["This hypothesis is highly consistent with the growing recognition that damage-associated molecular patterns (DAMPs) initiate noninfectious innate immune and inflammatory responses (Newton and Dixit, 2012).DISCUSSION", [["inflammatory responses", "PROBLEM", 157, 179], ["highly consistent with", "UNCERTAINTY", 19, 41], ["noninfectious", "OBSERVATION_MODIFIER", 125, 138], ["inflammatory", "OBSERVATION_MODIFIER", 157, 169]]]], "PMC7481863": [["IntroductionThe emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the coronavirus disease 2019 (COVID-19), is a global public health crisis.", [["acute respiratory syndrome coronavirus", "DISEASE", 40, 78], ["coronavirus disease", "DISEASE", 122, 141], ["COVID-19", "CHEMICAL", 148, 156], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 33, 80], ["SARS-CoV-2", "ORGANISM", 82, 92], ["severe acute respiratory syndrome coronavirus", "SPECIES", 33, 78], ["SARS-CoV-2", "SPECIES", 82, 92], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 29, 78], ["SARS-CoV", "TEST", 82, 90], ["the coronavirus disease", "PROBLEM", 118, 141], ["COVID", "TEST", 148, 153], ["a global public health crisis", "PROBLEM", 162, 191], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["respiratory syndrome", "OBSERVATION", 46, 66], ["coronavirus disease", "OBSERVATION", 122, 141], ["global", "OBSERVATION_MODIFIER", 164, 170], ["public", "OBSERVATION", 171, 177], ["health crisis", "OBSERVATION", 178, 191]]], ["Although respiratory symptoms mainly characterize this disease [1], SARS-CoV-2 has the potential to affect the nervous system, causing a wide range of neurological manifestations [2].", [["respiratory", "ANATOMY", 9, 20], ["nervous system", "ANATOMY", 111, 125], ["neurological", "ANATOMY", 151, 163], ["respiratory symptoms", "DISEASE", 9, 29], ["SARS", "DISEASE", 68, 72], ["SARS-CoV-2", "ORGANISM", 68, 78], ["nervous system", "ANATOMICAL_SYSTEM", 111, 125], ["SARS-CoV", "SPECIES", 68, 76], ["respiratory symptoms", "PROBLEM", 9, 29], ["this disease", "PROBLEM", 50, 62], ["SARS", "PROBLEM", 68, 72], ["neurological manifestations", "PROBLEM", 151, 178], ["nervous system", "ANATOMY", 111, 125]]], ["The spectrum of neurological findings observed in COVID-19 patients is associated with the affection of the brain and peripheral nerves.", [["neurological", "ANATOMY", 16, 28], ["brain", "ANATOMY", 108, 113], ["peripheral nerves", "ANATOMY", 118, 135], ["patients", "ORGANISM", 59, 67], ["brain", "ORGAN", 108, 113], ["peripheral nerves", "MULTI-TISSUE_STRUCTURE", 118, 135], ["patients", "SPECIES", 59, 67], ["neurological findings", "TEST", 16, 37], ["the affection of the brain and peripheral nerves", "PROBLEM", 87, 135], ["affection", "OBSERVATION", 91, 100], ["brain", "ANATOMY", 108, 113], ["peripheral nerves", "ANATOMY", 118, 135]]], ["In contrast, only a few reports have described the involvement of the spinal cord [3], [4], [5].", [["spinal cord", "ANATOMY", 70, 81], ["the involvement of the spinal cord", "PROBLEM", 47, 81], ["spinal cord", "ANATOMY", 70, 81]]], ["Also, little literature exists about the risk of patients with chronic degenerative disorders of the spine for exacerbations of their underlying conditions after SARS-CoV-2 infection.IntroductionHere, we report the case of a patient with chronic silent cervical spondylotic myelopathy who manifested neurological symptoms of spinal cord injury only after getting infected with the novel SARS-CoV-2.", [["spine", "ANATOMY", 101, 106], ["cervical", "ANATOMY", 253, 261], ["neurological", "ANATOMY", 300, 312], ["spinal cord", "ANATOMY", 325, 336], ["degenerative disorders of the spine", "DISEASE", 71, 106], ["SARS-CoV-2 infection", "DISEASE", 162, 182], ["cervical spondylotic myelopathy", "DISEASE", 253, 284], ["cord injury", "DISEASE", 332, 343], ["SARS", "DISEASE", 387, 391], ["patients", "ORGANISM", 49, 57], ["spine", "ORGAN", 101, 106], ["CoV-2", "ORGANISM", 167, 172], ["patient", "ORGANISM", 225, 232], ["spinal cord", "ORGAN", 325, 336], ["patients", "SPECIES", 49, 57], ["patient", "SPECIES", 225, 232], ["chronic degenerative disorders of the spine", "PROBLEM", 63, 106], ["exacerbations", "PROBLEM", 111, 124], ["their underlying conditions", "PROBLEM", 128, 155], ["SARS", "PROBLEM", 162, 166], ["CoV-2 infection", "PROBLEM", 167, 182], ["chronic silent cervical spondylotic myelopathy", "PROBLEM", 238, 284], ["neurological symptoms", "PROBLEM", 300, 321], ["spinal cord injury", "PROBLEM", 325, 343], ["chronic", "OBSERVATION_MODIFIER", 63, 70], ["degenerative", "OBSERVATION", 71, 83], ["spine", "ANATOMY", 101, 106], ["infection", "OBSERVATION", 173, 182], ["cervical spondylotic", "ANATOMY", 253, 273], ["myelopathy", "OBSERVATION", 274, 284], ["spinal cord", "ANATOMY", 325, 336], ["injury", "OBSERVATION", 337, 343]]], ["Our report provides evidence of the potential of COVID-19 to unmask and exacerbate chronic degenerative spinal conditions.Case presentationA 73-year-old right-handed man attended our center with a history of sub-acute quadriparesis, urinary retention, and fecal constipation.", [["spinal", "ANATOMY", 104, 110], ["urinary", "ANATOMY", 233, 240], ["fecal", "ANATOMY", 256, 261], ["quadriparesis", "DISEASE", 218, 231], ["urinary retention", "DISEASE", 233, 250], ["fecal constipation", "DISEASE", 256, 274], ["COVID-19", "CHEMICAL", 49, 57], ["man", "ORGANISM", 166, 169], ["urinary", "ORGANISM_SUBDIVISION", 233, 240], ["man", "SPECIES", 166, 169], ["COVID", "TEST", 49, 54], ["chronic degenerative spinal conditions", "PROBLEM", 83, 121], ["sub-acute quadriparesis", "PROBLEM", 208, 231], ["urinary retention", "PROBLEM", 233, 250], ["fecal constipation", "PROBLEM", 256, 274], ["chronic", "OBSERVATION_MODIFIER", 83, 90], ["degenerative", "OBSERVATION", 91, 103], ["spinal", "ANATOMY", 104, 110], ["acute", "OBSERVATION_MODIFIER", 212, 217], ["quadriparesis", "OBSERVATION", 218, 231], ["urinary", "ANATOMY", 233, 240], ["retention", "OBSERVATION", 241, 250], ["fecal", "ANATOMY", 256, 261], ["constipation", "OBSERVATION", 262, 274]]], ["Six weeks earlier, he tested positive for SARS-CoV-2 infection by real-time polymerase chain reaction (RT-PCR) in a nasopharyngeal swab sample.", [["nasopharyngeal swab sample", "ANATOMY", 116, 142], ["infection", "DISEASE", 53, 62], ["SARS-CoV-2", "ORGANISM", 42, 52], ["nasopharyngeal swab", "CANCER", 116, 135], ["SARS-CoV", "SPECIES", 42, 50], ["SARS", "PROBLEM", 42, 46], ["CoV", "PROBLEM", 47, 50], ["2 infection", "PROBLEM", 51, 62], ["real-time polymerase chain reaction", "PROBLEM", 66, 101], ["RT-PCR", "TEST", 103, 109], ["a nasopharyngeal swab sample", "TEST", 114, 142], ["nasopharyngeal", "ANATOMY", 116, 130]]], ["He presented a fever that remitted with antipyretics as his only clinical manifestation of illness.", [["fever", "DISEASE", 15, 20], ["a fever", "PROBLEM", 13, 20], ["antipyretics", "TREATMENT", 40, 52], ["illness", "PROBLEM", 91, 98], ["fever", "OBSERVATION", 15, 20]]], ["Seven days later, he developed acute urinary retention and fecal constipation, requiring admission to another hospital, vesical catheterization, and evacuating enemas.", [["urinary", "ANATOMY", 37, 44], ["fecal", "ANATOMY", 59, 64], ["vesical", "ANATOMY", 120, 127], ["urinary retention", "DISEASE", 37, 54], ["fecal constipation", "DISEASE", 59, 77], ["urinary", "ORGANISM_SUBDIVISION", 37, 44], ["vesical", "MULTI-TISSUE_STRUCTURE", 120, 127], ["acute urinary retention", "PROBLEM", 31, 54], ["fecal constipation", "PROBLEM", 59, 77], ["vesical catheterization", "TEST", 120, 143], ["evacuating enemas", "TREATMENT", 149, 166], ["acute", "OBSERVATION_MODIFIER", 31, 36], ["urinary", "ANATOMY", 37, 44], ["retention", "OBSERVATION", 45, 54], ["fecal constipation", "OBSERVATION", 59, 77], ["vesical", "ANATOMY", 120, 127], ["catheterization", "OBSERVATION", 128, 143]]], ["After three days, the patient developed myoclonic movements in both lower limbs that progressed to paraparesis.", [["lower limbs", "ANATOMY", 68, 79], ["myoclonic movements", "DISEASE", 40, 59], ["paraparesis", "DISEASE", 99, 110], ["patient", "ORGANISM", 22, 29], ["lower limbs", "ORGANISM_SUBDIVISION", 68, 79], ["patient", "SPECIES", 22, 29], ["myoclonic movements in both lower limbs", "PROBLEM", 40, 79], ["paraparesis", "PROBLEM", 99, 110], ["myoclonic movements", "OBSERVATION", 40, 59], ["both", "ANATOMY_MODIFIER", 63, 67], ["lower limbs", "ANATOMY", 68, 79], ["paraparesis", "OBSERVATION", 99, 110]]], ["He received unspecified medical management and discharged with minimal clinical improvement.", [["unspecified medical management", "TREATMENT", 12, 42]]], ["During the following month, he was evaluated by a gastroenterologist and a urologist, who ruled out primary disorders of the gastrointestinal and urinary tracts.", [["gastrointestinal", "ANATOMY", 125, 141], ["urinary tracts", "ANATOMY", 146, 160], ["primary disorders of the gastrointestinal and urinary tracts", "DISEASE", 100, 160], ["gastrointestinal", "ORGAN", 125, 141], ["urinary tracts", "PATHOLOGICAL_FORMATION", 146, 160], ["primary disorders of the gastrointestinal and urinary tracts", "PROBLEM", 100, 160], ["gastrointestinal", "ANATOMY", 125, 141], ["urinary tracts", "ANATOMY", 146, 160]]], ["Over such a period, he developed irradiated cervical pain and weakness of the upper limbs.", [["cervical", "ANATOMY", 44, 52], ["upper limbs", "ANATOMY", 78, 89], ["cervical pain", "DISEASE", 44, 57], ["weakness of the upper limbs", "DISEASE", 62, 89], ["cervical", "ORGANISM_SUBDIVISION", 44, 52], ["upper limbs", "ORGANISM_SUBDIVISION", 78, 89], ["irradiated cervical pain", "PROBLEM", 33, 57], ["weakness of the upper limbs", "PROBLEM", 62, 89], ["cervical", "ANATOMY", 44, 52], ["pain", "OBSERVATION", 53, 57], ["weakness", "OBSERVATION", 62, 70], ["upper limbs", "ANATOMY", 78, 89]]], ["Also, he presented a weight loss of 6 kilograms due to reduced food intake as a result of fecal constipation and restrictive abdominal distention.", [["fecal", "ANATOMY", 90, 95], ["abdominal", "ANATOMY", 125, 134], ["weight loss", "DISEASE", 21, 32], ["fecal constipation", "DISEASE", 90, 108], ["abdominal distention", "DISEASE", 125, 145], ["fecal", "ORGANISM_SUBDIVISION", 90, 95], ["abdominal", "ORGANISM_SUBDIVISION", 125, 134], ["a weight loss", "PROBLEM", 19, 32], ["reduced food intake", "PROBLEM", 55, 74], ["fecal constipation", "PROBLEM", 90, 108], ["restrictive abdominal distention", "PROBLEM", 113, 145], ["fecal", "ANATOMY", 90, 95], ["constipation", "OBSERVATION", 96, 108], ["restrictive", "OBSERVATION_MODIFIER", 113, 124], ["abdominal", "ANATOMY", 125, 134], ["distention", "OBSERVATION", 135, 145]]], ["The patient was referred to our center with the clinical suspicion of an upper spinal cord injury.Case presentationHis past medical history was unremarkable other than occasional alcohol consumption.", [["upper spinal cord", "ANATOMY", 73, 90], ["cord injury", "DISEASE", 86, 97], ["alcohol", "CHEMICAL", 179, 186], ["alcohol", "CHEMICAL", 179, 186], ["patient", "ORGANISM", 4, 11], ["upper", "ORGANISM_SUBDIVISION", 73, 78], ["spinal cord", "ORGANISM_SUBDIVISION", 79, 90], ["alcohol", "SIMPLE_CHEMICAL", 179, 186], ["patient", "SPECIES", 4, 11], ["an upper spinal cord injury", "PROBLEM", 70, 97], ["upper", "ANATOMY_MODIFIER", 73, 78], ["spinal cord", "ANATOMY", 79, 90], ["injury", "OBSERVATION", 91, 97], ["unremarkable", "OBSERVATION", 144, 156]]], ["He was a half-marathon runner (last running six months before symptoms onset) otherwise healthy.", [["symptoms", "PROBLEM", 62, 70]]], ["On admission, the patient was alert, oriented to person, place, and time.", [["patient", "ORGANISM", 18, 25], ["patient", "SPECIES", 18, 25], ["person", "SPECIES", 49, 55]]], ["The physical examination was relevant for painful abdominal distention, which also conditioned restrictive respiratory distress.", [["abdominal", "ANATOMY", 50, 59], ["respiratory", "ANATOMY", 107, 118], ["abdominal distention", "DISEASE", 50, 70], ["respiratory distress", "DISEASE", 107, 127], ["abdominal", "ORGANISM_SUBDIVISION", 50, 59], ["The physical examination", "TEST", 0, 24], ["painful abdominal distention", "PROBLEM", 42, 70], ["restrictive respiratory distress", "PROBLEM", 95, 127], ["abdominal", "ANATOMY", 50, 59], ["distention", "OBSERVATION", 60, 70], ["restrictive", "OBSERVATION_MODIFIER", 95, 106], ["respiratory distress", "OBSERVATION", 107, 127]]], ["His neurological examination showed general hyperreflexia and muscle weakness of left predominance.", [["neurological", "ANATOMY", 4, 16], ["muscle", "ANATOMY", 62, 68], ["hyperreflexia", "DISEASE", 44, 57], ["muscle weakness", "DISEASE", 62, 77], ["muscle", "ORGAN", 62, 68], ["His neurological examination", "TEST", 0, 28], ["general hyperreflexia", "PROBLEM", 36, 57], ["muscle weakness of left predominance", "PROBLEM", 62, 98], ["hyperreflexia", "OBSERVATION", 44, 57], ["muscle", "ANATOMY", 62, 68], ["weakness", "OBSERVATION", 69, 77], ["left", "ANATOMY_MODIFIER", 81, 85]]], ["Also, he presented the Babinski sign in the left lower limb and hyperalgesia in both left limbs.", [["left lower limb", "ANATOMY", 44, 59], ["left limbs", "ANATOMY", 85, 95], ["hyperalgesia", "DISEASE", 64, 76], ["left", "ORGANISM_SUBDIVISION", 44, 48], ["lower limb", "ORGANISM_SUBDIVISION", 49, 59], ["limbs", "ORGANISM_SUBDIVISION", 90, 95], ["the Babinski sign", "TEST", 19, 36], ["hyperalgesia in both left limbs", "PROBLEM", 64, 95], ["Babinski", "OBSERVATION", 23, 31], ["left", "ANATOMY_MODIFIER", 44, 48], ["lower limb", "ANATOMY", 49, 59], ["hyperalgesia", "OBSERVATION", 64, 76], ["both", "ANATOMY_MODIFIER", 80, 84], ["left", "ANATOMY_MODIFIER", 85, 89], ["limbs", "ANATOMY", 90, 95]]], ["He was unable to stand and walk unaided, and his gait was ataxic.", [["ataxic", "DISEASE", 58, 64], ["He", "ORGANISM", 0, 2], ["ataxic", "PROBLEM", 58, 64]]], ["The cerebellum was not evaluable clinically due to the presence of motor deficits, and meningeal signs were negative.", [["cerebellum", "ANATOMY", 4, 14], ["meningeal", "ANATOMY", 87, 96], ["motor deficits", "DISEASE", 67, 81], ["cerebellum", "ORGAN", 4, 14], ["motor deficits", "PROBLEM", 67, 81], ["meningeal signs", "TEST", 87, 102], ["cerebellum", "ANATOMY", 4, 14], ["motor deficits", "OBSERVATION", 67, 81], ["meningeal", "ANATOMY", 87, 96]]], ["The patient\u0301s clinical findings were consistent with the American Spinal Injury Association (ASIA) impairment scale Grade B [6].Case presentationDue to the recent antecedent of COVID-19, we suspected of an immune-mediated neuropathy vs. acute non-traumatic myelitis.", [["Spinal Injury", "DISEASE", 66, 79], ["neuropathy", "DISEASE", 222, 232], ["acute non-traumatic myelitis", "DISEASE", 237, 265], ["the American Spinal Injury", "PROBLEM", 53, 79], ["COVID", "TEST", 177, 182], ["an immune-mediated neuropathy", "PROBLEM", 203, 232], ["acute non-traumatic myelitis", "PROBLEM", 237, 265], ["consistent with", "UNCERTAINTY", 37, 52], ["Spinal", "ANATOMY", 66, 72], ["Injury", "OBSERVATION", 73, 79], ["neuropathy", "OBSERVATION", 222, 232], ["non-traumatic", "OBSERVATION_MODIFIER", 243, 256], ["myelitis", "OBSERVATION", 257, 265]]], ["The results of the laboratory workup showed hemoglobin of 13.3g/dL, platelets 249,000 (109/L), glucose 98.6mg/dL, and normal white blood cell counts.", [["platelets", "ANATOMY", 68, 77], ["white blood cell", "ANATOMY", 125, 141], ["glucose", "CHEMICAL", 95, 102], ["glucose", "CHEMICAL", 95, 102], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 44, 54], ["platelets", "CELL", 68, 77], ["glucose", "SIMPLE_CHEMICAL", 95, 102], ["white blood cell", "CELL", 125, 141], ["hemoglobin", "PROTEIN", 44, 54], ["platelets", "CELL_TYPE", 68, 77], ["the laboratory workup", "TEST", 15, 36], ["hemoglobin", "TEST", 44, 54], ["dL", "TEST", 64, 66], ["platelets", "TEST", 68, 77], ["glucose", "TEST", 95, 102], ["white blood cell counts", "TEST", 125, 148]]], ["Also, thyroid, liver, and renal function parameters, as well as the metabolic panel, lipid panel, prothrombin time (PT), partial thromboplastin time (PPT), International Normalized Ratio (INR), fibrinogen, procalcitonin, MB fraction of creatine phosphokinase (CPK-MB), serum levels of calcium, magnesium, sodium, potassium, and chloride were normal.", [["thyroid", "ANATOMY", 6, 13], ["liver", "ANATOMY", 15, 20], ["renal", "ANATOMY", 26, 31], ["serum", "ANATOMY", 269, 274], ["creatine", "CHEMICAL", 236, 244], ["calcium", "CHEMICAL", 285, 292], ["magnesium", "CHEMICAL", 294, 303], ["sodium", "CHEMICAL", 305, 311], ["potassium", "CHEMICAL", 313, 322], ["chloride", "CHEMICAL", 328, 336], ["creatine", "CHEMICAL", 236, 244], ["calcium", "CHEMICAL", 285, 292], ["magnesium", "CHEMICAL", 294, 303], ["sodium", "CHEMICAL", 305, 311], ["potassium", "CHEMICAL", 313, 322], ["chloride", "CHEMICAL", 328, 336], ["thyroid", "ORGAN", 6, 13], ["liver", "ORGAN", 15, 20], ["renal", "ORGAN", 26, 31], ["prothrombin", "GENE_OR_GENE_PRODUCT", 98, 109], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 129, 143], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 194, 204], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 206, 219], ["MB", "SIMPLE_CHEMICAL", 221, 223], ["creatine phosphokinase", "GENE_OR_GENE_PRODUCT", 236, 258], ["CPK-MB", "GENE_OR_GENE_PRODUCT", 260, 266], ["serum", "ORGANISM_SUBSTANCE", 269, 274], ["calcium", "SIMPLE_CHEMICAL", 285, 292], ["magnesium", "SIMPLE_CHEMICAL", 294, 303], ["sodium", "SIMPLE_CHEMICAL", 305, 311], ["potassium", "SIMPLE_CHEMICAL", 313, 322], ["chloride", "SIMPLE_CHEMICAL", 328, 336], ["INR", "PROTEIN", 188, 191], ["fibrinogen", "PROTEIN", 194, 204], ["procalcitonin", "PROTEIN", 206, 219], ["creatine phosphokinase", "PROTEIN", 236, 258], ["CPK", "PROTEIN", 260, 263], ["the metabolic panel", "TEST", 64, 83], ["lipid panel", "TEST", 85, 96], ["prothrombin time", "TEST", 98, 114], ["PT", "TEST", 116, 118], ["partial thromboplastin time", "TEST", 121, 148], ["PPT", "TEST", 150, 153], ["International Normalized Ratio", "TEST", 156, 186], ["INR", "TEST", 188, 191], ["fibrinogen", "TEST", 194, 204], ["procalcitonin", "TEST", 206, 219], ["MB fraction", "TEST", 221, 232], ["creatine phosphokinase", "TEST", 236, 258], ["CPK", "TEST", 260, 263], ["MB", "TEST", 264, 266], ["serum levels", "TEST", 269, 281], ["calcium", "TEST", 285, 292], ["magnesium", "TEST", 294, 303], ["sodium", "TEST", 305, 311], ["potassium", "TEST", 313, 322], ["chloride", "TEST", 328, 336], ["thyroid", "ANATOMY", 6, 13], ["liver", "ANATOMY", 15, 20], ["renal", "ANATOMY", 26, 31], ["normal", "OBSERVATION", 342, 348]]], ["The cerebrospinal fluid (CSF) analysis showed normal opening pressure, glucose 92mg/dL, proteins of 34.7mg/dL, normal adenosine deaminase, and no cells, oligoclonal bands, nor bacterial growth.", [["cerebrospinal fluid", "ANATOMY", 4, 23], ["cells", "ANATOMY", 146, 151], ["glucose", "CHEMICAL", 71, 78], ["adenosine", "CHEMICAL", 118, 127], ["glucose", "CHEMICAL", 71, 78], ["adenosine", "CHEMICAL", 118, 127], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 4, 23], ["CSF", "ORGANISM_SUBSTANCE", 25, 28], ["glucose", "SIMPLE_CHEMICAL", 71, 78], ["adenosine deaminase", "GENE_OR_GENE_PRODUCT", 118, 137], ["cells", "CELL", 146, 151], ["normal adenosine deaminase", "PROTEIN", 111, 137], ["The cerebrospinal fluid (CSF) analysis", "TEST", 0, 38], ["glucose", "TEST", 71, 78], ["proteins", "TEST", 88, 96], ["cells", "PROBLEM", 146, 151], ["oligoclonal bands", "PROBLEM", 153, 170], ["bacterial growth", "PROBLEM", 176, 192], ["cerebrospinal", "ANATOMY", 4, 17], ["fluid", "OBSERVATION", 18, 23], ["opening pressure", "OBSERVATION", 53, 69], ["adenosine deaminase", "OBSERVATION", 118, 137], ["no", "UNCERTAINTY", 143, 145], ["oligoclonal bands", "OBSERVATION", 153, 170], ["bacterial growth", "OBSERVATION", 176, 192]]], ["Assessment of other acute phase reactants and tumoral markers showed erythrocyte sedimentation rate (ESR) of 12mm/h, C-reactive protein (CRP) of 2mg/L, rheumatoid factor (RF) 40IU/mL, D-dimer 2.28mg/L, carcinoembryonic antigen (CEA) 0.69ng/mL, carbohydrate antigen CA 19-9 159.4U/mL, and alpha-fetoprotein (AFP) 1.44ng/mL.Case presentationThe thoracoabdominal computed tomography (CT) scan was relevant for bowel distention and retained excessive stool in the small intestine and colon, but negative for pneumonia, tumor, and lymphadenopathy (Figure 1).", [["tumoral", "ANATOMY", 46, 53], ["erythrocyte", "ANATOMY", 69, 80], ["bowel", "ANATOMY", 407, 412], ["stool", "ANATOMY", 447, 452], ["small intestine", "ANATOMY", 460, 475], ["colon", "ANATOMY", 480, 485], ["tumor", "ANATOMY", 515, 520], ["bowel distention", "DISEASE", 407, 423], ["pneumonia", "DISEASE", 504, 513], ["tumor", "DISEASE", 515, 520], ["lymphadenopathy", "DISEASE", 526, 541], ["carbohydrate", "CHEMICAL", 244, 256], ["tumoral", "CANCER", 46, 53], ["erythrocyte", "CELL", 69, 80], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 117, 135], ["CRP", "GENE_OR_GENE_PRODUCT", 137, 140], ["rheumatoid factor", "GENE_OR_GENE_PRODUCT", 152, 169], ["D-dimer", "SIMPLE_CHEMICAL", 184, 191], ["carcinoembryonic antigen", "GENE_OR_GENE_PRODUCT", 202, 226], ["CEA", "GENE_OR_GENE_PRODUCT", 228, 231], ["alpha-fetoprotein", "GENE_OR_GENE_PRODUCT", 288, 305], ["AFP", "GENE_OR_GENE_PRODUCT", 307, 310], ["bowel", "ORGAN", 407, 412], ["stool", "ORGANISM_SUBSTANCE", 447, 452], ["small intestine", "ORGAN", 460, 475], ["colon", "ORGAN", 480, 485], ["tumor", "CANCER", 515, 520], ["tumoral markers", "PROTEIN", 46, 61], ["C-reactive protein", "PROTEIN", 117, 135], ["CRP", "PROTEIN", 137, 140], ["rheumatoid factor", "PROTEIN", 152, 169], ["RF", "PROTEIN", 171, 173], ["D-dimer", "PROTEIN", 184, 191], ["carcinoembryonic antigen", "PROTEIN", 202, 226], ["CEA", "PROTEIN", 228, 231], ["carbohydrate antigen CA 19", "PROTEIN", 244, 270], ["alpha-fetoprotein", "PROTEIN", 288, 305], ["AFP", "PROTEIN", 307, 310], ["Assessment of other acute phase reactants", "TEST", 0, 41], ["tumoral markers", "TEST", 46, 61], ["erythrocyte sedimentation rate", "TEST", 69, 99], ["ESR", "TEST", 101, 104], ["C-reactive protein", "TEST", 117, 135], ["CRP", "TEST", 137, 140], ["rheumatoid factor", "TEST", 152, 169], ["D-dimer", "TEST", 184, 191], ["carcinoembryonic antigen", "TEST", 202, 226], ["CEA", "TEST", 228, 231], ["carbohydrate antigen CA", "TEST", 244, 267], ["alpha-fetoprotein", "TEST", 288, 305], ["AFP", "TEST", 307, 310], ["The thoracoabdominal computed tomography (CT) scan", "TEST", 339, 389], ["bowel distention", "PROBLEM", 407, 423], ["retained excessive stool in the small intestine and colon", "PROBLEM", 428, 485], ["pneumonia", "PROBLEM", 504, 513], ["tumor", "PROBLEM", 515, 520], ["lymphadenopathy", "PROBLEM", 526, 541], ["acute", "OBSERVATION_MODIFIER", 20, 25], ["thoracoabdominal", "ANATOMY", 343, 359], ["bowel", "ANATOMY", 407, 412], ["distention", "OBSERVATION", 413, 423], ["excessive", "OBSERVATION_MODIFIER", 437, 446], ["stool", "OBSERVATION", 447, 452], ["small intestine", "ANATOMY", 460, 475], ["colon", "ANATOMY", 480, 485], ["negative for", "UNCERTAINTY", 491, 503], ["pneumonia", "OBSERVATION", 504, 513], ["tumor", "OBSERVATION", 515, 520], ["lymphadenopathy", "OBSERVATION", 526, 541]]], ["Magnetic resonance imaging (MRI) of the brain was normal (Figure 2).", [["brain", "ANATOMY", 40, 45], ["brain", "ORGAN", 40, 45], ["Magnetic resonance imaging (MRI) of the brain", "TEST", 0, 45], ["brain", "ANATOMY", 40, 45], ["normal", "OBSERVATION", 50, 56]]], ["T2-weighted MRI of the spinal cord revealed enlargement of the posterior arch of the atlas (C1), and multiple anterior and posterior compressions at segments C3-C6 of the spinal cord associated with intervertebral disc herniations and yellow ligament hypertrophy (Figure 3a).", [["spinal cord", "ANATOMY", 23, 34], ["posterior arch", "ANATOMY", 63, 77], ["atlas", "ANATOMY", 85, 90], ["anterior", "ANATOMY", 110, 118], ["spinal cord", "ANATOMY", 171, 182], ["intervertebral disc herniations", "ANATOMY", 199, 230], ["yellow ligament", "ANATOMY", 235, 250], ["intervertebral disc herniations", "DISEASE", 199, 230], ["hypertrophy", "DISEASE", 251, 262], ["spinal cord", "ORGAN", 23, 34], ["posterior arch", "MULTI-TISSUE_STRUCTURE", 63, 77], ["anterior", "MULTI-TISSUE_STRUCTURE", 110, 118], ["spinal cord", "ORGAN", 171, 182], ["intervertebral disc", "TISSUE", 199, 218], ["ligament", "TISSUE", 242, 250], ["C3", "PROTEIN", 158, 160], ["T2-weighted MRI of the spinal cord", "TEST", 0, 34], ["enlargement", "PROBLEM", 44, 55], ["multiple anterior and posterior compressions at segments C3", "PROBLEM", 101, 160], ["intervertebral disc herniations", "PROBLEM", 199, 230], ["yellow ligament hypertrophy", "PROBLEM", 235, 262], ["spinal cord", "ANATOMY", 23, 34], ["enlargement", "OBSERVATION", 44, 55], ["posterior", "ANATOMY_MODIFIER", 63, 72], ["arch", "ANATOMY_MODIFIER", 73, 77], ["atlas", "ANATOMY_MODIFIER", 85, 90], ["C1", "ANATOMY_MODIFIER", 92, 94], ["multiple", "OBSERVATION_MODIFIER", 101, 109], ["anterior", "ANATOMY_MODIFIER", 110, 118], ["posterior", "ANATOMY_MODIFIER", 123, 132], ["compressions", "OBSERVATION", 133, 145], ["segments", "ANATOMY_MODIFIER", 149, 157], ["C3", "ANATOMY_MODIFIER", 158, 160], ["C6", "ANATOMY_MODIFIER", 161, 163], ["spinal cord", "ANATOMY", 171, 182], ["intervertebral", "ANATOMY_MODIFIER", 199, 213], ["disc", "ANATOMY", 214, 218], ["herniations", "OBSERVATION", 219, 230], ["yellow ligament hypertrophy", "OBSERVATION", 235, 262]]], ["These compressions conditioned myelopathy manifested as an intramedullary hyperintensity at segments C2-C3, which was not characteristic of acute transverse myelitis (ATM; Figure 3b).", [["myelopathy", "DISEASE", 31, 41], ["acute transverse myelitis", "DISEASE", 140, 165], ["C2", "PROTEIN", 101, 103], ["These compressions conditioned myelopathy", "PROBLEM", 0, 41], ["an intramedullary hyperintensity at segments C2-C3", "PROBLEM", 56, 106], ["acute transverse myelitis", "PROBLEM", 140, 165], ["myelopathy", "OBSERVATION", 31, 41], ["intramedullary", "ANATOMY_MODIFIER", 59, 73], ["hyperintensity", "OBSERVATION", 74, 88], ["segments", "ANATOMY_MODIFIER", 92, 100], ["C2", "ANATOMY_MODIFIER", 101, 103], ["C3", "ANATOMY", 104, 106], ["not characteristic of", "UNCERTAINTY", 118, 139], ["acute", "OBSERVATION_MODIFIER", 140, 145], ["transverse", "OBSERVATION_MODIFIER", 146, 156], ["myelitis", "OBSERVATION", 157, 165]]], ["Also, stenoses at segments L1-S1 of the spine were observed (Figure 3c).", [["spine", "ANATOMY", 40, 45], ["stenoses", "DISEASE", 6, 14], ["spine", "ORGAN", 40, 45], ["L1", "DNA", 27, 29], ["stenoses at segments L1", "PROBLEM", 6, 29], ["stenoses", "OBSERVATION", 6, 14], ["segments", "ANATOMY_MODIFIER", 18, 26], ["L1", "ANATOMY_MODIFIER", 27, 29], ["S1", "ANATOMY_MODIFIER", 30, 32], ["spine", "ANATOMY", 40, 45]]], ["The spinal nerve roots looked normal at all levels, including the cauda equina.Case presentationAdministration of methylprednisolone 1g IV for two days caused improvement of the motor deficits.", [["spinal nerve roots", "ANATOMY", 4, 22], ["cauda equina", "ANATOMY", 66, 78], ["methylprednisolone", "CHEMICAL", 114, 132], ["motor deficits", "DISEASE", 178, 192], ["methylprednisolone", "CHEMICAL", 114, 132], ["spinal nerve roots", "MULTI-TISSUE_STRUCTURE", 4, 22], ["methylprednisolone", "SIMPLE_CHEMICAL", 114, 132], ["methylprednisolone", "TREATMENT", 114, 132], ["the motor deficits", "PROBLEM", 174, 192], ["spinal", "ANATOMY_MODIFIER", 4, 10], ["nerve roots", "ANATOMY", 11, 22], ["normal", "OBSERVATION", 30, 36], ["cauda equina", "ANATOMY", 66, 78], ["motor deficits", "OBSERVATION", 178, 192]]], ["However, bowel and bladder dysfunction remained unchanged.", [["bowel", "ANATOMY", 9, 14], ["bladder", "ANATOMY", 19, 26], ["bowel and bladder dysfunction", "DISEASE", 9, 38], ["bowel", "ORGAN", 9, 14], ["bladder", "ORGAN", 19, 26], ["bowel and bladder dysfunction", "PROBLEM", 9, 38], ["bowel", "ANATOMY", 9, 14], ["bladder", "ANATOMY", 19, 26], ["dysfunction", "OBSERVATION", 27, 38], ["unchanged", "OBSERVATION_MODIFIER", 48, 57]]], ["Due to the risk of permanent serious neurological dysfunction and respiratory failure resulting from the affection of the upper spinal cord, we decided on the surgical decompression of the cervical stenoses.", [["neurological", "ANATOMY", 37, 49], ["respiratory", "ANATOMY", 66, 77], ["upper spinal cord", "ANATOMY", 122, 139], ["cervical stenoses", "ANATOMY", 189, 206], ["neurological dysfunction", "DISEASE", 37, 61], ["respiratory failure", "DISEASE", 66, 85], ["cervical stenoses", "DISEASE", 189, 206], ["upper", "ORGANISM_SUBDIVISION", 122, 127], ["spinal cord", "ORGAN", 128, 139], ["cervical stenoses", "PATHOLOGICAL_FORMATION", 189, 206], ["permanent serious neurological dysfunction", "PROBLEM", 19, 61], ["respiratory failure", "PROBLEM", 66, 85], ["the affection of the upper spinal cord", "PROBLEM", 101, 139], ["the surgical decompression", "TREATMENT", 155, 181], ["the cervical stenoses", "PROBLEM", 185, 206], ["permanent", "OBSERVATION_MODIFIER", 19, 28], ["serious", "OBSERVATION_MODIFIER", 29, 36], ["respiratory failure", "OBSERVATION", 66, 85], ["upper", "ANATOMY_MODIFIER", 122, 127], ["spinal cord", "ANATOMY", 128, 139], ["cervical", "ANATOMY", 189, 197], ["stenoses", "OBSERVATION", 198, 206]]], ["We performed a resection of the posterior arch of C1 and laminectomy of C3-C6 by a posterior approach without postoperative complications.", [["posterior arch", "ANATOMY", 32, 46], ["posterior arch", "MULTI-TISSUE_STRUCTURE", 32, 46], ["C3", "PROTEIN", 72, 74], ["a resection of the posterior arch of C1", "TREATMENT", 13, 52], ["laminectomy of C3-C6", "TREATMENT", 57, 77], ["a posterior approach", "TREATMENT", 81, 101], ["postoperative complications", "PROBLEM", 110, 137], ["resection", "OBSERVATION", 15, 24], ["posterior", "ANATOMY_MODIFIER", 32, 41], ["arch", "ANATOMY_MODIFIER", 42, 46], ["C1", "ANATOMY", 50, 52], ["laminectomy", "OBSERVATION", 57, 68], ["C3", "ANATOMY_MODIFIER", 72, 74], ["C6", "ANATOMY_MODIFIER", 75, 77], ["posterior", "ANATOMY_MODIFIER", 83, 92], ["without", "UNCERTAINTY", 102, 109], ["postoperative complications", "OBSERVATION", 110, 137]]], ["For this procedure, neurosurgeons, anesthesiologists, and nurse personnel were required to wear an N95 mask and appropriate personal protective equipment (PPE).", [["this procedure", "TREATMENT", 4, 18], ["an N95 mask", "TREATMENT", 96, 107]]], ["After the surgery, we continued the steroid administration for an additional three days.", [["steroid", "CHEMICAL", 36, 43], ["steroid", "CHEMICAL", 36, 43], ["steroid", "SIMPLE_CHEMICAL", 36, 43], ["the surgery", "TREATMENT", 6, 17], ["the steroid administration", "TREATMENT", 32, 58]]], ["The patient recovered the muscle strength of his upper and lower limbs and was able to stand with assistance seven days after surgery (ASIA Grade B).", [["muscle", "ANATOMY", 26, 32], ["upper", "ANATOMY", 49, 54], ["lower limbs", "ANATOMY", 59, 70], ["patient", "ORGANISM", 4, 11], ["muscle", "ORGAN", 26, 32], ["upper", "ORGANISM_SUBDIVISION", 49, 54], ["lower limbs", "ORGANISM_SUBDIVISION", 59, 70], ["patient", "SPECIES", 4, 11], ["surgery", "TREATMENT", 126, 133], ["muscle", "ANATOMY", 26, 32], ["upper", "ANATOMY_MODIFIER", 49, 54], ["lower limbs", "ANATOMY", 59, 70]]], ["Also, he presented an improvement of his intestinal motility and was able to pass stool.", [["intestinal", "ANATOMY", 41, 51], ["intestinal", "ORGAN", 41, 51], ["stool", "ORGANISM_SUBSTANCE", 82, 87], ["his intestinal motility", "PROBLEM", 37, 60], ["improvement", "OBSERVATION_MODIFIER", 22, 33], ["intestinal", "ANATOMY", 41, 51]]], ["A postoperative MRI of the cervical spine showed no residual compressions of the spinal cord (Figure 3d).", [["cervical spine", "ANATOMY", 27, 41], ["spinal cord", "ANATOMY", 81, 92], ["cervical spine", "MULTI-TISSUE_STRUCTURE", 27, 41], ["spinal cord", "ORGAN", 81, 92], ["A postoperative MRI of the cervical spine", "TEST", 0, 41], ["residual compressions of the spinal cord", "PROBLEM", 52, 92], ["cervical spine", "ANATOMY", 27, 41], ["no", "UNCERTAINTY", 49, 51], ["residual compressions", "OBSERVATION", 52, 73], ["spinal cord", "ANATOMY", 81, 92]]], ["The decompression of the lumbar canal was postponed.", [["lumbar canal", "ANATOMY", 25, 37], ["lumbar canal", "MULTI-TISSUE_STRUCTURE", 25, 37], ["The decompression of the lumbar canal", "TREATMENT", 0, 37], ["decompression", "OBSERVATION", 4, 17], ["lumbar canal", "ANATOMY", 25, 37]]], ["He was discharged with a urinary catheter and scheduled for neurological and bladder rehabilitation.", [["urinary", "ANATOMY", 25, 32], ["neurological", "ANATOMY", 60, 72], ["bladder", "ANATOMY", 77, 84], ["neurological and bladder rehabilitation", "DISEASE", 60, 99], ["bladder", "ORGAN", 77, 84], ["a urinary catheter", "TREATMENT", 23, 41], ["neurological and bladder rehabilitation", "TREATMENT", 60, 99], ["urinary", "ANATOMY", 25, 32], ["catheter", "OBSERVATION", 33, 41], ["bladder", "ANATOMY", 77, 84]]], ["The patient provided informed consent for the publication of the case report.DiscussionThe COVID-19 pandemic has modified the routine workflow of several areas of medicine, including spine surgery.", [["spine", "ANATOMY", 183, 188], ["patient", "ORGANISM", 4, 11], ["spine", "ORGANISM_SUBDIVISION", 183, 188], ["patient", "SPECIES", 4, 11], ["medicine", "TREATMENT", 163, 171], ["spine surgery", "TREATMENT", 183, 196], ["spine", "ANATOMY", 183, 188]]], ["In many centers, urgent spinal surgery has been reserved only for conditions of high risk for severe neurological sequela, and most procedures have been conducted following strict recommendations of PPE usage [7].", [["spinal", "ANATOMY", 24, 30], ["neurological", "ANATOMY", 101, 113], ["neurological sequela", "DISEASE", 101, 121], ["spinal", "ORGAN", 24, 30], ["urgent spinal surgery", "TREATMENT", 17, 38], ["severe neurological sequela", "PROBLEM", 94, 121], ["PPE usage", "TREATMENT", 199, 208], ["spinal", "ANATOMY", 24, 30], ["surgery", "OBSERVATION", 31, 38]]], ["Elective surgeries have been canceled or postponed to preventing possible contagions.", [["Elective surgeries", "TREATMENT", 0, 18], ["contagions", "PROBLEM", 74, 84]]], ["However, due to the continuously increasing number of COVID-19 cases around the world, it is highly likely that neurosurgeons would have to provide medical care to individuals with active COVID-19 and underlying disorders of the spine.", [["spine", "ANATOMY", 229, 234], ["disorders of the spine", "DISEASE", 212, 234], ["spine", "ORGAN", 229, 234], ["COVID", "TEST", 54, 59], ["active COVID", "TEST", 181, 193], ["underlying disorders of the spine", "PROBLEM", 201, 234], ["highly likely", "UNCERTAINTY", 93, 106], ["spine", "ANATOMY", 229, 234]]], ["Furthermore, patients with chronic degenerative spinal diseases may be at risk of acute disease exacerbations caused by the infection with SARS-CoV-2.DiscussionHere, we described the case of an elderly patient with a chronic subclinical cervical spondylotic myelopathy that developed neurological manifestations of acute spinal cord injury some days after getting infected with the novel SARS-CoV-2.", [["spinal", "ANATOMY", 48, 54], ["cervical", "ANATOMY", 237, 245], ["neurological", "ANATOMY", 284, 296], ["spinal cord", "ANATOMY", 321, 332], ["degenerative spinal diseases", "DISEASE", 35, 63], ["infection", "DISEASE", 124, 133], ["SARS", "DISEASE", 139, 143], ["cervical spondylotic myelopathy", "DISEASE", 237, 268], ["cord injury", "DISEASE", 328, 339], ["SARS", "DISEASE", 388, 392], ["patients", "ORGANISM", 13, 21], ["SARS-CoV-2", "ORGANISM", 139, 149], ["patient", "ORGANISM", 202, 209], ["spinal cord", "ORGAN", 321, 332], ["patients", "SPECIES", 13, 21], ["patient", "SPECIES", 202, 209], ["SARS-CoV", "SPECIES", 139, 147], ["chronic degenerative spinal diseases", "PROBLEM", 27, 63], ["acute disease exacerbations", "PROBLEM", 82, 109], ["the infection", "PROBLEM", 120, 133], ["SARS", "PROBLEM", 139, 143], ["a chronic subclinical cervical spondylotic myelopathy", "PROBLEM", 215, 268], ["neurological manifestations", "PROBLEM", 284, 311], ["acute spinal cord injury", "PROBLEM", 315, 339], ["chronic", "OBSERVATION_MODIFIER", 27, 34], ["degenerative", "OBSERVATION", 35, 47], ["spinal", "ANATOMY", 48, 54], ["diseases", "OBSERVATION", 55, 63], ["acute", "OBSERVATION_MODIFIER", 82, 87], ["disease", "OBSERVATION", 88, 95], ["infection", "OBSERVATION", 124, 133], ["chronic", "OBSERVATION_MODIFIER", 217, 224], ["subclinical", "OBSERVATION_MODIFIER", 225, 236], ["cervical spondylotic", "ANATOMY", 237, 257], ["myelopathy", "OBSERVATION", 258, 268], ["acute", "OBSERVATION_MODIFIER", 315, 320], ["spinal cord", "ANATOMY", 321, 332], ["injury", "OBSERVATION", 333, 339]]], ["We found particularly important to communicate this case as it illustrates an acute exacerbation of a chronic subclinical degenerative process of the spine/spinal cord induced by COVID-19.", [["spine", "ANATOMY", 150, 155], ["spinal cord", "ANATOMY", 156, 167], ["COVID-19", "CHEMICAL", 179, 187], ["COVID-19", "CHEMICAL", 179, 187], ["spine", "ORGAN", 150, 155], ["spinal cord", "ORGAN", 156, 167], ["an acute exacerbation", "PROBLEM", 75, 96], ["a chronic subclinical degenerative process of the spine/spinal cord", "PROBLEM", 100, 167], ["COVID", "TEST", 179, 184], ["acute", "OBSERVATION_MODIFIER", 78, 83], ["exacerbation", "OBSERVATION", 84, 96], ["chronic", "OBSERVATION_MODIFIER", 102, 109], ["subclinical", "OBSERVATION_MODIFIER", 110, 121], ["degenerative", "OBSERVATION", 122, 134], ["spine", "ANATOMY", 150, 155], ["spinal cord", "ANATOMY", 156, 167]]], ["In fact, our patient had stable clinical cervical myelopathy and was able to practice high-intensity sports until the SARS-CoV-2 infection precipitated the neurological decline.DiscussionThis case differs from other reports of COVID-19 patients with acute spinal cord injury.", [["cervical", "ANATOMY", 41, 49], ["neurological", "ANATOMY", 156, 168], ["spinal cord", "ANATOMY", 256, 267], ["cervical myelopathy", "DISEASE", 41, 60], ["SARS", "DISEASE", 118, 122], ["infection", "DISEASE", 129, 138], ["neurological decline", "DISEASE", 156, 176], ["cord injury", "DISEASE", 263, 274], ["patient", "ORGANISM", 13, 20], ["cervical", "ORGAN", 41, 49], ["SARS-CoV-2", "ORGANISM", 118, 128], ["patients", "ORGANISM", 236, 244], ["spinal cord", "ORGAN", 256, 267], ["patient", "SPECIES", 13, 20], ["patients", "SPECIES", 236, 244], ["stable clinical cervical myelopathy", "PROBLEM", 25, 60], ["the SARS", "TEST", 114, 122], ["2 infection", "PROBLEM", 127, 138], ["the neurological decline", "PROBLEM", 152, 176], ["acute spinal cord injury", "PROBLEM", 250, 274], ["stable", "OBSERVATION_MODIFIER", 25, 31], ["cervical", "ANATOMY", 41, 49], ["myelopathy", "OBSERVATION", 50, 60], ["infection", "OBSERVATION", 129, 138], ["neurological decline", "OBSERVATION", 156, 176], ["acute", "OBSERVATION_MODIFIER", 250, 255], ["spinal cord", "ANATOMY", 256, 267], ["injury", "OBSERVATION", 268, 274]]], ["Those cases have been characterized by ATM in individuals with a history of respiratory symptoms and with no demonstrated structural alterations of the spine [3], [4], [5].", [["respiratory", "ANATOMY", 76, 87], ["spine", "ANATOMY", 152, 157], ["respiratory symptoms", "DISEASE", 76, 96], ["ATM", "GENE_OR_GENE_PRODUCT", 39, 42], ["ATM", "PROTEIN", 39, 42], ["respiratory symptoms", "PROBLEM", 76, 96], ["structural alterations of the spine", "PROBLEM", 122, 157], ["spine", "ANATOMY", 152, 157]]], ["Conversely, our case does not resemble a classic ATM, since the T2-weighted MRI of the spinal cord showed an intramedullary hyperintensity occupying only two cervical segments, which coincided with the sites of spondylosis, whereas ATM mostly affects the thoracic spinal cord [8].", [["spinal cord", "ANATOMY", 87, 98], ["cervical segments", "ANATOMY", 158, 175], ["sites", "ANATOMY", 202, 207], ["thoracic spinal cord", "ANATOMY", 255, 275], ["spondylosis", "DISEASE", 211, 222], ["ATM", "GENE_OR_GENE_PRODUCT", 49, 52], ["spinal cord", "ORGAN", 87, 98], ["cervical segments", "MULTI-TISSUE_STRUCTURE", 158, 175], ["ATM", "GENE_OR_GENE_PRODUCT", 232, 235], ["ATM", "PROTEIN", 49, 52], ["T2", "DNA", 64, 66], ["ATM", "PROTEIN", 232, 235], ["the T2-weighted MRI of the spinal cord", "TEST", 60, 98], ["an intramedullary hyperintensity", "PROBLEM", 106, 138], ["spondylosis", "PROBLEM", 211, 222], ["spinal cord", "ANATOMY", 87, 98], ["intramedullary", "OBSERVATION_MODIFIER", 109, 123], ["hyperintensity", "OBSERVATION", 124, 138], ["two", "ANATOMY_MODIFIER", 154, 157], ["cervical segments", "ANATOMY", 158, 175], ["spondylosis", "OBSERVATION", 211, 222], ["thoracic", "ANATOMY_MODIFIER", 255, 263], ["spinal cord", "ANATOMY", 264, 275]]], ["Furthermore, we did not observe enlargement of the affected cervical segments, nor enhancement of the leptomeninges and dorsal nerve roots, which are features of parainfectious and idiopathic ATM [8].", [["cervical segments", "ANATOMY", 60, 77], ["leptomeninges", "ANATOMY", 102, 115], ["dorsal nerve roots", "ANATOMY", 120, 138], ["cervical segments", "MULTI-TISSUE_STRUCTURE", 60, 77], ["leptomeninges", "MULTI-TISSUE_STRUCTURE", 102, 115], ["dorsal nerve roots", "MULTI-TISSUE_STRUCTURE", 120, 138], ["enlargement of the affected cervical segments", "PROBLEM", 32, 77], ["enhancement of the leptomeninges and dorsal nerve roots", "PROBLEM", 83, 138], ["parainfectious and idiopathic ATM", "PROBLEM", 162, 195], ["enlargement", "OBSERVATION", 32, 43], ["affected", "ANATOMY_MODIFIER", 51, 59], ["cervical segments", "ANATOMY", 60, 77], ["enhancement", "OBSERVATION_MODIFIER", 83, 94], ["leptomeninges", "OBSERVATION", 102, 115], ["dorsal", "ANATOMY_MODIFIER", 120, 126], ["nerve roots", "ANATOMY", 127, 138], ["parainfectious", "OBSERVATION_MODIFIER", 162, 176], ["idiopathic", "OBSERVATION_MODIFIER", 181, 191]]], ["Also, the CSF analysis of our patient was not inflammatory, although the delayed diagnostic evaluation of our patient did not allow us to analyze the CSF during the acute phase of the patient\u0301s illness.", [["CSF", "GENE_OR_GENE_PRODUCT", 10, 13], ["patient", "ORGANISM", 30, 37], ["patient", "ORGANISM", 110, 117], ["CSF", "GENE_OR_GENE_PRODUCT", 150, 153], ["patient", "SPECIES", 30, 37], ["patient", "SPECIES", 110, 117], ["the CSF analysis", "TEST", 6, 22], ["inflammatory", "PROBLEM", 46, 58], ["the delayed diagnostic evaluation", "TEST", 69, 102], ["the CSF", "TEST", 146, 153], ["the patient\u0301s illness", "PROBLEM", 180, 201], ["not", "UNCERTAINTY", 42, 45], ["inflammatory", "OBSERVATION_MODIFIER", 46, 58]]], ["Furthermore, our patient showed clinical improvement after treatment with steroids and decompressive surgery, even when these interventions were administered six weeks after disease onset.DiscussionInterestingly, our patient did not present respiratory symptoms.", [["respiratory", "ANATOMY", 241, 252], ["steroids", "CHEMICAL", 74, 82], ["respiratory symptoms", "DISEASE", 241, 261], ["steroids", "CHEMICAL", 74, 82], ["patient", "ORGANISM", 17, 24], ["patient", "ORGANISM", 217, 224], ["patient", "SPECIES", 17, 24], ["patient", "SPECIES", 217, 224], ["treatment", "TREATMENT", 59, 68], ["steroids", "TREATMENT", 74, 82], ["decompressive surgery", "TREATMENT", 87, 108], ["these interventions", "TREATMENT", 120, 139], ["disease onset", "PROBLEM", 174, 187], ["respiratory symptoms", "PROBLEM", 241, 261]]], ["This supports a possible neurotropism for SARS-CoV-2 and suggests that direct effects driven by the virus could cause the spinal cord injury.", [["spinal cord", "ANATOMY", 122, 133], ["SARS", "DISEASE", 42, 46], ["cord injury", "DISEASE", 129, 140], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 42, 52], ["spinal cord", "ORGAN", 122, 133], ["SARS-CoV", "SPECIES", 42, 50], ["SARS", "PROBLEM", 42, 46], ["CoV", "TEST", 47, 50], ["direct effects", "PROBLEM", 71, 85], ["the virus", "PROBLEM", 96, 105], ["the spinal cord injury", "PROBLEM", 118, 140], ["possible", "UNCERTAINTY", 16, 24], ["spinal cord", "ANATOMY", 122, 133], ["injury", "OBSERVATION", 134, 140]]], ["The chronic inflammatory process induced by ischemia and mechanical compression could make the spinal cord more prone to the detrimental effects of the infection.", [["spinal cord", "ANATOMY", 95, 106], ["ischemia", "DISEASE", 44, 52], ["infection", "DISEASE", 152, 161], ["spinal cord", "ORGAN", 95, 106], ["The chronic inflammatory process", "PROBLEM", 0, 32], ["ischemia", "PROBLEM", 44, 52], ["mechanical compression", "PROBLEM", 57, 79], ["the spinal cord", "PROBLEM", 91, 106], ["the infection", "PROBLEM", 148, 161], ["chronic", "OBSERVATION_MODIFIER", 4, 11], ["inflammatory", "OBSERVATION", 12, 24], ["ischemia", "OBSERVATION", 44, 52], ["mechanical compression", "OBSERVATION", 57, 79], ["spinal cord", "ANATOMY", 95, 106], ["infection", "OBSERVATION", 152, 161]]], ["In this regard, it has been demonstrated that the expression of the angiotensin-converting enzyme 2 (ACE2), the putative receptor for the \u201cspike\u201d (S) protein of SARS-CoV-2, is overregulated by inflammatory signals [9].DiscussionFinally, segments of the spinal cord under chronic compression display a range of pathological alterations, including ischemia, vascular remodeling, and endothelial dysfunction [10].", [["spinal cord", "ANATOMY", 253, 264], ["vascular", "ANATOMY", 356, 364], ["endothelial", "ANATOMY", 381, 392], ["angiotensin", "CHEMICAL", 68, 79], ["chronic compression", "DISEASE", 271, 290], ["ischemia", "DISEASE", 346, 354], ["endothelial dysfunction", "DISEASE", 381, 404], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 68, 99], ["ACE2", "GENE_OR_GENE_PRODUCT", 101, 105], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 161, 171], ["spinal cord", "ORGAN", 253, 264], ["vascular", "MULTI-TISSUE_STRUCTURE", 356, 364], ["endothelial", "TISSUE", 381, 392], ["angiotensin-converting enzyme 2", "PROTEIN", 68, 99], ["ACE2", "PROTEIN", 101, 105], ["\u201cspike\u201d (S) protein", "PROTEIN", 138, 157], ["the angiotensin-converting enzyme", "TEST", 64, 97], ["the putative receptor", "TEST", 108, 129], ["the \u201cspike", "TEST", 134, 144], ["SARS", "TEST", 161, 165], ["CoV", "TEST", 166, 169], ["inflammatory signals", "PROBLEM", 193, 213], ["chronic compression", "PROBLEM", 271, 290], ["pathological alterations", "PROBLEM", 310, 334], ["ischemia", "PROBLEM", 346, 354], ["vascular remodeling", "PROBLEM", 356, 375], ["endothelial dysfunction", "PROBLEM", 381, 404], ["inflammatory", "OBSERVATION", 193, 205], ["segments", "ANATOMY_MODIFIER", 237, 245], ["spinal cord", "ANATOMY", 253, 264], ["chronic", "OBSERVATION_MODIFIER", 271, 278], ["compression", "OBSERVATION", 279, 290], ["range", "OBSERVATION_MODIFIER", 301, 306], ["ischemia", "OBSERVATION", 346, 354], ["vascular", "ANATOMY", 356, 364], ["remodeling", "OBSERVATION", 365, 375], ["endothelial dysfunction", "OBSERVATION", 381, 404]]], ["These changes contribute to a disruption of the blood-spinal cord barrier (BSCB) and increased vascular permeability, which might result in increased inflammatory infiltration to the spinal cord parenchyma.", [["blood-spinal cord", "ANATOMY", 48, 65], ["BSCB", "ANATOMY", 75, 79], ["vascular", "ANATOMY", 95, 103], ["spinal cord parenchyma", "ANATOMY", 183, 205], ["blood-spinal cord barrier", "TISSUE", 48, 73], ["BSCB", "CANCER", 75, 79], ["vascular", "MULTI-TISSUE_STRUCTURE", 95, 103], ["spinal cord parenchyma", "TISSUE", 183, 205], ["a disruption of the blood-spinal cord barrier", "PROBLEM", 28, 73], ["increased vascular permeability", "PROBLEM", 85, 116], ["increased inflammatory infiltration to the spinal cord parenchyma", "PROBLEM", 140, 205], ["disruption", "OBSERVATION", 30, 40], ["blood", "ANATOMY", 48, 53], ["spinal cord", "ANATOMY", 54, 65], ["increased", "OBSERVATION_MODIFIER", 85, 94], ["vascular", "ANATOMY", 95, 103], ["permeability", "OBSERVATION", 104, 116], ["increased", "OBSERVATION_MODIFIER", 140, 149], ["inflammatory", "OBSERVATION_MODIFIER", 150, 162], ["infiltration", "OBSERVATION", 163, 175], ["spinal cord", "ANATOMY", 183, 194], ["parenchyma", "ANATOMY_MODIFIER", 195, 205]]], ["Hence, the anti-viral inflammatory response could have further exacerbated the local inflammation at sites of compressive myelopathy.ConclusionsOur report provides evidence about the potential of SARS-CoV-2 to cause disease exacerbations in patients with chronic degenerative conditions of the spinal cord, such as spondylotic myelopathy.", [["spinal cord", "ANATOMY", 294, 305], ["spondylotic", "ANATOMY", 315, 326], ["inflammation", "DISEASE", 85, 97], ["myelopathy", "DISEASE", 122, 132], ["exacerbations", "DISEASE", 224, 237], ["chronic degenerative conditions of the spinal cord", "DISEASE", 255, 305], ["spondylotic myelopathy", "DISEASE", 315, 337], ["SARS-CoV-2", "ORGANISM", 196, 206], ["patients", "ORGANISM", 241, 249], ["spinal cord", "ORGAN", 294, 305], ["patients", "SPECIES", 241, 249], ["SARS-CoV", "SPECIES", 196, 204], ["the anti-viral inflammatory response", "PROBLEM", 7, 43], ["the local inflammation", "PROBLEM", 75, 97], ["compressive myelopathy", "PROBLEM", 110, 132], ["SARS", "PROBLEM", 196, 200], ["CoV", "PROBLEM", 201, 204], ["disease exacerbations", "PROBLEM", 216, 237], ["chronic degenerative conditions of the spinal cord", "PROBLEM", 255, 305], ["spondylotic myelopathy", "PROBLEM", 315, 337], ["anti-viral inflammatory", "OBSERVATION", 11, 34], ["local", "OBSERVATION_MODIFIER", 79, 84], ["inflammation", "OBSERVATION", 85, 97], ["compressive", "OBSERVATION_MODIFIER", 110, 121], ["myelopathy", "OBSERVATION", 122, 132], ["chronic", "OBSERVATION_MODIFIER", 255, 262], ["degenerative", "OBSERVATION", 263, 275], ["spinal cord", "ANATOMY", 294, 305], ["spondylotic", "ANATOMY", 315, 326], ["myelopathy", "OBSERVATION", 327, 337]]]], "PMC7417102": [["BackgroundFirstly identified and characterized as 2019-nCOV [1], human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been reported as a novel infective agent arisen at the end of the 2019 [2].", [["acute respiratory syndrome coronavirus", "DISEASE", 78, 116], ["SARS-CoV-2", "CHEMICAL", 120, 130], ["human", "ORGANISM", 65, 70], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 71, 118], ["SARS-CoV-2", "ORGANISM", 120, 130], ["human", "SPECIES", 65, 70], ["human severe acute respiratory syndrome coronavirus", "SPECIES", 65, 116], ["SARS-CoV-2", "SPECIES", 120, 130], ["human severe acute respiratory syndrome coronavirus", "PROBLEM", 65, 116], ["SARS-CoV", "TEST", 120, 128], ["a novel infective agent", "PROBLEM", 153, 176], ["severe", "OBSERVATION_MODIFIER", 71, 77], ["acute", "OBSERVATION_MODIFIER", 78, 83], ["respiratory syndrome", "OBSERVATION", 84, 104]]], ["SARS-CoV-2 is a positive-sense, single strand, enveloped RNA virus belonging to the family of Coronaviridae, and is the 7th beta-coronavirus recognized to infect humans [3].", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 94, 107], ["humans", "ORGANISM", 162, 168], ["humans", "SPECIES", 162, 168], ["SARS-CoV", "SPECIES", 0, 8], ["humans", "SPECIES", 162, 168], ["SARS", "TEST", 0, 4], ["single strand, enveloped RNA virus", "PROBLEM", 32, 66], ["Coronaviridae", "TREATMENT", 94, 107]]], ["First metagenomic RNA sequencing of SARS-CoV-2 showed the single-strand RNA consisted of 29,906 nucleotides, and was closely related to a group of bat SARS-like coronaviruses (89,1%) [4].", [["nucleotides", "CHEMICAL", 96, 107], ["SARS-CoV-2", "ORGANISM", 36, 46], ["bat SARS-like coronaviruses", "ORGANISM", 147, 174], ["single-strand RNA", "RNA", 58, 75], ["SARS-CoV", "SPECIES", 36, 44], ["SARS", "TEST", 36, 40], ["CoV", "TEST", 41, 44], ["strand RNA", "TEST", 65, 75], ["bat SARS", "TEST", 147, 155]]], ["Further observations confirmed that SARS-CoV-2 was closely related (88%) with two bat SARS-like coronavirus (bat-SL-CoVZC45 and bat-SL-CoVZXC21), but was distant from other two human coronaviruses responsible for severe infective pneumonia: SARS-CoV (79%) and Middle East respiratory syndrome coronavirus (MERS-CoV) (50%) [5].", [["SARS", "DISEASE", 36, 40], ["coronaviruses", "DISEASE", 183, 196], ["infective pneumonia", "DISEASE", 220, 239], ["SARS-CoV", "DISEASE", 241, 249], ["Middle East respiratory syndrome coronavirus", "DISEASE", 260, 304], ["SARS-CoV-2", "ORGANISM", 36, 46], ["bat SARS-like coronavirus", "ORGANISM", 82, 107], ["bat-SL-CoVZC45", "ORGANISM", 109, 123], ["bat-SL-CoVZXC21", "ORGANISM", 128, 143], ["human", "ORGANISM", 177, 182], ["SARS-CoV", "ORGANISM", 241, 249], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 260, 304], ["MERS-CoV", "ORGANISM", 306, 314], ["CoVZXC21", "DNA", 135, 143], ["human", "SPECIES", 177, 182], ["SARS-CoV", "SPECIES", 36, 44], ["human coronaviruses", "SPECIES", 177, 196], ["SARS-CoV", "SPECIES", 241, 249], ["Middle East respiratory syndrome coronavirus", "SPECIES", 260, 304], ["MERS-CoV", "SPECIES", 306, 314], ["Further observations", "TEST", 0, 20], ["SARS", "TEST", 36, 40], ["CoV", "TEST", 41, 44], ["two bat SARS", "TEST", 78, 90], ["coronavirus", "TEST", 96, 107], ["bat", "TEST", 109, 112], ["SL", "TEST", 113, 115], ["CoVZC45", "TEST", 116, 123], ["bat", "TEST", 128, 131], ["severe infective pneumonia", "PROBLEM", 213, 239], ["SARS", "PROBLEM", 241, 245], ["CoV", "TEST", 246, 249], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 260, 304], ["severe", "OBSERVATION_MODIFIER", 213, 219], ["infective", "OBSERVATION_MODIFIER", 220, 229], ["pneumonia", "OBSERVATION", 230, 239], ["Middle", "ANATOMY_MODIFIER", 260, 266], ["respiratory syndrome", "OBSERVATION", 272, 292]]], ["A high grade of homology between genomic sequences of SARS-CoV-2 form different patients (99.98%) has also been reported, thus confirming a human-to-human transmission of the novel infective agent [5].", [["SARS", "DISEASE", 54, 58], ["SARS-CoV-2", "ORGANISM", 54, 64], ["patients", "ORGANISM", 80, 88], ["human", "ORGANISM", 140, 145], ["human", "ORGANISM", 149, 154], ["genomic sequences", "DNA", 33, 50], ["patients", "SPECIES", 80, 88], ["human", "SPECIES", 140, 145], ["human", "SPECIES", 149, 154], ["SARS-CoV", "SPECIES", 54, 62], ["human", "SPECIES", 140, 145], ["human", "SPECIES", 149, 154], ["A high grade of homology between genomic sequences", "PROBLEM", 0, 50], ["SARS", "PROBLEM", 54, 58], ["CoV", "TEST", 59, 62], ["the novel infective agent", "TREATMENT", 171, 196], ["high grade", "OBSERVATION_MODIFIER", 2, 12]]], ["Phylogenetic analysis suggested that SARS-CoV-2 progenitors circulated in animal host including bats [6], snakes, Malayan pangolins, civets, mouse [7, 8], and underwent to a naturally occurred selection before the zoonotic spillover finally adapting to persistently infect the new host [9].", [["SARS-CoV-2", "ORGANISM", 37, 47], ["progenitors", "CELL", 48, 59], ["snakes", "ORGANISM_SUBDIVISION", 106, 112], ["mouse", "ORGANISM", 141, 146], ["mouse", "SPECIES", 141, 146], ["SARS-CoV", "SPECIES", 37, 45], ["Malayan pangolins", "SPECIES", 114, 131], ["mouse", "SPECIES", 141, 146], ["Phylogenetic analysis", "TEST", 0, 21], ["SARS", "PROBLEM", 37, 41], ["CoV", "TEST", 42, 45], ["the zoonotic spillover", "PROBLEM", 210, 232], ["zoonotic spillover", "OBSERVATION", 214, 232]]], ["Official epidemiological report declared that the early cases of infections were detected in December 2019, and involved people who worked or visited the Hua Nan South China Seafood Market [10], in Wuhan capital city (Hubei province; People\u2019s Republic of China).", [["infections", "DISEASE", 65, 75], ["people", "ORGANISM", 121, 127], ["people", "SPECIES", 121, 127], ["infections", "PROBLEM", 65, 75], ["Hua", "ANATOMY", 154, 157]]], ["However, it remains still debated whether the zoonotic spillover might have been occurred in other places [11], particularly in Southeast Asia [12], and consequently SARS-CoV-2 infection might have been imported to Wuhan.", [["SARS-CoV-2 infection", "DISEASE", 166, 186], ["SARS-CoV-2", "ORGANISM", 166, 176], ["SARS-CoV-2", "SPECIES", 166, 176], ["the zoonotic spillover", "PROBLEM", 42, 64], ["SARS-CoV-2 infection", "PROBLEM", 166, 186], ["zoonotic", "OBSERVATION_MODIFIER", 46, 54], ["spillover", "OBSERVATION", 55, 64], ["infection", "OBSERVATION", 177, 186]]], ["Epidemiological analysis showed a marked widespread of the infection within community places due to a large human-to-human transmission [13] and Wuhan rapidly became the hub of a new pneumonia outbreak [14].", [["infection", "DISEASE", 59, 68], ["human-to-human transmission", "DISEASE", 108, 135], ["pneumonia", "DISEASE", 183, 192], ["human", "ORGANISM", 108, 113], ["human", "ORGANISM", 117, 122], ["human", "SPECIES", 108, 113], ["human", "SPECIES", 117, 122], ["human", "SPECIES", 108, 113], ["human", "SPECIES", 117, 122], ["Epidemiological analysis", "TEST", 0, 24], ["the infection", "PROBLEM", 55, 68], ["a new pneumonia outbreak", "PROBLEM", 177, 201], ["marked", "OBSERVATION_MODIFIER", 34, 40], ["widespread", "OBSERVATION_MODIFIER", 41, 51], ["infection", "OBSERVATION", 59, 68], ["large", "OBSERVATION_MODIFIER", 102, 107], ["new", "OBSERVATION_MODIFIER", 179, 182], ["pneumonia", "OBSERVATION", 183, 192]]], ["Due to a consistent widespread of detected cases among several countries, the World Health Organization declared the state of pandemic on March 11, 2020 when confirmed cases raised up to 118,000, and SARS-CoV-2 spread into 114 countries [15].COVID-19 and clinical matterClinical manifestations of the novel coronavirus disease 2019 (COVID-19) include fever (87%), cough (58%), dyspnoea (38%), muscle soreness (35%), chest distress (31%) in a context of bilateral pneumonia (76%) with ground glass opacification (70%) at CT scan due to lung interstitial involvement [16].", [["muscle", "ANATOMY", 393, 399], ["chest", "ANATOMY", 416, 421], ["lung interstitial", "ANATOMY", 535, 552], ["SARS", "DISEASE", 200, 204], ["coronavirus disease", "DISEASE", 307, 326], ["fever", "DISEASE", 351, 356], ["cough", "DISEASE", 364, 369], ["dyspnoea", "DISEASE", 377, 385], ["muscle soreness", "DISEASE", 393, 408], ["chest distress", "DISEASE", 416, 430], ["pneumonia", "DISEASE", 463, 472], ["muscle", "ORGAN", 393, 399], ["chest", "ORGANISM_SUBDIVISION", 416, 421], ["lung interstitial", "MULTI-TISSUE_STRUCTURE", 535, 552], ["coronavirus", "SPECIES", 307, 318], ["SARS-CoV", "SPECIES", 200, 208], ["SARS", "TEST", 200, 204], ["CoV", "TEST", 205, 208], ["COVID", "TEST", 242, 247], ["the novel coronavirus disease", "PROBLEM", 297, 326], ["COVID", "TEST", 333, 338], ["fever", "PROBLEM", 351, 356], ["cough", "PROBLEM", 364, 369], ["dyspnoea", "PROBLEM", 377, 385], ["muscle soreness", "PROBLEM", 393, 408], ["chest distress", "PROBLEM", 416, 430], ["bilateral pneumonia", "PROBLEM", 453, 472], ["ground glass opacification", "PROBLEM", 484, 510], ["CT scan", "TEST", 520, 527], ["lung interstitial involvement", "PROBLEM", 535, 564], ["widespread", "OBSERVATION_MODIFIER", 20, 30], ["coronavirus disease", "OBSERVATION", 307, 326], ["muscle", "ANATOMY", 393, 399], ["chest", "ANATOMY", 416, 421], ["bilateral", "ANATOMY_MODIFIER", 453, 462], ["pneumonia", "OBSERVATION", 463, 472], ["ground glass opacification", "OBSERVATION", 484, 510], ["lung", "ANATOMY", 535, 539], ["interstitial", "ANATOMY_MODIFIER", 540, 552]]], ["Autoptic studies described macroscopic features of pleuro-pericarditis, lung consolidation, oedema with overall increased pulmonary weight; while microscopic hallmarks are characterized by pneumocyte hyperplasia, lymphocytic and multinucleated giant cells infiltration, hyaline membranes [17\u201319].", [["pleuro", "ANATOMY", 51, 57], ["lung", "ANATOMY", 72, 76], ["pulmonary", "ANATOMY", 122, 131], ["pneumocyte", "ANATOMY", 189, 199], ["lymphocytic", "ANATOMY", 213, 224], ["multinucleated giant cells", "ANATOMY", 229, 255], ["hyaline membranes", "ANATOMY", 270, 287], ["pleuro-pericarditis", "DISEASE", 51, 70], ["lung consolidation", "DISEASE", 72, 90], ["oedema", "DISEASE", 92, 98], ["hyperplasia", "DISEASE", 200, 211], ["lung", "ORGAN", 72, 76], ["pulmonary", "ORGAN", 122, 131], ["pneumocyte hyperplasia", "PATHOLOGICAL_FORMATION", 189, 211], ["multinucleated giant cells", "CELL", 229, 255], ["hyaline membranes", "CELLULAR_COMPONENT", 270, 287], ["lymphocytic and multinucleated giant cells", "CELL_TYPE", 213, 255], ["Autoptic studies", "TEST", 0, 16], ["pleuro-pericarditis", "PROBLEM", 51, 70], ["lung consolidation", "PROBLEM", 72, 90], ["oedema", "PROBLEM", 92, 98], ["overall increased pulmonary weight", "PROBLEM", 104, 138], ["microscopic hallmarks", "TEST", 146, 167], ["pneumocyte hyperplasia", "PROBLEM", 189, 211], ["lymphocytic and multinucleated giant cells infiltration", "PROBLEM", 213, 268], ["hyaline membranes", "PROBLEM", 270, 287], ["pericarditis", "OBSERVATION", 58, 70], ["lung", "ANATOMY", 72, 76], ["consolidation", "OBSERVATION", 77, 90], ["oedema", "OBSERVATION", 92, 98], ["overall", "OBSERVATION_MODIFIER", 104, 111], ["increased", "OBSERVATION_MODIFIER", 112, 121], ["pulmonary", "ANATOMY", 122, 131], ["pneumocyte hyperplasia", "OBSERVATION", 189, 211], ["lymphocytic", "OBSERVATION_MODIFIER", 213, 224], ["multinucleated", "OBSERVATION_MODIFIER", 229, 243], ["giant", "OBSERVATION_MODIFIER", 244, 249], ["cells infiltration", "OBSERVATION", 250, 268], ["hyaline membranes", "OBSERVATION", 270, 287]]], ["Other signs and symptoms of COVID-19 include acute conjunctivitis [20, 21]; diarrhoea, abdominal pain/discomfort and vomiting [22\u201324]; convulsion, headache, muscle soreness [25]; diffuse erythematous rush and widespread urticaria [26]; acute kidney injury [27, 28]; pharyngodynia, nasal congestion with rhinorrhoea and smell/taste impairment [29].", [["abdominal", "ANATOMY", 87, 96], ["muscle", "ANATOMY", 157, 163], ["kidney", "ANATOMY", 242, 248], ["pharyngodynia", "ANATOMY", 266, 279], ["nasal", "ANATOMY", 281, 286], ["COVID", "DISEASE", 28, 33], ["conjunctivitis", "DISEASE", 51, 65], ["diarrhoea", "DISEASE", 76, 85], ["abdominal pain", "DISEASE", 87, 101], ["vomiting", "DISEASE", 117, 125], ["convulsion", "DISEASE", 135, 145], ["headache", "DISEASE", 147, 155], ["muscle soreness", "DISEASE", 157, 172], ["urticaria", "DISEASE", 220, 229], ["acute kidney injury", "DISEASE", 236, 255], ["pharyngodynia", "DISEASE", 266, 279], ["nasal congestion", "DISEASE", 281, 297], ["rhinorrhoea", "DISEASE", 303, 314], ["taste impairment", "DISEASE", 325, 341], ["COVID-19", "CHEMICAL", 28, 36], ["abdominal", "ORGANISM_SUBDIVISION", 87, 96], ["muscle", "ORGAN", 157, 163], ["kidney", "ORGAN", 242, 248], ["nasal", "ORGANISM_SUBDIVISION", 281, 286], ["Other signs", "TEST", 0, 11], ["symptoms", "PROBLEM", 16, 24], ["COVID", "TEST", 28, 33], ["acute conjunctivitis", "PROBLEM", 45, 65], ["diarrhoea", "PROBLEM", 76, 85], ["abdominal pain", "PROBLEM", 87, 101], ["discomfort", "PROBLEM", 102, 112], ["vomiting", "PROBLEM", 117, 125], ["convulsion", "PROBLEM", 135, 145], ["headache", "PROBLEM", 147, 155], ["muscle soreness", "PROBLEM", 157, 172], ["diffuse erythematous rush", "PROBLEM", 179, 204], ["widespread urticaria", "PROBLEM", 209, 229], ["acute kidney injury", "PROBLEM", 236, 255], ["pharyngodynia", "PROBLEM", 266, 279], ["nasal congestion", "PROBLEM", 281, 297], ["rhinorrhoea", "PROBLEM", 303, 314], ["smell/taste impairment", "PROBLEM", 319, 341], ["acute", "OBSERVATION_MODIFIER", 45, 50], ["conjunctivitis", "OBSERVATION", 51, 65], ["abdominal", "ANATOMY", 87, 96], ["muscle", "ANATOMY", 157, 163], ["diffuse", "OBSERVATION_MODIFIER", 179, 186], ["erythematous", "OBSERVATION_MODIFIER", 187, 199], ["widespread", "OBSERVATION_MODIFIER", 209, 219], ["urticaria", "OBSERVATION", 220, 229], ["kidney", "ANATOMY", 242, 248], ["injury", "OBSERVATION", 249, 255], ["nasal", "ANATOMY", 281, 286], ["congestion", "OBSERVATION", 287, 297], ["rhinorrhoea", "OBSERVATION", 303, 314]]], ["SARS-CoV-2 may directly affect myocardial tissue, and significantly complicate the prognosis of underlying cardiovascular diseases [30, 31].", [["myocardial tissue", "ANATOMY", 31, 48], ["cardiovascular", "ANATOMY", 107, 121], ["SARS", "DISEASE", 0, 4], ["cardiovascular diseases", "DISEASE", 107, 130], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["myocardial tissue", "TISSUE", 31, 48], ["cardiovascular", "ANATOMICAL_SYSTEM", 107, 121], ["myocardial tissue", "PROBLEM", 31, 48], ["underlying cardiovascular diseases", "PROBLEM", 96, 130], ["myocardial tissue", "ANATOMY", 31, 48], ["cardiovascular", "ANATOMY", 107, 121], ["diseases", "OBSERVATION", 122, 130]]], ["SARS-CoV-2 infection usually occurs asymptomatically or mildly symptomatic form of the disease but in predis posed patients with specific clinical conditions, a serious clinical course could be observed thus leading to worse prognosis or death [12].", [["SARS", "DISEASE", 0, 4], ["infection", "DISEASE", 11, 20], ["death", "DISEASE", 238, 243], ["SARS-CoV-2", "ORGANISM", 0, 10], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["SARS-CoV-2", "SPECIES", 0, 10], ["SARS", "PROBLEM", 0, 4], ["CoV-2 infection", "PROBLEM", 5, 20], ["mildly symptomatic", "PROBLEM", 56, 74], ["the disease", "PROBLEM", 83, 94], ["death", "PROBLEM", 238, 243], ["infection", "OBSERVATION", 11, 20], ["mildly", "OBSERVATION_MODIFIER", 56, 62], ["symptomatic", "OBSERVATION_MODIFIER", 63, 74], ["disease", "OBSERVATION", 87, 94]]], ["Worldwide reported case-fatality rate for COVID-19 differs considerably among geographical areas [32], and could be attributable to several variables, such as testing strategies for screen suspected cases and identification of infectious patients (statistical); accessibility to intensive care according to restricted national healthcare system capacities (organization); baseline patient age and comorbidities (medical) [33, 34].", [["patients", "ORGANISM", 238, 246], ["patient", "ORGANISM", 381, 388], ["patients", "SPECIES", 238, 246], ["patient", "SPECIES", 381, 388], ["fatality rate", "TEST", 24, 37], ["COVID", "TEST", 42, 47], ["testing strategies", "TEST", 159, 177], ["intensive care", "TREATMENT", 279, 293], ["infectious", "OBSERVATION_MODIFIER", 227, 237]]], ["From the latter point of view, a poor prognosis is usually observed in elderly patients [35] and worldwide age-specific case-fatality rate occurred very high among patients with one or more underlying chronic diseases including cardiocirculatory, renal, pulmonary, central nervous system and mental illness, diabetes mellitus (DM) and malignancies [36, 37].", [["cardiocirculatory", "ANATOMY", 228, 245], ["renal", "ANATOMY", 247, 252], ["pulmonary", "ANATOMY", 254, 263], ["central nervous system", "ANATOMY", 265, 287], ["malignancies", "ANATOMY", 335, 347], ["cardiocirculatory, renal, pulmonary, central nervous system and mental illness", "DISEASE", 228, 306], ["diabetes mellitus", "DISEASE", 308, 325], ["DM", "DISEASE", 327, 329], ["malignancies", "DISEASE", 335, 347], ["patients", "ORGANISM", 79, 87], ["patients", "ORGANISM", 164, 172], ["renal", "ORGAN", 247, 252], ["pulmonary", "ORGAN", 254, 263], ["central nervous system", "ANATOMICAL_SYSTEM", 265, 287], ["malignancies", "CANCER", 335, 347], ["patients", "SPECIES", 79, 87], ["patients", "SPECIES", 164, 172], ["fatality rate", "PROBLEM", 125, 138], ["underlying chronic diseases", "PROBLEM", 190, 217], ["cardiocirculatory, renal, pulmonary, central nervous system", "PROBLEM", 228, 287], ["mental illness", "PROBLEM", 292, 306], ["diabetes mellitus (DM)", "PROBLEM", 308, 330], ["malignancies", "PROBLEM", 335, 347], ["chronic", "OBSERVATION_MODIFIER", 201, 208], ["diseases", "OBSERVATION", 209, 217], ["renal", "ANATOMY", 247, 252], ["pulmonary", "ANATOMY", 254, 263], ["central", "ANATOMY_MODIFIER", 265, 272], ["nervous system", "ANATOMY", 273, 287], ["mental illness", "OBSERVATION", 292, 306]]], ["According to the data shared by the Italian National Institute of Health, patients who died while tested positive for SARS-CoV-2 exhibited an elevated mean age (78.5 years old), mostly men (70%) and with one or more pre-existent chronic diseases (2.7 in mean) [38].", [["SARS", "DISEASE", 118, 122], ["chronic diseases", "DISEASE", 229, 245], ["patients", "ORGANISM", 74, 82], ["SARS-CoV-2", "ORGANISM", 118, 128], ["men", "ORGANISM", 185, 188], ["patients", "SPECIES", 74, 82], ["men", "SPECIES", 185, 188], ["SARS-CoV", "SPECIES", 118, 126], ["SARS", "PROBLEM", 118, 122], ["CoV", "TEST", 123, 126], ["an elevated mean age", "PROBLEM", 139, 159], ["more pre-existent chronic diseases", "PROBLEM", 211, 245], ["pre-existent", "OBSERVATION_MODIFIER", 216, 228], ["chronic", "OBSERVATION_MODIFIER", 229, 236], ["diseases", "OBSERVATION", 237, 245]]], ["Of these, blood arterial hypertension (78%) and DM (34%) were the most commonly reported clinical comorbidities, followed by ischaemic heart disease (30%) and atrial fibrillation (22%).", [["blood arterial", "ANATOMY", 10, 24], ["heart", "ANATOMY", 135, 140], ["atrial", "ANATOMY", 159, 165], ["blood arterial hypertension", "DISEASE", 10, 37], ["DM", "DISEASE", 48, 50], ["ischaemic heart disease", "DISEASE", 125, 148], ["atrial fibrillation", "DISEASE", 159, 178], ["blood arterial", "MULTI-TISSUE_STRUCTURE", 10, 24], ["heart", "ORGAN", 135, 140], ["blood arterial hypertension", "PROBLEM", 10, 37], ["DM", "PROBLEM", 48, 50], ["clinical comorbidities", "PROBLEM", 89, 111], ["ischaemic heart disease", "PROBLEM", 125, 148], ["atrial fibrillation", "PROBLEM", 159, 178], ["blood arterial", "ANATOMY", 10, 24], ["hypertension", "OBSERVATION", 25, 37], ["ischaemic", "OBSERVATION_MODIFIER", 125, 134], ["heart", "ANATOMY", 135, 140], ["disease", "OBSERVATION", 141, 148], ["atrial", "ANATOMY", 159, 165], ["fibrillation", "OBSERVATION", 166, 178]]], ["The leading cause of deaths was attributable to acute respiratory distress (97%) [38].Epidemiological considerations in patients with type 2 diabetesThe global estimated prevalence of T2D accounts for more than 450 millions affected patients corresponding to 9.3% of the worldwide population [39].", [["respiratory", "ANATOMY", 54, 65], ["deaths", "DISEASE", 21, 27], ["acute respiratory distress", "DISEASE", 48, 74], ["type 2 diabetes", "DISEASE", 134, 149], ["T2D", "DISEASE", 184, 187], ["patients", "ORGANISM", 120, 128], ["patients", "ORGANISM", 233, 241], ["patients", "SPECIES", 120, 128], ["patients", "SPECIES", 233, 241], ["deaths", "PROBLEM", 21, 27], ["acute respiratory distress", "PROBLEM", 48, 74], ["type 2 diabetes", "PROBLEM", 134, 149], ["acute", "OBSERVATION_MODIFIER", 48, 53], ["respiratory distress", "OBSERVATION", 54, 74], ["diabetes", "OBSERVATION", 141, 149], ["global", "OBSERVATION_MODIFIER", 153, 159], ["T2D", "OBSERVATION", 184, 187]]], ["Therefore, the number of patients with T2D who will contract SARS-CoV-2 infection is expected to be considerable, and should increase over time.", [["T2D", "DISEASE", 39, 42], ["SARS", "DISEASE", 61, 65], ["infection", "DISEASE", 72, 81], ["patients", "ORGANISM", 25, 33], ["SARS-CoV-2", "ORGANISM", 61, 71], ["patients", "SPECIES", 25, 33], ["SARS", "PROBLEM", 61, 65], ["CoV-2 infection", "PROBLEM", 66, 81], ["infection", "OBSERVATION", 72, 81]]], ["T2D per se does not increase the risk of contracting SARS-CoV-2 infection but could exacerbate the clinical course of COVID-19 leading to a detrimental prognosis [40].", [["T2D", "DISEASE", 0, 3], ["SARS", "DISEASE", 53, 57], ["infection", "DISEASE", 64, 73], ["COVID-19", "CHEMICAL", 118, 126], ["COVID-19", "CHEMICAL", 118, 126], ["SARS-CoV-2", "ORGANISM", 53, 63], ["SARS-CoV-2", "SPECIES", 53, 63], ["contracting SARS", "PROBLEM", 41, 57], ["CoV", "PROBLEM", 58, 61], ["2 infection", "PROBLEM", 62, 73], ["COVID", "TEST", 118, 123], ["contracting", "OBSERVATION_MODIFIER", 41, 52], ["SARS", "OBSERVATION", 53, 57]]], ["Indeed, the frequency of diabetes in patients with COVID-19 has been reported to 9\u201312% [41\u201343], raising up to 16\u201320% in hospitalized patients including those who required intensive care for severe disease [44, 45].", [["diabetes", "DISEASE", 25, 33], ["COVID-19", "CHEMICAL", 51, 59], ["patients", "ORGANISM", 37, 45], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 133, 141], ["diabetes", "PROBLEM", 25, 33], ["COVID", "TEST", 51, 56], ["intensive care", "TREATMENT", 171, 185], ["severe disease", "PROBLEM", 190, 204], ["diabetes", "OBSERVATION", 25, 33]]], ["More recently, data collected from nine hospitals from Seattle-area in the United States demonstrated that 58% of patients who required hospitalization for respiratory symptoms attributable to COVID-19 had T2D [46].", [["respiratory", "ANATOMY", 156, 167], ["respiratory symptoms", "DISEASE", 156, 176], ["COVID", "DISEASE", 193, 198], ["T2D", "DISEASE", 206, 209], ["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["respiratory symptoms", "PROBLEM", 156, 176], ["COVID", "TEST", 193, 198]]], ["In severely ill patients with COVID-19 a pre-existent T2D was observed in about 35% of the cases and, according to the results of an univariate analysis, the presence of T2D resulted a significant risk factor for poor prognosis in this clinical setting (OR 8.14; p < 0.0001) [47].", [["T2D", "DISEASE", 54, 57], ["T2D", "DISEASE", 170, 173], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["COVID", "TEST", 30, 35], ["a pre-existent T2D", "PROBLEM", 39, 57], ["an univariate analysis", "TEST", 130, 152], ["T2D", "PROBLEM", 170, 173], ["severely", "OBSERVATION_MODIFIER", 3, 11], ["ill", "OBSERVATION_MODIFIER", 12, 15]]], ["DM has also been reported as the main clinical condition observed in non-survived patients with COVID-19 (22%) [48], thus resulting one of the most frequently associated comorbidity in COVID-19 deceased patients [33].", [["DM", "DISEASE", 0, 2], ["patients", "ORGANISM", 82, 90], ["patients", "ORGANISM", 203, 211], ["patients", "SPECIES", 82, 90], ["patients", "SPECIES", 203, 211], ["DM", "PROBLEM", 0, 2], ["COVID", "TEST", 96, 101], ["COVID", "TEST", 185, 190]]], ["This concern has been further confirmed by the results of a cohort study among 85 fatal cases of COVID-19 in Wuhan, hence defining DM as a potentially harmful comorbidity predisposing to worse clinical course or death once SARS-CoV-2 infection occurred [49].Epidemiological considerations in patients with type 2 diabetesDifferent hypothesis should be considered for explaining this clinical phenomenon, including glucose control at baseline and during the infection course, pathophysiology and immune system response in SARS-CoV-2 infected patients with T2D, diabetes-related comorbidities and concomitant medications.", [["DM", "DISEASE", 131, 133], ["death", "DISEASE", 212, 217], ["SARS-CoV-2 infection", "DISEASE", 223, 243], ["type 2 diabetes", "DISEASE", 306, 321], ["glucose", "CHEMICAL", 414, 421], ["infection", "DISEASE", 457, 466], ["SARS-CoV-2 infected", "DISEASE", 521, 540], ["T2D", "DISEASE", 555, 558], ["diabetes", "DISEASE", 560, 568], ["glucose", "CHEMICAL", 414, 421], ["SARS-CoV-2", "ORGANISM", 223, 233], ["patients", "ORGANISM", 292, 300], ["glucose", "SIMPLE_CHEMICAL", 414, 421], ["SARS-CoV-2", "ORGANISM", 521, 531], ["patients", "ORGANISM", 541, 549], ["patients", "SPECIES", 292, 300], ["patients", "SPECIES", 541, 549], ["SARS-CoV", "SPECIES", 521, 529], ["a cohort study", "TEST", 58, 72], ["COVID", "TEST", 97, 102], ["DM", "PROBLEM", 131, 133], ["harmful comorbidity", "PROBLEM", 151, 170], ["death", "PROBLEM", 212, 217], ["SARS", "PROBLEM", 223, 227], ["CoV", "PROBLEM", 228, 231], ["2 infection", "PROBLEM", 232, 243], ["type 2 diabetesDifferent hypothesis", "PROBLEM", 306, 341], ["this clinical phenomenon", "PROBLEM", 378, 402], ["glucose control", "TREATMENT", 414, 429], ["the infection course", "PROBLEM", 453, 473], ["immune system response", "TEST", 495, 517], ["SARS", "PROBLEM", 521, 525], ["T2D", "PROBLEM", 555, 558], ["diabetes", "PROBLEM", 560, 568], ["related comorbidities", "PROBLEM", 569, 590], ["concomitant medications", "TREATMENT", 595, 618], ["infection", "OBSERVATION", 457, 466]]], ["Herein, a point-to-point discussion about these putative mechanisms has been carried out.Glucose controlEpidemiological data showed that T2D represents a risk factor for infectious diseases, mostly with bacterial aetiology, particularly at the level of skin and soft tissue, genitourinary, gastrointestinal and respiratory systems [50].", [["skin", "ANATOMY", 253, 257], ["soft tissue", "ANATOMY", 262, 273], ["genitourinary", "ANATOMY", 275, 288], ["gastrointestinal", "ANATOMY", 290, 306], ["Glucose", "CHEMICAL", 89, 96], ["T2D", "DISEASE", 137, 140], ["infectious diseases", "DISEASE", 170, 189], ["genitourinary, gastrointestinal and respiratory systems", "DISEASE", 275, 330], ["Glucose", "CHEMICAL", 89, 96], ["Glucose", "SIMPLE_CHEMICAL", 89, 96], ["skin", "ORGAN", 253, 257], ["soft tissue", "TISSUE", 262, 273], ["genitourinary", "ORGAN", 275, 288], ["gastrointestinal", "ORGAN", 290, 306], ["Glucose controlEpidemiological data", "TEST", 89, 124], ["T2D", "PROBLEM", 137, 140], ["infectious diseases", "PROBLEM", 170, 189], ["bacterial aetiology", "PROBLEM", 203, 222], ["skin", "ANATOMY", 253, 257], ["soft tissue", "ANATOMY", 262, 273], ["genitourinary", "ANATOMY", 275, 288], ["gastrointestinal", "ANATOMY", 290, 306], ["respiratory", "ANATOMY", 311, 322]]], ["Moreover, life expectancy in individuals with T2D may be affected due to infectious diseases and in certain clusters of patients, such as in elderly with T2D, the leading cause of mortality is attributable to severe pulmonary infections rather than other highly prevalent comorbidities, including cardiovascular diseases and malignancies [51].", [["pulmonary", "ANATOMY", 216, 225], ["cardiovascular", "ANATOMY", 297, 311], ["malignancies", "ANATOMY", 325, 337], ["T2D", "DISEASE", 46, 49], ["infectious diseases", "DISEASE", 73, 92], ["T2D", "DISEASE", 154, 157], ["pulmonary infections", "DISEASE", 216, 236], ["cardiovascular diseases", "DISEASE", 297, 320], ["malignancies", "DISEASE", 325, 337], ["individuals", "ORGANISM", 29, 40], ["patients", "ORGANISM", 120, 128], ["pulmonary", "ORGAN", 216, 225], ["malignancies", "CANCER", 325, 337], ["patients", "SPECIES", 120, 128], ["T2D", "PROBLEM", 46, 49], ["infectious diseases", "PROBLEM", 73, 92], ["T2D", "PROBLEM", 154, 157], ["mortality", "PROBLEM", 180, 189], ["severe pulmonary infections", "PROBLEM", 209, 236], ["cardiovascular diseases", "PROBLEM", 297, 320], ["malignancies", "PROBLEM", 325, 337], ["infectious", "OBSERVATION", 73, 83], ["severe", "OBSERVATION_MODIFIER", 209, 215], ["pulmonary", "ANATOMY", 216, 225], ["infections", "OBSERVATION", 226, 236]]], ["On the other hand, DM increases the cumulative risk of medical consultation, hospital admission, intensive care requirement and poor prognosis because of pandemic influenza [52].", [["DM", "DISEASE", 19, 21], ["influenza", "DISEASE", 163, 172], ["DM", "PROBLEM", 19, 21], ["intensive care requirement", "TREATMENT", 97, 123], ["pandemic influenza", "PROBLEM", 154, 172], ["DM", "OBSERVATION", 19, 21]]], ["Further data reported that airways and pulmonary infections with different aetiologies, including SARS and MERS, were more frequently diagnosed in T2D patients, also showing a severe clinical course [53\u201356].", [["airways", "ANATOMY", 27, 34], ["pulmonary", "ANATOMY", 39, 48], ["airways and pulmonary infections", "DISEASE", 27, 59], ["SARS", "DISEASE", 98, 102], ["T2D", "DISEASE", 147, 150], ["airways", "MULTI-TISSUE_STRUCTURE", 27, 34], ["pulmonary", "ORGAN", 39, 48], ["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 151, 159], ["Further data", "TEST", 0, 12], ["airways and pulmonary infections", "PROBLEM", 27, 59], ["different aetiologies", "PROBLEM", 65, 86], ["SARS", "PROBLEM", 98, 102], ["MERS", "PROBLEM", 107, 111], ["a severe clinical course", "PROBLEM", 174, 198], ["airways", "ANATOMY", 27, 34], ["pulmonary", "ANATOMY", 39, 48], ["infections", "OBSERVATION", 49, 59], ["severe", "OBSERVATION_MODIFIER", 176, 182]]], ["In DM, hyperglycaemia is considered one of the most important factor in determining this burden [57].", [["DM", "DISEASE", 3, 5], ["hyperglycaemia", "DISEASE", 7, 21], ["DM", "PROBLEM", 3, 5], ["hyperglycaemia", "PROBLEM", 7, 21], ["DM", "OBSERVATION", 3, 5], ["hyperglycaemia", "OBSERVATION", 7, 21]]], ["Indeed, osteomyelitis, soft tissues infections, endocarditis, tuberculosis and sepsis are most commonly observed in diabetic patients with poor glycaemic control compared to those who achieve better glucose management, and a worse glucose control contributes to increase the rate of hospitalization and mortality, too [57].", [["soft tissues", "ANATOMY", 23, 35], ["osteomyelitis", "DISEASE", 8, 21], ["soft tissues infections", "DISEASE", 23, 46], ["endocarditis", "DISEASE", 48, 60], ["tuberculosis", "DISEASE", 62, 74], ["sepsis", "DISEASE", 79, 85], ["diabetic", "DISEASE", 116, 124], ["glucose", "CHEMICAL", 199, 206], ["glucose", "CHEMICAL", 231, 238], ["glucose", "CHEMICAL", 199, 206], ["glucose", "CHEMICAL", 231, 238], ["soft tissues", "TISSUE", 23, 35], ["patients", "ORGANISM", 125, 133], ["glucose", "SIMPLE_CHEMICAL", 199, 206], ["glucose", "SIMPLE_CHEMICAL", 231, 238], ["patients", "SPECIES", 125, 133], ["osteomyelitis", "PROBLEM", 8, 21], ["soft tissues infections", "PROBLEM", 23, 46], ["endocarditis", "PROBLEM", 48, 60], ["tuberculosis", "PROBLEM", 62, 74], ["sepsis", "PROBLEM", 79, 85], ["poor glycaemic control", "PROBLEM", 139, 161], ["glucose management", "TREATMENT", 199, 217], ["a worse glucose control", "PROBLEM", 223, 246], ["osteomyelitis", "OBSERVATION", 8, 21], ["soft tissues", "ANATOMY", 23, 35], ["infections", "OBSERVATION", 36, 46], ["endocarditis", "OBSERVATION", 48, 60], ["tuberculosis", "OBSERVATION", 62, 74], ["sepsis", "OBSERVATION", 79, 85]]], ["Both hyperglycaemia and high glucose variability may consistently complicate the clinical course also in case of influenza A [58].", [["hyperglycaemia", "DISEASE", 5, 19], ["glucose", "CHEMICAL", 29, 36], ["influenza", "DISEASE", 113, 122], ["glucose", "CHEMICAL", 29, 36], ["glucose", "SIMPLE_CHEMICAL", 29, 36], ["Both hyperglycaemia", "PROBLEM", 0, 19], ["high glucose variability", "PROBLEM", 24, 48], ["influenza A", "PROBLEM", 113, 124], ["hyperglycaemia", "OBSERVATION", 5, 19], ["high", "OBSERVATION_MODIFIER", 24, 28], ["glucose variability", "OBSERVATION", 29, 48]]], ["More recently, a retrospective observational study recruiting more than 7000 cases of COVID-19 from Hubei province (China) and including 952 patients with a pre-existent T2D displayed a higher mortality rate (HR 1.49), more prevalence of multiorgan damage and a greater requirement of medications (antibiotics, systemic corticosteroids, vasoactive substances, oxygen inhalation and either non-invasive or invasive mechanical ventilation) in patients with DM than in non-diabetics [59].", [["multiorgan", "ANATOMY", 238, 248], ["T2D", "DISEASE", 170, 173], ["multiorgan damage", "DISEASE", 238, 255], ["oxygen", "CHEMICAL", 360, 366], ["DM", "DISEASE", 455, 457], ["oxygen", "CHEMICAL", 360, 366], ["patients", "ORGANISM", 141, 149], ["multiorgan", "ORGAN", 238, 248], ["oxygen", "SIMPLE_CHEMICAL", 360, 366], ["patients", "ORGANISM", 441, 449], ["patients", "SPECIES", 141, 149], ["patients", "SPECIES", 441, 449], ["a retrospective observational study", "TEST", 15, 50], ["COVID", "TEST", 86, 91], ["a pre-existent T2D", "PROBLEM", 155, 173], ["HR", "TEST", 209, 211], ["multiorgan damage", "PROBLEM", 238, 255], ["medications", "TREATMENT", 285, 296], ["antibiotics", "TREATMENT", 298, 309], ["systemic corticosteroids", "TREATMENT", 311, 335], ["vasoactive substances", "TREATMENT", 337, 358], ["oxygen inhalation", "TREATMENT", 360, 377], ["invasive mechanical ventilation", "TREATMENT", 405, 436], ["DM", "PROBLEM", 455, 457], ["multiorgan damage", "OBSERVATION", 238, 255], ["greater", "OBSERVATION_MODIFIER", 262, 269]]], ["Interestingly, authors also found that, among T2D patients, those with better glucose control (glucose levels between 70 and 180 mg/dl) respective to those with worse glucose control (>180 mg/dl) during hospitalization exhibited a significantly lower rate of mortality (HR 0.14; p < 0.008), and a fewer risk of progression to acute respiratory distress syndrome (HR 0.47; p < 0.009), acute kidney (HR 0.12; p < 0.046) and myocardial (HR 0.24; p < 0.01) injury [59].", [["respiratory", "ANATOMY", 332, 343], ["kidney", "ANATOMY", 390, 396], ["myocardial", "ANATOMY", 422, 432], ["T2D", "DISEASE", 46, 49], ["glucose", "CHEMICAL", 78, 85], ["glucose", "CHEMICAL", 95, 102], ["glucose", "CHEMICAL", 167, 174], ["acute respiratory distress syndrome", "DISEASE", 326, 361], ["glucose", "CHEMICAL", 78, 85], ["glucose", "CHEMICAL", 95, 102], ["glucose", "CHEMICAL", 167, 174], ["patients", "ORGANISM", 50, 58], ["glucose", "SIMPLE_CHEMICAL", 78, 85], ["glucose", "SIMPLE_CHEMICAL", 95, 102], ["glucose", "SIMPLE_CHEMICAL", 167, 174], ["kidney", "ORGAN", 390, 396], ["myocardial", "MULTI-TISSUE_STRUCTURE", 422, 432], ["patients", "SPECIES", 50, 58], ["glucose levels", "TEST", 95, 109], ["worse glucose control", "TREATMENT", 161, 182], ["a significantly lower rate of mortality", "PROBLEM", 229, 268], ["HR", "TEST", 270, 272], ["acute respiratory distress syndrome", "PROBLEM", 326, 361], ["HR", "TEST", 363, 365], ["acute kidney (HR", "TEST", 384, 400], ["myocardial (HR", "TEST", 422, 436], ["injury", "PROBLEM", 453, 459], ["acute", "OBSERVATION_MODIFIER", 326, 331], ["respiratory distress", "OBSERVATION", 332, 352], ["acute", "OBSERVATION_MODIFIER", 384, 389], ["kidney", "ANATOMY", 390, 396], ["myocardial", "ANATOMY", 422, 432]]], ["Similar results were found by another observation in which worse glucose control (glucose levels >110 mg/dl) at the admission and during hospitalization was found to be an independent risk factor for progression to critical ill or death among T2D patients with confirmed COVID-19 [60].", [["glucose", "CHEMICAL", 65, 72], ["glucose", "CHEMICAL", 82, 89], ["death", "DISEASE", 231, 236], ["T2D", "DISEASE", 243, 246], ["glucose", "CHEMICAL", 65, 72], ["glucose", "CHEMICAL", 82, 89], ["COVID-19", "CHEMICAL", 271, 279], ["glucose", "SIMPLE_CHEMICAL", 65, 72], ["glucose", "SIMPLE_CHEMICAL", 82, 89], ["patients", "ORGANISM", 247, 255], ["patients", "SPECIES", 247, 255], ["glucose levels", "TEST", 82, 96], ["critical ill", "PROBLEM", 215, 227], ["death", "PROBLEM", 231, 236], ["COVID", "TEST", 271, 276]]], ["Therefore, hyperglycaemia represents a relevant matter in patients with COVID-19 fostering poor prognosis once the infection occurred.", [["hyperglycaemia", "DISEASE", 11, 25], ["infection", "DISEASE", 115, 124], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["hyperglycaemia", "PROBLEM", 11, 25], ["COVID", "TEST", 72, 77], ["the infection", "PROBLEM", 111, 124], ["hyperglycaemia", "OBSERVATION", 11, 25], ["infection", "OBSERVATION", 115, 124]]], ["In addition, recent evidences suggest that SARS-CoV-2 may induce beta-cells damage thus leading to insulin secretion impairment.", [["beta-cells", "ANATOMY", 65, 75], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 43, 53], ["beta-cells", "GENE_OR_GENE_PRODUCT", 65, 75], ["insulin", "GENE_OR_GENE_PRODUCT", 99, 106], ["SARS", "PROBLEM", 43, 47], ["CoV", "TEST", 48, 51], ["beta-cells damage", "PROBLEM", 65, 82], ["insulin secretion impairment", "PROBLEM", 99, 127], ["SARS", "OBSERVATION", 43, 47], ["beta-cells", "OBSERVATION", 65, 75]]], ["This phenomenon, in addition to a pre-existent hyperglycaemia and considering that systemic inflammation due to the infection exacerbates the insulin-resistance, is thought to play a significative role to further worsen glucose control and complicate the clinical course of COVID-19 [61].", [["hyperglycaemia", "DISEASE", 47, 61], ["systemic inflammation", "DISEASE", 83, 104], ["infection", "DISEASE", 116, 125], ["glucose", "CHEMICAL", 220, 227], ["COVID-19", "CHEMICAL", 274, 282], ["insulin", "GENE_OR_GENE_PRODUCT", 142, 149], ["glucose", "SIMPLE_CHEMICAL", 220, 227], ["This phenomenon", "PROBLEM", 0, 15], ["a pre-existent hyperglycaemia", "PROBLEM", 32, 61], ["systemic inflammation", "PROBLEM", 83, 104], ["the infection", "PROBLEM", 112, 125], ["glucose control", "TREATMENT", 220, 235], ["COVID", "TEST", 274, 279], ["pre-existent", "OBSERVATION_MODIFIER", 34, 46], ["hyperglycaemia", "OBSERVATION", 47, 61], ["systemic", "OBSERVATION_MODIFIER", 83, 91], ["inflammation", "OBSERVATION", 92, 104], ["infection", "OBSERVATION", 116, 125]]], ["In conclusion, epidemiological data suggested that DM, particularly T2D, is a frequently observed comorbidity in patients with SARS-CoV-2 infection who require hospitalization, more intensive treatment and exhibit poor prognosis or death.", [["DM", "DISEASE", 51, 53], ["T2D", "DISEASE", 68, 71], ["SARS-CoV-2 infection", "DISEASE", 127, 147], ["death", "DISEASE", 232, 237], ["patients", "ORGANISM", 113, 121], ["SARS-CoV-2", "ORGANISM", 127, 137], ["patients", "SPECIES", 113, 121], ["SARS-CoV-2", "SPECIES", 127, 137], ["epidemiological data", "TEST", 15, 35], ["DM", "PROBLEM", 51, 53], ["T2D", "PROBLEM", 68, 71], ["a frequently observed comorbidity", "PROBLEM", 76, 109], ["SARS", "PROBLEM", 127, 131], ["CoV-2 infection", "PROBLEM", 132, 147], ["hospitalization", "TREATMENT", 160, 175], ["intensive treatment", "TREATMENT", 182, 201], ["death", "PROBLEM", 232, 237], ["DM", "OBSERVATION", 51, 53]]], ["Poor baseline and ongoing glucose control in hospitalized patients rather than the presence of T2D per se seems to facilitate COVID-19 progression [62].", [["glucose", "CHEMICAL", 26, 33], ["T2D", "DISEASE", 95, 98], ["glucose", "CHEMICAL", 26, 33], ["glucose", "SIMPLE_CHEMICAL", 26, 33], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["Poor baseline", "PROBLEM", 0, 13], ["ongoing glucose control", "TREATMENT", 18, 41], ["COVID", "TEST", 126, 131]]], ["Hence, an optimal and timely blood glucose management during pandemic should be considered as an effective strategy to reduce the probability of hospitalization requirement of infected patients, and for improving the clinical course of those hospitalized for receiving either non-intensive or intensive care.Immune system responseInnate and adaptive immune responses play a crucial role against viral infections [63].", [["blood", "ANATOMY", 29, 34], ["Immune system", "ANATOMY", 308, 321], ["glucose", "CHEMICAL", 35, 42], ["viral infections", "DISEASE", 395, 411], ["glucose", "CHEMICAL", 35, 42], ["blood", "ORGANISM_SUBSTANCE", 29, 34], ["glucose", "SIMPLE_CHEMICAL", 35, 42], ["patients", "ORGANISM", 185, 193], ["patients", "SPECIES", 185, 193], ["timely blood glucose management", "TREATMENT", 22, 53], ["pandemic", "PROBLEM", 61, 69], ["intensive care", "TREATMENT", 293, 307], ["Immune system responseInnate", "PROBLEM", 308, 336], ["viral infections", "PROBLEM", 395, 411]]], ["Immune response against coronaviruses has been reviewed elsewhere, highlighting the role of both innate and adaptive systems to promptly contrast virus replication, facilitate virus clearance, stimulate tissue repair and develop persistent defence [64].", [["tissue", "ANATOMY", 203, 209], ["coronaviruses", "ORGANISM", 24, 37], ["tissue", "TISSUE", 203, 209], ["coronaviruses", "PROBLEM", 24, 37], ["adaptive systems", "TREATMENT", 108, 124], ["contrast virus replication", "TREATMENT", 137, 163], ["virus clearance", "TREATMENT", 176, 191], ["stimulate tissue repair", "TREATMENT", 193, 216]]], ["Immune response in COVID-19 is not still completely understood making necessary further investigation to better control the pandemic evolution [65].", [["COVID-19", "CELL", 19, 27], ["COVID", "TEST", 19, 24], ["further investigation", "TEST", 80, 101]]], ["However, seriously ill COVID-19 patients exhibit an exaggerate response of neutrophils and alveolar macrophages, and a relevant peripheral lymphocytes dysfunction [66], which lead to an uncontrolled viral shedding, consequent viremia and further systemic immune-mediated damage, thus triggering a harmful vicious circle [66].", [["neutrophils", "ANATOMY", 75, 86], ["alveolar macrophages", "ANATOMY", 91, 111], ["peripheral lymphocytes", "ANATOMY", 128, 150], ["peripheral lymphocytes dysfunction", "DISEASE", 128, 162], ["viremia", "DISEASE", 226, 233], ["patients", "ORGANISM", 32, 40], ["neutrophils", "CELL", 75, 86], ["alveolar macrophages", "CELL", 91, 111], ["peripheral lymphocytes", "CELL", 128, 150], ["neutrophils", "CELL_TYPE", 75, 86], ["alveolar macrophages", "CELL_TYPE", 91, 111], ["peripheral lymphocytes", "CELL_TYPE", 128, 150], ["patients", "SPECIES", 32, 40], ["ill COVID", "TEST", 19, 28], ["an exaggerate response of neutrophils", "PROBLEM", 49, 86], ["alveolar macrophages", "PROBLEM", 91, 111], ["a relevant peripheral lymphocytes dysfunction", "PROBLEM", 117, 162], ["an uncontrolled viral shedding", "PROBLEM", 183, 213], ["consequent viremia", "PROBLEM", 215, 233], ["further systemic immune-mediated damage", "PROBLEM", 238, 277], ["neutrophils", "OBSERVATION", 75, 86], ["alveolar macrophages", "OBSERVATION", 91, 111], ["peripheral lymphocytes dysfunction", "OBSERVATION", 128, 162], ["uncontrolled", "OBSERVATION_MODIFIER", 186, 198], ["viral shedding", "OBSERVATION", 199, 213], ["viremia", "OBSERVATION", 226, 233], ["damage", "OBSERVATION", 271, 277]]], ["Glucose levels may significantly influence immune response as observed in patients with DM.", [["Glucose", "CHEMICAL", 0, 7], ["DM", "DISEASE", 88, 90], ["Glucose", "CHEMICAL", 0, 7], ["Glucose", "SIMPLE_CHEMICAL", 0, 7], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["Glucose levels", "TEST", 0, 14], ["DM", "PROBLEM", 88, 90]]], ["Natural killer (NK) cells activity is weakened in case of hyperglycaemia, and is inversely related with fasting plasma glucose, 2-h postprandial glycaemia and HbA1c levels [67].", [["Natural killer (NK) cells", "ANATOMY", 0, 25], ["plasma", "ANATOMY", 112, 118], ["hyperglycaemia", "DISEASE", 58, 72], ["glucose", "CHEMICAL", 119, 126], ["glucose", "CHEMICAL", 119, 126], ["Natural killer (NK) cells", "CELL", 0, 25], ["plasma", "ORGANISM_SUBSTANCE", 112, 118], ["glucose", "SIMPLE_CHEMICAL", 119, 126], ["HbA1c", "SIMPLE_CHEMICAL", 159, 164], ["Natural killer (NK) cells", "CELL_TYPE", 0, 25], ["hyperglycaemia", "PROBLEM", 58, 72], ["fasting plasma glucose", "TEST", 104, 126], ["postprandial glycaemia", "TEST", 132, 154], ["HbA1c levels", "TEST", 159, 171], ["hyperglycaemia", "OBSERVATION", 58, 72]]], ["Macrophage activation and phagocytosis are both decreased in patients with poor glucose control, but should be restored after an adequate optimization of metabolic control [68].", [["Macrophage", "ANATOMY", 0, 10], ["glucose", "CHEMICAL", 80, 87], ["Macrophage", "CELL", 0, 10], ["patients", "ORGANISM", 61, 69], ["glucose", "SIMPLE_CHEMICAL", 80, 87], ["patients", "SPECIES", 61, 69], ["Macrophage activation", "PROBLEM", 0, 21], ["phagocytosis", "PROBLEM", 26, 38], ["poor glucose control", "TREATMENT", 75, 95], ["metabolic control", "TREATMENT", 154, 171], ["phagocytosis", "OBSERVATION_MODIFIER", 26, 38], ["decreased", "OBSERVATION_MODIFIER", 48, 57]]], ["Neutrophil activation and phagocytosis are both impaired by hyperglycaemia as demonstrated in animal models and humans, thus suggesting a relevant impairment of innate immune response in patients with chronic hyperglycaemia [69].", [["Neutrophil", "ANATOMY", 0, 10], ["hyperglycaemia", "DISEASE", 60, 74], ["hyperglycaemia", "DISEASE", 209, 223], ["Neutrophil", "CELL", 0, 10], ["humans", "ORGANISM", 112, 118], ["patients", "ORGANISM", 187, 195], ["humans", "SPECIES", 112, 118], ["patients", "SPECIES", 187, 195], ["humans", "SPECIES", 112, 118], ["Neutrophil activation", "TEST", 0, 21], ["phagocytosis", "PROBLEM", 26, 38], ["hyperglycaemia", "PROBLEM", 60, 74], ["chronic hyperglycaemia", "PROBLEM", 201, 223], ["hyperglycaemia", "OBSERVATION", 60, 74], ["chronic", "OBSERVATION_MODIFIER", 201, 208], ["hyperglycaemia", "OBSERVATION", 209, 223]]], ["In an animal model, obese and hyperglycaemic mice experienced higher rate of respiratory infection due to influenza and bacterial pneumonia and that was related to a lower efficient alveolar macrophage response against infections.", [["respiratory", "ANATOMY", 77, 88], ["alveolar macrophage", "ANATOMY", 182, 201], ["hyperglycaemic", "DISEASE", 30, 44], ["respiratory infection", "DISEASE", 77, 98], ["influenza", "DISEASE", 106, 115], ["pneumonia", "DISEASE", 130, 139], ["infections", "DISEASE", 219, 229], ["mice", "ORGANISM", 45, 49], ["alveolar macrophage", "CELL", 182, 201], ["mice", "SPECIES", 45, 49], ["mice", "SPECIES", 45, 49], ["obese", "PROBLEM", 20, 25], ["hyperglycaemic mice", "PROBLEM", 30, 49], ["respiratory infection", "PROBLEM", 77, 98], ["influenza", "PROBLEM", 106, 115], ["bacterial pneumonia", "PROBLEM", 120, 139], ["a lower efficient alveolar macrophage response", "PROBLEM", 164, 210], ["infections", "PROBLEM", 219, 229], ["obese", "OBSERVATION", 20, 25], ["respiratory", "ANATOMY", 77, 88], ["infection", "OBSERVATION", 89, 98], ["influenza", "OBSERVATION", 106, 115], ["bacterial", "OBSERVATION_MODIFIER", 120, 129], ["pneumonia", "OBSERVATION", 130, 139], ["lower", "OBSERVATION_MODIFIER", 166, 171], ["efficient", "OBSERVATION_MODIFIER", 172, 181], ["alveolar macrophage", "OBSERVATION", 182, 201], ["infections", "OBSERVATION", 219, 229]]], ["In addition, a defective Toll-like receptor 4 signalling has been recognized in neutrophils exposed to the gram-negative lipopolysaccharide, leading to a blunted release of chemokines and cytokine, and decreased myeloperoxidase activity [69].", [["neutrophils", "ANATOMY", 80, 91], ["lipopolysaccharide", "CHEMICAL", 121, 139], ["Toll-like receptor 4", "GENE_OR_GENE_PRODUCT", 25, 45], ["neutrophils", "CELL", 80, 91], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 121, 139], ["myeloperoxidase", "SIMPLE_CHEMICAL", 212, 227], ["Toll-like receptor 4", "PROTEIN", 25, 45], ["neutrophils", "CELL_TYPE", 80, 91], ["chemokines", "PROTEIN", 173, 183], ["cytokine", "PROTEIN", 188, 196], ["myeloperoxidase", "PROTEIN", 212, 227], ["a defective Toll-like receptor 4 signalling", "PROBLEM", 13, 56], ["the gram", "TEST", 103, 111], ["a blunted release of chemokines", "PROBLEM", 152, 183], ["cytokine", "TREATMENT", 188, 196], ["decreased myeloperoxidase activity", "PROBLEM", 202, 236], ["defective", "OBSERVATION", 15, 24], ["negative lipopolysaccharide", "OBSERVATION_MODIFIER", 112, 139]]], ["Moreover, T-cells function is significantly dysregulated in T2D and CD4+ lymphocytes preferentially differentiate in T-helper 1 and T-helper 17 instead of T-helper 2 with a consequent imbalance between pro-inflammatory and anti-inflammatory activities [70].", [["T-cells", "ANATOMY", 10, 17], ["CD4+ lymphocytes", "ANATOMY", 68, 84], ["T2D", "DISEASE", 60, 63], ["T-cells", "CELL", 10, 17], ["CD4", "GENE_OR_GENE_PRODUCT", 68, 71], ["T-helper 1", "GENE_OR_GENE_PRODUCT", 117, 127], ["T-helper 17", "GENE_OR_GENE_PRODUCT", 132, 143], ["T-helper 2", "GENE_OR_GENE_PRODUCT", 155, 165], ["T-cells", "CELL_TYPE", 10, 17], ["CD4+ lymphocytes", "CELL_TYPE", 68, 84], ["T-cells function", "TEST", 10, 26], ["significantly dysregulated", "PROBLEM", 30, 56], ["T2D", "TEST", 60, 63], ["CD4", "TEST", 68, 71], ["lymphocytes", "TEST", 73, 84], ["T", "TEST", 132, 133], ["pro-inflammatory and anti-inflammatory activities", "TREATMENT", 202, 251]]], ["On the other hand, the levels of interferon gamma\u2014which normally stimulates CD4+ T cells maturation in sense of T-helper 1 rather than T-helper 2\u2014were found to be lower in T2D patients sera, and can contribute in a blunted T-cell response in T2D [71].", [["CD4+ T cells", "ANATOMY", 76, 88], ["sera", "ANATOMY", 185, 189], ["T-cell", "ANATOMY", 223, 229], ["T2D", "DISEASE", 172, 175], ["T2D", "DISEASE", 242, 245], ["interferon", "GENE_OR_GENE_PRODUCT", 33, 43], ["CD4", "GENE_OR_GENE_PRODUCT", 76, 79], ["T-helper 1", "GENE_OR_GENE_PRODUCT", 112, 122], ["T-helper 2", "GENE_OR_GENE_PRODUCT", 135, 145], ["patients", "ORGANISM", 176, 184], ["sera", "ORGANISM_SUBSTANCE", 185, 189], ["T-cell", "CELL", 223, 229], ["interferon", "PROTEIN", 33, 43], ["CD4", "PROTEIN", 76, 79], ["T cells", "CELL_TYPE", 81, 88], ["patients", "SPECIES", 176, 184], ["interferon gamma\u2014which", "TREATMENT", 33, 55]]], ["Nevertheless, lower levels of interleukin (IL)-10 have also been described in T2D patients.", [["T2D", "DISEASE", 78, 81], ["interleukin (IL)-10", "GENE_OR_GENE_PRODUCT", 30, 49], ["patients", "ORGANISM", 82, 90], ["interleukin (IL)-10", "PROTEIN", 30, 49], ["patients", "SPECIES", 82, 90], ["interleukin (IL)", "TREATMENT", 30, 46]]], ["Considering that IL-10 is capable to suppress the release of pro-inflammatory cytokines, lower levels of IL-10 could be related with higher IL-6-to-IFN gamma and TNF-alpha-to-IFN gamma ratios hence suggesting an enhanced activation of circulating monocytes [71].", [["monocytes", "ANATOMY", 247, 256], ["IL-10", "GENE_OR_GENE_PRODUCT", 17, 22], ["IL-10", "GENE_OR_GENE_PRODUCT", 105, 110], ["IL-6", "GENE_OR_GENE_PRODUCT", 140, 144], ["IFN gamma", "GENE_OR_GENE_PRODUCT", 148, 157], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 162, 171], ["IFN gamma", "GENE_OR_GENE_PRODUCT", 175, 184], ["monocytes", "CELL", 247, 256], ["IL-10", "PROTEIN", 17, 22], ["pro-inflammatory cytokines", "PROTEIN", 61, 87], ["IL", "PROTEIN", 105, 107], ["IFN gamma", "PROTEIN", 148, 157], ["IFN gamma", "PROTEIN", 175, 184], ["circulating monocytes", "CELL_TYPE", 235, 256], ["pro-inflammatory cytokines", "TEST", 61, 87], ["IL", "TEST", 105, 107], ["IL", "TEST", 140, 142], ["IFN gamma", "TEST", 148, 157], ["TNF", "TEST", 162, 165], ["alpha", "TEST", 166, 171], ["IFN gamma ratios", "TEST", 175, 191], ["circulating monocytes", "TEST", 235, 256]]], ["High levels of IL-6 have been detected in diabetic patients respective to those with euglycemia, suggesting that hyperglycaemia play a crucial role in determining this immunological effect [72, 73].", [["diabetic", "DISEASE", 42, 50], ["hyperglycaemia", "DISEASE", 113, 127], ["IL-6", "GENE_OR_GENE_PRODUCT", 15, 19], ["patients", "ORGANISM", 51, 59], ["IL-6", "PROTEIN", 15, 19], ["patients", "SPECIES", 51, 59], ["euglycemia", "TREATMENT", 85, 95], ["hyperglycaemia", "PROBLEM", 113, 127]]], ["In animal models, hyperglycaemia and insulin-resistance increase the level of circulating pro-inflammatory cytokines and oxidative stress at baseline [74].", [["hyperglycaemia", "DISEASE", 18, 32], ["insulin", "GENE_OR_GENE_PRODUCT", 37, 44], ["pro-inflammatory cytokines", "PROTEIN", 90, 116], ["hyperglycaemia", "PROBLEM", 18, 32], ["insulin", "TREATMENT", 37, 44], ["circulating pro-inflammatory cytokines", "PROBLEM", 78, 116], ["oxidative stress", "PROBLEM", 121, 137], ["hyperglycaemia", "OBSERVATION", 18, 32], ["pro-inflammatory cytokines", "OBSERVATION", 90, 116]]], ["Since this pro-inflammatory background usually results reversible after an effective treatment of hyperglycaemia, a low dose endotoxemia consistently enhances systemic inflammation in a animal model [75].", [["hyperglycaemia", "DISEASE", 98, 112], ["endotoxemia", "DISEASE", 125, 136], ["inflammation", "DISEASE", 168, 180], ["an effective treatment", "TREATMENT", 72, 94], ["hyperglycaemia", "PROBLEM", 98, 112], ["a low dose endotoxemia", "PROBLEM", 114, 136], ["systemic inflammation", "PROBLEM", 159, 180], ["hyperglycaemia", "OBSERVATION", 98, 112], ["low dose", "OBSERVATION_MODIFIER", 116, 124], ["systemic", "OBSERVATION_MODIFIER", 159, 167], ["inflammation", "OBSERVATION", 168, 180]]], ["Therefore, hyperglycaemia may predispose to an exaggerate immune response even in case of a mild-to-moderate viral load.", [["hyperglycaemia", "DISEASE", 11, 25], ["hyperglycaemia", "PROBLEM", 11, 25], ["an exaggerate immune response", "PROBLEM", 44, 73], ["a mild-to-moderate viral load", "PROBLEM", 90, 119], ["mild", "OBSERVATION_MODIFIER", 92, 96], ["moderate", "OBSERVATION_MODIFIER", 100, 108], ["viral load", "OBSERVATION", 109, 119]]], ["As known, a hyperinflammatory syndrome with cytokine dysregulation has been well recognized in seriously ill patients [76], thus highlighting its crucial role in serious manifestations of COVID-19 [77].", [["hyperinflammatory syndrome", "DISEASE", 12, 38], ["COVID", "DISEASE", 188, 193], ["COVID-19", "CHEMICAL", 188, 196], ["patients", "ORGANISM", 109, 117], ["cytokine", "PROTEIN", 44, 52], ["patients", "SPECIES", 109, 117], ["a hyperinflammatory syndrome", "PROBLEM", 10, 38], ["cytokine dysregulation", "PROBLEM", 44, 66], ["COVID", "TEST", 188, 193], ["hyperinflammatory syndrome", "OBSERVATION", 12, 38], ["cytokine dysregulation", "OBSERVATION", 44, 66]]], ["Specific interleukins and chemokines (IL-2, IL-7, IL-6, TNF-alpha, interferon gamma induced protein 10, granulocyte-colony stimulating factor) are upregulated in patients who exhibited a worsen prognosis [78] and particularly high levels of IL-6 have been detected in case of serious pulmonary involvement or in patients requiring intensive care [79].", [["pulmonary", "ANATOMY", 284, 293], ["interleukins", "GENE_OR_GENE_PRODUCT", 9, 21], ["IL-2", "GENE_OR_GENE_PRODUCT", 38, 42], ["IL-7", "GENE_OR_GENE_PRODUCT", 44, 48], ["IL-6", "GENE_OR_GENE_PRODUCT", 50, 54], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 56, 65], ["interferon gamma induced protein 10", "GENE_OR_GENE_PRODUCT", 67, 102], ["granulocyte-colony stimulating factor", "GENE_OR_GENE_PRODUCT", 104, 141], ["patients", "ORGANISM", 162, 170], ["IL-6", "GENE_OR_GENE_PRODUCT", 241, 245], ["pulmonary", "ORGAN", 284, 293], ["patients", "ORGANISM", 312, 320], ["interleukins", "PROTEIN", 9, 21], ["chemokines", "PROTEIN", 26, 36], ["IL-2, IL-7, IL-6", "PROTEIN", 38, 54], ["TNF", "PROTEIN", 56, 59], ["interferon gamma induced protein 10", "PROTEIN", 67, 102], ["granulocyte-colony stimulating factor", "PROTEIN", 104, 141], ["IL-6", "PROTEIN", 241, 245], ["patients", "SPECIES", 162, 170], ["patients", "SPECIES", 312, 320], ["Specific interleukins", "TEST", 0, 21], ["chemokines", "TEST", 26, 36], ["IL", "TEST", 38, 40], ["IL", "TEST", 44, 46], ["IL", "TEST", 50, 52], ["TNF", "TEST", 56, 59], ["alpha", "TEST", 60, 65], ["interferon gamma induced protein", "TREATMENT", 67, 99], ["granulocyte", "TEST", 104, 115], ["serious pulmonary involvement", "PROBLEM", 276, 305], ["serious", "OBSERVATION_MODIFIER", 276, 283], ["pulmonary", "ANATOMY", 284, 293], ["involvement", "OBSERVATION", 294, 305]]], ["These findings are also more evident in elderly patients who display less vigorous immune response against viral shedding, greater susceptibility to more serious pulmonary and systemic involvement, and are finally predisposed to COVID-19 progression [80].", [["pulmonary", "ANATOMY", 162, 171], ["patients", "ORGANISM", 48, 56], ["pulmonary", "ORGAN", 162, 171], ["patients", "SPECIES", 48, 56], ["viral shedding", "PROBLEM", 107, 121], ["serious pulmonary and systemic involvement", "PROBLEM", 154, 196], ["COVID", "TEST", 229, 234], ["serious", "OBSERVATION_MODIFIER", 154, 161], ["pulmonary", "ANATOMY", 162, 171], ["systemic", "OBSERVATION_MODIFIER", 176, 184], ["involvement", "OBSERVATION", 185, 196]]], ["Both the number and function of T cells (both CD4+ and CD8+) [81, 82], B cells depletion, and hypercoagulability have also been observed in seriously ill cases and the greater the magnitude of these haematological and biochemical alterations then the greater the severity of the prognosis [83, 84].", [["T cells", "ANATOMY", 32, 39], ["CD4+", "ANATOMY", 46, 50], ["B cells", "ANATOMY", 71, 78], ["hypercoagulability", "DISEASE", 94, 112], ["T cells", "CELL", 32, 39], ["CD4", "GENE_OR_GENE_PRODUCT", 46, 49], ["CD8", "GENE_OR_GENE_PRODUCT", 55, 58], ["B cells", "CELL", 71, 78], ["T cells", "CELL_TYPE", 32, 39], ["CD4", "PROTEIN", 46, 49], ["CD8", "PROTEIN", 55, 58], ["B cells", "CELL_TYPE", 71, 78], ["T cells", "TEST", 32, 39], ["CD4", "TEST", 46, 49], ["CD8", "TEST", 55, 58], ["B cells depletion", "PROBLEM", 71, 88], ["hypercoagulability", "PROBLEM", 94, 112], ["these haematological and biochemical alterations", "PROBLEM", 193, 241], ["number", "OBSERVATION_MODIFIER", 9, 15], ["cells depletion", "OBSERVATION", 73, 88]]], ["In conclusion, diabetic patients especially elderly individuals and those with worse baseline glucose control may exhibit immune system dysregulation that predispose them to a less effective response against SARS-CoV-2 and to a dysfunctional inflammation that requires to be carefully monitored in confirmed cases of COVID-19, for preventing or avoiding a harmful progression of the disease.Pathophysiological characteristicsAngiotensin-converting enzyme 2 (ACE2) is a carboxypeptidase normally involved in the cleavage of angiotensin I and angiotensin II, and is the main receptor for SARS-CoV-2 playing a determinant role in viral entry into the host, and clearly explaining both the transmissibility and severity of COVID-19 among humans [85].", [["immune system", "ANATOMY", 122, 135], ["diabetic", "DISEASE", 15, 23], ["glucose", "CHEMICAL", 94, 101], ["SARS", "DISEASE", 208, 212], ["inflammation", "DISEASE", 242, 254], ["COVID-19", "CHEMICAL", 317, 325], ["Angiotensin", "CHEMICAL", 425, 436], ["angiotensin I", "CHEMICAL", 523, 536], ["angiotensin II", "CHEMICAL", 541, 555], ["glucose", "CHEMICAL", 94, 101], ["COVID-19", "CHEMICAL", 317, 325], ["patients", "ORGANISM", 24, 32], ["glucose", "SIMPLE_CHEMICAL", 94, 101], ["SARS-CoV-2", "ORGANISM", 208, 218], ["Angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 425, 456], ["ACE2", "GENE_OR_GENE_PRODUCT", 458, 462], ["carboxypeptidase", "GENE_OR_GENE_PRODUCT", 469, 485], ["angiotensin I", "GENE_OR_GENE_PRODUCT", 523, 536], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 541, 555], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 586, 596], ["humans", "ORGANISM", 734, 740], ["Angiotensin-converting enzyme 2", "PROTEIN", 425, 456], ["ACE2", "PROTEIN", 458, 462], ["carboxypeptidase", "PROTEIN", 469, 485], ["angiotensin I", "PROTEIN", 523, 536], ["angiotensin II", "PROTEIN", 541, 555], ["patients", "SPECIES", 24, 32], ["humans", "SPECIES", 734, 740], ["SARS-CoV", "SPECIES", 208, 216], ["humans", "SPECIES", 734, 740], ["glucose control", "TREATMENT", 94, 109], ["immune system dysregulation", "PROBLEM", 122, 149], ["SARS", "PROBLEM", 208, 212], ["a dysfunctional inflammation", "PROBLEM", 226, 254], ["COVID", "TEST", 317, 322], ["the disease", "PROBLEM", 379, 390], ["Pathophysiological characteristics", "PROBLEM", 391, 425], ["Angiotensin", "TEST", 425, 436], ["converting enzyme", "TEST", 437, 454], ["a carboxypeptidase", "TREATMENT", 467, 485], ["angiotensin I and angiotensin II", "TREATMENT", 523, 555], ["COVID", "TEST", 719, 724], ["diabetic", "OBSERVATION", 15, 23], ["dysfunctional", "OBSERVATION_MODIFIER", 228, 241], ["inflammation", "OBSERVATION", 242, 254], ["disease", "OBSERVATION", 383, 390]]], ["ACE2 is expressed at the level of several tissues (transmembrane and soluble forms), such as lung [86], oral mucosa [87], intestine [88], brain [89], pancreatic islets [90], testis [91] and kidney [92].", [["tissues", "ANATOMY", 42, 49], ["transmembrane", "ANATOMY", 51, 64], ["lung", "ANATOMY", 93, 97], ["oral mucosa", "ANATOMY", 104, 115], ["intestine", "ANATOMY", 122, 131], ["brain", "ANATOMY", 138, 143], ["pancreatic islets", "ANATOMY", 150, 167], ["testis", "ANATOMY", 174, 180], ["kidney", "ANATOMY", 190, 196], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["tissues", "TISSUE", 42, 49], ["transmembrane", "CELLULAR_COMPONENT", 51, 64], ["lung", "ORGAN", 93, 97], ["oral mucosa", "MULTI-TISSUE_STRUCTURE", 104, 115], ["intestine", "ORGAN", 122, 131], ["brain", "ORGAN", 138, 143], ["pancreatic islets", "MULTI-TISSUE_STRUCTURE", 150, 167], ["testis", "ORGAN", 174, 180], ["kidney", "ORGAN", 190, 196], ["ACE2", "PROTEIN", 0, 4], ["transmembrane and soluble forms", "PROTEIN", 51, 82], ["ACE2", "TREATMENT", 0, 4], ["oral mucosa", "TEST", 104, 115], ["pancreatic islets", "TEST", 150, 167], ["testis", "TEST", 174, 180], ["kidney", "TEST", 190, 196], ["several tissues", "ANATOMY", 34, 49], ["lung", "ANATOMY", 93, 97], ["mucosa", "ANATOMY", 109, 115], ["intestine", "ANATOMY", 122, 131], ["brain", "ANATOMY", 138, 143], ["pancreatic", "ANATOMY", 150, 160], ["testis", "ANATOMY", 174, 180], ["kidney", "ANATOMY", 190, 196]]], ["Differentiated type 2 pneumocytes normally express ACE2, which is essential to regulate pulmonary homoeostasis and protects against pulmonary injury [93].", [["type 2 pneumocytes", "ANATOMY", 15, 33], ["pulmonary", "ANATOMY", 88, 97], ["pulmonary", "ANATOMY", 132, 141], ["pulmonary injury", "DISEASE", 132, 148], ["type 2 pneumocytes", "CELL", 15, 33], ["ACE2", "GENE_OR_GENE_PRODUCT", 51, 55], ["pulmonary", "ORGAN", 88, 97], ["pulmonary", "ORGAN", 132, 141], ["ACE2", "PROTEIN", 51, 55], ["Differentiated type 2 pneumocytes", "PROBLEM", 0, 33], ["ACE2", "TEST", 51, 55], ["pulmonary injury", "PROBLEM", 132, 148], ["pneumocytes", "OBSERVATION", 22, 33], ["pulmonary", "ANATOMY", 88, 97], ["homoeostasis", "OBSERVATION", 98, 110], ["pulmonary", "ANATOMY", 132, 141], ["injury", "OBSERVATION", 142, 148]]], ["Indeed, low levels of ACE2 have been described in severe acute and chronic pulmonary diseases thus predisposing to poor prognosis [94].", [["pulmonary", "ANATOMY", 75, 84], ["chronic pulmonary diseases", "DISEASE", 67, 93], ["ACE2", "GENE_OR_GENE_PRODUCT", 22, 26], ["pulmonary", "ORGAN", 75, 84], ["ACE2", "PROTEIN", 22, 26], ["low levels of ACE2", "PROBLEM", 8, 26], ["severe acute and chronic pulmonary diseases", "PROBLEM", 50, 93], ["low levels", "OBSERVATION_MODIFIER", 8, 18], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["acute", "OBSERVATION_MODIFIER", 57, 62], ["chronic", "OBSERVATION_MODIFIER", 67, 74], ["pulmonary", "ANATOMY", 75, 84], ["diseases", "OBSERVATION", 85, 93]]], ["However, ACE2 is overexpressed in chronic diseases, including T2D, and this phenomenon could be also related with chronical exposure to several medications [94, 95].", [["chronic diseases", "DISEASE", 34, 50], ["T2D", "DISEASE", 62, 65], ["ACE2", "GENE_OR_GENE_PRODUCT", 9, 13], ["ACE2", "PROTEIN", 9, 13], ["ACE2", "PROBLEM", 9, 13], ["chronic diseases", "PROBLEM", 34, 50], ["T2D", "PROBLEM", 62, 65], ["this phenomenon", "PROBLEM", 71, 86], ["several medications", "TREATMENT", 136, 155], ["overexpressed", "OBSERVATION_MODIFIER", 17, 30], ["chronic", "OBSERVATION_MODIFIER", 34, 41], ["diseases", "OBSERVATION", 42, 50]]], ["This biochemical condition is believed to facilitate the internalization of SARS-CoV-2 into pneumocytes, thus contributing to worse prognosis in COVID-19 [94, 95].", [["pneumocytes", "ANATOMY", 92, 103], ["SARS", "DISEASE", 76, 80], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 76, 86], ["pneumocytes", "CELL", 92, 103], ["pneumocytes", "CELL_TYPE", 92, 103], ["This biochemical condition", "PROBLEM", 0, 26], ["SARS", "PROBLEM", 76, 80], ["CoV", "TEST", 81, 84], ["pneumocytes", "PROBLEM", 92, 103], ["COVID", "TEST", 145, 150]]], ["However, the role of ACE2 overexpression in worsening the prognosis is an emergent issue, and remains currently debated [96].Diabetes-related comorbiditiesCardiovascular diseases, including coronary and cerebrovascular artery disease and heart failure, are frequently observed in T2D patients and it has been estimated that about a third of them displayed these kind of complications over time [97].", [["Cardiovascular", "ANATOMY", 155, 169], ["coronary", "ANATOMY", 190, 198], ["cerebrovascular artery", "ANATOMY", 203, 225], ["heart", "ANATOMY", 238, 243], ["Diabetes", "DISEASE", 125, 133], ["Cardiovascular diseases", "DISEASE", 155, 178], ["coronary and cerebrovascular artery disease", "DISEASE", 190, 233], ["heart failure", "DISEASE", 238, 251], ["T2D", "DISEASE", 280, 283], ["ACE2", "GENE_OR_GENE_PRODUCT", 21, 25], ["coronary", "MULTI-TISSUE_STRUCTURE", 190, 198], ["cerebrovascular artery", "MULTI-TISSUE_STRUCTURE", 203, 225], ["heart", "ORGAN", 238, 243], ["patients", "ORGANISM", 284, 292], ["ACE2", "PROTEIN", 21, 25], ["patients", "SPECIES", 284, 292], ["ACE2 overexpression", "PROBLEM", 21, 40], ["Diabetes", "PROBLEM", 125, 133], ["Cardiovascular diseases", "PROBLEM", 155, 178], ["coronary and cerebrovascular artery disease", "PROBLEM", 190, 233], ["heart failure", "PROBLEM", 238, 251], ["worsening", "OBSERVATION_MODIFIER", 44, 53], ["coronary", "ANATOMY", 190, 198], ["cerebrovascular artery", "ANATOMY", 203, 225], ["disease", "OBSERVATION", 226, 233], ["heart", "ANATOMY", 238, 243], ["failure", "OBSERVATION", 244, 251]]], ["Cardiovascular system is the main extrapulmonary compartment extensively involved in COVID-19, as suggested by a frequent myocardial involvement in affected patients especially in those having hypertension, T2D and cardiovascular diseases at baseline [98].", [["Cardiovascular system", "ANATOMY", 0, 21], ["extrapulmonary compartment", "ANATOMY", 34, 60], ["myocardial", "ANATOMY", 122, 132], ["cardiovascular", "ANATOMY", 215, 229], ["myocardial involvement", "DISEASE", 122, 144], ["hypertension", "DISEASE", 193, 205], ["T2D", "DISEASE", 207, 210], ["cardiovascular diseases", "DISEASE", 215, 238], ["compartment", "IMMATERIAL_ANATOMICAL_ENTITY", 49, 60], ["myocardial", "MULTI-TISSUE_STRUCTURE", 122, 132], ["patients", "ORGANISM", 157, 165], ["cardiovascular", "ANATOMICAL_SYSTEM", 215, 229], ["patients", "SPECIES", 157, 165], ["COVID", "TEST", 85, 90], ["a frequent myocardial involvement", "PROBLEM", 111, 144], ["hypertension", "PROBLEM", 193, 205], ["T2D", "PROBLEM", 207, 210], ["cardiovascular diseases", "PROBLEM", 215, 238], ["main", "OBSERVATION_MODIFIER", 29, 33], ["extrapulmonary compartment", "OBSERVATION", 34, 60], ["myocardial", "ANATOMY", 122, 132], ["involvement", "OBSERVATION", 133, 144], ["hypertension", "OBSERVATION", 193, 205], ["cardiovascular diseases", "OBSERVATION", 215, 238]]], ["Vascular inflammation and endothelial dysfunction [99], myocardial injury and cardiac arrhythmias are not-infrequently observed in COVID-19 confirmed cases, significantly influencing the risk of poor prognosis or death in this cluster of patients [100\u2013102].Diabetes-related comorbiditiesOverweight-obesity syndrome is a multifactorial disease which significantly predispose to cardiometabolic risk, and is strictly associated with insulin-resistance, glucose metabolism impairment and T2D [103\u2013105].", [["Vascular", "ANATOMY", 0, 8], ["endothelial", "ANATOMY", 26, 37], ["myocardial", "ANATOMY", 56, 66], ["cardiac", "ANATOMY", 78, 85], ["inflammation", "DISEASE", 9, 21], ["endothelial dysfunction", "DISEASE", 26, 49], ["myocardial injury", "DISEASE", 56, 73], ["cardiac arrhythmias", "DISEASE", 78, 97], ["death", "DISEASE", 213, 218], ["Diabetes", "DISEASE", 257, 265], ["Overweight-obesity syndrome", "DISEASE", 287, 314], ["cardiometabolic risk", "DISEASE", 377, 397], ["glucose metabolism impairment", "DISEASE", 451, 480], ["T2D", "DISEASE", 485, 488], ["glucose", "CHEMICAL", 451, 458], ["Vascular", "MULTI-TISSUE_STRUCTURE", 0, 8], ["endothelial", "TISSUE", 26, 37], ["myocardial", "MULTI-TISSUE_STRUCTURE", 56, 66], ["cardiac", "ORGAN", 78, 85], ["patients", "ORGANISM", 238, 246], ["insulin", "GENE_OR_GENE_PRODUCT", 431, 438], ["glucose", "SIMPLE_CHEMICAL", 451, 458], ["patients", "SPECIES", 238, 246], ["Vascular inflammation", "PROBLEM", 0, 21], ["endothelial dysfunction", "PROBLEM", 26, 49], ["myocardial injury", "PROBLEM", 56, 73], ["cardiac arrhythmias", "PROBLEM", 78, 97], ["COVID", "TEST", 131, 136], ["death", "PROBLEM", 213, 218], ["Diabetes", "PROBLEM", 257, 265], ["related comorbidities", "PROBLEM", 266, 287], ["obesity syndrome", "PROBLEM", 298, 314], ["a multifactorial disease", "PROBLEM", 318, 342], ["cardiometabolic risk", "PROBLEM", 377, 397], ["insulin-resistance", "PROBLEM", 431, 449], ["glucose metabolism impairment", "PROBLEM", 451, 480], ["T2D", "PROBLEM", 485, 488], ["inflammation", "OBSERVATION", 9, 21], ["endothelial dysfunction", "OBSERVATION", 26, 49], ["myocardial", "ANATOMY", 56, 66], ["injury", "OBSERVATION", 67, 73], ["cardiac", "ANATOMY", 78, 85], ["arrhythmias", "OBSERVATION", 86, 97], ["obesity", "OBSERVATION", 298, 305], ["multifactorial", "OBSERVATION_MODIFIER", 320, 334], ["disease", "OBSERVATION", 335, 342]]], ["Despite obesity is usually associated with decreased risk of death in patients with severe acute respiratory distress (obesity paradox), currently available data suggest that an elevated body mass index should be considered as an independent risk factor predisposing to poor prognosis [106] and death in COVID-19 [107\u2013110].", [["respiratory", "ANATOMY", 97, 108], ["body", "ANATOMY", 187, 191], ["obesity", "DISEASE", 8, 15], ["death", "DISEASE", 61, 66], ["acute respiratory distress", "DISEASE", 91, 117], ["obesity paradox", "DISEASE", 119, 134], ["death", "DISEASE", 295, 300], ["patients", "ORGANISM", 70, 78], ["body", "ORGANISM_SUBDIVISION", 187, 191], ["patients", "SPECIES", 70, 78], ["obesity", "PROBLEM", 8, 15], ["death", "PROBLEM", 61, 66], ["severe acute respiratory distress", "PROBLEM", 84, 117], ["obesity paradox", "PROBLEM", 119, 134], ["an elevated body mass index", "PROBLEM", 175, 202], ["poor prognosis", "PROBLEM", 270, 284], ["death", "PROBLEM", 295, 300], ["COVID", "TEST", 304, 309], ["obesity", "OBSERVATION", 8, 15], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["acute", "OBSERVATION_MODIFIER", 91, 96], ["respiratory", "ANATOMY", 97, 108], ["distress", "OBSERVATION", 109, 117], ["mass", "OBSERVATION", 192, 196]]], ["Indeed, the prevalence rate of obesity in this cluster of patients has been reported in 42% of the cases [111] and a BMI greater than 35 kg/m2 has been usually observed in patients requiring hospitalization and invasive mechanical ventilation [112] also in younger patients (<60 years) [113].", [["obesity", "DISEASE", 31, 38], ["patients", "ORGANISM", 58, 66], ["patients", "ORGANISM", 172, 180], ["patients", "ORGANISM", 265, 273], ["patients", "SPECIES", 58, 66], ["patients", "SPECIES", 172, 180], ["patients", "SPECIES", 265, 273], ["obesity", "PROBLEM", 31, 38], ["a BMI", "TEST", 115, 120], ["invasive mechanical ventilation", "TREATMENT", 211, 242], ["obesity", "OBSERVATION", 31, 38]]], ["Pathophysiological mechanisms possibly related with poor prognosis in obese patients are not completely understood but may be attributable to a greater inflammatory background as similarly found in DM due to hyperglycaemia and insulin resistance [70].", [["obese", "DISEASE", 70, 75], ["DM", "DISEASE", 198, 200], ["hyperglycaemia", "DISEASE", 208, 222], ["patients", "ORGANISM", 76, 84], ["insulin", "GENE_OR_GENE_PRODUCT", 227, 234], ["patients", "SPECIES", 76, 84], ["Pathophysiological mechanisms", "PROBLEM", 0, 29], ["a greater inflammatory background", "PROBLEM", 142, 175], ["DM", "PROBLEM", 198, 200], ["hyperglycaemia", "PROBLEM", 208, 222], ["insulin resistance", "PROBLEM", 227, 245], ["possibly related with", "UNCERTAINTY", 30, 51], ["greater", "OBSERVATION_MODIFIER", 144, 151], ["inflammatory", "OBSERVATION", 152, 164], ["hyperglycaemia", "OBSERVATION", 208, 222], ["insulin resistance", "OBSERVATION", 227, 245]]], ["Obesity is usually associated to other severe comorbidities with high impact on cardio-metabolic health, such as fatty liver disease, vascular inflammation, cardiovascular atherosclerotic diseases and heart failure [114] that might be related with a higher burden of lethal complications, especially in hospitalized patients with COVID-19 [115].", [["fatty liver", "ANATOMY", 113, 124], ["vascular", "ANATOMY", 134, 142], ["cardiovascular", "ANATOMY", 157, 171], ["heart", "ANATOMY", 201, 206], ["Obesity", "DISEASE", 0, 7], ["cardio-metabolic health", "DISEASE", 80, 103], ["fatty liver disease", "DISEASE", 113, 132], ["vascular inflammation", "DISEASE", 134, 155], ["cardiovascular atherosclerotic diseases", "DISEASE", 157, 196], ["heart failure", "DISEASE", 201, 214], ["COVID-19", "CHEMICAL", 330, 338], ["liver", "ORGAN", 119, 124], ["vascular", "MULTI-TISSUE_STRUCTURE", 134, 142], ["heart", "ORGAN", 201, 206], ["patients", "ORGANISM", 316, 324], ["patients", "SPECIES", 316, 324], ["Obesity", "PROBLEM", 0, 7], ["other severe comorbidities", "PROBLEM", 33, 59], ["high impact", "PROBLEM", 65, 76], ["fatty liver disease", "PROBLEM", 113, 132], ["vascular inflammation", "PROBLEM", 134, 155], ["cardiovascular atherosclerotic diseases", "PROBLEM", 157, 196], ["heart failure", "PROBLEM", 201, 214], ["lethal complications", "PROBLEM", 267, 287], ["COVID", "TEST", 330, 335], ["severe", "OBSERVATION_MODIFIER", 39, 45], ["comorbidities", "OBSERVATION", 46, 59], ["metabolic health", "OBSERVATION", 87, 103], ["fatty", "OBSERVATION", 113, 118], ["liver", "ANATOMY", 119, 124], ["vascular", "ANATOMY", 134, 142], ["inflammation", "OBSERVATION", 143, 155], ["cardiovascular", "OBSERVATION_MODIFIER", 157, 171], ["atherosclerotic", "OBSERVATION_MODIFIER", 172, 187], ["heart", "ANATOMY", 201, 206], ["failure", "OBSERVATION", 207, 214]]], ["In addition to cardio-metabolic risk factors, obese patients are more prone to have a decreased pulmonary ventilation or obstructive sleep apnoea, which predispose them to low levels of blood oxygenation at baseline and consequently to worse respiratory outcomes in case of acute infective respiratory diseases [116, 117].", [["pulmonary", "ANATOMY", 96, 105], ["blood", "ANATOMY", 186, 191], ["respiratory", "ANATOMY", 242, 253], ["respiratory", "ANATOMY", 290, 301], ["obstructive sleep apnoea", "DISEASE", 121, 145], ["infective respiratory diseases", "DISEASE", 280, 310], ["patients", "ORGANISM", 52, 60], ["pulmonary", "ORGAN", 96, 105], ["blood", "ORGANISM_SUBSTANCE", 186, 191], ["patients", "SPECIES", 52, 60], ["cardio-metabolic risk factors", "PROBLEM", 15, 44], ["obese", "PROBLEM", 46, 51], ["a decreased pulmonary ventilation", "PROBLEM", 84, 117], ["obstructive sleep apnoea", "PROBLEM", 121, 145], ["blood oxygenation", "TEST", 186, 203], ["acute infective respiratory diseases", "PROBLEM", 274, 310], ["obese", "OBSERVATION", 46, 51], ["decreased", "OBSERVATION_MODIFIER", 86, 95], ["pulmonary", "ANATOMY", 96, 105], ["ventilation", "OBSERVATION", 106, 117], ["obstructive", "OBSERVATION_MODIFIER", 121, 132], ["sleep apnoea", "OBSERVATION", 133, 145], ["acute", "OBSERVATION_MODIFIER", 274, 279], ["infective", "OBSERVATION_MODIFIER", 280, 289], ["respiratory diseases", "OBSERVATION", 290, 310]]], ["Nutritional patterns usually exhibited by obese patients are frequently characterized by an elevated dietary consumption of processed food rich in saturated fat, cholesterol, sugar and a low consumption of fibres and micronutrients, such as vitamin D [118].", [["fat", "ANATOMY", 157, 160], ["fibres", "ANATOMY", 206, 212], ["cholesterol", "CHEMICAL", 162, 173], ["vitamin D", "CHEMICAL", 241, 250], ["cholesterol", "CHEMICAL", 162, 173], ["sugar", "CHEMICAL", 175, 180], ["vitamin D [118]", "CHEMICAL", 241, 256], ["patients", "ORGANISM", 48, 56], ["fat", "TISSUE", 157, 160], ["cholesterol", "SIMPLE_CHEMICAL", 162, 173], ["sugar", "SIMPLE_CHEMICAL", 175, 180], ["fibres", "TISSUE", 206, 212], ["vitamin D", "SIMPLE_CHEMICAL", 241, 250], ["patients", "SPECIES", 48, 56], ["an elevated dietary consumption", "PROBLEM", 89, 120], ["micronutrients", "TREATMENT", 217, 231], ["vitamin D", "TREATMENT", 241, 250]]], ["These dietary patterns may affect physiological microbiome composition, weaken the immune response against microbial agent and foster immune system dysfunction [115].", [["immune system", "ANATOMY", 134, 147], ["immune system dysfunction", "DISEASE", 134, 159], ["microbial agent", "TREATMENT", 107, 122], ["foster immune system dysfunction", "PROBLEM", 127, 159]]], ["In addition, vitamin D deficiency/insufficiency and sedentary lifestyle, which are highly prevalent among obese patients, should be considered as predisposing factors for worse prognosis in response to acute infections, including COVID-19 [119].", [["vitamin D", "CHEMICAL", 13, 22], ["insufficiency", "DISEASE", 34, 47], ["infections", "DISEASE", 208, 218], ["vitamin D", "CHEMICAL", 13, 22], ["vitamin D", "SIMPLE_CHEMICAL", 13, 22], ["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["vitamin D deficiency", "PROBLEM", 13, 33], ["insufficiency", "PROBLEM", 34, 47], ["sedentary lifestyle", "PROBLEM", 52, 71], ["acute infections", "PROBLEM", 202, 218], ["COVID", "TEST", 230, 235], ["insufficiency", "OBSERVATION", 34, 47], ["acute", "OBSERVATION_MODIFIER", 202, 207], ["infections", "OBSERVATION", 208, 218]]], ["Abdominal obesity usually leads to a low cardiorespiratory reserve and systemic inflammatory dysfunction which predispose to a worse prognosis in COVID-19 [120].", [["Abdominal", "ANATOMY", 0, 9], ["Abdominal obesity", "DISEASE", 0, 17], ["Abdominal obesity", "PROBLEM", 0, 17], ["a low cardiorespiratory reserve", "PROBLEM", 35, 66], ["systemic inflammatory dysfunction", "PROBLEM", 71, 104], ["a worse prognosis", "PROBLEM", 125, 142], ["COVID", "TEST", 146, 151], ["obesity", "OBSERVATION", 10, 17], ["low", "OBSERVATION_MODIFIER", 37, 40], ["cardiorespiratory reserve", "OBSERVATION", 41, 66], ["systemic", "OBSERVATION_MODIFIER", 71, 79], ["inflammatory dysfunction", "OBSERVATION", 80, 104]]], ["Conversely, regular physical exercise, which is normally lacking in an obesogenic lifestyle, is associated to higher levels of cardiorespiratory fitness, and is believed to improve the innate immune response and attenuate cytokine dysregulation often experienced by high risk patients with the so called cytokine storm [121].", [["patients", "ORGANISM", 276, 284], ["cytokine", "PROTEIN", 222, 230], ["cytokine", "PROTEIN", 304, 312], ["patients", "SPECIES", 276, 284], ["cytokine dysregulation", "PROBLEM", 222, 244]]], ["Visceral obesity is also a risk factor for both the development and progression of cardiovascular diseases [114] considering that it fosters higher level of pro-thrombotic circulating factors and predisposes to thrombotic events [122].", [["Visceral", "ANATOMY", 0, 8], ["cardiovascular", "ANATOMY", 83, 97], ["Visceral obesity", "DISEASE", 0, 16], ["cardiovascular diseases", "DISEASE", 83, 106], ["thrombotic", "DISEASE", 211, 221], ["cardiovascular", "ANATOMICAL_SYSTEM", 83, 97], ["pro-thrombotic circulating factors", "PROTEIN", 157, 191], ["Visceral obesity", "PROBLEM", 0, 16], ["a risk factor", "PROBLEM", 25, 38], ["cardiovascular diseases", "PROBLEM", 83, 106], ["pro-thrombotic circulating factors", "PROBLEM", 157, 191], ["thrombotic events", "PROBLEM", 211, 228], ["obesity", "OBSERVATION", 9, 16], ["progression", "OBSERVATION_MODIFIER", 68, 79], ["cardiovascular diseases", "OBSERVATION", 83, 106], ["thrombotic", "OBSERVATION", 211, 221]]], ["Furthermore, visceral obesity is more prevalent in men than women and this biological phenomenon has been hypothesized to have a putative role in driven poor prognosis of COVID-19 especially in men.", [["visceral", "ANATOMY", 13, 21], ["visceral obesity", "DISEASE", 13, 29], ["COVID", "DISEASE", 171, 176], ["visceral", "ORGANISM_SUBDIVISION", 13, 21], ["men", "ORGANISM", 51, 54], ["women", "ORGANISM", 60, 65], ["COVID-19", "CELL", 171, 179], ["men", "ORGANISM", 194, 197], ["men", "SPECIES", 51, 54], ["women", "SPECIES", 60, 65], ["men", "SPECIES", 194, 197], ["visceral obesity", "PROBLEM", 13, 29], ["COVID", "TEST", 171, 176], ["visceral", "ANATOMY", 13, 21], ["obesity", "OBSERVATION", 22, 29], ["more prevalent", "OBSERVATION_MODIFIER", 33, 47]]], ["From this point of view, male obesity is usually associated with a functional hypogonadism and these clinical conditions are both associated with one other [123], according to a complex and multifactorial pathogenesis [124] that fosters higher baseline levels of inflammation and endothelial dysfunction [125].", [["endothelial", "ANATOMY", 280, 291], ["obesity", "DISEASE", 30, 37], ["hypogonadism", "DISEASE", 78, 90], ["inflammation", "DISEASE", 263, 275], ["endothelial dysfunction", "DISEASE", 280, 303], ["endothelial", "TISSUE", 280, 291], ["male obesity", "PROBLEM", 25, 37], ["a functional hypogonadism", "PROBLEM", 65, 90], ["these clinical conditions", "PROBLEM", 95, 120], ["multifactorial pathogenesis", "PROBLEM", 190, 217], ["inflammation", "PROBLEM", 263, 275], ["endothelial dysfunction", "PROBLEM", 280, 303], ["obesity", "OBSERVATION", 30, 37], ["hypogonadism", "OBSERVATION", 78, 90], ["inflammation", "OBSERVATION", 263, 275], ["endothelial dysfunction", "OBSERVATION", 280, 303]]], ["Aromatase gene expression is enhanced by prostaglandin E2, whose levels were found to be higher in visceral adipose tissue of obese men [126].", [["visceral adipose tissue", "ANATOMY", 99, 122], ["prostaglandin E2", "CHEMICAL", 41, 57], ["prostaglandin E2", "CHEMICAL", 41, 57], ["Aromatase", "GENE_OR_GENE_PRODUCT", 0, 9], ["prostaglandin E2", "SIMPLE_CHEMICAL", 41, 57], ["visceral adipose tissue", "TISSUE", 99, 122], ["men", "ORGANISM", 132, 135], ["men", "SPECIES", 132, 135], ["Aromatase gene expression", "PROBLEM", 0, 25], ["prostaglandin E2", "TEST", 41, 57], ["whose levels", "TEST", 59, 71], ["higher", "OBSERVATION_MODIFIER", 89, 95], ["visceral adipose", "ANATOMY", 99, 115], ["obese", "OBSERVATION", 126, 131]]], ["An enhanced aromatase activity at the level of adipose tissue increases local levels of estradiol that is thought to be a defensive mechanism against local inflammation and insulin resistance [127].", [["adipose tissue", "ANATOMY", 47, 61], ["estradiol", "CHEMICAL", 88, 97], ["inflammation", "DISEASE", 156, 168], ["estradiol", "CHEMICAL", 88, 97], ["aromatase", "GENE_OR_GENE_PRODUCT", 12, 21], ["adipose tissue", "TISSUE", 47, 61], ["estradiol", "SIMPLE_CHEMICAL", 88, 97], ["insulin", "GENE_OR_GENE_PRODUCT", 173, 180], ["aromatase", "PROTEIN", 12, 21], ["An enhanced aromatase activity", "PROBLEM", 0, 30], ["adipose tissue", "PROBLEM", 47, 61], ["estradiol", "TREATMENT", 88, 97], ["a defensive mechanism", "PROBLEM", 120, 141], ["local inflammation", "PROBLEM", 150, 168], ["insulin resistance", "PROBLEM", 173, 191], ["enhanced", "OBSERVATION_MODIFIER", 3, 11], ["aromatase activity", "OBSERVATION", 12, 30], ["adipose tissue", "ANATOMY", 47, 61], ["thought to be", "UNCERTAINTY", 106, 119], ["inflammation", "OBSERVATION", 156, 168], ["insulin resistance", "OBSERVATION", 173, 191]]], ["Whether augmented aromatase levels (and activity) at the level of adipose tissue in men may be responsible for a systemic testosterone-to-oestrogen imbalance remains questionable.", [["adipose tissue", "ANATOMY", 66, 80], ["testosterone", "CHEMICAL", 122, 134], ["testosterone", "CHEMICAL", 122, 134], ["oestrogen", "CHEMICAL", 138, 147], ["aromatase", "GENE_OR_GENE_PRODUCT", 18, 27], ["adipose tissue", "TISSUE", 66, 80], ["men", "ORGANISM", 84, 87], ["testosterone", "SIMPLE_CHEMICAL", 122, 134], ["oestrogen", "SIMPLE_CHEMICAL", 138, 147], ["aromatase", "PROTEIN", 18, 27], ["men", "SPECIES", 84, 87], ["augmented aromatase levels", "TEST", 8, 34], ["a systemic testosterone", "TEST", 111, 134], ["oestrogen imbalance", "PROBLEM", 138, 157], ["adipose tissue", "ANATOMY", 66, 80]]], ["However, obese men are usually affected by this biochemical condition and body mass index is inversely correlated to testosterone-to-oestrogen ratio [128].", [["body", "ANATOMY", 74, 78], ["testosterone", "CHEMICAL", 117, 129], ["oestrogen", "CHEMICAL", 133, 142], ["testosterone", "CHEMICAL", 117, 129], ["oestrogen", "CHEMICAL", 133, 142], ["men", "ORGANISM", 15, 18], ["body", "ORGANISM_SUBDIVISION", 74, 78], ["testosterone", "SIMPLE_CHEMICAL", 117, 129], ["oestrogen", "SIMPLE_CHEMICAL", 133, 142], ["men", "SPECIES", 15, 18], ["this biochemical condition", "PROBLEM", 43, 69], ["body mass index", "TEST", 74, 89], ["testosterone", "TEST", 117, 129], ["oestrogen ratio", "TEST", 133, 148], ["obese", "OBSERVATION", 9, 14], ["mass", "OBSERVATION", 79, 83]]], ["A low testosterone-to-estradiol ratio contributes to increase the cardiovascular risk particularly in elderly [129] and in those with previous cardiovascular diseases [130\u2013132].", [["cardiovascular", "ANATOMY", 66, 80], ["cardiovascular", "ANATOMY", 143, 157], ["testosterone", "CHEMICAL", 6, 18], ["estradiol", "CHEMICAL", 22, 31], ["cardiovascular diseases", "DISEASE", 143, 166], ["testosterone", "CHEMICAL", 6, 18], ["estradiol", "CHEMICAL", 22, 31], ["testosterone", "SIMPLE_CHEMICAL", 6, 18], ["estradiol", "SIMPLE_CHEMICAL", 22, 31], ["cardiovascular", "ANATOMICAL_SYSTEM", 66, 80], ["A low testosterone", "TREATMENT", 0, 18], ["estradiol ratio", "TREATMENT", 22, 37], ["the cardiovascular risk", "PROBLEM", 62, 85], ["previous cardiovascular diseases", "PROBLEM", 134, 166], ["cardiovascular", "ANATOMY", 143, 157], ["diseases", "OBSERVATION", 158, 166]]], ["In addition, hormonal pattern associated with visceral obesity may play a relevant role in reducing the efficacy of immune response against infectious agents, predisposing to cytokine dysregulation, endothelial dysfunction, thrombosis, finally driving patients, particularly men, to poor prognosis or death [133].Diabetes-related comorbiditiesMoreover, ACE2 is also expressed on adipose cells [134] and a larger extension of adipose tissue in obese patients may significantly increase the number of available receptors for SARS-CoV-2, thus leading to a much greater viral shedding once the infection occurs [135].Diabetes-related comorbiditiesIn conclusion, multiple diabetes-associated chronic comorbidities, particularly obesity, have been found to worsen the prognosis in COVID-19 affected patients by acting as independent risk factors.", [["visceral", "ANATOMY", 46, 54], ["endothelial", "ANATOMY", 199, 210], ["adipose cells", "ANATOMY", 379, 392], ["adipose tissue", "ANATOMY", 425, 439], ["visceral obesity", "DISEASE", 46, 62], ["endothelial dysfunction", "DISEASE", 199, 222], ["thrombosis", "DISEASE", 224, 234], ["death", "DISEASE", 301, 306], ["Diabetes", "DISEASE", 313, 321], ["infection", "DISEASE", 590, 599], ["Diabetes", "DISEASE", 613, 621], ["diabetes", "DISEASE", 667, 675], ["obesity", "DISEASE", 723, 730], ["visceral", "ORGANISM_SUBDIVISION", 46, 54], ["endothelial", "TISSUE", 199, 210], ["patients", "ORGANISM", 252, 260], ["men", "ORGANISM", 275, 278], ["ACE2", "GENE_OR_GENE_PRODUCT", 353, 357], ["adipose cells", "CELL", 379, 392], ["adipose tissue", "TISSUE", 425, 439], ["patients", "ORGANISM", 449, 457], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 523, 533], ["patients", "ORGANISM", 793, 801], ["cytokine", "PROTEIN", 175, 183], ["ACE2", "PROTEIN", 353, 357], ["adipose cells", "CELL_TYPE", 379, 392], ["patients", "SPECIES", 252, 260], ["men", "SPECIES", 275, 278], ["patients", "SPECIES", 449, 457], ["patients", "SPECIES", 793, 801], ["SARS-CoV", "SPECIES", 523, 531], ["visceral obesity", "PROBLEM", 46, 62], ["immune response", "PROBLEM", 116, 131], ["infectious agents", "TREATMENT", 140, 157], ["cytokine dysregulation", "PROBLEM", 175, 197], ["endothelial dysfunction", "PROBLEM", 199, 222], ["thrombosis", "PROBLEM", 224, 234], ["death", "PROBLEM", 301, 306], ["Diabetes", "PROBLEM", 313, 321], ["related comorbidities", "PROBLEM", 322, 343], ["ACE2", "TEST", 353, 357], ["adipose cells", "TEST", 379, 392], ["a larger extension of adipose tissue", "PROBLEM", 403, 439], ["SARS", "PROBLEM", 523, 527], ["CoV", "TEST", 528, 531], ["a much greater viral shedding", "PROBLEM", 551, 580], ["the infection", "PROBLEM", 586, 599], ["Diabetes", "PROBLEM", 613, 621], ["related comorbidities", "PROBLEM", 622, 643], ["multiple diabetes", "PROBLEM", 658, 675], ["chronic comorbidities", "PROBLEM", 687, 708], ["obesity", "PROBLEM", 723, 730], ["hormonal pattern", "OBSERVATION", 13, 29], ["visceral", "ANATOMY", 46, 54], ["obesity", "OBSERVATION", 55, 62], ["cytokine dysregulation", "OBSERVATION", 175, 197], ["endothelial dysfunction", "OBSERVATION", 199, 222], ["thrombosis", "OBSERVATION", 224, 234], ["larger", "OBSERVATION_MODIFIER", 405, 411], ["adipose tissue", "OBSERVATION", 425, 439], ["obese", "OBSERVATION", 443, 448], ["infection", "OBSERVATION", 590, 599], ["multiple", "OBSERVATION_MODIFIER", 658, 666], ["diabetes", "OBSERVATION", 667, 675], ["chronic", "OBSERVATION_MODIFIER", 687, 694], ["comorbidities", "OBSERVATION", 695, 708], ["obesity", "OBSERVATION", 723, 730]]], ["Careful management and prompt interventions are thus required for improve clinical outcome predominantly in type 2 diabetic patients.Concomitant medicationsPathogenetic mechanisms basically involved in SARS-CoV-2 infection may be exacerbated by the use of concomitant medications for the management of T2D.", [["diabetic", "DISEASE", 115, 123], ["SARS-CoV-2 infection", "DISEASE", 202, 222], ["T2D", "DISEASE", 302, 305], ["patients", "ORGANISM", 124, 132], ["SARS-CoV-2", "ORGANISM", 202, 212], ["patients", "SPECIES", 124, 132], ["SARS-CoV", "SPECIES", 202, 210], ["Careful management", "TREATMENT", 0, 18], ["prompt interventions", "TREATMENT", 23, 43], ["Concomitant medications", "TREATMENT", 133, 156], ["Pathogenetic mechanisms", "PROBLEM", 156, 179], ["SARS", "PROBLEM", 202, 206], ["CoV-2 infection", "PROBLEM", 207, 222], ["concomitant medications", "TREATMENT", 256, 279], ["the management", "TREATMENT", 284, 298], ["T2D", "PROBLEM", 302, 305], ["infection", "OBSERVATION", 213, 222]]], ["Of note, an exaggerate pulmonary and systemic expression of ACE2 facilitates SARS-CoV-2 replication and may be responsible for worse clinical course and poor prognosis [94, 95].", [["pulmonary", "ANATOMY", 23, 32], ["pulmonary", "ORGAN", 23, 32], ["ACE2", "GENE_OR_GENE_PRODUCT", 60, 64], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 77, 87], ["ACE2", "PROTEIN", 60, 64], ["ACE2", "TEST", 60, 64], ["SARS", "PROBLEM", 77, 81], ["CoV-2 replication", "TREATMENT", 82, 99], ["pulmonary", "ANATOMY", 23, 32], ["may be responsible", "UNCERTAINTY", 104, 122]]], ["In animal model, pioglitazone has demonstrated to increase ACE2 expression particularly at the level of hepatic and adipose tissue [136, 137].", [["hepatic", "ANATOMY", 104, 111], ["adipose tissue", "ANATOMY", 116, 130], ["pioglitazone", "CHEMICAL", 17, 29], ["pioglitazone", "CHEMICAL", 17, 29], ["pioglitazone", "SIMPLE_CHEMICAL", 17, 29], ["ACE2", "GENE_OR_GENE_PRODUCT", 59, 63], ["hepatic", "MULTI-TISSUE_STRUCTURE", 104, 111], ["adipose tissue", "TISSUE", 116, 130], ["ACE2", "PROTEIN", 59, 63], ["pioglitazone", "TREATMENT", 17, 29], ["increase ACE2 expression", "PROBLEM", 50, 74], ["increase", "OBSERVATION_MODIFIER", 50, 58], ["ACE2 expression", "OBSERVATION", 59, 74], ["hepatic", "ANATOMY", 104, 111], ["adipose tissue", "ANATOMY", 116, 130]]], ["On the other hand, the analysis of potential therapeutic targets for SARS-CoV-2 assessed by a computational model found pioglitazone to have a potential for inhibiting 3CLpro, an essential target for viral replication [138].", [["SARS", "DISEASE", 69, 73], ["pioglitazone", "CHEMICAL", 120, 132], ["pioglitazone", "CHEMICAL", 120, 132], ["SARS-CoV-2", "ORGANISM", 69, 79], ["pioglitazone", "SIMPLE_CHEMICAL", 120, 132], ["3CLpro", "GENE_OR_GENE_PRODUCT", 168, 174], ["3CLpro", "PROTEIN", 168, 174], ["SARS", "PROBLEM", 69, 73], ["CoV", "TEST", 74, 77], ["pioglitazone", "TREATMENT", 120, 132], ["inhibiting 3CLpro", "TREATMENT", 157, 174], ["viral replication", "PROBLEM", 200, 217]]], ["These findings did not provide conclusive assumption and diabetologists can safely prescribe pioglitazone taking into account general concerns including fluid retention and heart failure [139].Concomitant medicationsGliflozins prescription is increasing over time, also considering a long-term beneficial cardiovascular and renal protection [140, 141].", [["fluid", "ANATOMY", 153, 158], ["heart", "ANATOMY", 173, 178], ["cardiovascular", "ANATOMY", 305, 319], ["renal", "ANATOMY", 324, 329], ["pioglitazone", "CHEMICAL", 93, 105], ["fluid retention", "DISEASE", 153, 168], ["heart failure", "DISEASE", 173, 186], ["Gliflozins", "CHEMICAL", 216, 226], ["cardiovascular and renal protection", "DISEASE", 305, 340], ["pioglitazone", "CHEMICAL", 93, 105], ["Gliflozins", "CHEMICAL", 216, 226], ["pioglitazone", "SIMPLE_CHEMICAL", 93, 105], ["fluid", "ORGANISM_SUBSTANCE", 153, 158], ["heart", "ORGAN", 173, 178], ["Gliflozins", "SIMPLE_CHEMICAL", 216, 226], ["cardiovascular", "ANATOMICAL_SYSTEM", 305, 319], ["renal", "ORGAN", 324, 329], ["diabetologists", "TREATMENT", 57, 71], ["pioglitazone", "TREATMENT", 93, 105], ["fluid retention", "PROBLEM", 153, 168], ["heart failure", "PROBLEM", 173, 186], ["Concomitant medications", "TREATMENT", 193, 216], ["Gliflozins prescription", "TREATMENT", 216, 239], ["a long-term beneficial cardiovascular and renal protection", "TREATMENT", 282, 340], ["fluid retention", "OBSERVATION", 153, 168], ["heart", "ANATOMY", 173, 178], ["failure", "OBSERVATION", 179, 186], ["increasing", "OBSERVATION_MODIFIER", 243, 253], ["renal", "ANATOMY", 324, 329]]], ["Many mechanisms of cardiovascular and renal protection have been proposed, including an enhanced induction of ACE2 expression at the level of heart and kidney but it is unclear whether this effect may negatively influence clinical course in COVID-19 [142].", [["cardiovascular", "ANATOMY", 19, 33], ["renal", "ANATOMY", 38, 43], ["heart", "ANATOMY", 142, 147], ["kidney", "ANATOMY", 152, 158], ["cardiovascular and renal protection", "DISEASE", 19, 54], ["cardiovascular", "ANATOMICAL_SYSTEM", 19, 33], ["renal", "ORGAN", 38, 43], ["ACE2", "GENE_OR_GENE_PRODUCT", 110, 114], ["heart", "ORGAN", 142, 147], ["kidney", "ORGAN", 152, 158], ["ACE2", "PROTEIN", 110, 114], ["cardiovascular and renal protection", "TREATMENT", 19, 54], ["ACE2 expression", "PROBLEM", 110, 125], ["COVID", "TEST", 241, 246], ["cardiovascular", "ANATOMY", 19, 33], ["renal", "ANATOMY", 38, 43], ["protection", "OBSERVATION", 44, 54], ["heart", "ANATOMY", 142, 147], ["kidney", "ANATOMY", 152, 158]]], ["Moreover, despite gliflozins reduce inflammatory injury and endothelial dysfunction, none conclusive data are currently available to confirm their potential beneficial effect in diabetics with COVID-19 [143].", [["endothelial", "ANATOMY", 60, 71], ["gliflozins", "CHEMICAL", 18, 28], ["endothelial dysfunction", "DISEASE", 60, 83], ["COVID-19 [143", "CHEMICAL", 193, 206], ["gliflozins", "CHEMICAL", 18, 28], ["COVID-19", "CHEMICAL", 193, 201], ["gliflozins", "SIMPLE_CHEMICAL", 18, 28], ["endothelial", "CELL", 60, 71], ["gliflozins", "TREATMENT", 18, 28], ["inflammatory injury", "PROBLEM", 36, 55], ["endothelial dysfunction", "PROBLEM", 60, 83], ["COVID", "TEST", 193, 198], ["inflammatory", "OBSERVATION_MODIFIER", 36, 48], ["endothelial dysfunction", "OBSERVATION", 60, 83]]], ["Concerns about gliflozins use in COVID-19 are attributable to volume contraction, renal insufficiency and increased risk of ketoacidosis that may be supposed to occur particularly in hospitalized patients, including those severely ills.Concomitant medicationsDipeptidyl peptidase IV (DPP-IV or CD26) is a transmembrane and soluble ectopeptidase largely expressed in human tissues, including airways, lung and leucocytes [144].", [["renal", "ANATOMY", 82, 87], ["transmembrane", "ANATOMY", 305, 318], ["tissues", "ANATOMY", 372, 379], ["airways", "ANATOMY", 391, 398], ["lung", "ANATOMY", 400, 404], ["leucocytes", "ANATOMY", 409, 419], ["gliflozins", "CHEMICAL", 15, 25], ["volume contraction", "DISEASE", 62, 80], ["renal insufficiency", "DISEASE", 82, 101], ["ketoacidosis", "DISEASE", 124, 136], ["Dipeptidyl peptidase IV", "CHEMICAL", 259, 282], ["gliflozins", "CHEMICAL", 15, 25], ["COVID-19", "CHEMICAL", 33, 41], ["gliflozins", "SIMPLE_CHEMICAL", 15, 25], ["renal", "ORGAN", 82, 87], ["patients", "ORGANISM", 196, 204], ["Dipeptidyl peptidase IV", "GENE_OR_GENE_PRODUCT", 259, 282], ["DPP-IV", "GENE_OR_GENE_PRODUCT", 284, 290], ["CD26", "GENE_OR_GENE_PRODUCT", 294, 298], ["transmembrane", "CELLULAR_COMPONENT", 305, 318], ["ectopeptidase", "GENE_OR_GENE_PRODUCT", 331, 344], ["human", "ORGANISM", 366, 371], ["tissues", "TISSUE", 372, 379], ["airways", "MULTI-TISSUE_STRUCTURE", 391, 398], ["lung", "ORGAN", 400, 404], ["leucocytes", "CELL", 409, 419], ["Dipeptidyl peptidase IV", "PROTEIN", 259, 282], ["DPP-IV", "PROTEIN", 284, 290], ["CD26", "PROTEIN", 294, 298], ["ectopeptidase", "PROTEIN", 331, 344], ["patients", "SPECIES", 196, 204], ["human", "SPECIES", 366, 371], ["human", "SPECIES", 366, 371], ["volume contraction", "PROBLEM", 62, 80], ["renal insufficiency", "PROBLEM", 82, 101], ["ketoacidosis", "PROBLEM", 124, 136], ["Concomitant medications", "TREATMENT", 236, 259], ["Dipeptidyl peptidase IV (DPP-IV or CD26)", "TREATMENT", 259, 299], ["a transmembrane and soluble ectopeptidase", "TREATMENT", 303, 344], ["volume contraction", "OBSERVATION", 62, 80], ["renal", "ANATOMY", 82, 87], ["insufficiency", "OBSERVATION", 88, 101], ["increased", "OBSERVATION_MODIFIER", 106, 115], ["ketoacidosis", "OBSERVATION", 124, 136], ["human tissues", "ANATOMY", 366, 379], ["airways", "ANATOMY", 391, 398], ["lung", "ANATOMY", 400, 404], ["leucocytes", "ANATOMY", 409, 419]]], ["Particularly, DPP-IV is specifically involved in MERS pathogenesis given that it mediate MERS-CoV-2 internalization in host cells [145].", [["cells", "ANATOMY", 124, 129], ["DPP-IV", "GENE_OR_GENE_PRODUCT", 14, 20], ["MERS", "CANCER", 49, 53], ["MERS-CoV-2", "GENE_OR_GENE_PRODUCT", 89, 99], ["host cells", "CELL", 119, 129], ["DPP-IV", "PROTEIN", 14, 20], ["host cells", "CELL_TYPE", 119, 129], ["MERS pathogenesis", "PROBLEM", 49, 66], ["CoV", "TEST", 94, 97]]], ["No data actually support the role of DPP-IV in the internalization of SARS-CoV-2 and further study are needed to verify this aspect, and for demonstrating clear protective effects [146].", [["SARS", "DISEASE", 70, 74], ["DPP-IV", "GENE_OR_GENE_PRODUCT", 37, 43], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 70, 80], ["DPP-IV", "PROTEIN", 37, 43], ["SARS-CoV", "SPECIES", 70, 78], ["DPP-IV", "TREATMENT", 37, 43], ["SARS", "PROBLEM", 70, 74], ["CoV", "TEST", 75, 78], ["further study", "TEST", 85, 98]]], ["However, DPP-IV inhibitors have shown to potentiate immune response by increasing T-cells survival, consequently enhance immune response [147], and possibly playing a relevant role in reducing the onset or progression of acute pulmonary manifestations in COVID-19 [145].Concomitant medicationsGlucagon-like peptide 1 receptor agonists (GLP-1RAs) belong to an effective class of medications approved for the treatment of T2D and for preventing diabetes-related cardiovascular and renal complications over time [148\u2013151].", [["T-cells", "ANATOMY", 82, 89], ["pulmonary", "ANATOMY", 227, 236], ["cardiovascular", "ANATOMY", 460, 474], ["renal", "ANATOMY", 479, 484], ["Glucagon", "CHEMICAL", 293, 301], ["T2D", "DISEASE", 420, 423], ["diabetes", "DISEASE", 443, 451], ["cardiovascular and renal complications", "DISEASE", 460, 498], ["DPP-IV", "GENE_OR_GENE_PRODUCT", 9, 15], ["T-cells", "CELL", 82, 89], ["pulmonary", "ORGAN", 227, 236], ["Glucagon-like peptide 1 receptor agonists", "GENE_OR_GENE_PRODUCT", 293, 334], ["GLP-1RAs", "SIMPLE_CHEMICAL", 336, 344], ["cardiovascular", "ANATOMICAL_SYSTEM", 460, 474], ["renal", "ORGAN", 479, 484], ["T-cells", "CELL_TYPE", 82, 89], ["DPP-IV inhibitors", "TREATMENT", 9, 26], ["immune response", "PROBLEM", 52, 67], ["increasing T-cells survival", "PROBLEM", 71, 98], ["acute pulmonary manifestations", "PROBLEM", 221, 251], ["COVID", "TEST", 255, 260], ["Concomitant medications", "TREATMENT", 270, 293], ["Glucagon", "TREATMENT", 293, 301], ["peptide 1 receptor agonists", "TREATMENT", 307, 334], ["GLP", "TEST", 336, 339], ["medications", "TREATMENT", 378, 389], ["T2D", "PROBLEM", 420, 423], ["diabetes", "PROBLEM", 443, 451], ["cardiovascular and renal complications", "PROBLEM", 460, 498], ["acute", "OBSERVATION_MODIFIER", 221, 226], ["pulmonary", "ANATOMY", 227, 236], ["manifestations", "OBSERVATION", 237, 251], ["renal", "ANATOMY", 479, 484], ["complications", "OBSERVATION", 485, 498]]], ["Immune response and systemic inflammation play a crucial role in SARS-CoV-2 infection, particularly in case of severe clinical course of the disease.", [["inflammation", "DISEASE", 29, 41], ["SARS-CoV-2 infection", "DISEASE", 65, 85], ["SARS-CoV-2", "ORGANISM", 65, 75], ["SARS-CoV-2", "SPECIES", 65, 75], ["Immune response", "PROBLEM", 0, 15], ["systemic inflammation", "PROBLEM", 20, 41], ["SARS", "PROBLEM", 65, 69], ["CoV", "PROBLEM", 70, 73], ["2 infection", "PROBLEM", 74, 85], ["the disease", "PROBLEM", 137, 148], ["systemic", "OBSERVATION_MODIFIER", 20, 28], ["inflammation", "OBSERVATION", 29, 41], ["SARS", "OBSERVATION", 65, 69], ["infection", "OBSERVATION", 76, 85], ["severe", "OBSERVATION_MODIFIER", 111, 117], ["disease", "OBSERVATION", 141, 148]]], ["In this clinical scenario, it is speculated that the use of GLP-1RAs could provide both a better glucose control and anti-inflammatory effects with consequent improvement of outcomes in COVID-19 affected patients [143].", [["GLP-1RAs", "CHEMICAL", 60, 68], ["glucose", "CHEMICAL", 97, 104], ["GLP-1RAs", "SIMPLE_CHEMICAL", 60, 68], ["glucose", "SIMPLE_CHEMICAL", 97, 104], ["patients", "ORGANISM", 204, 212], ["patients", "SPECIES", 204, 212], ["GLP-1RAs", "TREATMENT", 60, 68], ["a better glucose control", "TREATMENT", 88, 112], ["anti-inflammatory effects", "TREATMENT", 117, 142], ["COVID", "TEST", 186, 191]]], ["In patients with pulmonary inflammation, mononuclear circulating cells express lower level of GLP-1 receptors than controls and this condition is associated with a blunted production of interferon gamma by T cells and NK cells.", [["pulmonary", "ANATOMY", 17, 26], ["mononuclear circulating cells", "ANATOMY", 41, 70], ["T cells", "ANATOMY", 206, 213], ["NK cells", "ANATOMY", 218, 226], ["pulmonary inflammation", "DISEASE", 17, 39], ["patients", "ORGANISM", 3, 11], ["pulmonary", "ORGAN", 17, 26], ["mononuclear circulating cells", "CELL", 41, 70], ["GLP-1 receptors", "GENE_OR_GENE_PRODUCT", 94, 109], ["interferon gamma", "GENE_OR_GENE_PRODUCT", 186, 202], ["T cells", "CELL", 206, 213], ["NK cells", "CELL", 218, 226], ["mononuclear circulating cells", "CELL_TYPE", 41, 70], ["GLP-1 receptors", "PROTEIN", 94, 109], ["interferon gamma", "PROTEIN", 186, 202], ["T cells", "CELL_TYPE", 206, 213], ["NK cells", "CELL_TYPE", 218, 226], ["patients", "SPECIES", 3, 11], ["pulmonary inflammation", "PROBLEM", 17, 39], ["mononuclear circulating cells", "PROBLEM", 41, 70], ["this condition", "PROBLEM", 128, 142], ["a blunted production of interferon gamma", "PROBLEM", 162, 202], ["NK cells", "PROBLEM", 218, 226], ["pulmonary", "ANATOMY", 17, 26], ["inflammation", "OBSERVATION", 27, 39], ["mononuclear circulating cells", "OBSERVATION", 41, 70], ["lower", "OBSERVATION_MODIFIER", 79, 84], ["interferon gamma", "OBSERVATION", 186, 202], ["NK cells", "OBSERVATION", 218, 226]]], ["In addition, the expression of programmed death cell protein 1, which mediates T-cell apoptosis, is enhanced on T-cell surface and consequently the efficiency of cell-mediated immune response is weaken.", [["T-cell", "ANATOMY", 79, 85], ["T-cell surface", "ANATOMY", 112, 126], ["cell", "ANATOMY", 162, 166], ["programmed death cell protein 1", "GENE_OR_GENE_PRODUCT", 31, 62], ["T-cell", "CELL", 79, 85], ["T-cell surface", "CELL", 112, 126], ["cell", "CELL", 162, 166], ["programmed death cell protein 1", "PROTEIN", 31, 62], ["programmed death cell protein", "TEST", 31, 60], ["T-cell apoptosis", "PROBLEM", 79, 95], ["cell apoptosis", "OBSERVATION", 81, 95], ["enhanced", "OBSERVATION_MODIFIER", 100, 108], ["cell", "OBSERVATION", 162, 166], ["immune response", "OBSERVATION", 176, 191]]], ["Liraglutide, a once-daily administered long-acting GLP-1RA, demonstrated to restore the expression of GLP-1 receptors on macrophage surface, and potentiate immune-mediated response [152].", [["macrophage surface", "ANATOMY", 121, 139], ["Liraglutide", "CHEMICAL", 0, 11], ["Liraglutide", "CHEMICAL", 0, 11], ["Liraglutide", "SIMPLE_CHEMICAL", 0, 11], ["GLP-1RA", "GENE_OR_GENE_PRODUCT", 51, 58], ["GLP-1 receptors", "GENE_OR_GENE_PRODUCT", 102, 117], ["macrophage", "CELL", 121, 131], ["GLP-1 receptors", "PROTEIN", 102, 117], ["Liraglutide", "TREATMENT", 0, 11], ["long-acting GLP", "TREATMENT", 39, 54], ["GLP", "TEST", 102, 105], ["macrophage surface", "TEST", 121, 139]]], ["In addition, both DPP-IV pharmacological inhibition (linagliptin) and GLP-1RA (liraglutide) were found to contrast pulmonary injury, reduce platelet activation, microvascular thrombosis, and oxidative stress in mice model of endotoxemia [153].", [["pulmonary", "ANATOMY", 115, 124], ["platelet", "ANATOMY", 140, 148], ["microvascular", "ANATOMY", 161, 174], ["linagliptin", "CHEMICAL", 53, 64], ["liraglutide", "CHEMICAL", 79, 90], ["pulmonary injury", "DISEASE", 115, 131], ["thrombosis", "DISEASE", 175, 185], ["endotoxemia", "DISEASE", 225, 236], ["linagliptin", "CHEMICAL", 53, 64], ["DPP-IV", "GENE_OR_GENE_PRODUCT", 18, 24], ["linagliptin", "SIMPLE_CHEMICAL", 53, 64], ["GLP-1RA", "SIMPLE_CHEMICAL", 70, 77], ["liraglutide", "SIMPLE_CHEMICAL", 79, 90], ["pulmonary", "ORGAN", 115, 124], ["platelet", "CELL", 140, 148], ["microvascular", "MULTI-TISSUE_STRUCTURE", 161, 174], ["mice", "ORGANISM", 211, 215], ["mice", "SPECIES", 211, 215], ["mice", "SPECIES", 211, 215], ["DPP", "TEST", 18, 21], ["IV pharmacological inhibition", "TREATMENT", 22, 51], ["linagliptin", "TREATMENT", 53, 64], ["GLP", "TEST", 70, 73], ["liraglutide", "TREATMENT", 79, 90], ["contrast pulmonary injury", "PROBLEM", 106, 131], ["platelet activation", "PROBLEM", 140, 159], ["microvascular thrombosis", "PROBLEM", 161, 185], ["oxidative stress in mice model of endotoxemia", "PROBLEM", 191, 236], ["pulmonary", "ANATOMY", 115, 124], ["injury", "OBSERVATION", 125, 131], ["platelet activation", "OBSERVATION", 140, 159], ["microvascular thrombosis", "OBSERVATION", 161, 185], ["oxidative stress", "OBSERVATION", 191, 207], ["endotoxemia", "OBSERVATION", 225, 236]]], ["Moreover, GLP-1RAs have been found to reduce the expression of pulmonary IL-33, thus playing an interesting role in contrasting a IL-33 mediated damage in immune-allergic diseases and viral infections [154].Concomitant medicationsConsidering that pancreatic islets express ACE2, glucose impairment in COVID-19 diabetic patients could be attributable to a partial insulin deficiency [56].", [["pulmonary", "ANATOMY", 63, 72], ["pancreatic islets", "ANATOMY", 247, 264], ["immune-allergic diseases", "DISEASE", 155, 179], ["viral infections", "DISEASE", 184, 200], ["glucose impairment", "DISEASE", 279, 297], ["diabetic", "DISEASE", 310, 318], ["insulin deficiency", "DISEASE", 363, 381], ["glucose", "CHEMICAL", 279, 286], ["GLP-1RAs", "GENE_OR_GENE_PRODUCT", 10, 18], ["IL-33", "GENE_OR_GENE_PRODUCT", 73, 78], ["IL-33", "GENE_OR_GENE_PRODUCT", 130, 135], ["pancreatic islets", "MULTI-TISSUE_STRUCTURE", 247, 264], ["ACE2", "GENE_OR_GENE_PRODUCT", 273, 277], ["glucose", "SIMPLE_CHEMICAL", 279, 286], ["patients", "ORGANISM", 319, 327], ["insulin", "GENE_OR_GENE_PRODUCT", 363, 370], ["GLP-1RAs", "PROTEIN", 10, 18], ["pulmonary IL-33", "PROTEIN", 63, 78], ["pancreatic islets", "CELL_TYPE", 247, 264], ["ACE2", "PROTEIN", 273, 277], ["patients", "SPECIES", 319, 327], ["GLP", "TEST", 10, 13], ["pulmonary IL", "TEST", 63, 75], ["a IL", "TREATMENT", 128, 132], ["allergic diseases", "PROBLEM", 162, 179], ["viral infections", "PROBLEM", 184, 200], ["Concomitant medications", "TREATMENT", 207, 230], ["pancreatic islets", "PROBLEM", 247, 264], ["ACE2", "TEST", 273, 277], ["glucose impairment", "PROBLEM", 279, 297], ["COVID", "TEST", 301, 306], ["a partial insulin deficiency", "PROBLEM", 353, 381], ["pulmonary", "ANATOMY", 63, 72], ["allergic diseases", "OBSERVATION", 162, 179], ["pancreatic", "ANATOMY", 247, 257], ["partial", "OBSERVATION_MODIFIER", 355, 362], ["insulin deficiency", "OBSERVATION", 363, 381]]], ["However, glucose impairment could also be attributable to SARS-CoV-2 infection-induced stress or as the consequence of some medications or treatment protocols, including high-dose glucocorticoids, particularly used in hospitalized patients [155].", [["glucose impairment", "DISEASE", 9, 27], ["infection", "DISEASE", 69, 78], ["glucocorticoids", "CHEMICAL", 180, 195], ["glucose", "CHEMICAL", 9, 16], ["glucose", "SIMPLE_CHEMICAL", 9, 16], ["CoV-2", "ORGANISM", 63, 68], ["patients", "ORGANISM", 231, 239], ["patients", "SPECIES", 231, 239], ["glucose impairment", "PROBLEM", 9, 27], ["SARS", "PROBLEM", 58, 62], ["CoV", "PROBLEM", 63, 66], ["2 infection", "PROBLEM", 67, 78], ["induced stress", "PROBLEM", 79, 93], ["some medications", "TREATMENT", 119, 135], ["treatment protocols", "TREATMENT", 139, 158], ["high-dose glucocorticoids", "TREATMENT", 170, 195]]], ["Insulin therapy is recommended in hospitalized patients [156], including those with COVID-19, and a basal-bolus respective to a sliding scale regimen should be preferred in infected patients for avoiding glycaemic excursion and greater glucose variability [157, 158].Concomitant medicationsHypertension is frequently observed in T2D patients leading to a consistent increase in the risk of atherosclerotic cardiovascular and renal diseases [159].", [["cardiovascular", "ANATOMY", 406, 420], ["renal", "ANATOMY", 425, 430], ["Insulin", "CHEMICAL", 0, 7], ["glucose", "CHEMICAL", 236, 243], ["Hypertension", "DISEASE", 290, 302], ["T2D", "DISEASE", 329, 332], ["atherosclerotic cardiovascular and renal diseases", "DISEASE", 390, 439], ["COVID-19", "CHEMICAL", 84, 92], ["glucose", "CHEMICAL", 236, 243], ["Insulin", "GENE_OR_GENE_PRODUCT", 0, 7], ["patients", "ORGANISM", 47, 55], ["patients", "ORGANISM", 182, 190], ["glucose", "SIMPLE_CHEMICAL", 236, 243], ["patients", "ORGANISM", 333, 341], ["cardiovascular", "ANATOMICAL_SYSTEM", 406, 420], ["renal", "ORGAN", 425, 430], ["patients", "SPECIES", 47, 55], ["patients", "SPECIES", 182, 190], ["patients", "SPECIES", 333, 341], ["Insulin therapy", "TREATMENT", 0, 15], ["COVID", "TREATMENT", 84, 89], ["a basal-bolus respective", "TREATMENT", 98, 122], ["a sliding scale regimen", "TREATMENT", 126, 149], ["glycaemic excursion", "TEST", 204, 223], ["greater glucose variability", "TEST", 228, 255], ["Concomitant medications", "TREATMENT", 267, 290], ["Hypertension", "PROBLEM", 290, 302], ["atherosclerotic cardiovascular and renal diseases", "PROBLEM", 390, 439], ["Hypertension", "OBSERVATION", 290, 302], ["increase", "OBSERVATION_MODIFIER", 366, 374], ["atherosclerotic", "OBSERVATION_MODIFIER", 390, 405], ["cardiovascular", "OBSERVATION", 406, 420], ["renal", "ANATOMY", 425, 430], ["diseases", "OBSERVATION", 431, 439]]], ["ACE inhibitors and angiotensin receptor blockers compared to other antihypertensive medications demonstrated to be more effective to prevent or delay the onset of cardiovascular and renal complications in people with T2D, and are currently used as the first-line treatment in these patients [160, 161].", [["cardiovascular", "ANATOMY", 163, 177], ["renal", "ANATOMY", 182, 187], ["ACE inhibitors", "CHEMICAL", 0, 14], ["angiotensin", "CHEMICAL", 19, 30], ["cardiovascular and renal complications", "DISEASE", 163, 201], ["T2D", "DISEASE", 217, 220], ["ACE", "GENE_OR_GENE_PRODUCT", 0, 3], ["angiotensin receptor blockers", "SIMPLE_CHEMICAL", 19, 48], ["cardiovascular", "ANATOMICAL_SYSTEM", 163, 177], ["renal", "ORGAN", 182, 187], ["people", "ORGANISM", 205, 211], ["patients", "ORGANISM", 282, 290], ["people", "SPECIES", 205, 211], ["patients", "SPECIES", 282, 290], ["ACE inhibitors", "TREATMENT", 0, 14], ["angiotensin receptor blockers", "TREATMENT", 19, 48], ["other antihypertensive medications", "TREATMENT", 61, 95], ["cardiovascular and renal complications", "PROBLEM", 163, 201], ["T2D", "PROBLEM", 217, 220], ["the first-line treatment", "TREATMENT", 248, 272], ["renal", "ANATOMY", 182, 187], ["complications", "OBSERVATION", 188, 201]]], ["Evidence from animal models suggested that ACE inhibitors are able to increase the expression of ACE2 at the level of lung, thus leading to initial clinical concerns about the management of arterial hypertension in diabetic patients [162].", [["lung", "ANATOMY", 118, 122], ["arterial", "ANATOMY", 190, 198], ["arterial hypertension", "DISEASE", 190, 211], ["diabetic", "DISEASE", 215, 223], ["ACE", "GENE_OR_GENE_PRODUCT", 43, 46], ["ACE2", "GENE_OR_GENE_PRODUCT", 97, 101], ["lung", "ORGAN", 118, 122], ["arterial", "MULTI-TISSUE_STRUCTURE", 190, 198], ["patients", "ORGANISM", 224, 232], ["ACE2", "PROTEIN", 97, 101], ["patients", "SPECIES", 224, 232], ["ACE inhibitors", "TREATMENT", 43, 57], ["arterial hypertension in diabetic patients", "PROBLEM", 190, 232], ["lung", "ANATOMY", 118, 122], ["arterial", "ANATOMY", 190, 198], ["hypertension", "OBSERVATION", 199, 211]]], ["First suggestions advised to replace these medications with calcium-channel blockers in order to avoid undesirable detrimental effects of COVID-19 clinical course [95].", [["calcium", "CHEMICAL", 60, 67], ["calcium", "CHEMICAL", 60, 67], ["COVID-19", "CHEMICAL", 138, 146], ["calcium-channel blockers", "SIMPLE_CHEMICAL", 60, 84], ["these medications", "TREATMENT", 37, 54], ["calcium-channel blockers", "TREATMENT", 60, 84], ["COVID", "TREATMENT", 138, 143]]], ["Nevertheless, no sufficient data supported the hypothesis that the use of renin-angiotensin system blockers may interfere with the internalization of SARS-CoV-2 in respiratory cells hence increasing its virulence [163].", [["respiratory cells", "ANATOMY", 164, 181], ["SARS", "DISEASE", 150, 154], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 74, 91], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 150, 160], ["respiratory cells", "CELL", 164, 181], ["renin", "PROTEIN", 74, 79], ["respiratory cells", "CELL_TYPE", 164, 181], ["renin-angiotensin system blockers", "TREATMENT", 74, 107], ["SARS", "PROBLEM", 150, 154], ["CoV", "TEST", 155, 158], ["respiratory cells", "ANATOMY", 164, 181]]], ["In addition, ACE inhibitors and angiotensin receptor blockers protect lung, heart and kidney against inflammation, thus playing a potential beneficial role also in T2D patients with COVID-19 [164].Concomitant medicationsStatins are usually prescribed especially in T2D patients to protect against cardiovascular complications [165].", [["lung", "ANATOMY", 70, 74], ["heart", "ANATOMY", 76, 81], ["kidney", "ANATOMY", 86, 92], ["cardiovascular", "ANATOMY", 297, 311], ["angiotensin", "CHEMICAL", 32, 43], ["inflammation", "DISEASE", 101, 113], ["T2D", "DISEASE", 164, 167], ["COVID-19 [164", "CHEMICAL", 182, 195], ["T2D", "DISEASE", 265, 268], ["cardiovascular complications", "DISEASE", 297, 325], ["COVID-19", "CHEMICAL", 182, 190], ["ACE", "GENE_OR_GENE_PRODUCT", 13, 16], ["angiotensin receptor blockers", "SIMPLE_CHEMICAL", 32, 61], ["lung", "ORGAN", 70, 74], ["heart", "ORGAN", 76, 81], ["kidney", "ORGAN", 86, 92], ["patients", "ORGANISM", 168, 176], ["medicationsStatins", "SIMPLE_CHEMICAL", 209, 227], ["patients", "ORGANISM", 269, 277], ["cardiovascular", "ANATOMICAL_SYSTEM", 297, 311], ["patients", "SPECIES", 168, 176], ["patients", "SPECIES", 269, 277], ["ACE inhibitors", "TREATMENT", 13, 27], ["angiotensin receptor blockers", "TREATMENT", 32, 61], ["inflammation", "PROBLEM", 101, 113], ["COVID", "TEST", 182, 187], ["Concomitant medicationsStatins", "TREATMENT", 197, 227], ["cardiovascular complications", "PROBLEM", 297, 325], ["lung", "ANATOMY", 70, 74], ["heart", "ANATOMY", 76, 81], ["kidney", "ANATOMY", 86, 92], ["inflammation", "OBSERVATION", 101, 113]]], ["The role of statins in COVID-19 is not clearly established, however, some observation should be done.", [["statins", "CHEMICAL", 12, 19], ["statins", "CHEMICAL", 12, 19], ["COVID-19", "CHEMICAL", 23, 31], ["statins", "SIMPLE_CHEMICAL", 12, 19], ["statins", "TREATMENT", 12, 19], ["COVID", "TEST", 23, 28]]], ["First, COVID-19 is associated with higher cardiovascular mortality specifically in patients with more risk factors, including hypertension and T2D, and statins could be useful to maintain or optimize lipid management and improve endothelial dysfunction in this clinical setting [166].", [["cardiovascular", "ANATOMY", 42, 56], ["endothelial", "ANATOMY", 229, 240], ["hypertension", "DISEASE", 126, 138], ["T2D", "DISEASE", 143, 146], ["statins", "CHEMICAL", 152, 159], ["endothelial dysfunction", "DISEASE", 229, 252], ["statins", "CHEMICAL", 152, 159], ["patients", "ORGANISM", 83, 91], ["statins", "SIMPLE_CHEMICAL", 152, 159], ["lipid", "SIMPLE_CHEMICAL", 200, 205], ["endothelial", "CELL", 229, 240], ["patients", "SPECIES", 83, 91], ["COVID", "TEST", 7, 12], ["higher cardiovascular mortality", "PROBLEM", 35, 66], ["hypertension", "PROBLEM", 126, 138], ["T2D", "PROBLEM", 143, 146], ["statins", "TREATMENT", 152, 159], ["lipid management", "TREATMENT", 200, 216], ["endothelial dysfunction", "PROBLEM", 229, 252], ["hypertension", "OBSERVATION", 126, 138]]], ["In animal models, statins inhibit the myeloid differentiation primary response 88 (MYD88) [167].", [["myeloid", "ANATOMY", 38, 45], ["statins", "CHEMICAL", 18, 25], ["statins", "CHEMICAL", 18, 25], ["statins", "SIMPLE_CHEMICAL", 18, 25], ["myeloid differentiation primary response 88", "GENE_OR_GENE_PRODUCT", 38, 81], ["MYD88", "GENE_OR_GENE_PRODUCT", 83, 88], ["statins", "TREATMENT", 18, 25], ["myeloid", "ANATOMY", 38, 45]]], ["MYD88 is a protein adaptor for inflammatory signalling pathways downstream of members of Toll-like receptors and IL-1 receptor families, and plays a critical function in the activation and amplification of innate immune response [168].", [["MYD88", "CHEMICAL", 0, 5], ["MYD88", "GENE_OR_GENE_PRODUCT", 0, 5], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 89, 108], ["IL-1 receptor", "GENE_OR_GENE_PRODUCT", 113, 126], ["MYD88", "PROTEIN", 0, 5], ["Toll-like receptors", "PROTEIN", 89, 108], ["IL-1 receptor families", "PROTEIN", 113, 135], ["a protein adaptor", "TREATMENT", 9, 26], ["inflammatory signalling pathways", "PROBLEM", 31, 63]]], ["The inhibition of MYD88 seems to reduce pulmonary inflammatory damage, and to improve survival in SARS-CoV and MERS-CoV infected mice [167].", [["pulmonary", "ANATOMY", 40, 49], ["MYD88", "CHEMICAL", 18, 23], ["pulmonary inflammatory damage", "DISEASE", 40, 69], ["SARS", "DISEASE", 98, 102], ["MYD88", "GENE_OR_GENE_PRODUCT", 18, 23], ["pulmonary", "ORGAN", 40, 49], ["SARS-CoV", "ORGANISM", 98, 106], ["MERS-CoV", "ORGANISM", 111, 119], ["mice", "ORGANISM", 129, 133], ["MYD88", "PROTEIN", 18, 23], ["mice", "SPECIES", 129, 133], ["SARS-CoV", "SPECIES", 98, 106], ["MERS-CoV", "SPECIES", 111, 119], ["mice", "SPECIES", 129, 133], ["The inhibition of MYD88", "TREATMENT", 0, 23], ["pulmonary inflammatory damage", "PROBLEM", 40, 69], ["SARS", "PROBLEM", 98, 102], ["CoV", "TEST", 103, 106], ["pulmonary", "ANATOMY", 40, 49], ["inflammatory", "OBSERVATION", 50, 62]]], ["Patients with established cardiovascular disease, and those at higher risk of atherosclerotic cardiovascular disease including T2D (also in primary prevention) should be advised to maintain current statin treatment also in case of confirmed COVID-19.", [["cardiovascular", "ANATOMY", 26, 40], ["cardiovascular", "ANATOMY", 94, 108], ["cardiovascular disease", "DISEASE", 26, 48], ["atherosclerotic cardiovascular disease", "DISEASE", 78, 116], ["T2D", "DISEASE", 127, 130], ["statin", "CHEMICAL", 198, 204], ["statin", "CHEMICAL", 198, 204], ["COVID-19", "CHEMICAL", 241, 249], ["Patients", "ORGANISM", 0, 8], ["cardiovascular", "ANATOMICAL_SYSTEM", 26, 40], ["statin", "SIMPLE_CHEMICAL", 198, 204], ["Patients", "SPECIES", 0, 8], ["established cardiovascular disease", "PROBLEM", 14, 48], ["atherosclerotic cardiovascular disease", "PROBLEM", 78, 116], ["T2D", "PROBLEM", 127, 130], ["current statin treatment", "TREATMENT", 190, 214], ["COVID", "TEST", 241, 246], ["cardiovascular", "ANATOMY", 26, 40], ["disease", "OBSERVATION", 41, 48], ["atherosclerotic", "OBSERVATION_MODIFIER", 78, 93], ["cardiovascular disease", "OBSERVATION", 94, 116]]], ["In patient with active COVID-19, an increased risk of muscular damage has been described and statin therapy could be interrupted for a short period of time in order to favour muscular recovery [169].Discussion and conclusionsT2D should be considered as a risk factor for poor prognosis in COVID-19 due to several reasons, including poor baseline glucose control and high glycaemic variability, diabetes-related immune dysfunction and concurrent comorbidities, also proven to act as independent risk factors for poor prognosis in this clinical setting.", [["muscular", "ANATOMY", 54, 62], ["muscular", "ANATOMY", 175, 183], ["muscular damage", "DISEASE", 54, 69], ["statin", "CHEMICAL", 93, 99], ["T2D", "DISEASE", 225, 228], ["glucose", "CHEMICAL", 346, 353], ["diabetes", "DISEASE", 394, 402], ["immune dysfunction", "DISEASE", 411, 429], ["statin", "CHEMICAL", 93, 99], ["glucose", "CHEMICAL", 346, 353], ["patient", "ORGANISM", 3, 10], ["muscular", "ORGAN", 54, 62], ["muscular", "ORGANISM_SUBDIVISION", 175, 183], ["glucose", "SIMPLE_CHEMICAL", 346, 353], ["patient", "SPECIES", 3, 10], ["active COVID", "TEST", 16, 28], ["muscular damage", "PROBLEM", 54, 69], ["statin therapy", "TREATMENT", 93, 107], ["COVID", "TEST", 289, 294], ["poor baseline glucose control", "PROBLEM", 332, 361], ["high glycaemic variability", "PROBLEM", 366, 392], ["diabetes", "PROBLEM", 394, 402], ["immune dysfunction", "PROBLEM", 411, 429], ["concurrent comorbidities", "PROBLEM", 434, 458], ["poor prognosis", "PROBLEM", 511, 525], ["increased", "OBSERVATION_MODIFIER", 36, 45], ["muscular damage", "OBSERVATION", 54, 69], ["immune dysfunction", "OBSERVATION", 411, 429]]], ["Considering that respiratory system remains essentially the leading way for SARS-CoV-2 entering in host, and given that immune barriers are weaken in T2D patients, including resident pulmonary macrophages, neutrophils and T cells [70], diabetologists could improve clinical outcomes in COVID-19 simply by the use of such a medication with potential for positive immune-modulation and anti-inflammatory effects.", [["respiratory system", "ANATOMY", 17, 35], ["pulmonary macrophages", "ANATOMY", 183, 204], ["neutrophils", "ANATOMY", 206, 217], ["T cells", "ANATOMY", 222, 229], ["SARS", "DISEASE", 76, 80], ["T2D", "DISEASE", 150, 153], ["SARS-CoV-2", "ORGANISM", 76, 86], ["patients", "ORGANISM", 154, 162], ["pulmonary macrophages", "CELL", 183, 204], ["neutrophils", "CELL", 206, 217], ["T cells", "CELL", 222, 229], ["resident pulmonary macrophages", "CELL_TYPE", 174, 204], ["neutrophils", "CELL_TYPE", 206, 217], ["T cells", "CELL_TYPE", 222, 229], ["patients", "SPECIES", 154, 162], ["SARS", "PROBLEM", 76, 80], ["CoV", "TEST", 81, 84], ["immune barriers", "TREATMENT", 120, 135], ["pulmonary macrophages", "TEST", 183, 204], ["neutrophils", "TEST", 206, 217], ["T cells", "TEST", 222, 229], ["COVID", "TEST", 286, 291], ["a medication", "TREATMENT", 321, 333], ["positive immune-modulation", "TREATMENT", 353, 379], ["anti-inflammatory effects", "TREATMENT", 384, 409], ["pulmonary", "ANATOMY", 183, 192], ["macrophages", "OBSERVATION", 193, 204]]], ["Unfortunately, inconclusive deductions are currently available for considering concomitant medications favourable (as well as detrimental) factors in COVID-19 patients with T2D.", [["T2D", "DISEASE", 173, 176], ["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 159, 167], ["concomitant medications", "TREATMENT", 79, 102], ["T2D", "PROBLEM", 173, 176]]], ["Despite some putative mechanisms have been identified and some speculative hypothesis have also been formulated indicating that some anti-diabetes medications may improve clinical course in COVID-19 (pioglitazone, gliflozins, DPP-IV inhibitors, GLP-1RA), further studies are needed to clarify the issue.", [["COVID-19", "CHEMICAL", 190, 198], ["pioglitazone", "CHEMICAL", 200, 212], ["gliflozins", "CHEMICAL", 214, 224], ["COVID-19", "CHEMICAL", 190, 198], ["pioglitazone", "CHEMICAL", 200, 212], ["gliflozins", "CHEMICAL", 214, 224], ["COVID-19", "SIMPLE_CHEMICAL", 190, 198], ["pioglitazone", "SIMPLE_CHEMICAL", 200, 212], ["gliflozins", "SIMPLE_CHEMICAL", 214, 224], ["DPP-IV", "GENE_OR_GENE_PRODUCT", 226, 232], ["GLP-1RA", "GENE_OR_GENE_PRODUCT", 245, 252], ["some putative mechanisms", "PROBLEM", 8, 32], ["some speculative hypothesis", "PROBLEM", 58, 85], ["some anti-diabetes medications", "TREATMENT", 128, 158], ["COVID", "TEST", 190, 195], ["pioglitazone", "TREATMENT", 200, 212], ["gliflozins", "TREATMENT", 214, 224], ["DPP-IV inhibitors", "TREATMENT", 226, 243], ["GLP", "TEST", 245, 248], ["further studies", "TEST", 255, 270]]], ["A timely glucose control should be obtained in diabetic patients during pandemic for the purpose to avoid potentially harmful outcomes in case of SARS-CoV-2 infection [170].", [["glucose", "CHEMICAL", 9, 16], ["diabetic", "DISEASE", 47, 55], ["SARS-CoV-2 infection", "DISEASE", 146, 166], ["glucose", "CHEMICAL", 9, 16], ["glucose", "SIMPLE_CHEMICAL", 9, 16], ["patients", "ORGANISM", 56, 64], ["SARS-CoV-2", "ORGANISM", 146, 156], ["patients", "SPECIES", 56, 64], ["SARS-CoV-2", "SPECIES", 146, 156], ["A timely glucose control", "TREATMENT", 0, 24], ["SARS", "PROBLEM", 146, 150], ["CoV-2 infection", "PROBLEM", 151, 166]]], ["Anti-diabetic medications should be used with caution, also considering their impact on patient safety in case of complications related with COVID-19 infection (renal failure, cardio-respiratory burden, ketoacidosis, etc).", [["renal", "ANATOMY", 161, 166], ["respiratory", "ANATOMY", 183, 194], ["infection", "DISEASE", 150, 159], ["renal failure", "DISEASE", 161, 174], ["cardio-respiratory burden", "DISEASE", 176, 201], ["ketoacidosis", "DISEASE", 203, 215], ["patient", "ORGANISM", 88, 95], ["renal", "ORGAN", 161, 166], ["patient", "SPECIES", 88, 95], ["Anti-diabetic medications", "TREATMENT", 0, 25], ["complications", "PROBLEM", 114, 127], ["COVID-19 infection", "PROBLEM", 141, 159], ["renal failure", "PROBLEM", 161, 174], ["cardio-respiratory burden", "PROBLEM", 176, 201], ["ketoacidosis", "PROBLEM", 203, 215], ["infection", "OBSERVATION", 150, 159], ["renal", "ANATOMY", 161, 166], ["failure", "OBSERVATION", 167, 174], ["cardio", "ANATOMY", 176, 182], ["respiratory", "ANATOMY", 183, 194]]], ["Oral and non-insulin injectable medications (GLP-1RAs) should be considered to maintain or intensify household glucose control, while insulin treatment is currently known to be safer in case of hospitalized and seriously ill patients [171].Discussion and conclusionsGiven this consideration, in seriously ill patients, immune response should be adequately monitored in order to carefully predict or precociously diagnose a severe disease [172] and cytokines, including IL-6, may be considered as a goal for novel and more specific target therapies particularly in T2D individuals [173\u2013175].Discussion and conclusionsBeyond the risks strictly related with COVID-19 infections in diabetic patients, further concerns should be taken into account.", [["Oral", "ANATOMY", 0, 4], ["glucose", "CHEMICAL", 111, 118], ["T2D", "DISEASE", 564, 567], ["infections", "DISEASE", 664, 674], ["diabetic", "DISEASE", 678, 686], ["glucose", "CHEMICAL", 111, 118], ["Oral", "ORGANISM_SUBDIVISION", 0, 4], ["GLP-1RAs", "SIMPLE_CHEMICAL", 45, 53], ["glucose", "SIMPLE_CHEMICAL", 111, 118], ["insulin", "GENE_OR_GENE_PRODUCT", 134, 141], ["patients", "ORGANISM", 225, 233], ["patients", "ORGANISM", 309, 317], ["IL-6", "GENE_OR_GENE_PRODUCT", 469, 473], ["patients", "ORGANISM", 687, 695], ["cytokines", "PROTEIN", 448, 457], ["IL-6", "PROTEIN", 469, 473], ["patients", "SPECIES", 225, 233], ["patients", "SPECIES", 309, 317], ["patients", "SPECIES", 687, 695], ["Oral and non-insulin injectable medications", "TREATMENT", 0, 43], ["GLP-1RAs)", "TREATMENT", 45, 54], ["glucose control", "TREATMENT", 111, 126], ["insulin treatment", "TREATMENT", 134, 151], ["a severe disease", "PROBLEM", 421, 437], ["cytokines", "TREATMENT", 448, 457], ["specific target therapies", "TREATMENT", 522, 547], ["COVID-19 infections in diabetic patients", "PROBLEM", 655, 695], ["severe", "OBSERVATION_MODIFIER", 423, 429], ["disease", "OBSERVATION", 430, 437]]], ["Social distancing and lockdown have been proposed as the most effective action to prevent and reduce spread of SARS-CoV-2 infection [176].", [["SARS", "DISEASE", 111, 115], ["infection", "DISEASE", 122, 131], ["SARS-CoV-2", "ORGANISM", 111, 121], ["CoV-2", "SPECIES", 116, 121], ["SARS-CoV-2", "SPECIES", 111, 121], ["SARS", "PROBLEM", 111, 115], ["CoV-2 infection", "PROBLEM", 116, 131]]], ["Consequently, more time has been spent in household and access to public and private services has been consistently reduced.", [["reduced", "OBSERVATION_MODIFIER", 116, 123]]], ["Thus, several barriers exist for diabetic patients to maintain an adequate fitness status and weight management as well as access to ambulatory care for obtaining adequate treatment adjustments [177].", [["diabetic", "DISEASE", 33, 41], ["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["diabetic patients", "TREATMENT", 33, 50], ["weight management", "TREATMENT", 94, 111], ["ambulatory care", "TREATMENT", 133, 148], ["adequate treatment adjustments", "TREATMENT", 163, 193]]], ["In the last few months, home confinement led to physical inactivity and low exposure to sunlight, with possible detrimental effects particularly in diabetic and obese patients [119].", [["diabetic and obese", "DISEASE", 148, 166], ["patients", "ORGANISM", 167, 175], ["patients", "SPECIES", 167, 175], ["physical inactivity", "PROBLEM", 48, 67], ["detrimental effects", "PROBLEM", 112, 131]]], ["Physical exercise should be encouraged also at home or outdoor, even respecting social distancing rules, since it promotes weight loss, and improves cardiorespiratory fitness [121]; reduces levels of cortisol thus reinforcing immune response against infections; induces T-cell differentiation and maturation [178].Discussion and conclusionsImportantly, patients should be advised about risks and supported regarding pandemic-related concerns.", [["T-cell", "ANATOMY", 270, 276], ["weight loss", "DISEASE", 123, 134], ["cortisol", "CHEMICAL", 200, 208], ["infections", "DISEASE", 250, 260], ["cortisol", "CHEMICAL", 200, 208], ["cortisol", "GENE_OR_GENE_PRODUCT", 200, 208], ["T-cell", "CELL", 270, 276], ["patients", "ORGANISM", 353, 361], ["patients", "SPECIES", 353, 361], ["weight loss", "PROBLEM", 123, 134], ["cortisol", "TREATMENT", 200, 208], ["infections", "PROBLEM", 250, 260]]], ["Particularly, they should be elucidated about general hygienic tips to protect themselves and others from SARS-CoV-2 spread; promptly recognize COVID-19 signs and symptoms; access orderly to approved testing if exposed; furthermore, it is important to avoid unnecessary routine appointment in person especially for elderly patients [179].", [["SARS", "DISEASE", 106, 110], ["patients", "ORGANISM", 323, 331], ["person", "SPECIES", 293, 299], ["patients", "SPECIES", 323, 331], ["SARS-CoV", "SPECIES", 106, 114], ["general hygienic tips", "TREATMENT", 46, 67], ["SARS", "PROBLEM", 106, 110], ["CoV", "TEST", 111, 114], ["COVID", "TEST", 144, 149], ["symptoms", "PROBLEM", 163, 171]]], ["Closely monitoring of glucose control should be recommended at home and glucose reports should be periodically sent to the diabetologist for proper therapy adjustments [180].Discussion and conclusionsThe hard lesson form Lombardy disaster probably teaches to change prospective in the conception of patients care during the present and in case of further pandemic.", [["glucose", "CHEMICAL", 22, 29], ["glucose", "CHEMICAL", 22, 29], ["glucose", "CHEMICAL", 72, 79], ["glucose", "SIMPLE_CHEMICAL", 22, 29], ["glucose", "SIMPLE_CHEMICAL", 72, 79], ["patients", "ORGANISM", 299, 307], ["patients", "SPECIES", 299, 307], ["glucose control", "TREATMENT", 22, 37], ["glucose", "TEST", 72, 79], ["proper therapy adjustments", "TREATMENT", 141, 167], ["patients care", "TREATMENT", 299, 312], ["further pandemic", "PROBLEM", 347, 363]]], ["Implementation of community-centred care system (home care and mobile clinics) may result in a prompt detection and better management of infected patients particularly for frail individuals.", [["patients", "ORGANISM", 146, 154], ["patients", "SPECIES", 146, 154], ["a prompt detection", "TEST", 93, 111], ["frail individuals", "PROBLEM", 172, 189], ["infected", "OBSERVATION", 137, 145]]], ["Moreover, it might contain an unnecessary hospital workload, letting hospital activities to focus mainly on acute cares and limiting contagion risks among inpatients and healthcare personnel.", [["acute cares", "TREATMENT", 108, 119]]], ["Finally, it could provide at home special cares for elderly and comorbid patients [181].", [["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81]]], ["In this historical moment, the use of technologies appears certainly appropriated to better manage chronic clinical conditions, including DM [182\u2013184].", [["DM", "DISEASE", 138, 140], ["chronic clinical conditions", "PROBLEM", 99, 126], ["DM", "PROBLEM", 138, 140]]], ["Diabetic outpatients should be conveniently managed by means of telemedicine that includes several services such as emergency phone calls, social media messaging, teleconsulting and ambulatories should be fitted with technological tools according to patients ability, healthcare personnel characteristics and available economic resources [62].", [["Diabetic", "DISEASE", 0, 8], ["outpatients", "ORGANISM", 9, 20], ["patients", "ORGANISM", 250, 258], ["outpatients", "SPECIES", 9, 20], ["patients", "SPECIES", 250, 258]]]], "PMC7273938": [["Risk of SARS-CoV-2 Transmission ::: INFECTION CONTROLOur understanding of coronavirus transmission risk remains incomplete.", [["SARS", "DISEASE", 8, 12], ["coronavirus transmission", "DISEASE", 74, 98], ["coronavirus", "ORGANISM", 74, 85], ["SARS", "PROBLEM", 8, 12], ["INFECTION", "PROBLEM", 36, 45], ["coronavirus transmission risk", "PROBLEM", 74, 103], ["SARS", "OBSERVATION", 8, 12], ["coronavirus", "OBSERVATION", 74, 85]]], ["Pathogen transmission is thought to occur mainly via inhalation of respiratory droplets containing virus, resembling the spread of influenza.", [["influenza", "DISEASE", 131, 140], ["Pathogen transmission", "TEST", 0, 21], ["respiratory droplets containing virus", "PROBLEM", 67, 104], ["influenza", "PROBLEM", 131, 140], ["respiratory droplets", "OBSERVATION", 67, 87], ["spread", "OBSERVATION_MODIFIER", 121, 127], ["influenza", "OBSERVATION", 131, 140]]], ["With droplet transmission, virus released in the respiratory secretions when a person with infection coughs, sneezes, or talks can infect another person on contacting mucous membranes.", [["respiratory secretions", "ANATOMY", 49, 71], ["mucous membranes", "ANATOMY", 167, 183], ["infection", "DISEASE", 91, 100], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 167, 183], ["person", "SPECIES", 79, 85], ["person", "SPECIES", 146, 152], ["droplet transmission", "PROBLEM", 5, 25], ["virus", "PROBLEM", 27, 32], ["the respiratory secretions", "PROBLEM", 45, 71], ["infection coughs", "PROBLEM", 91, 107], ["sneezes", "PROBLEM", 109, 116], ["virus", "OBSERVATION", 27, 32], ["respiratory", "ANATOMY", 49, 60], ["secretions", "OBSERVATION", 61, 71], ["mucous membranes", "ANATOMY", 167, 183]]], ["Infection can also occur if a person touches an infected surface and then touches his or her eyes, nose, or mouth.", [["surface", "ANATOMY", 57, 64], ["eyes", "ANATOMY", 93, 97], ["nose", "ANATOMY", 99, 103], ["mouth", "ANATOMY", 108, 113], ["Infection", "DISEASE", 0, 9], ["eyes", "ORGAN", 93, 97], ["nose", "ORGANISM_SUBDIVISION", 99, 103], ["mouth", "ORGANISM_SUBDIVISION", 108, 113], ["person", "SPECIES", 30, 36], ["Infection", "PROBLEM", 0, 9], ["infected", "OBSERVATION", 48, 56], ["eyes", "ANATOMY", 93, 97], ["nose", "ANATOMY", 99, 103], ["mouth", "ANATOMY", 108, 113]]], ["Although SARS and COVID-19 are both transmitted by droplets, COVID-19 has higher infectivity than SARS, with an estimated R0 of approximately 2.2 and significant asymptomatic carrier transmission.17,18 Health care workers (HCWs) working closely with these patients are at a higher risk of coronavirus infection.", [["SARS", "DISEASE", 9, 13], ["COVID-19", "CHEMICAL", 61, 69], ["SARS", "DISEASE", 98, 102], ["coronavirus infection", "DISEASE", 289, 310], ["COVID-19", "GENE_OR_GENE_PRODUCT", 18, 26], ["patients", "ORGANISM", 256, 264], ["coronavirus", "ORGANISM", 289, 300], ["SARS and COVID-19", "DNA", 9, 26], ["patients", "SPECIES", 256, 264], ["SARS", "TEST", 9, 13], ["COVID", "TEST", 18, 23], ["COVID", "TEST", 61, 66], ["higher infectivity than SARS", "PROBLEM", 74, 102], ["an estimated R0", "TEST", 109, 124], ["significant asymptomatic carrier transmission", "PROBLEM", 150, 195], ["coronavirus infection", "PROBLEM", 289, 310], ["higher infectivity", "OBSERVATION_MODIFIER", 74, 92], ["significant", "OBSERVATION_MODIFIER", 150, 161], ["asymptomatic", "OBSERVATION_MODIFIER", 162, 174], ["carrier transmission", "OBSERVATION", 175, 195], ["coronavirus", "OBSERVATION_MODIFIER", 289, 300], ["infection", "OBSERVATION", 301, 310]]], ["During the SARS epidemic, of the 1755 patients in Hong Kong, over 400 were HCWs.14 Furthermore, during the SARS outbreak at Sunnybrook and Women\u2019s College Health Sciences Centre, in Toronto, 9 HCWs were infected when involved in a difficult airway situation.19 The experience during the current pandemic has been similar.", [["airway", "ANATOMY", 241, 247], ["SARS", "DISEASE", 11, 15], ["SARS", "DISEASE", 107, 111], ["patients", "ORGANISM", 38, 46], ["HCWs", "ORGANISM", 193, 197], ["airway", "MULTI-TISSUE_STRUCTURE", 241, 247], ["patients", "SPECIES", 38, 46], ["Women", "SPECIES", 139, 144], ["a difficult airway situation", "PROBLEM", 229, 257], ["similar", "OBSERVATION_MODIFIER", 313, 320]]], ["Reports from China and Italy indicate that thousands of health care personnel acquired COVID-19.20,21 In the United States, a report from the Centers for Disease Control and Prevention (CDC) indicates that over 9000 HCWs have already been infected with COVID-19.22 Several guidelines have recommended best practices and ensure adequate protection of HCWs.23\u201325Aerosol-Generating Procedures ::: INFECTION CONTROLGiven the current uncertainty regarding transmission mechanisms, airborne precautions are recommended in high-risk situations such as aerosol-generating procedures (AGPs).", [["23\u201325Aerosol", "CHEMICAL", 355, 367], ["23\u201325Aerosol", "CHEMICAL", 355, 367], ["HCWs", "ORGANISM", 216, 220], ["Disease Control", "TREATMENT", 154, 169], ["COVID", "TREATMENT", 253, 258], ["best practices", "TREATMENT", 301, 315], ["INFECTION", "PROBLEM", 394, 403], ["transmission mechanisms", "TREATMENT", 451, 474], ["airborne precautions", "TREATMENT", 476, 496], ["aerosol-generating procedures", "TREATMENT", 545, 574], ["INFECTION", "OBSERVATION", 394, 403]]], ["In AGPs, there is formation of a gas cloud that entrains ambient air propelling pathogen-bearing droplets much farther than if they were emitted in isolation.26\u201328 AGPs include cardiopulmonary resuscitation, noninvasive positive pressure ventilation (bilevel positive airway pressure [BiPAP] and continuous positive airway pressure [CPAP]), disconnection of the patient from the ventilator during invasive mechanical ventilation, endotracheal intubation, endotracheal tube (ETT) advancement or exchange, airway suctioning, high-frequency oscillatory ventilation, tracheostomy, chest physiotherapy, nebulizer treatment, sputum induction, and bronchoscopy.29 For HCWs performing AGPs on patients with COVID-19, the Surviving Sepsis Campaign recommend the use of fitted respirator masks (N95, FF2, or equivalent) in addition to other personal protective equipment (PPE), such as gloves, gown, and eye protection.23 When possible, AGPs on ICU patients with COVID-19 should be performed in a negative-pressure room to limit the spread of virus outside the room.23General Considerations ::: PERIOPERATIVE CONSIDERATIONS FOR TRACHEOSTOMY PROCEDURESTracheostomy (open or percutaneous) and bronchoscopy are AGPs that may risk exposing HCWs to virions suspended in aerosolized particles.", [["cardiopulmonary", "ANATOMY", 177, 192], ["airway", "ANATOMY", 268, 274], ["airway", "ANATOMY", 316, 322], ["endotracheal", "ANATOMY", 430, 442], ["airway", "ANATOMY", 504, 510], ["chest", "ANATOMY", 577, 582], ["sputum", "ANATOMY", 619, 625], ["eye", "ANATOMY", 894, 897], ["percutaneous", "ANATOMY", 1163, 1175], ["Sepsis", "DISEASE", 723, 729], ["COVID-19", "CHEMICAL", 953, 961], ["AGPs", "GENE_OR_GENE_PRODUCT", 3, 7], ["airway", "MULTI-TISSUE_STRUCTURE", 268, 274], ["airway", "MULTI-TISSUE_STRUCTURE", 316, 322], ["patient", "ORGANISM", 362, 369], ["airway", "MULTI-TISSUE_STRUCTURE", 504, 510], ["patients", "ORGANISM", 685, 693], ["eye", "ORGAN", 894, 897], ["AGPs", "GENE_OR_GENE_PRODUCT", 927, 931], ["patients", "ORGANISM", 939, 947], ["AGPs", "PROTEIN", 3, 7], ["patient", "SPECIES", 362, 369], ["patients", "SPECIES", 685, 693], ["patients", "SPECIES", 939, 947], ["a gas cloud", "PROBLEM", 31, 42], ["cardiopulmonary resuscitation", "TREATMENT", 177, 206], ["noninvasive positive pressure ventilation", "TREATMENT", 208, 249], ["bilevel positive airway pressure", "TREATMENT", 251, 283], ["BiPAP", "TREATMENT", 285, 290], ["continuous positive airway pressure", "TREATMENT", 296, 331], ["CPAP", "TREATMENT", 333, 337], ["disconnection", "TREATMENT", 341, 354], ["the ventilator", "TREATMENT", 375, 389], ["invasive mechanical ventilation", "TREATMENT", 397, 428], ["endotracheal intubation", "TREATMENT", 430, 453], ["endotracheal tube (ETT) advancement", "TREATMENT", 455, 490], ["airway suctioning", "TREATMENT", 504, 521], ["high-frequency oscillatory ventilation", "TREATMENT", 523, 561], ["tracheostomy", "TREATMENT", 563, 575], ["chest physiotherapy", "TREATMENT", 577, 596], ["nebulizer treatment", "TREATMENT", 598, 617], ["sputum induction", "TREATMENT", 619, 635], ["bronchoscopy", "TEST", 641, 653], ["COVID", "TEST", 699, 704], ["fitted respirator masks", "TREATMENT", 760, 783], ["FF2", "TREATMENT", 790, 793], ["personal protective equipment (PPE)", "TREATMENT", 831, 866], ["gloves", "TREATMENT", 876, 882], ["gown", "TREATMENT", 884, 888], ["eye protection", "TREATMENT", 894, 908], ["COVID", "TEST", 953, 958], ["TRACHEOSTOMY PROCEDURESTracheostomy", "TREATMENT", 1118, 1153], ["open or percutaneous)", "TREATMENT", 1155, 1176], ["bronchoscopy", "TREATMENT", 1181, 1193], ["AGPs", "PROBLEM", 1198, 1202], ["gas cloud", "OBSERVATION", 33, 42], ["pressure ventilation", "OBSERVATION", 229, 249], ["airway pressure", "OBSERVATION", 268, 283], ["airway pressure", "OBSERVATION", 316, 331], ["invasive", "OBSERVATION_MODIFIER", 397, 405], ["mechanical ventilation", "OBSERVATION", 406, 428], ["endotracheal intubation", "OBSERVATION", 430, 453], ["endotracheal tube", "OBSERVATION", 455, 472], ["airway", "ANATOMY", 504, 510], ["suctioning", "OBSERVATION", 511, 521], ["tracheostomy", "OBSERVATION", 563, 575], ["chest", "ANATOMY", 577, 582], ["Sepsis", "OBSERVATION", 723, 729], ["eye", "ANATOMY", 894, 897], ["aerosolized particles", "OBSERVATION", 1255, 1276]]], ["Many tracheostomies performed in the ICU are semielective and can safely be delayed.", [["Many tracheostomies", "TREATMENT", 0, 19], ["tracheostomies", "OBSERVATION", 5, 19]]], ["The nature of respiratory failure in COVID-19 patients is such that it may often require prolonged mechanical ventilation.", [["respiratory", "ANATOMY", 14, 25], ["respiratory failure", "DISEASE", 14, 33], ["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["respiratory failure", "PROBLEM", 14, 33], ["prolonged mechanical ventilation", "TREATMENT", 89, 121], ["respiratory failure", "OBSERVATION", 14, 33], ["mechanical ventilation", "OBSERVATION", 99, 121]]], ["In the setting of limited ICU beds, ventilators, and increasing shortages of sedative drugs\u2014earlier tracheostomy\u2014may become medically more appropriate as the best form of continuation of care.", [["limited ICU beds", "TREATMENT", 18, 34], ["ventilators", "TREATMENT", 36, 47], ["sedative drugs\u2014earlier tracheostomy", "TREATMENT", 77, 112]]], ["The care team should aim for performing the procedure at a time that minimizes risk to the staff involved while not compromising best practices in patient care.Institutional Experience ::: PERIOPERATIVE CONSIDERATIONS FOR TRACHEOSTOMY PROCEDURESAs of May 1, 2020, we have safely performed more than 15 tracheostomies in COVID-19 patients, using open, percutaneous, and modified-percutaneous techniques.", [["percutaneous", "ANATOMY", 351, 363], ["percutaneous", "ANATOMY", 378, 390], ["patient", "ORGANISM", 147, 154], ["patients", "ORGANISM", 329, 337], ["patient", "SPECIES", 147, 154], ["patients", "SPECIES", 329, 337], ["the procedure", "TREATMENT", 40, 53], ["TRACHEOSTOMY PROCEDURESAs", "TREATMENT", 222, 247], ["15 tracheostomies", "TREATMENT", 299, 316], ["open, percutaneous, and modified-percutaneous techniques", "TREATMENT", 345, 401]]], ["Procedures have been performed by an interventional pulmonary/thoracic surgery, otolaryngology/head and neck surgery, or general surgery team accompanied by an anesthesiologist and in occasionally a respiratory therapist.", [["pulmonary", "ANATOMY", 52, 61], ["thoracic", "ANATOMY", 62, 70], ["head", "ANATOMY", 95, 99], ["neck", "ANATOMY", 104, 108], ["respiratory", "ANATOMY", 199, 210], ["pulmonary", "ORGAN", 52, 61], ["thoracic", "ORGAN", 62, 70], ["head", "ORGANISM_SUBDIVISION", 95, 99], ["neck", "ORGAN", 104, 108], ["thoracic surgery", "TREATMENT", 62, 78], ["pulmonary", "ANATOMY", 52, 61], ["thoracic", "ANATOMY", 62, 70], ["head", "ANATOMY", 95, 99], ["neck", "ANATOMY", 104, 108]]], ["To standardize this high-risk procedure, guidelines for safe perioperative management of tracheostomies were developed via multidisciplinary discussions between anesthesia, critical care, and procedural teams.", [["this high-risk procedure", "TREATMENT", 15, 39], ["safe perioperative management", "TREATMENT", 56, 85], ["tracheostomies", "TREATMENT", 89, 103], ["tracheostomies", "OBSERVATION", 89, 103]]], ["Simulation and team training sessions were run for involved personnel to become familiar with the modified workflows before the first tracheostomy.", [["the first tracheostomy", "TREATMENT", 124, 146], ["tracheostomy", "OBSERVATION", 134, 146]]], ["The following recommendations are summarized in the Table.Personal Protective Equipment ::: PERIOPERATIVE CONSIDERATIONS FOR TRACHEOSTOMY PROCEDURESPPE, defined as is strongly recommended for all personnel present during tracheostomy.", [["TRACHEOSTOMY PROCEDURESPPE", "TREATMENT", 125, 151], ["tracheostomy", "TREATMENT", 221, 233], ["tracheostomy", "OBSERVATION", 221, 233]]], ["The ability of PPE to reduce disease transmission is supported by a case series of 15 surgical tracheostomies in SARS-related patients performed during the SARS epidemic with no transmission despite 124 HCW having had direct contact with these patients.12 Every provider in the room should wear a fitted respirator mask, surgical cap, impermeable gown, shoe covers, gloves, goggles, and full-face shields, or as guided by local/institutional protocols.", [["PPE", "CHEMICAL", 15, 18], ["tracheostomies", "DISEASE", 95, 109], ["SARS", "DISEASE", 113, 117], ["SARS", "DISEASE", 156, 160], ["PPE", "ORGANISM", 15, 18], ["patients", "ORGANISM", 126, 134], ["patients", "ORGANISM", 244, 252], ["patients", "SPECIES", 126, 134], ["patients", "SPECIES", 244, 252], ["PPE", "TREATMENT", 15, 18], ["disease transmission", "PROBLEM", 29, 49], ["15 surgical tracheostomies", "TREATMENT", 83, 109], ["SARS", "PROBLEM", 113, 117], ["the SARS epidemic", "PROBLEM", 152, 169], ["a fitted respirator mask", "TREATMENT", 295, 319], ["surgical cap", "TREATMENT", 321, 333], ["impermeable gown", "TREATMENT", 335, 351], ["shoe covers", "TREATMENT", 353, 364], ["gloves", "TREATMENT", 366, 372], ["goggles", "TREATMENT", 374, 381], ["full-face shields", "TREATMENT", 387, 404]]], ["Special attention to the neck area is needed, as it may be left exposed by standard PPE.30 In this case, a face shield which is long enough to protect the neck may be used or staff may opt for an additional element of PPE to cover the neck.", [["neck area", "ANATOMY", 25, 34], ["neck", "ANATOMY", 155, 159], ["neck", "ANATOMY", 235, 239], ["neck area", "MULTI-TISSUE_STRUCTURE", 25, 34], ["neck", "ORGAN", 155, 159], ["neck", "ORGAN", 235, 239], ["a face shield", "TREATMENT", 105, 118], ["an additional element of PPE", "TREATMENT", 193, 221], ["neck", "ANATOMY", 25, 29], ["left", "ANATOMY_MODIFIER", 59, 63], ["neck", "ANATOMY", 155, 159], ["neck", "ANATOMY", 235, 239]]], ["Compelling evidence regarding optimal coverage is lacking, and surface coverage area, barrier material, comfort, ease of donning and doffing are all relevant factors in PPE appropriateness.31Personal Protective Equipment ::: PERIOPERATIVE CONSIDERATIONS FOR TRACHEOSTOMY PROCEDURESAlthough N95 may provide similar protection, some institutions have required the use of powered air-purifying respirators (PAPRs) for all providers performing AGPs.31 Following proper donning and doffing procedures with PPE is important to reducing infection.", [["surface", "ANATOMY", 63, 70], ["infection", "DISEASE", 530, 539], ["AGPs", "PROTEIN", 440, 444], ["optimal coverage", "TREATMENT", 30, 46], ["surface coverage area", "TREATMENT", 63, 84], ["barrier material", "TREATMENT", 86, 102], ["TRACHEOSTOMY PROCEDURESAlthough N95", "TREATMENT", 258, 293], ["powered air-purifying respirators", "TREATMENT", 369, 402], ["doffing procedures", "TREATMENT", 477, 495], ["PPE", "TREATMENT", 501, 504], ["reducing infection", "PROBLEM", 521, 539], ["optimal", "OBSERVATION_MODIFIER", 30, 37], ["coverage", "OBSERVATION", 38, 46], ["infection", "OBSERVATION", 530, 539]]], ["Team members should have undergone training protocols before performing their roles during AGPs.", [["AGPs", "GENE_OR_GENE_PRODUCT", 91, 95], ["AGPs", "PROTEIN", 91, 95], ["training protocols", "TREATMENT", 35, 53]]], ["In the absence of specific institutional guidance, both CDC and/or professional society recommendations are available.32 Thorough hand hygiene, including cleansing of any exposed skin surfaces, should be practiced before and after the procedure.", [["hand", "ANATOMY", 130, 134], ["skin", "ANATOMY", 179, 183], ["hand", "ORGANISM_SUBDIVISION", 130, 134], ["skin", "ORGAN", 179, 183], ["cleansing", "TREATMENT", 154, 163], ["any exposed skin surfaces", "TREATMENT", 167, 192], ["the procedure", "TREATMENT", 231, 244], ["skin", "ANATOMY", 179, 183]]], ["Procedures should preferably be performed in negative-pressure rooms, ideally with adjacent anterooms, to minimize escape of aerosolized viral particles.", [["aerosolized viral particles", "PROBLEM", 125, 152], ["aerosolized viral particles", "OBSERVATION", 125, 152]]], ["When negative-pressure rooms are not available, we recommend that procedures take place in rooms with high-efficiency particulate air (HEPA) filters.", [["procedures", "TREATMENT", 66, 76], ["high-efficiency particulate air (HEPA) filters", "TREATMENT", 102, 148]]], ["At our institution, we use HEPA filters beginning 30 minutes before the procedure and continuing for at least 30 minutes afterward to ensure safety of staff and clearance of virus.Personal Protective Equipment ::: PERIOPERATIVE CONSIDERATIONS FOR TRACHEOSTOMY PROCEDURESTransport to the operating room (OR) represents additional risk of exposure to other hospital staff, and the risk-benefit ratio of patient transport should be carefully weighed in each clinical scenario.", [["patient", "ORGANISM", 401, 408], ["patient", "SPECIES", 401, 408], ["HEPA filters", "TREATMENT", 27, 39], ["the procedure", "TREATMENT", 68, 81], ["virus", "PROBLEM", 174, 179], ["TRACHEOSTOMY", "TREATMENT", 247, 259]]], ["During the high volume of critically ill patients, many institutions have had to adapt non-ICU locations to accommodate these patients (so-called surge units).", [["critically ill", "DISEASE", 26, 40], ["patients", "ORGANISM", 41, 49], ["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 126, 134]]], ["The \u201csurge units\u201d are often open, with no isolation or physical barrier between patients.", [["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["The \u201csurge units", "TREATMENT", 0, 16], ["isolation", "TREATMENT", 42, 51]]], ["In this case, it may be prudent to perform the procedure in the OR to avoid higher exposure risk to additional staff not directly involved with the procedure.", [["the procedure", "TREATMENT", 43, 56], ["the procedure", "TREATMENT", 144, 157]]], ["When the procedure is performed in the OR, patients should be transported directly to the room, bypassing the holding area.", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["the procedure", "TREATMENT", 5, 18]]], ["Similar considerations apply postprocedure and patients should be transported straight from the OR back to a negative-pressure room.", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55]]], ["HCWs in direct contact with the patient should avoid touching environmental surfaces (eg, elevator buttons) during transport.", [["patient", "ORGANISM", 32, 39], ["patient", "SPECIES", 32, 39]]], ["Although a negative-pressure room in the ICUs is preferred for performance of these procedures, logistic considerations may preclude this option.", [["these procedures", "TREATMENT", 78, 94], ["this option", "TREATMENT", 133, 144], ["negative", "OBSERVATION", 11, 19]]], ["If such a circumstance may arise, we use a HEPA filter as described above.Staff and Personnel ::: PERIOPERATIVE CONSIDERATIONS FOR TRACHEOSTOMY PROCEDURESAll planned tracheostomy cases on patients with COVID-19 should be preceded by a multidisciplinary discussion, including the procedural service, critical care, anesthesia, infectious diseases, respiratory therapy, and nursing teams.", [["respiratory", "ANATOMY", 347, 358], ["infectious diseases", "DISEASE", 326, 345], ["patients", "ORGANISM", 188, 196], ["patients", "SPECIES", 188, 196], ["a HEPA filter", "TREATMENT", 41, 54], ["TRACHEOSTOMY PROCEDURESAll planned tracheostomy", "TREATMENT", 131, 178], ["COVID", "TREATMENT", 202, 207], ["anesthesia", "TREATMENT", 314, 324], ["respiratory therapy", "TREATMENT", 347, 366], ["HEPA filter", "OBSERVATION", 43, 54]]], ["This discussion should include appropriateness, risk assessment, and optimal timing.", [["risk assessment", "TEST", 48, 63]]], ["Preprocedure huddles, design, and practice of high-fidelity simulation sessions with different patient scenarios are highly encouraged.", [["patient", "ORGANISM", 95, 102], ["patient", "SPECIES", 95, 102], ["Preprocedure huddles", "TREATMENT", 0, 20], ["high-fidelity simulation sessions", "TREATMENT", 46, 79], ["different patient scenarios", "TREATMENT", 85, 112]]], ["To minimize staff exposure during the procedure, the number of people in the room should be limited to those absolute necessary.", [["people", "ORGANISM", 63, 69], ["people", "SPECIES", 63, 69], ["the procedure", "TREATMENT", 34, 47]]], ["Open tracheostomies can safely be performed with 3 people in the room (2 procedural staff and anesthesiologist).", [["people", "ORGANISM", 51, 57], ["people", "SPECIES", 51, 57], ["Open tracheostomies", "TREATMENT", 0, 19], ["tracheostomies", "OBSERVATION", 5, 19]]], ["The same number (proceduralist, anesthesiologist, and bronchoscopist) is required for a percutaneous approach.", [["percutaneous", "ANATOMY", 88, 100], ["a percutaneous approach", "TREATMENT", 86, 109]]], ["The ICU nurse caring for the patient, respiratory therapist, and additional member of anesthesia team should remain outside of the room, immediately available to help, and provide ancillary support as needed.", [["patient", "ORGANISM", 29, 36], ["patient", "SPECIES", 29, 36], ["ancillary support", "TREATMENT", 180, 197]]], ["To minimize the number of people in the room and ensure patient safety and clear communication, we have been using a communication system consisting of headphones with mouth pieces (C-COM Pro, Carrot Medical, Bothell, WA) which are worn by personnel inside (2 proceduralists and anesthesiologist) and outside (nurse and respiratory therapist) the room.", [["people", "ORGANISM", 26, 32], ["patient", "ORGANISM", 56, 63], ["people", "SPECIES", 26, 32], ["patient", "SPECIES", 56, 63], ["a communication system", "TREATMENT", 115, 137], ["headphones with mouth pieces", "TREATMENT", 152, 180], ["C-COM Pro", "TREATMENT", 182, 191]]], ["Infusion pumps are left outside of the room and the anesthesiologist and nurse can communicate efficiently to make prompt changes in medication dosages as required.Timing of Procedure ::: PERIOPERATIVE CONSIDERATIONS FOR TRACHEOSTOMY PROCEDURESConflicting data regarding optimal indications and timing for tracheostomy in COVID-19 have resulted in wide practice variability.33\u201336 For patients who are being kept on mechanical ventilation due to inability to protect their airway, manage secretions, or poor mental status but do not require ventilator support otherwise, we recommend that the procedure is performed between ventilator days 14\u201321.", [["airway", "ANATOMY", 472, 478], ["secretions", "ANATOMY", 487, 497], ["patients", "ORGANISM", 384, 392], ["airway", "MULTI-TISSUE_STRUCTURE", 472, 478], ["patients", "SPECIES", 384, 392], ["Infusion pumps", "TREATMENT", 0, 14], ["medication dosages", "TREATMENT", 133, 151], ["TRACHEOSTOMY PROCEDURESConflicting data", "TREATMENT", 221, 260], ["tracheostomy in COVID", "TREATMENT", 306, 327], ["wide practice variability", "PROBLEM", 348, 373], ["mechanical ventilation", "TREATMENT", 415, 437], ["inability to protect their airway", "PROBLEM", 445, 478], ["secretions", "PROBLEM", 487, 497], ["poor mental status", "PROBLEM", 502, 520], ["ventilator support", "TREATMENT", 540, 558], ["the procedure", "TREATMENT", 588, 601], ["left", "ANATOMY_MODIFIER", 19, 23], ["airway", "ANATOMY", 472, 478]]], ["Frequent pronation, supination, risk of ETT migration, copious secretions associated with plugging, and pronounced laryngeal edema associated with COVID-19 can be difficult with an ETT instead of a tracheostomy.", [["laryngeal", "ANATOMY", 115, 124], ["laryngeal edema", "DISEASE", 115, 130], ["COVID-19", "CHEMICAL", 147, 155], ["laryngeal edema", "PATHOLOGICAL_FORMATION", 115, 130], ["supination", "TREATMENT", 20, 30], ["ETT migration", "PROBLEM", 40, 53], ["copious secretions", "PROBLEM", 55, 73], ["plugging", "PROBLEM", 90, 98], ["pronounced laryngeal edema", "PROBLEM", 104, 130], ["COVID", "TREATMENT", 147, 152], ["an ETT", "TREATMENT", 178, 184], ["a tracheostomy", "TREATMENT", 196, 210], ["ETT migration", "OBSERVATION", 40, 53], ["copious secretions", "OBSERVATION", 55, 73], ["plugging", "OBSERVATION", 90, 98], ["pronounced", "OBSERVATION_MODIFIER", 104, 114], ["laryngeal", "ANATOMY", 115, 124], ["edema", "OBSERVATION", 125, 130], ["tracheostomy", "OBSERVATION", 198, 210]]], ["In addition, prolonged ventilation times for COVID-19 patients may consume ICU beds and ventilators.", [["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["prolonged ventilation", "TREATMENT", 13, 34], ["COVID", "TREATMENT", 45, 50], ["ICU beds", "TREATMENT", 75, 83], ["ventilators", "TREATMENT", 88, 99]]], ["Under such circumstances, early tracheostomy may liberate patients from the ventilator and facilitate transfer out of the ICU to a lower level of care.", [["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["early tracheostomy", "TREATMENT", 26, 44], ["the ventilator", "TREATMENT", 72, 86], ["a lower level of care", "TREATMENT", 129, 150], ["early", "OBSERVATION_MODIFIER", 26, 31], ["tracheostomy", "OBSERVATION", 32, 44]]], ["On the other hand, a 2013 study reports that fewer patients underwent tracheostomies when a late strategy was applied.37 A late strategy may ultimately reduce the need for the procedure.Timing of Procedure ::: PERIOPERATIVE CONSIDERATIONS FOR TRACHEOSTOMY PROCEDURESIn some cases, prolonged ventilator weaning of COVID-19 patients may nullify the ability reduce ICU patient census.", [["patients", "ORGANISM", 51, 59], ["patients", "ORGANISM", 322, 330], ["patient", "ORGANISM", 366, 373], ["patients", "SPECIES", 51, 59], ["patients", "SPECIES", 322, 330], ["patient", "SPECIES", 366, 373], ["a 2013 study", "TEST", 19, 31], ["tracheostomies", "TREATMENT", 70, 84], ["a late strategy", "TREATMENT", 90, 105], ["A late strategy", "TREATMENT", 121, 136], ["the procedure", "TREATMENT", 172, 185], ["TRACHEOSTOMY", "TREATMENT", 243, 255], ["prolonged ventilator weaning", "TREATMENT", 281, 309], ["COVID", "TREATMENT", 313, 318], ["tracheostomies", "OBSERVATION", 70, 84]]], ["The vast majority of patients with COVID-19 achieve seroconversion by day 14, with a slow but steady decline of respiratory viral load.37 Although viral shedding from nasopharyngeal aspirates may occur up to 24 days after symptom onset, viral loads are significantly lower 14 days after presentation.38\u201340 It is probable, although not confirmed, that transmission may be more likely in earlier stages of infection.", [["respiratory", "ANATOMY", 112, 123], ["nasopharyngeal aspirates", "ANATOMY", 167, 191], ["38\u201340", "CHEMICAL", 300, 305], ["infection", "DISEASE", 404, 413], ["patients", "ORGANISM", 21, 29], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 167, 191], ["patients", "SPECIES", 21, 29], ["COVID", "TEST", 35, 40], ["a slow but steady decline of respiratory viral load", "PROBLEM", 83, 134], ["viral shedding", "PROBLEM", 147, 161], ["nasopharyngeal aspirates", "PROBLEM", 167, 191], ["symptom onset", "PROBLEM", 222, 235], ["viral loads", "PROBLEM", 237, 248], ["infection", "PROBLEM", 404, 413], ["respiratory viral load", "OBSERVATION", 112, 134], ["nasopharyngeal", "ANATOMY", 167, 181], ["aspirates", "OBSERVATION", 182, 191], ["probable", "UNCERTAINTY", 312, 320], ["may be more likely", "UNCERTAINTY", 364, 382], ["infection", "OBSERVATION", 404, 413]]], ["If so, performing the procedure after 2 weeks might pose less risk to the staff involved.", [["the procedure", "TREATMENT", 18, 31]]], ["This window may be revised as more tests to assess seroconversion become available.", [["more tests", "TEST", 30, 40], ["seroconversion", "PROBLEM", 51, 65]]], ["If patient transfer to a lower level of care is not a priority, ensuring seroconversion or negative polymerase chain reaction (PCR) testing before performing the procedure is a reasonable step to protect personnel.", [["patient", "ORGANISM", 3, 10], ["patient", "SPECIES", 3, 10], ["negative polymerase chain reaction", "PROBLEM", 91, 125], ["PCR) testing", "TEST", 127, 139], ["the procedure", "TREATMENT", 158, 171]]], ["Although testing can be performed for infectious risk stratification, factors such as a patient\u2019s transmissibility of the infection should be weighed against the need for the procedure and benefits achieved with it at a given time.Surgical ::: INTRAOPERATIVE IMPLICATIONSTo minimize the total time that staff is exposed to an infectious aerosolized environment, tracheostomy should be performed by the most experienced available operators.", [["infection", "DISEASE", 122, 131], ["patient", "ORGANISM", 88, 95], ["patient", "SPECIES", 88, 95], ["testing", "TEST", 9, 16], ["infectious risk stratification", "PROBLEM", 38, 68], ["the infection", "PROBLEM", 118, 131], ["the procedure", "TREATMENT", 171, 184], ["an infectious aerosolized environment", "TREATMENT", 323, 360], ["tracheostomy", "TREATMENT", 362, 374], ["infection", "OBSERVATION", 122, 131], ["infectious", "OBSERVATION_MODIFIER", 326, 336]]], ["If an indication for gastrostomy tube placement is present, performing both procedures concurrently may avoid subsequent exposure of another procedure team.", [["gastrostomy tube", "MULTI-TISSUE_STRUCTURE", 21, 37], ["gastrostomy tube placement", "TREATMENT", 21, 47], ["another procedure team", "TREATMENT", 133, 155], ["gastrostomy tube", "OBSERVATION", 21, 37]]], ["The surgical team should be mindful that suctioning is aerosol-generating and its use must be minimized.", [["aerosol", "TREATMENT", 55, 62]]], ["If suction is used, a closed system should be used with a viral filter.Surgical ::: INTRAOPERATIVE IMPLICATIONSSeveral different techniques have been described.", [["suction", "TREATMENT", 3, 10], ["a closed system", "TREATMENT", 20, 35], ["a viral filter", "TREATMENT", 56, 70], ["INTRAOPERATIVE IMPLICATIONSSeveral different techniques", "TREATMENT", 84, 139], ["viral filter", "OBSERVATION", 58, 70]]], ["Similar principles apply for both open and percutaneous tracheostomies:Anesthetic ::: INTRAOPERATIVE IMPLICATIONSDeep neuromuscular blockade (train-of-four ratio equal 0) is highly recommended to facilitate surgical exposure and prevent patient movement or coughing, which may prolong operative time and increase the risk of pathogen exposure.", [["percutaneous", "ANATOMY", 43, 55], ["neuromuscular", "ANATOMY", 118, 131], ["neuromuscular blockade", "DISEASE", 118, 140], ["coughing", "DISEASE", 257, 265], ["patient", "ORGANISM", 237, 244], ["patient", "SPECIES", 237, 244], ["both open and percutaneous tracheostomies", "TREATMENT", 29, 70], ["INTRAOPERATIVE IMPLICATIONSDeep neuromuscular blockade", "TREATMENT", 86, 140], ["surgical exposure", "TREATMENT", 207, 224], ["coughing", "PROBLEM", 257, 265], ["pathogen exposure", "PROBLEM", 325, 342], ["percutaneous tracheostomies", "OBSERVATION", 43, 70], ["pathogen exposure", "OBSERVATION", 325, 342]]], ["A viral filter should be placed on the endotracheal and tracheostomy tubes to prevent shedding of the virus in the event of ventilator disconnection.", [["endotracheal", "ANATOMY", 39, 51], ["A viral filter", "TREATMENT", 0, 14], ["the endotracheal", "TREATMENT", 35, 51], ["tracheostomy tubes", "TREATMENT", 56, 74], ["the virus", "PROBLEM", 98, 107], ["ventilator disconnection", "PROBLEM", 124, 148], ["viral filter", "OBSERVATION", 2, 14], ["endotracheal", "ANATOMY", 39, 51], ["tracheostomy tubes", "OBSERVATION", 56, 74], ["ventilator disconnection", "OBSERVATION", 124, 148]]], ["Circuit disconnection should occur distal to the filter, if necessary.", [["Circuit disconnection", "TREATMENT", 0, 21], ["the filter", "TREATMENT", 45, 55], ["filter", "OBSERVATION", 49, 55]]], ["If possible, mechanical ventilation should be interrupted just before entering the trachea via tracheotomy to reduce aerosolization of secretions.", [["trachea", "ANATOMY", 83, 90], ["secretions", "ANATOMY", 135, 145], ["trachea", "ORGAN", 83, 90], ["secretions", "ORGANISM_SUBSTANCE", 135, 145], ["mechanical ventilation", "TREATMENT", 13, 35], ["tracheotomy", "TREATMENT", 95, 106], ["secretions", "PROBLEM", 135, 145], ["mechanical ventilation", "OBSERVATION", 13, 35], ["trachea", "ANATOMY", 83, 90], ["tracheotomy", "OBSERVATION", 95, 106], ["secretions", "OBSERVATION", 135, 145]]], ["In percutaneous approaches, ventilation should also be interrupted, if possible, during tracheal dilation.", [["percutaneous", "ANATOMY", 3, 15], ["tracheal", "ANATOMY", 88, 96], ["tracheal", "MULTI-TISSUE_STRUCTURE", 88, 96], ["percutaneous approaches", "TREATMENT", 3, 26], ["ventilation", "TREATMENT", 28, 39], ["tracheal dilation", "TREATMENT", 88, 105], ["tracheal", "ANATOMY", 88, 96], ["dilation", "OBSERVATION", 97, 105]]], ["After insertion of the tracheostomy cannula, the anesthesiologist must verify that the cuff is inflated before recommencing ventilation.Ventilatory Support ::: INTRAOPERATIVE IMPLICATIONSPatients must ideally be medically stable to undergo tracheostomy, with resolution of severe hypoxemia.", [["hypoxemia", "DISEASE", 280, 289], ["the tracheostomy cannula", "TREATMENT", 19, 43], ["ventilation", "TREATMENT", 124, 135], ["tracheostomy", "TREATMENT", 240, 252], ["severe hypoxemia", "PROBLEM", 273, 289], ["tracheostomy cannula", "OBSERVATION", 23, 43], ["cuff", "OBSERVATION", 87, 91], ["inflated", "OBSERVATION", 95, 103], ["tracheostomy", "OBSERVATION", 240, 252], ["severe", "OBSERVATION_MODIFIER", 273, 279], ["hypoxemia", "OBSERVATION", 280, 289]]], ["When deciding whether a specific patient is clinically stable to undergo the procedure, it is important to have a multidisciplinary discussion and take into account not only mechanical ventilation settings, but also patient-related factors (eg, anatomy, presence of neck scar, radiation, body habitus) that may render the procedure more challenging.", [["neck scar", "ANATOMY", 266, 275], ["body", "ANATOMY", 288, 292], ["patient", "ORGANISM", 33, 40], ["patient", "ORGANISM", 216, 223], ["neck", "ORGANISM_SUBDIVISION", 266, 270], ["body", "ORGANISM_SUBDIVISION", 288, 292], ["patient", "SPECIES", 33, 40], ["patient", "SPECIES", 216, 223], ["the procedure", "TREATMENT", 73, 86], ["mechanical ventilation settings", "TREATMENT", 174, 205], ["neck scar", "PROBLEM", 266, 275], ["radiation, body habitus", "TREATMENT", 277, 300], ["the procedure", "TREATMENT", 318, 331], ["neck", "ANATOMY", 266, 270], ["scar", "OBSERVATION", 271, 275]]], ["To protect staff and minimize exposure, more procedural apnea time is possibly expected in patients with COVID-19, in comparison to other patients.", [["apnea", "DISEASE", 56, 61], ["patients", "ORGANISM", 91, 99], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 91, 99], ["patients", "SPECIES", 138, 146], ["COVID", "TEST", 105, 110]]], ["Hence, the surgical and anesthesia teams should be reasonably confident that the patient would be able to tolerate periods of apnea as necessary for safe conduct of the procedure.", [["apnea", "DISEASE", 126, 131], ["patient", "ORGANISM", 81, 88], ["patient", "SPECIES", 81, 88], ["apnea", "PROBLEM", 126, 131], ["the procedure", "TREATMENT", 165, 178]]], ["At our institution, we established minimal cut-offs of partial pressure of oxygen (Pao2) \u226560 mm Hg on fraction of inspired oxygen (Fio2) \u226450% and positive end-expiratory pressure (PEEP) \u226410 cm H2O to consider the patient a safe candidate for the procedure.", [["oxygen", "CHEMICAL", 75, 81], ["oxygen", "CHEMICAL", 123, 129], ["H2O", "CHEMICAL", 193, 196], ["oxygen", "CHEMICAL", 75, 81], ["Hg", "CHEMICAL", 96, 98], ["oxygen", "CHEMICAL", 123, 129], ["H2O", "CHEMICAL", 193, 196], ["oxygen", "SIMPLE_CHEMICAL", 75, 81], ["Pao2", "SIMPLE_CHEMICAL", 83, 87], ["oxygen", "SIMPLE_CHEMICAL", 123, 129], ["Fio2", "SIMPLE_CHEMICAL", 131, 135], ["patient", "ORGANISM", 213, 220], ["patient", "SPECIES", 213, 220], ["partial pressure of oxygen", "TREATMENT", 55, 81], ["Pao2", "TEST", 83, 87], ["inspired oxygen", "TREATMENT", 114, 129], ["Fio2", "TREATMENT", 131, 135], ["positive end-expiratory pressure", "TREATMENT", 146, 178], ["PEEP", "TREATMENT", 180, 184], ["the procedure", "TREATMENT", 242, 255], ["minimal", "OBSERVATION_MODIFIER", 35, 42], ["partial", "OBSERVATION_MODIFIER", 55, 62], ["pressure", "OBSERVATION_MODIFIER", 63, 71], ["oxygen", "OBSERVATION_MODIFIER", 75, 81]]], ["However, decisions should be made on a case-by-case basis by a multidisciplinary team.Management of Anticoagulation ::: INTRAOPERATIVE IMPLICATIONSIndividuals with COVID-19 may have a number of coagulation abnormalities leading to a hypercoagulable state.41\u201344 The pathogenesis of hypercoagulability in COVID-19 is incompletely understood, but likely involves a combination of complement-mediated endothelial injury, blood stasis (especially in hospitalized critically ill patients), and changes in circulating prothrombotic factors.41,42,45 Observational studies have also reported an increased risk of venous thromboembolism (VTE) in these patients as well as large-vessel stroke in patients with no significant risk factors.46\u201354 Moreover, autopsy studies in individuals who have died from COVID-19 have demonstrated microvascular thrombosis in the lungs.44,45,53Management of Anticoagulation ::: INTRAOPERATIVE IMPLICATIONSThis prothrombotic state appears to adversely affect outcomes in these patients.54 Despite the lack of high-quality studies supporting therapeutic anticoagulation in patients with coronavirus pneumonia, emerging observational data may indicate a possible survival benefit.55,56 Several institutions across the world have instituted aggressive protocols with full-dose anticoagulation of critically ill patients with COVID-19.Management of Anticoagulation ::: INTRAOPERATIVE IMPLICATIONSSuch anticoagulation protocols present a challenge in patients undergoing tracheostomy.", [["endothelial", "ANATOMY", 397, 408], ["blood", "ANATOMY", 417, 422], ["venous", "ANATOMY", 604, 610], ["vessel", "ANATOMY", 668, 674], ["microvascular", "ANATOMY", 820, 833], ["lungs", "ANATOMY", 852, 857], ["coagulation abnormalities", "DISEASE", 194, 219], ["hypercoagulability", "DISEASE", 281, 299], ["COVID-19", "CHEMICAL", 303, 311], ["blood stasis", "DISEASE", 417, 429], ["critically ill", "DISEASE", 458, 472], ["venous thromboembolism", "DISEASE", 604, 626], ["VTE", "DISEASE", 628, 631], ["vessel stroke", "DISEASE", 668, 681], ["microvascular thrombosis", "DISEASE", 820, 844], ["coronavirus pneumonia", "DISEASE", 1107, 1128], ["critically ill", "DISEASE", 1314, 1328], ["COVID-19", "CHEMICAL", 793, 801], ["COVID-19", "CHEMICAL", 1343, 1351], ["endothelial", "TISSUE", 397, 408], ["blood", "ORGANISM_SUBSTANCE", 417, 422], ["patients", "ORGANISM", 473, 481], ["venous thromboembolism", "PATHOLOGICAL_FORMATION", 604, 626], ["patients", "ORGANISM", 642, 650], ["vessel", "MULTI-TISSUE_STRUCTURE", 668, 674], ["patients", "ORGANISM", 685, 693], ["individuals", "ORGANISM", 762, 773], ["microvascular", "TISSUE", 820, 833], ["lungs", "ORGAN", 852, 857], ["patients", "ORGANISM", 998, 1006], ["patients", "ORGANISM", 1093, 1101], ["coronavirus", "ORGANISM", 1107, 1118], ["patients", "ORGANISM", 1329, 1337], ["patients", "ORGANISM", 1467, 1475], ["prothrombotic factors", "PROTEIN", 511, 532], ["patients", "SPECIES", 473, 481], ["patients", "SPECIES", 642, 650], ["patients", "SPECIES", 685, 693], ["patients", "SPECIES", 998, 1006], ["patients", "SPECIES", 1093, 1101], ["patients", "SPECIES", 1329, 1337], ["patients", "SPECIES", 1467, 1475], ["Anticoagulation", "TREATMENT", 100, 115], ["INTRAOPERATIVE IMPLICATIONSIndividuals", "TEST", 120, 158], ["COVID", "TEST", 164, 169], ["coagulation abnormalities", "PROBLEM", 194, 219], ["a hypercoagulable state", "PROBLEM", 231, 254], ["hypercoagulability", "PROBLEM", 281, 299], ["COVID", "TEST", 303, 308], ["complement-mediated endothelial injury", "PROBLEM", 377, 415], ["blood stasis", "PROBLEM", 417, 429], ["changes in circulating prothrombotic factors", "PROBLEM", 488, 532], ["Observational studies", "TEST", 542, 563], ["venous thromboembolism", "PROBLEM", 604, 626], ["VTE", "PROBLEM", 628, 631], ["large-vessel stroke", "PROBLEM", 662, 681], ["significant risk factors", "PROBLEM", 702, 726], ["autopsy studies", "TEST", 743, 758], ["COVID", "TEST", 793, 798], ["microvascular thrombosis in the lungs", "PROBLEM", 820, 857], ["Anticoagulation", "TREATMENT", 880, 895], ["INTRAOPERATIVE IMPLICATIONSThis prothrombotic state", "PROBLEM", 900, 951], ["therapeutic anticoagulation", "TREATMENT", 1062, 1089], ["coronavirus pneumonia", "PROBLEM", 1107, 1128], ["emerging observational data", "TEST", 1130, 1157], ["aggressive protocols", "TREATMENT", 1259, 1279], ["full-dose anticoagulation", "TREATMENT", 1285, 1310], ["COVID", "TEST", 1343, 1348], ["Anticoagulation", "TREATMENT", 1366, 1381], ["INTRAOPERATIVE IMPLICATIONSSuch anticoagulation protocols", "TREATMENT", 1386, 1443], ["a challenge", "TREATMENT", 1452, 1463], ["tracheostomy", "TREATMENT", 1487, 1499], ["coagulation", "OBSERVATION", 194, 205], ["hypercoagulable", "OBSERVATION", 233, 248], ["hypercoagulability", "OBSERVATION", 281, 299], ["endothelial", "ANATOMY", 397, 408], ["injury", "OBSERVATION", 409, 415], ["blood stasis", "OBSERVATION", 417, 429], ["circulating prothrombotic factors", "OBSERVATION", 499, 532], ["increased", "OBSERVATION_MODIFIER", 586, 595], ["venous", "ANATOMY", 604, 610], ["thromboembolism", "OBSERVATION", 611, 626], ["large", "OBSERVATION_MODIFIER", 662, 667], ["vessel", "ANATOMY", 668, 674], ["stroke", "OBSERVATION", 675, 681], ["microvascular", "ANATOMY", 820, 833], ["thrombosis", "OBSERVATION", 834, 844], ["lungs", "ANATOMY", 852, 857], ["coronavirus", "OBSERVATION_MODIFIER", 1107, 1118], ["pneumonia", "OBSERVATION", 1119, 1128], ["tracheostomy", "OBSERVATION", 1487, 1499]]], ["Studies have found that tracheostomies might be safely performed while on therapeutic anticoagulation, but considerable practice variability exists.57\u201359 While full-dose anticoagulation might not, when discontinued appropriately before procedure, predispose patients to bleeding, when bleeding occurs, it appears to be associated with significant events.60 At our institution, we usually stop heparin infusions between 2 and 4 hours before the procedure and have not had any bleeding complications to date.", [["bleeding", "DISEASE", 270, 278], ["bleeding", "DISEASE", 285, 293], ["heparin", "CHEMICAL", 393, 400], ["bleeding", "DISEASE", 475, 483], ["patients", "ORGANISM", 258, 266], ["heparin", "SIMPLE_CHEMICAL", 393, 400], ["patients", "SPECIES", 258, 266], ["Studies", "TEST", 0, 7], ["tracheostomies", "TREATMENT", 24, 38], ["therapeutic anticoagulation", "TREATMENT", 74, 101], ["full-dose anticoagulation", "TREATMENT", 160, 185], ["procedure", "TREATMENT", 236, 245], ["bleeding", "PROBLEM", 270, 278], ["bleeding", "PROBLEM", 285, 293], ["significant events", "PROBLEM", 335, 353], ["heparin infusions", "TREATMENT", 393, 410], ["the procedure", "TREATMENT", 440, 453], ["any bleeding complications", "PROBLEM", 471, 497], ["tracheostomies", "OBSERVATION", 24, 38], ["bleeding", "OBSERVATION", 270, 278]]], ["Heparin infusion is typically restarted within 2 hours after procedure depending on the intraoperative course and proceduralist\u2019s preference.", [["Heparin", "CHEMICAL", 0, 7], ["Heparin", "SIMPLE_CHEMICAL", 0, 7], ["Heparin infusion", "TREATMENT", 0, 16], ["procedure", "TREATMENT", 61, 70]]], ["We also recommend a platelet count >50,000/\u03bcL and international normalized ratio (INR) <1.5.Choice of Approach (Open Versus Percutaneous) ::: INTRAOPERATIVE IMPLICATIONSThe choice of approach should be made by the procedural staff as each has its advantages and disadvantages.", [["platelet", "ANATOMY", 20, 28], ["platelet", "CELL", 20, 28], ["a platelet count", "TEST", 18, 34], ["international normalized ratio", "TEST", 50, 80], ["INR", "TEST", 82, 85]]], ["We recommend that the route that secures the airway in the safest and quickest manner is chosen and this should remain at the discretion of the proceduralist.", [["airway", "ANATOMY", 45, 51], ["airway", "MULTI-TISSUE_STRUCTURE", 45, 51], ["the route", "TREATMENT", 18, 27], ["airway", "ANATOMY", 45, 51]]], ["No evidence supports the superiority of percutaneous versus open tracheostomy.", [["percutaneous", "ANATOMY", 40, 52], ["percutaneous versus open tracheostomy", "TREATMENT", 40, 77], ["percutaneous", "OBSERVATION", 40, 52], ["tracheostomy", "OBSERVATION", 65, 77]]], ["Percutaneous tracheostomies are more often performed at the bedside but can be challenging in some patient populations, such as morbidly obese patients with large neck circumference.", [["neck", "ANATOMY", 163, 167], ["patient", "ORGANISM", 99, 106], ["patients", "ORGANISM", 143, 151], ["neck", "ORGANISM_SUBDIVISION", 163, 167], ["patient", "SPECIES", 99, 106], ["patients", "SPECIES", 143, 151], ["Percutaneous tracheostomies", "TREATMENT", 0, 27], ["large neck circumference", "PROBLEM", 157, 181], ["tracheostomies", "OBSERVATION", 13, 27], ["neck", "ANATOMY", 163, 167]]], ["If strict infectious precautions are followed, an open approach can be safely conducted.Choice of Approach (Open Versus Percutaneous) ::: INTRAOPERATIVE IMPLICATIONSFor percutaneous tracheostomies, the bronchoscopist should be capable of reestablishing airway access (with laryngoscopy and endotracheal intubation), if necessary.", [["percutaneous", "ANATOMY", 169, 181], ["airway", "ANATOMY", 253, 259], ["endotracheal", "ANATOMY", 290, 302], ["airway", "MULTI-TISSUE_STRUCTURE", 253, 259], ["strict infectious precautions", "TREATMENT", 3, 32], ["an open approach", "TREATMENT", 47, 63], ["Approach (Open Versus Percutaneous)", "TREATMENT", 98, 133], ["INTRAOPERATIVE IMPLICATIONSFor percutaneous tracheostomies", "TREATMENT", 138, 196], ["the bronchoscopist", "TREATMENT", 198, 216], ["reestablishing airway access", "TREATMENT", 238, 266], ["laryngoscopy", "TEST", 273, 285], ["endotracheal intubation", "TREATMENT", 290, 313], ["infectious", "OBSERVATION_MODIFIER", 10, 20], ["percutaneous tracheostomies", "OBSERVATION", 169, 196]]], ["After tracheostomy placement and confirmation with end-tidal carbon dioxide, fiberoptic bronchoscopy must be performed to confirm appropriate positioning.", [["carbon dioxide", "CHEMICAL", 61, 75], ["carbon dioxide", "CHEMICAL", 61, 75], ["tracheostomy placement", "TREATMENT", 6, 28], ["confirmation", "TEST", 33, 45], ["end-tidal carbon dioxide", "TREATMENT", 51, 75], ["fiberoptic bronchoscopy", "TEST", 77, 100]]], ["This procedure should be performed under apnea, if tolerated.", [["apnea", "DISEASE", 41, 46], ["This procedure", "TREATMENT", 0, 14], ["apnea", "PROBLEM", 41, 46]]], ["A modified-percutaneous approach has also been performed at our institution.", [["percutaneous", "ANATOMY", 11, 23], ["A modified-percutaneous approach", "TREATMENT", 0, 32], ["percutaneous", "OBSERVATION", 11, 23]]], ["During this approach, the ETT is advanced distally near the carina and cuff is left inflated.", [["carina", "ANATOMY", 60, 66], ["carina", "MULTI-TISSUE_STRUCTURE", 60, 66], ["ETT", "DNA", 26, 29], ["this approach", "TREATMENT", 7, 20], ["the ETT", "TREATMENT", 22, 29], ["ETT", "OBSERVATION", 26, 29], ["distally", "OBSERVATION_MODIFIER", 42, 50], ["carina", "ANATOMY", 60, 66], ["cuff", "OBSERVATION_MODIFIER", 71, 75], ["left", "ANATOMY_MODIFIER", 79, 83], ["inflated", "OBSERVATION", 84, 92]]], ["The bronchoscope is then inserted along the side of the ETT (instead of within the ETT normally used in a conventional approach) to minimize aerosolization and guide percutaneous puncture of the trachea.Postprocedural Debrief ::: INTRAOPERATIVE IMPLICATIONSWe recommend a postprocedural debriefing among members of the procedural team to discuss the processes, obtain real-time feedback, and therefore streamline workflows for future cases.Postprocedure Waste Disposal ::: INTRAOPERATIVE IMPLICATIONSAfter completion of the procedure, careful attention must be paid to waste disposal and decontamination of equipment.", [["percutaneous", "ANATOMY", 166, 178], ["trachea", "ANATOMY", 195, 202], ["trachea", "MULTI-TISSUE_STRUCTURE", 195, 202], ["The bronchoscope", "TREATMENT", 0, 16], ["the ETT", "TREATMENT", 79, 86], ["a conventional approach", "TREATMENT", 104, 127], ["aerosolization", "TREATMENT", 141, 155], ["guide percutaneous puncture of the trachea", "TREATMENT", 160, 202], ["the procedure", "TREATMENT", 520, 533], ["decontamination of equipment", "TREATMENT", 588, 616], ["bronchoscope", "OBSERVATION", 4, 16], ["ETT", "OBSERVATION", 56, 59], ["aerosolization", "OBSERVATION", 141, 155], ["percutaneous puncture", "OBSERVATION", 166, 187], ["trachea", "ANATOMY", 195, 202]]], ["Whenever possible, disposable equipment should be used.", [["disposable equipment", "TREATMENT", 19, 39]]], ["Staff handling decontamination of surgical equipment should wear adequate PPE.", [["surgical equipment", "TREATMENT", 34, 52]]], ["HCWs should be aware of risk of self-contamination during doffing of PPE, which was reported during the recent Ebola epidemic.61,62 To minimize these risks, strict adherence to standard operating procedure is needed.", [["Ebola", "DISEASE", 111, 116], ["Ebola", "ORGANISM", 111, 116], ["self-contamination", "PROBLEM", 32, 50], ["PPE", "PROBLEM", 69, 72], ["standard operating procedure", "TREATMENT", 177, 205]]], ["The presence of a trained observer supervising each step of doffing is highly encouraged to improve compliance.Posttracheostomy Care ::: INTRAOPERATIVE IMPLICATIONSWe recommend that the following supply be left at the bedside of COVID-19 patients who have undergone tracheostomy: manual bag ventilator with viral filter, suction equipment (gauge, canister/tubing, appropriate suction catheters), spare inner cannula, spare tracheostomy tube, plus spare tracheostomy tube that is one size smaller.", [["inner cannula", "ANATOMY", 402, 415], ["patients", "ORGANISM", 238, 246], ["patients", "SPECIES", 238, 246], ["tracheostomy", "TREATMENT", 266, 278], ["manual bag ventilator", "TREATMENT", 280, 301], ["viral filter", "TREATMENT", 307, 319], ["suction equipment (gauge, canister/tubing", "TREATMENT", 321, 362], ["appropriate suction catheters", "TREATMENT", 364, 393], ["spare inner cannula", "TREATMENT", 396, 415], ["spare tracheostomy tube", "TREATMENT", 417, 440], ["spare tracheostomy tube", "TREATMENT", 447, 470], ["tracheostomy", "OBSERVATION", 266, 278], ["viral filter", "OBSERVATION", 307, 319], ["cannula", "ANATOMY", 408, 415], ["tracheostomy tube", "OBSERVATION", 423, 440], ["tracheostomy tube", "OBSERVATION", 453, 470], ["one", "OBSERVATION_MODIFIER", 479, 482], ["size", "OBSERVATION_MODIFIER", 483, 487], ["smaller", "OBSERVATION_MODIFIER", 488, 495]]], ["When the patient is ready to be liberated from the ventilator, a T-piece system with a viral filter on the expiratory end, and inline suction catheter may be used.", [["patient", "ORGANISM", 9, 16], ["patient", "SPECIES", 9, 16], ["the ventilator", "TREATMENT", 47, 61], ["a T-piece system", "TREATMENT", 63, 79], ["a viral filter", "TREATMENT", 85, 99], ["the expiratory end", "TREATMENT", 103, 121], ["inline suction catheter", "TREATMENT", 127, 150], ["viral filter", "OBSERVATION", 87, 99]]], ["Particular attention should be given to the extra weight and tension on the tracheostomy site63 (Figure).Posttracheostomy Care ::: INTRAOPERATIVE IMPLICATIONSTracheostomy collar trials should ideally be done in a negative-pressure isolation room.", [["the tracheostomy site63", "TREATMENT", 72, 95], ["INTRAOPERATIVE IMPLICATIONSTracheostomy collar trials", "TREATMENT", 131, 184], ["tension", "OBSERVATION", 61, 68], ["tracheostomy", "OBSERVATION", 76, 88]]], ["When such room is unavailable, a portable HEPA filter can be used to minimize environmental contamination.", [["a portable HEPA filter", "TREATMENT", 31, 53], ["environmental contamination", "PROBLEM", 78, 105]]], ["Placing a surgical mask over the tracheostomy site may also limit droplet spread.", [["a surgical mask", "TREATMENT", 8, 23], ["the tracheostomy site", "TREATMENT", 29, 50], ["surgical mask", "OBSERVATION", 10, 23], ["tracheostomy", "OBSERVATION", 33, 45], ["droplet spread", "OBSERVATION", 66, 80]]], ["Patients who are stably breathing on a tracheostomy mask can undergo speaking valve trials.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["a tracheostomy mask", "TREATMENT", 37, 56], ["speaking valve trials", "TREATMENT", 69, 90], ["valve", "OBSERVATION", 78, 83]]], ["It is important to remember that placement of the speaking valve and capping should be considered AGPs, so airborne precautions are warranted.", [["valve", "PATHOLOGICAL_FORMATION", 59, 64], ["the speaking valve", "TREATMENT", 46, 64], ["capping", "TREATMENT", 69, 76], ["AGPs", "PROBLEM", 98, 102], ["airborne precautions", "TREATMENT", 107, 127], ["valve", "OBSERVATION", 59, 64]]], ["However, once the tracheostomy is capped, airborne precautions are not necessary and patients may wear a facemask.Posttracheostomy Care ::: INTRAOPERATIVE IMPLICATIONSIf possible, we recommend refraining from tracheostomy changes, downsizing or decannulation until COVID-19 infection has cleared.", [["infection", "DISEASE", 274, 283], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["the tracheostomy", "TREATMENT", 14, 30], ["airborne precautions", "TREATMENT", 42, 62], ["a facemask", "TREATMENT", 103, 113], ["tracheostomy changes", "TREATMENT", 209, 229], ["decannulation", "TREATMENT", 245, 258], ["COVID", "TEST", 265, 270], ["infection", "PROBLEM", 274, 283], ["tracheostomy", "OBSERVATION", 18, 30], ["infection", "OBSERVATION", 274, 283]]], ["In the event of an emergency, when tube exchange is clinically indicated (malposition, cuff rupture), all precautions mandated for the original procedure apply.CONCLUSIONSAs the SARS-CoV-2 pandemic progresses, we expect health care systems across the globe to be severely strained, taking a toll on the health care workforce and patients alike.", [["tube", "ANATOMY", 35, 39], ["SARS", "DISEASE", 178, 182], ["tube", "TISSUE", 35, 39], ["patients", "ORGANISM", 329, 337], ["patients", "SPECIES", 329, 337], ["tube exchange", "TREATMENT", 35, 48], ["malposition, cuff rupture", "TREATMENT", 74, 99], ["all precautions", "TREATMENT", 102, 117], ["the original procedure", "TREATMENT", 131, 153], ["the SARS", "TEST", 174, 182], ["severely strained", "PROBLEM", 263, 280], ["cuff", "ANATOMY", 87, 91], ["rupture", "OBSERVATION", 92, 99], ["globe", "ANATOMY", 251, 256]]], ["Tracheostomies in COVID-19 patients present themselves as extremely high-risk procedures for all members of the procedural team.", [["Tracheostomies", "DISEASE", 0, 14], ["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["Tracheostomies", "TREATMENT", 0, 14]]], ["Systematic meticulous planning of each procedural step is warranted along with strict adherence to local/institutional protocols to mitigate risk to procedural members.ACKNOWLEDGMENTSThe authors thank Respiratory therapists at Beth Israel Deaconess Medical Center; Lenny Rabkin, RT, Renny Sanchez, RT, and Joe Previtera, RT, for aid in the development of protocols, procedures, and equipment utilized in this article.DISCLOSURESName: Andre F. Gosling, MD.DISCLOSURESContribution: This author helped design the review, review the literature, and prepare the manuscript.DISCLOSURESName: Somnath Bose, MD.DISCLOSURESContribution: This author helped design the review, review the literature, and prepare the manuscript.DISCLOSURESName: Ernest Gomez, MD.DISCLOSURESContribution: This author helped review the literature and prepare the manuscript.DISCLOSURESName: Mihir Parikh, MD.DISCLOSURESContribution: This author helped review the literature and prepare the manuscript.DISCLOSURESName: Charles Cook, MD.DISCLOSURESContribution: This author helped review the literature and prepare the manuscript.DISCLOSURESName: Todd Sarge, MD.DISCLOSURESContribution: This author helped review the literature and prepare the manuscript.DISCLOSURESName: Shahzad Shaefi, MD, MPH.DISCLOSURESContribution: This author helped design the review, review the literature, and prepare the manuscript.DISCLOSURESName: Akiva Leibowitz, MD.DISCLOSURESContribution: This author helped design the review, review the literature, and prepare the manuscript.DISCLOSURESThis manuscript was handled by: Avery Tung, MD, FCCM.", [["each procedural step", "TREATMENT", 34, 54], ["local/institutional protocols", "TREATMENT", 99, 128], ["RT", "TREATMENT", 298, 300], ["RT", "TREATMENT", 321, 323], ["procedures", "TREATMENT", 366, 376], ["equipment", "TREATMENT", 382, 391], ["RT", "ANATOMY", 298, 300]]]], "PMC7386827": [["IntroductionGabriel Schwartz and Jaquelyn Jahn analyzed data from Fatal Encounters\u2014the most comprehensive database tracking police-involved deaths in the United States\u2014and uncovered vast differences across metropolitan statistical areas (MSAs) in the overall rates of persons killed by police officers, as well as racial inequities in those rates, between 2013 and 2017 [1].", [["deaths", "DISEASE", 140, 146], ["persons", "ORGANISM", 268, 275], ["persons", "SPECIES", 268, 275]]], ["First, overall rates varied extensively, from a low of 0.13 police-involved fatalities per 100,000 in Buffalo-Cheektowaga-Niagara Falls, NY to 1.17 police-involved fatalities per 100,000 in Anniston-Oxford-Jacksonville, AL.", [["fatalities", "DISEASE", 76, 86], ["fatalities", "DISEASE", 164, 174]]], ["Second, western MSAs generally experienced higher annual rates of police-involved fatalities than their counterparts in the northern Midwest and Northeast.", [["fatalities", "DISEASE", 82, 92]]], ["Third, across 382 MSAs, the Black incidence rate of fatalities involving police was at least 1.81 times higher than the White incidence rate (though notably, the 95% confidence intervals were wide and the vast majority included 1.00).", [["fatalities", "DISEASE", 52, 62], ["Black", "OBSERVATION_MODIFIER", 28, 33]]], ["In the Chicago-Naperville-Elgin MSA, for example, the Black incidence rate of fatalities involving police was 6.51 times (95% CI 1.84, 23.09) higher than the White incidence rate.", [["fatalities", "DISEASE", 78, 88], ["CI", "TEST", 126, 128], ["the White incidence rate", "TEST", 154, 178]]], ["Finally, Latinx-White inequities were less pronounced than Black-White inequities.", [["Latinx", "TEST", 9, 15], ["less pronounced", "OBSERVATION_MODIFIER", 38, 53]]], ["In the Pueblo, CO MSA\u2014which had the most extreme Latinx-White inequity from 2013 to 2017 \u2013the Latinx incidence rate of fatalities involving the police was 1.50 times higher than the White incidence rate.IntroductionSchwartz and Jahn performed a purely descriptive, demographic analysis.", [["fatalities", "DISEASE", 119, 129], ["CO MSA", "TEST", 15, 21], ["demographic analysis", "TEST", 265, 285]]], ["Second, although Fatal Encounters offers the most comprehensive data on police use of deadly force in the United States, it likely misses hundreds, if not thousands, of police uses of deadly force each year [3].", [["Fatal", "OBSERVATION_MODIFIER", 17, 22]]], ["Finally, the authors\u2019 use of census data to construct the denominator for each MSA\u2019s police-involved fatality rate rests on a strong assumption: that every person residing in each MSA is exposed to the risk of being killed by a police officer.", [["person", "SPECIES", 156, 162]]], ["Accordingly, I applaud Schwartz and Jahn for excluding from their analysis 1,670 deaths that resulted from suicides, accidents, or vehicular collisions (in a supplemental analysis, they show what the results would be with these incidents included).", [["deaths", "DISEASE", 81, 87], ["accidents", "DISEASE", 117, 126], ["a supplemental analysis", "TEST", 156, 179], ["vehicular collisions", "OBSERVATION", 131, 151]]], ["However, as is common practice in public health and epidemiological research, the authors framed their study as one pertaining to fatal police violence [5\u20138], which they define as \u201cfatalities in police custody or involving the police that would not have occurred in the absence of police intervention.\u201d", [["fatalities", "DISEASE", 181, 191]]], ["There is no disputing that when police kill, they do so via acts of physical violence.", [["physical violence", "DISEASE", 68, 85], ["no disputing", "UNCERTAINTY", 9, 21]]], ["But labelling every police-involved death \u201cfatal police violence\u201d assigns all responsibility to officers, as if none of the citizens involved contributed in any way to the violence.FramingCriminologist Philip Stinson, an expert on police crime and integrity, defines police violence as \u201cany amount of force\u2026that cannot be accounted for under the auspices of lawful necessity in the line of duty\u201d (p.", [["death", "DISEASE", 36, 41], ["violence", "DISEASE", 172, 180], ["violence", "DISEASE", 274, 282]]], ["A vast literature on framing theory suggests they can have powerful effects on the way people \u201cdevelop a particular conceptualization of an issue or reorient their thinking about an issue\u201d [11; see also 12].", [["people", "ORGANISM", 87, 93], ["people", "SPECIES", 87, 93]]], ["Recently, Fridkin et al. [13] conducted an experiment where 225 political science students viewed dashcam footage of the arrest of Ersula Ore, \u201can African American professor at a major southwestern university [who] was \u2018body slammed\u2019 to the ground\u2026for jaywalking.\u201d", [["body", "ANATOMY", 220, 224], ["body", "ORGANISM_SUBDIVISION", 220, 224]]], ["Prior to watching the footage, students were randomly assigned to read brief introductory paragraphs that framed the incident in terms of law and order (emphasizing the jaywalking violation, the officer\u2019s concern for public safety, and the professor\u2019s \u201cviolent outburst\u201d), police brutality (emphasizing the body slam and charges being pressed against the officer for excessive force), or race (emphasizing the race of both the officer and the professor, and mentioning a civil rights investigation).", [["body", "ANATOMY", 307, 311], ["body", "ORGANISM_SUBDIVISION", 307, 311]]], ["A fourth control stimulus simply informed students that a professor\u2019s arrest was \u201ccreating quite a stir,\u201d and directed them to watch the footage.", [["A fourth control stimulus", "TREATMENT", 0, 25]]], ["Unsurprisingly, despite the fact that all participants viewed the same video, exposure to the law and order and police brutality frames significantly affected students\u2019 evaluations of both the officer and the professor.", [["participants", "SPECIES", 42, 54]]], ["This occurred following a three-hour standoff with Reyes, an estranged ex-husband who had broken into his ex-wife\u2019s home, grabbed her two-year-old daughter, and held the girl at gunpoint on a balcony.", [["girl", "SPECIES", 170, 174]]], ["Ultimately, a police sniper shot and killed Reyes, saving the little girl\u2019s life (see S1-A of S1 Data).", [["girl", "SPECIES", 69, 73]]], ["Although the Fatal Encounters dataset does not include a field indicating whether the decedent was armed, as of March 18, 2020, The Washington Post reports that roughly 87% of the 5,134 citizens fatally shot by police officers since 2015 were in possession of a potentially deadly weapon (i.e., a firearm, knife/cutting instrument, or blunt object).", [["knife/cutting instrument", "TREATMENT", 306, 330]]], ["It also has the potential to drive away readers who understand how statistically rare police use of deadly force is, and that it usually occurs in response to violence (e.g., police officers themselves, and those who view police as \u201cprofessionals\u201d; see [14] and [15\u201322]).", [["violence", "DISEASE", 159, 167]]], ["I suspect police-involved fatalities is less leading, but this is ultimately an empirical question that future research should consider.Generalizing from a nonrandom sample of deadly force incidentsThe foremost cause of death at the hands of police, by far, is gunshot wounds.", [["wounds", "ANATOMY", 269, 275], ["fatalities", "DISEASE", 26, 36], ["death", "DISEASE", 220, 225], ["gunshot", "DISEASE", 261, 268], ["wounds", "PATHOLOGICAL_FORMATION", 269, 275], ["death", "PROBLEM", 220, 225], ["gunshot wounds", "PROBLEM", 261, 275], ["gunshot", "OBSERVATION_MODIFIER", 261, 268], ["wounds", "OBSERVATION", 269, 275]]], ["Ninety-four percent of the deaths in Schwartz and Jahn\u2019s sample resulted from police gunfire.", [["deaths", "DISEASE", 27, 33]]], ["However, like other crowdsourced datasets tracking police use of deadly force, Fatal Encounters only documents police shootings that result in the death of a person.", [["death", "DISEASE", 147, 152], ["person", "SPECIES", 158, 164]]], ["According to the late James Fyfe [23], a pioneer in the study of officer-involved shootings:Generalizing from a nonrandom sample of deadly force incidentsThat is, each time a police officer points and shoots a firearm at a person, a deadly force incident has transpired\u2014even if the shot(s) misses or the person survives.Generalizing from a nonrandom sample of deadly force incidentsIn the absence of national-level data on nonfatal police shootings, we are left to estimate how often they occur.", [["person", "SPECIES", 223, 229], ["person", "SPECIES", 304, 310]]], ["Studies conducted at lower levels of analysis (i.e., one or more agencies) suggest police shootings result in death anywhere from 15 to 50% of the time [3, 24\u201330].", [["death", "DISEASE", 110, 115], ["Studies", "TEST", 0, 7], ["analysis", "TEST", 37, 45], ["death", "PROBLEM", 110, 115]]], ["The five years of Fatal Encounters data analyzed by Schwartz and Jahn include approximately 5,000 deaths resulting from police shootings.", [["deaths", "DISEASE", 98, 104]]], ["If we assumed that the police shooting fatality rate over this period was 50% (a liberal estimate), it would mean the authors\u2019 analysis excluded 5,000 police shootings that did not result in death (but nevertheless qualify as police uses of deadly force).Generalizing from a nonrandom sample of deadly force incidentsHere is why this matters: the numerators of Schwartz and Jahn\u2019s fatality rates are a nonrandom sample of all deadly force incidents that occurred from 2013 to 2017.", [["death", "DISEASE", 191, 196], ["death", "PROBLEM", 191, 196]]], ["To be sure, there is some degree of chance in whether a person who is shot lives or dies (e.g., whether bullets pierce a vital organ) [31\u201333].", [["organ", "ANATOMY", 127, 132], ["organ", "ORGAN", 127, 132], ["person", "SPECIES", 56, 62]]], ["But part of the variation across MSAs both in terms of rates of police-involved fatalities and racial disparities therein might be driven by nonrandom factors apart from police behavior.", [["fatalities", "DISEASE", 80, 90]]], ["One such factor is trauma care accessibility.", [["trauma", "DISEASE", 19, 25]]], ["Proximity to trauma centers varies systematically across communities [34\u201336], and prior research indicates that shooting victims face an elevated risk of dying from their wounds when they are shot farther away from trauma-certified hospitals [37\u201340].", [["wounds", "ANATOMY", 171, 177], ["trauma", "DISEASE", 13, 19], ["trauma", "DISEASE", 215, 221], ["wounds", "PATHOLOGICAL_FORMATION", 171, 177], ["their wounds", "PROBLEM", 165, 177], ["trauma", "OBSERVATION", 13, 19], ["elevated", "OBSERVATION", 137, 145]]], ["This is a crucial distinction.Generalizing from a nonrandom sample of deadly force incidentsAny two MSAs could be remarkably similar in terms of the rate at which officers use deadly force, yet quite different in terms of the rate at which people succumb to wounds inflicted by police officers.", [["wounds", "ANATOMY", 258, 264], ["wounds", "DISEASE", 258, 264], ["people", "ORGANISM", 240, 246], ["wounds", "PATHOLOGICAL_FORMATION", 258, 264], ["people", "SPECIES", 240, 246], ["Any two MSAs", "PROBLEM", 92, 104], ["crucial distinction", "OBSERVATION", 10, 29], ["MSAs", "OBSERVATION", 100, 104], ["similar", "OBSERVATION_MODIFIER", 125, 132]]], ["However, LVMPD\u2019s fatality rate was 40.9% versus SLMPD\u2019s 16.8%.", [["LVMPD", "TEST", 9, 14], ["fatality rate", "TEST", 17, 30], ["SLMPD\u2019s", "TEST", 48, 55]]], ["An analysis like Schwartz and Jahn\u2019s, conducted with these two cities, would lead to the mistaken conclusion that fatal police violence was twice as common in Las Vegas as St. Louis, despite officers in these departments using deadly force on a similar number of occasions.", [["violence", "DISEASE", 127, 135], ["An analysis", "TEST", 0, 11]]], ["Meanwhile, whereas the Boston and Atlanta Police Departments were involved in 10 fatal police shootings each, Boston had just 4 additional nonfatal shootings (fatality rate = 71.4%), while Atlanta had an additional 32 (fatality rate = 23.8%) [41].", [["fatality rate", "TEST", 159, 172], ["fatality rate", "TEST", 219, 232]]], ["Here, an analysis like Schwartz and Jahn\u2019s would lead to the conclusion that fatal police violence occurred with the same frequency in each city, when in fact Atlanta officers were involved in 3x as many deadly force incidents.", [["violence", "DISEASE", 90, 98], ["an analysis", "TEST", 6, 17]]], ["Descriptive studies limited primarily to police shootings that result in the death of a person, instead of all occasions in which officers used deadly force, can lead to mistaken inferences about racial disparities in the rate at which the police use deadly force [42].Generalizing from a nonrandom sample of deadly force incidentsTo be clear, the lack of national data on nonfatal police shootings is a frustrating limitation with which we all must grapple.", [["death", "DISEASE", 77, 82], ["person", "SPECIES", 88, 94], ["Descriptive studies", "TEST", 0, 19], ["a frustrating limitation", "PROBLEM", 402, 426], ["clear", "OBSERVATION", 337, 342]]], ["As researchers, we can either (1) abandon the study of national trends in police use of deadly force and focus on smaller units of analysis [43, 44] or (2) own the limitations of the data and be transparent about what can and cannot be concluded from analyses of them.", [["the study", "TEST", 42, 51], ["analysis", "TEST", 131, 139]]], ["Instead, their analysis tells us that overall and race-specific fatality rates vary across MSAs.", [["their analysis", "TEST", 9, 23]]], ["In Schwartz and Jahn\u2019s case, this would be the population of individuals who interacted with a police officer from 2013 to 2017 but were not killed.", [["individuals", "ORGANISM", 61, 72]]], ["Everyone in this population was exposed to the risk, however small, of being killed by a police officer [46].", [["small", "OBSERVATION_MODIFIER", 61, 66]]], ["However, Schwartz and Jahn calculated their fatality rates with census data\u2014meaning they included in their denominators millions of people who did not interact with a police officer, and whose risk of being killed by a police officer was approximately 0% (see S1-D of S1 Data).", [["people", "ORGANISM", 132, 138], ["people", "SPECIES", 132, 138]]], ["Meta-analytic studies have documented clear racial disparities in arrests [49], and furthermore, the available data demonstrate that deadly force incidents do not occur exclusively during the investigation of criminal activity or in the course of making arrests [45].", [["Meta-analytic studies", "TEST", 0, 21], ["clear racial disparities in arrests", "PROBLEM", 38, 73], ["clear", "OBSERVATION_MODIFIER", 38, 43], ["racial", "OBSERVATION_MODIFIER", 44, 50], ["disparities", "OBSERVATION_MODIFIER", 51, 62]]], ["In other words, being killed by a police officer is not conditional on committing a crime or being arrested.The challenge of defining the at-risk populationThe authors continue:The challenge of defining the at-risk populationAnswering these questions requires knowing how many people in each MSA were not killed by police.", [["people", "ORGANISM", 277, 283], ["people", "SPECIES", 277, 283]]], ["A Venn diagram of the \u201cat risk\u201d and general populations would not perfectly align\u2014instead, the \u201cat risk\u201d circle would be a small circle within the much larger general population circle.", [["small", "OBSERVATION_MODIFIER", 123, 128], ["circle", "OBSERVATION", 129, 135], ["larger", "OBSERVATION_MODIFIER", 152, 158], ["population circle", "OBSERVATION", 167, 184]]], ["To estimate maternal mortality rates, researchers do not include all women in the denominator, but instead the number of live births [50].", [["women", "ORGANISM", 69, 74], ["women", "SPECIES", 69, 74]]], ["To estimate meaningfully the rate at which sexually transmitted diseases proliferate, researchers would want to identify the sexually active population [51].", [["sexually transmitted diseases", "DISEASE", 43, 72]]], ["Finally, to estimate the rate at which sharks bite people, researchers would need to determine who goes into the water [52].", [["people", "ORGANISM", 51, 57], ["people", "SPECIES", 51, 57]]], ["This is no easy task, as reliable data on the rate at which police officers interact with people are not systematically collected.", [["people", "ORGANISM", 90, 96], ["people", "SPECIES", 90, 96], ["no", "UNCERTAINTY", 8, 10]]], ["As such, conditioning on stops could bias analyses by (1) blocking a mediating path and (2) inducing collider stratification bias [58, 60].", [["collider stratification bias", "TEST", 101, 129]]], ["Stopping a person and using deadly force on a person are two different decision points, with different antecedents, and need to be analyzed as such.The challenge of defining the at-risk populationTo be clear, there is nothing inherently wrong about Schwartz and Jahn\u2019s use of population denominators in their analysis, so long as readers bear in mind there are many factors (including police behavior) that drive the disparities [53\u201367].", [["person", "SPECIES", 11, 17], ["person", "SPECIES", 46, 52], ["clear", "OBSERVATION", 202, 207]]], ["Future research must do so.Where to go from here?I believe a lot can be gleaned from Schwartz and Jahn\u2019s article, and agree that \u201cplace-specific policy contexts are likely a major cause of the distribution of overall incidence rates.\u201d", [["overall incidence rates", "PROBLEM", 209, 232]]], ["Daniel Nagin, for example, uncovered a \u201ccorrelation between statewide prevalence of gun ownership and fatal police shootings for both all decedents and unarmed decedents,\u201d and confirmed that \u201cgreater access to trauma centers is associated with lower rates of citizen deaths\u201d [68].", [["trauma", "DISEASE", 210, 216], ["deaths", "DISEASE", 267, 273]]], ["In a separate study, Jay Jennings and Meghan Rubado showed that agencies requiring officers to file a report when they point their firearms at people experience significantly lower rates of fatal police shootings [69].", [["people", "ORGANISM", 143, 149], ["people", "SPECIES", 143, 149], ["a separate study", "TEST", 3, 19]]], ["In short, reducing police-involved fatalities requires a multi-faceted approach.Where to go from here?From the police perspective, it will require reducing the frequency with which officers are forced to make \u201csplit-second decisions.\u201d", [["fatalities", "DISEASE", 35, 45], ["a multi-faceted approach", "TREATMENT", 55, 79], ["short", "OBSERVATION_MODIFIER", 3, 8]]], ["In part, this means getting officers to slow down and reduce their sense of urgency [70].", [["urgency", "PROBLEM", 76, 83]]], ["As communities explore these and other ways to reduce police-involved fatalities, it is imperative that they set clear and manageable goals, define at the onset what they would consider success or failure, and rigorously evaluate the effects of the policies or interventions implemented.Where to go from here?As important, our understanding of police use of deadly force continues to be hindered by a lack of comprehensive, national data.", [["failure", "PROBLEM", 197, 204], ["the policies", "TREATMENT", 245, 257], ["interventions", "TREATMENT", 261, 274], ["failure", "OBSERVATION", 197, 204]]]]}